Molecules for disease detection and treatment

ABSTRACT

Various embodiments of the invention provide human molecules for disease detection and treatment (MDDT) and polynucleotides which identify and encode MDDT. Embodiments of the invention also provide expression vectors, host cells, anti-bodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of MDDT.

TECHNICAL FIELD

[0001] The invention relates to novel nucleic acids, molecules for disease detection and treatment encoded by these nucleic acids, and to the use of these nucleic acids and proteins in the diagnosis, treatment, and prevention of cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, diseases treated with steroids and disorders caused by the metabolic response to treatment with steroids. The invention also relates to the assessment of the effects of exogenous compounds on the expression of nucleic acids and molecules for disease detection and treatment.

BACKGROUND OF THE INVENTION

[0002] It is estimated that only 2% of mammalian DNA encodes proteins, and only a small fraction of the genes that encode proteins are actually expressed in a particular cell at any time. The various types of cells in a multicellular organism differ dramatically both in structure and function, and the identity of a particular cell is conferred by its unique pattern of gene expression. In addition, different cell types express overlapping but distinctive sets of genes throughout development. Cell growth and proliferation, cell differentiation, the immune response, apoptosis, and other processes that contribute to organismal development and survival are governed by regulation of gene expression. An example of a mammalian apoptosis-associated protein is Diablo, which can bind to apoptosis inhibition proteins and antagonize their antiapoptotic effect, a function analogous to that of the proapoptotic Drosophila molecules, Grim, Reaper, and EID (Ekert, P. G. et al. (2001) J. Cell Biol. 152:483-90). Appropriate gene regulation also ensures that cells function efficiently by expressing only those genes whose functions are required at a given time. Factors that influence gene expression include extracellular signals that mediate cell-cell communication and coordinate the activities of different cell types. Gene expression is regulated at the level of DNA and RNA transcription, and at the level of mRNA translation.

[0003] Aberrant expression or mutations in genes and their products may cause, or increase susceptibility to, a variety of human diseases such as cancer and other cell proliferative disorders. The identification of these genes and their products is the basis of an ever-expanding effort to find markers for early detection of diseases and targets for their prevention and treatment. For example, cancer represents a type of cell proliferative disorder that affects nearly every tissue in the body. The development of cancer, or oncogenesis, is often correlated with the conversion of a normal gene into a cancer-causing gene, or oncogene, through abnormal expression or mutation. Oncoproteins, the products of oncogenes, include a variety of molecules that influence cell proliferation, such as growth factors, growth factor receptors, intracellular signal transducers, nuclear transcription factors, and cell-cycle control proteins. In contrast, tumor-suppressor genes are involved in inhibiting cell proliferation. Mutations which reduce or abrogate the function of tumor-suppressor genes result in aberrant cell proliferation and cancer. Thus a wide variety of genes and their products have been found that are associated with cell proliferative disorders such as cancer, but many more may exist that are yet to be discovered.

[0004] DNA-based arrays can provide an efficient, high-throughput method to examine gene expression and genetic variability. For example, SNPs, or single nucleotide polymorphisms, are the most common type of human genetic variation. DNA-based arrays can dramatically accelerate the discovery of SNPs in hundreds and even thousands of genes. Likewise, such arrays can be used for SNP genotyping in which DNA samples from individuals or populations are assayed for the presence of selected SNPs. These approaches will ultimately lead to the systematic identification of all genetic variations in the human genome and the correlation of certain genetic variations with disease susceptibility, responsiveness to drug treatments, and other medically relevant information. (See, for example, Wang, D. G. et al. (1998) Science 280:1077-1082.)

[0005] DNA-based arrays can also provide a simple way to explore the expression of a single polymorphic gene. When the expression of a single gene is explored, DNA-based arrays are employed to detect the expression of specific gene variants. For example, a p53 tumor suppressor gene array is used to determine whether individuals are carrying mutations that predispose them to cancer. A cytochrome p450 gene array is useful to determine whether individuals have one of a number of specific mutations that could result in increased drug metabolism, drug resistance or drug toxicity.

[0006] DNA-based array technology is especially important for the rapid analysis of global gene expression patterns. There is a growing awareness that gene expression is affected in a global fashion. In some cases the interactions may be expected, such as when the genes are part of the same signaling pathway. In other cases, such as when the genes participate in separate signaling pathways, the interactions may be totally unexpected. Therefore, DNA-based arrays can be used to investigate how genetic predisposition, disease, or therapeutic treatment affects the expression of a large number of genes. In this case, it is useful to develop a profile, or transcript image, of all the genes that are expressed and the levels at which they are expressed in that particular tissue. A profile generated from an individual or population affected with a certain disease or undergoing a particular therapy may be compared with a profile generated from a control individual or population. Such analysis does not require knowledge of gene function, as the expression profiles can be subjected to mathematical analyses which simply treat each gene as a marker. Furthermore, gene expression profiles may help dissect biological pathways by identifying all the genes expressed, for example, at a certain developmental stage, in a particular tissue, or in response to disease or treatment (See, for example, Lander, E. S. et al. (1996) Science 274:536-539.)

[0007] Certain genes are known to be associated with diseases because of their chromosomal location, such as the genes in the myotonic dystrophy (DM) regions of mouse and human. The mutation underlying DM has been localized to a gene encoding the DM-kinase protein, but another active gene, DMR-N9, is in close proximity to the DM-kinase gene (Jansen, G. et al. (1992) Nat. Genet. 1:261-266). DMR-N9 encodes a 650 amino acid protein that contains WD repeats, motifs found in cell signaling proteins. DMR-N9 is expressed in all neural tissues and in the testis, suggesting a role for DMR-N9 in the manifestation of mental and testicular symptoms in severe cases of DM (Jansen, G. et al. (1995) Hum. Mol. Genet. 4:843-852).

[0008] Other genes are identified based upon their expression patterns or association with disease syndromes. For example, autoantibodies to subcellular organelles are found in patients with systemic rheumatic diseases. A recently identified protein, golgin-67, belongs to a family of Golgi autoantigens having alpha-helical coiled-coil domains (Eystathioy, T. et al. (2000) J. Autoimmun. 14:179-187). The Stac gene was identified as a brain specific, developmentally regulated gene. The Stac protein contains an SH3 domain, and is thought to be involved in neuron-specific signal transduction (Suzuki, H. et al. (1996) Biochem. Biophys. Res. Commun. 229:902-909).

[0009] Evi-5 is a site of retroviral integration in AKXD T-cell lymphoma cells. Tumors with Evi-5 integrations have also been shown to possess other integration sites associated with T-cell disease. Retroviral disease induction occurs as a result of insertional mutagenesis of cellular proto-oncogenes or tumor suppressor genes. The AKXD recombinant inbred murine model is useful in the study of retrovirally-induced myeloid tumors, as well as T- and B-cell leukemias (Liao, X. et al. (1997) Oncogene 14:1023-1029). Lymphomas with integrations in Evi-5 may also possess integrations in Myc, in sites located near and activating Myc, or that synergize with Myc. This suggests a possible cooperation between Evi-5 with Myc in tumor induction, consistent with other observations showing that Myc is a frequent target of retroviral integration in mouse and rat T-cell lymphomas.

[0010] The contiguous gene deletion syndrome AMME is characterized by Alport syndrome, midface hypoplasia, mental retardation and elliptocytosis and is caused by a deletion in Xq22.3, comprising several genes including COL4A5, FACL4 and AMMECR1. AMMECR1, found in eukaryotic and prokaryotic cells, contains six exons and codes for a protein with a molecular mass of 35.5 kDa. Evidence suggests that this protein is a regulatory factor potentially involved in the development of AMME contiguous gene deletion syndrome. The mouse ortholog has 95.2% identity at the amino acid level with human AMMECR1 and maps to chromosome MmuXF1—F3 (Vitelli, F. et al. (1999) Genomics 55:335-340; Vitelli, F. et al. (2000) Cytogenet. Cell Genet. 88:259-263).

[0011] Sporulation-induced transcript 4 (SIT4) gene is a type 2A-related serine/threonine protein phosphatase which when overexpressed confers lithium tolerance in galactose medium to the budding yeast, Saccharomyces cerevisiae. It is a regulator of the cell cycle and is involved in nitrogen sensing, normal g1 cyclin expression, and bud initiation (Masuda, C. A. et al. (2000) J. Biol. Chem 275:30957-30961). The SIT4-associated proteins (SAPs), SAP155, SAP185, SAP190, and probably SAP4, associate with SIT4 in separate complexes. The SAPs are not functional in the absence of SIT4 and likewise, SIT4 is not functional in the absence of the SAPs. However, SAPs and SIt4 have distinct functions (Luke, M. M. et al. (1996) Mol. Cell. Biol. 16:2744-2755). C11 or f23 is a human ortholog of the yeast SAP family. C11 or f23 has been mapped to the 400-kb region of the IDDM4 locus of chromosome 11q13, a region involved in type 1 diabetes (Twells, R. C. et al. (2001) Genomics 72:231-242).

[0012] Dendritic cells are antigen-presenting cells that play a major role in the initial phases of the immune response. Dendritic cells located in peripheral tissues are generally immature and exhibit a strong capacity to capture surrounding antigens whereas they exhibit limited T cell activation capacity. Reciprocally, mature dendritic cells found in lymphoid organs exhibit a strong capacity to activate T cells but have lost most of their ability to pick up new antigens. Dendritic cells migrating out of transplanted organ play a major role in the induction of graft rejection. Therefore, genes that are modulated during the maturation of dendritic cells represent potential targets for drugs aimed at limiting the rejection of transplanted organs.

[0013] Rho-family GTPases are critical mediators of dendritic growth and remodeling. Three of these Rho GTPases, RhoA, Rac1 and Cdc42 (cell division cycle 42), regulate distinct aspects of dendritic development, such as dendrite initiation, dendrite growth, dendrite branching, and spine formation. In cortical neurons, Rho-family GTPases play a central role in determining the number of primary dendrites in both pyramidal and non-pyramidal neurons. Research suggests that Rac1 is an important effector of dendrite initiation and that a common effector of Rac 1 and Cdc42 mediates dendrite initiation. Suggested effectors include the p21-activated kinase (PAK) family of serine threonine kinases and LIM-domain-containing protein kinase, which can modulate actin dynamics by phosphorylation of cofilin.

[0014] Rho-family GTPases also can influence large-scale dendritic remodeling. Many neurons in the cortex initially acquire a pyramidal morphology and undergo a developmentally-regulated transformation into non-pyramidal neurons. This transformation involves the withdrawal of the apical dendrite and the extension of new primary dendrites, and is inhibited by expression of dominant-negative Cdc42 and, to a lesser extent, by dominant-negative Rac1. This inhibition suggests that the acquisition of cell-type-specific dendritic morphologies is under the control of Rac1 and Cdc42 signaling Redmond, L. and Ghosh, A. (2001) Curr. Opin. Neurobiol. 11:111-117).

[0015] ADP-ribosylation factors (ARFs) are small guanine-nucleotide-binding proteins that regulate membrane traffic and organelle structure in eukaryotic cells. In general, the inactive GDP-bound form of ARF is soluble, although it can associate weakly with membranes, whereas the active GTP-bound form binds tightly to the membrane. ARFs function on membrane surfaces where they encounter their effectors and regulators, the guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). ARF effectors include lipid-modifying enzymes and cytosolic coat complexes (such as COPI) that are recruited onto membranes by ARF-GTP. Hence, ARF activation leads to changes in both the lipid and protein composition of the membrane on which it is localized; changes which in turn result in modulation of membrane structure and function.

[0016] ARF proteins are highly conserved and have been found in all eukaryotic organisms examined. Mammalian ARF proteins are divided into three classes: Class I (ARF1-ARF3), Class II (ARF4 and ARF5) and Class m (ARF6). Class I ARFs are involved in trafficking in the ER-Golgi and endosomal systems, and their functions have been extensively studied. ARF1 binding to endosomal membranes is regulated by endosomal pH, which explains the pH dependence of COPI binding to endosomes. The Class m ARF, ARF6, functions exclusively in the endosomal-plasma membrane systerm. ARF6 is involved in endosomal recycling to the plasma membrane (PM), in regulated secretion, and in coordinating actin cytoskeleton changes at the PM. ARF6 is present at the apical surface of Madin Darby Canine Kidney (MDCK) epithelial cells, where it plays a role in modulating clathrin endocytosis. ARF6 has also been implicated in Fc-mediated phagocytosis in macrophages and in insulin stimulation of adipsin secretion and Glut4 translocation. By contrast, virtually nothing is known about the functions of the class II ARFs (Donaldson, J. D. and Jackson, C. L. (2000) Curr. Opin. Cell Biol. 12:475-482).

[0017] Expression Profiling

[0018] Microarrays are analytical tools used in bioanalysis. A microarray has a plurality of molecules spatially distributed over, and stably associated with, the surface of a solid support. Microarrays of polypeptides, polynucleotides, and/or antibodies have been developed and find use in a variety of applications, such as gene sequencing, monitoring gene expression, gene mapping, bacterial identification, drug discovery, and combinatorial chemistry.

[0019] One area in particular in which microarrays find use is in gene expression analysis. Array technology can provide a simple way to explore the expression of a single polymorphic gene or the expression profile of a large number of related or unrelated genes. When the expression of a single gene is examined, arrays are employed to detect the expression of a specific gene or its variants. When an expression profile is examined, arrays provide a platform for identifying genes that are tissue specific, are affected by a substance being tested in a toxicology assay, are part of a signaling cascade, carry out housekeeping functions, or are specifically related to a particular genetic predisposition, condition, disease, or disorder.

[0020] The potential application of gene expression profiling is particularly relevant to improving diagnosis, prognosis, and treatment of disease. For example, both the levels and sequences expressed in tissues from subjects with a cardiovascular disorder may be compared with the levels and sequences expressed in normal tissue.

[0021] Atherosclerosis and the associated coronary artery disease and cerebral stroke represent the most common cause of death in industrialized nations. Although certain key risk factors have been identified, a full molecular characterization that elucidates the causes and provides care for this complex disease has not been achieved. Molecular characterization of growth and regression of atherosclerotic vascular lesions requires identification of the genes that contribute to features of the lesion including growth, stability, dissolution, rupture and, most lethally, induction of occlusive vessel thrombus. Vascular lesions principally involve the vascular endothelium and the surrounding smooth muscle tissue.

[0022] Development of atherosclerosis is understood to be induced by the presence of circulating lipoprotein. Lipoproteins, such as the cholesterol-rich low-density lipoprotein (LDL), accumulate in the extracellular space of the vascular intima, and undergo modification. Oxidation of LDL (Ox-LDL) occurs most avidly in the sub-endothelial space where circulating antioxidant defenses are less effective. Mononuclear phagocytes enter the intima, differentiate into macrophages, and ingest modified lipids including Ox-LDL. During Ox-LDL uptake, macrophages produce cytokines (e.g. tumor necrosis factor α (TNF-α) and interleukin-1 (IL-1)) and growth factors (e.g. M-CSF, VEGF, and PDGF-BB) that elicit further cellular events that modulate atherogenesis such as smooth muscle cell proliferation and production of extracellular matrix by vascular endothelium Additionally, these macrophages may activate genes in endothelium and smooth muscle tissue involved in inflammation and tissue differentiation, including superoxide dismutatse (SOD), IL-8, and ICAM-1.

[0023] The vascular endothelium influences not only the three classically interacting components of hemostasis: the vessel, the blood platelets and the clotting and fibrinolytic systems of plasma, but also the natural sequelae: inflammation and tissue repair. Two principal modes of endothelial behavior may be differentiated, best defined as an anti- and a prothrombotic state. Under physiological conditions endothelium mediates vascular dilatation (formation of nitric oxide (NO), PGI₂, adenosine, hyperpolarising factor), prevents platelet adhesion and activation (production of adenosine, NO and PGI₂, removal of ADP), blocks thrombin formation (tissue factor pathway inhibitor, activation of protein C via thrombomodulin, activation of antithrombin III) and mitigates fibrin deposition (t- and scuplasminogen activator production). Adhesion and transmigration of inflammatory leukocytes are attenuated, e.g. by NO and IL-10, and oxygen radicals are efficiently scavenged (urate, NO, glutathione, SOD).

[0024] When the endothelium is physically disrupted or functionally perturbed by postischemic reperfusion, acute and chronic inflammation, atherosclerosis, diabetes and chronic arterial hypertension, then completely opposing actions pertain. This prothrombotic, proinflammatory state is characterised by vaso-constriction, platelet and leukocyte activation and adhesion (externalization, expression and upregulation of, for example, von Willebrand factor, platelet activating factor, P-selectin, ICAM-1, IL-8, MCP-1, and TNF-α), promotion of thrombin formation, coagulation and fibrin deposition at the vascular wall (expression of tissue factor, PAI-1, and phosphatidyl serine) and, in platelet-leukocyte coaggregates, additional inflammatory interactions via attachment of platelet CD40-ligand to endothelial, monocyte and B-cell CD40. Since thrombin formation and inflammatory stimulation set the stage for later tissue repair, complete abolition of such endothelial responses cannot be the goal of clinical interventions aimed at limiting procoagulatory, prothrombotic actions of a dysfunctional vascular endothelium (See, e.g., Becker et al. (2000) Z Kardiol 89:160-167.)

[0025] Tumor necrosis factor α is a pleiotropic cytokine that a mediates immune regulation and inflammatory responses. TNF-α related cytokines generate partially overlapping cellular responses, including differentiation, proliferation, nuclear factor-κb (NF-KB) activation, and cell death, by triggering the aggregation of receptor monomers (Smith, C. A. et al. (1994) Cell 76:959-962). The cellular responses triggered by TNF-α are initiated through its interaction with distinct cell surface receptors (TNFRs). NF-κB is a transcription factor with a pivotal role in inducing genes involved in physiological processes as well as in the response to injury and infection. Activation of NF-κB involves the phosphorylation and subsequent degradation of an inhibitory protein, IKB, and many of the proximal kinases and adaptor molecules involved in this process have been elucidated. Additionally, the NF-κB activation pathway from cell membrane to nucleus for IL-1 and TNF-α is now understood (Bowie and O'Neill (2000) Biochem Pharmacol 59:13-23).

[0026] Monocyte chemoattractant protein-1 (MCP-1) is known to play an important role in the pathogenesis of atherosclerosis by inducing monocyte migration. TNF-α treatment of human umbilical vein endothelial cells (HVECs) increased the cellular secretions of MCP-1 119-fold compared with untreated cells. Troglitazone, an insulin-sensitizing drug, significantly inhibited this TNF-α-induced increase in MCP-1 secretions and decreased mRNA levels (Ohta et al. (2000) Diabetes Res Clin Pract 48:171-176).

[0027] Treatment of confluent cultures of vascular smooth muscle cells (SMCs) with TNF-α suppresses the incorporation of [³H]proline into both collagenase-digestible proteins (CDP) and noncollagenous proteins (NCP). Such suppression by TNF-α is not observed in confluent bovine aortic endothelial cells and human fibroblastic IMR-90 cells. TNF-α decreases the relative proportion of collagen types IV and V suggesting that TNF-α modulates collagen synthesis by SMCs depending on their cell density and therefore may modify formation of atherosclerotic lesions (Hiraga et al. (2000) Life Sci 66:235-244).

[0028] Human coronary artery smooth muscle cells (CASMC) are primary cells isolated from the tunica media (an intermediate muscular layer) of a human coronary artery. Vascular smooth muscle cells are a model of increasing significance in vascular biology. It is now well known that besides their obvious role in the regulation of vascular tone and, consequently, oxygen supply to various tissues, their behavior under inflammatory conditions is an important factor in the development of atherosclerosis and restenosis.

[0029] Human aortic endothelial cells (HAECs) are primary cells derived from the endothelium of a human aorta. HAECs have been used as an experimental model for investigating in vitro the role of the endothelium in human vascular biology. Activation of the vascular endothelium is considered to be a central event in a wide range of both physiological and pathophysiological processes, such as vascular tone regulation, coagulation and thrombosis, atherosclerosis, and inflammation.

[0030] Thus, vascular tissue genes differentially expressed during treatment of CASMC and HAEC cell cultures with TNFa may reasonably be expected to be markers of the atherosclerotic process.

[0031] The potential application of gene expression profiling is particularly relevant to improving diagnosis, prognosis, and treatment of disease. For example, both the levels and sequences expressed in tissues from subjects with ovarian cancer may be compared with the levels and sequences expressed in normal tissue. Ovarian cancer is the leading cause of death from a gynecologic cancer. The majority of ovarian cancers are derived from epithelial cells, and 70% of patients with epithelial ovarian cancers present with late-stage disease. As a result, the long-term survival rate for individuals with this disease is very low. Identification of early-stage markers for ovarian cancer would significantly increase the survival rate. The molecular events that lead to ovarian cancer are poorly understood. Some of the known aberrations include mutation of p53 and microsatellite instability. Since gene expression patterns likely vary when normal ovary is compared to ovarian tumors, examination of gene expression in these tissues can identify possible markers for ovarian cancer.

[0032] Steroids are a class of lipid-soluble molecules, including cholesterol, bile acids, vitamin D, and hormones, that share a common four-ring structure based on cyclopentanoperhydrophenanthrene and that carry out a wide variety of functions. Cholesterol, for example, is a component of cell membranes that controls membrane fluidity. It is also a precursor for bile acids which solubilize lipids and facilitate absorption in the small intestine during digestion. Vitamin D regulates the absorption of calcium in the small intestine and controls the concentration of calcium in plasma. Steroid hormones, produced by the adrenal cortex, ovaries, and testes, include glucocorticoids, mineralocorticoids, androgens, and estrogens. They control various biological processes by binding to intracellular receptors that regulate transcription of specific genes in the nucleus. Glucocorticoids, for example, increase blood glucose concentrations by regulation of gluconeogenesis in the liver, increase blood concentrations of fatty acids by promoting lipolysis in adipose tissues, modulate sensitivity to catcholamines in the central nervous system, and reduce inflammation. The principal mineralocorticoid, aldosterone, is produced by the adrenal cortex and acts on cells of the distal tubules of the kidney to enhance sodium ion reabsorption. Androgens, produced by the interstitial cells of Leydig in the testis, include the male sex hormone testosterone, which triggers changes at puberty, the production of sperm and maintenance of secondary sexual characteristics. Female sex hormones, estrogen and progesterone, are produced by the ovaries and also by the placenta and adrenal cortex of the fetus during pregnancy. Estrogen regulates female reproductive processes and secondary sexual characteristics. Progesterone regulates changes in the endometrium during the menstrual cycle and pregnancy.

[0033] Steroid hormones are widely used for fertility control and in anti-inflammatory treatments for physical injuries and diseases such as arthritis, asthma, and auto-immune disorders. Progesterone, a naturally occurring progestin, is primarily used to treat amenorrhea, abnormal uterine bleeding, or as a contraceptive. Endogenous progesterone is responsible for inducing secretory activity in the endometrium of the estrogen-primed uterus in preparation for the implantation of a fertilized egg and for the maintenance of pregnancy. It is secreted from the corpus luteum in response to luteinizing hormone (LH). The primary contraceptive effect of exogenous progestins involves the suppression of the midcycle surge of LH. At the cellular level, progestins diffuse freely into target cells and bind to the progesterone receptor. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins slow the frequency of release of gonadotropin releasing hormone from the hypothalamus and blunt the pre-ovulatory LH surge, thereby preventing follicular maturation and ovulation. Progesterone has minimal estrogenic and androgenic activity. Progesterone is metabolized hepatically to pregnanediol and conjugated with glucuronic acid.

[0034] Medroxyprogesterone (MAH), also known as 6α-methyl-17-hydroxyprogesterone, is a synthetic progestin with a pharmacological activity about 15 times greater than progesterone. MAH is used for the treatment of renal and endometrial carcinomas, amenorrhea, abnormal uterine bleeding, and endometriosis associated with hormonal imbalance. MAH has a stimulatory effect on respiratory centers and has been used in cases of low blood oxygenation caused by sleep apnea, chronic obstructive pulmonary disease, or hypercapnia.

[0035] Danazol is a synthetic steroid derived from ethinyl testosterone. Danazol indirectly reduces estrogen production by lowering pituitary synthesis of follicle-stimulating hormone and LH. Danazol also binds to sex hormone receptors in target tissues, thereby exhibiting anabolic, antiestrognic, and weakly androgenic activity. Danazol does not possess any progestogenic activity, and does not suppress normal pituitary release of corticotropin or release of cortisol by the adrenal glands. Danazol is used in the treatment of endometriosis to relieve pain and inhibit endometrial cell growth. It is also used to treat fibrocystic breast disease and hereditary angioedema.

[0036] Corticosteroids are used to relieve inflammation and to suppress the immune response. They inhibit eosinophil, basophil, and airway epithelial cell function by regulation of cytokines that mediate the inflammatory response. They inhibit leukocyte infiltration at the site of inflammation, interfere in the function of mediators of the inflammatory response, and suppress the humoral immune response. Corticosteroids are used to treat allergies, asthma, arthritis, and skin conditions. Beclomethasone is a synthetic glucocorticoid that is used to treat steroid-dependent asthma, to relieve symptoms associated with allergic or nonallergic (vasomotor) rhinitis, or to prevent recurrent nasal polyps following surgical removal. The anti-inflammatory and vasoconstrictive effects of intranasal beclomethasone are 5000 times greater than those produced by hydrocortisone.

[0037] The anti-inflammatory actions of corticosteroids are thought to involve phospholipase A₂ inhibitory proteins, collectively called lipocortins. Lipocortins, in turn, control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of the precursor molecule arachidonic acid. Proposed mechanisms of action include decreased IgE synthesis, increased number of β-adrenergic receptors on leukocytes, and decreased arachidonic acid metabolism. During an immediate allergic reaction, such as in chronic bronchial asthma, allergens bridge the IgE antibodies on the surface of mast cells, which triggers these cells to release chemotactic substances. Mast cell influx and activation, therefore, is partially responsible for the inflammation and hyperirritability of the oral mucosa in asthmatic patients. This inflammation can be retarded by administration of corticosteroids. ENDFIELD

[0038] The potential application of gene expression profiling is particularly relevant to measuring the toxic response to potential therapeutic compounds and the metabolic response to therapeutic agents. Diseases treated with steroids and disorders caused by the metabolic response to treatment with steroids include adenomatosis, cholestasis, cirrhosis, hemangioma, Henoch-Schonlein purpura, hepatitis, hepatocellular and metastatic carcinomas, idiopathic thrombocytopenic purpura, porphyria, sarcoidosis, and Wilson disease. Response may be measured by comparing both the levels and sequences expressed in tissues from subjects exposed to or treated with steroid compounds such as medroxyprogesterone (MAH) or budesonide (bude) with the levels and sequences expressed in normal untreated tissue.

[0039] The effects upon liver metabolism and hormone clearance mechanisms are important to understand the pharmacodynamics of a drug. The human C3A cell line is a clonal derivative of HepG2/C3 (hepatoma cell line, isolated from a 15-year-old male with liver tumor), which was selected for strong contact inhibition of growth. The use of a clonal population enhances the reproducibility of the cells. C3A cells have many characteristics of primary human hepatocytes in culture: i) expression of insulin receptor and insulin-like growth factor II receptor; ii) secretion of a high ratio of serum albumin compared with α-fetoprotein iii) conversion of ammonia to urea and glutamine; iv) metabolism of aromatic amino acids; and v) proliferation in glucose-free and insulin-free medium. The C3A cell line is now well established as an in vitro model of the mature human liver (Mickelson et al. (1995) Hepatology 22:866-875; Nagendra et al. (1997) Am J Physiol 272:G408-G416).

[0040] There is a need in the art for new compositions, including nucleic acids and proteins, for the diagnosis, prevention, and treatment of cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, diseases treated with steroids and disorders caused by the metabolic response to treatment with steroids.

SUMMARY OF THE INVENTION

[0041] Various embodiments of the invention provide purified polypeptides, molecules for disease detection and treatment, referred to collectively as “MDDT” and individually as “MDDT-1,” “MDDT-2,” “MDDT-3,” “MDDT-4,” “MDDT-5,” “MDDT-6,” “MDDT-7,” “MDDT-8,” “MDDT-9,” “MDDT-10,” “MDDT-11,” “MDDT-12,” “MDDT-13,” “MDDT-14,” “MDDT-15,” “MDDT-16,” “MDDT-17,” “MDDT-18,” “MDDT-19,” “MDDT-20,” “MDDT-21,” “MDDT-22,” “MDDT-23,” “MDDT-24,” “MDDT-25,” “MDDT-26,” “MDDT-27,” “MDDT-28,” “MDDT-29,” “MDDT-30,” “MDDT-31,” “MDDT-32,” “MDDT-33,” “MDDT-34,” “MDDT-35,” “MDDT-36,” “MDDT-37,” “MDDT-38,” “MDDT-39,” “MDDT-40,” “MDDT-1,” “MDDT-42,” “MDDT43,” “MDDT-44,” “MDDT-45,” “MDDT-46,” “MDDT-47,” “MDDT-48,” “MDDT-49,” “MDDT-50,” “MDT-51,” “MDDT-52,” “MDDT-53,” “MDDT-54,” “MDDT-55,” and “MDDT-56” and methods for using these proteins and their encoding polynucleotides for the detection, diagnosis, and treatment of diseases and medical conditions. Embodiments also provide methods for utilizing the purified molecules for disease detection and treatment and/or their encoding polynucleotides for facilitating the drug discovery process, including determination of efficacy, dosage, toxicity, and pharmacology. Related embodiments provide methods for utilizing the purified molecules for disease detection and treatment and/or their encoding polynucleotides for investigating the pathogenesis of diseases and medical conditions.

[0042] An embodiment provides an isolated polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. Another embodiment provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO:1-56.

[0043] Still another embodiment provides an isolated polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. In another embodiment, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-56. In an alternative embodiment, the polynucleotide is selected from the group consisting of SEQ ID NO:57-112.

[0044] Still another embodiment provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. Another embodiment provides a cell transformed with the recombinant polynucleotide. Yet another embodiment provides a transgenic organism comprising the recombinant polynucleotide.

[0045] Another embodiment provides a method for producing a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

[0046] Yet another embodiment provides an isolated antibody which specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56.

[0047] Still yet another embodiment provides an isolated polynucleotide selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). In other embodiments, the polynucleotide can comprise at least about 20, 30, 40, 60, 80, or 100 contiguous nucleotides. Yet another embodiment provides a method for detecting a target polynucleotide in a sample, said target polynucleotide being selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex. In a related embodiment, the method can include detecting the amount of the hybridization complex. In still other embodiments, the probe can comprise at least about 20, 30, 40, 60, 80, or 100 contiguous nucleotides.

[0048] Still yet another embodiment provides a method for detecting a target polynucleotide in a sample, said target polynucleotide being selected from the group consisting of a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, c) a polynucleotide complementary to the polynucleotide of a), d) a polynucleotide complementary to the polynucleotide of b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof. In a related embodiment, the method can include detecting the amount of the amplified target polynucleotide or fragment thereof.

[0049] Another embodiment provides a composition comprising an effective amount of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and a pharmaceutically acceptable excipient. In one embodiment, the composition can comprise an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. Other embodiments provide a method of treating a disease or condition associated with decreased or abnormal expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0050] Yet another embodiment provides a method for screening a compound for effectiveness as an agonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. Another embodiment provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. Yet another embodiment provides a method of treating a disease or condition associated with decreased expression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0051] Still yet another embodiment provides a method for screening a compound for effectiveness as an antagonist of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. Another embodiment provides a composition comprising an antagonist compound identified by the method and a pharmaceutically acceptable excipient. Yet another embodiment provides a method of treating a disease or condition associated with overexpression of functional MDDT, comprising administering to a patient in need of such treatment the composition.

[0052] Another embodiment provides a method of screening for a compound that specifically binds to a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

[0053] Yet another embodiment provides a method of screening for a compound that modulates the activity of a polypeptide selected from the group consisting of a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical or at least about 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of the polypeptide in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide.

[0054] Still yet another embodiment provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, b) detecting altered expression of the target polynucleotide, and c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

[0055] Another embodiment provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, iii) a polynucleotide having a sequence complementary to i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide selected from the group consisting of i) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical or at least about 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, iii) a polynucleotide complementary to the polynucleotide of i), iv) a polynucleotide complementary to the polynucleotide of ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide can comprise a fragment of a polynucleotide selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

BRIEF DESCRIPTION OF THE TABLES

[0056] Table 1 summarizes the nomenclature for full length polynucleotide and polypeptide embodiments of the invention.

[0057] Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for polypeptide embodiments of the invention. The probability scores for the matches between each polypeptide and its homolog(s) are also shown.

[0058] Table 3 shows structural features of polypeptide embodiments, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of the polypeptides.

[0059] Table 4 lists the cDNA and/or genomic DNA fragments which were used to assemble polynucleotide embodiments, along with selected fragments of the polynucleotides.

[0060] Table 5 shows representative cDNA libraries for polynucleotide embodiments.

[0061] Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

[0062] Table 7 shows the tools, programs, and algorithms used to analyze polynucleotides and polypeptides, along with applicable descriptions, references, and threshold parameters.

[0063] Table 8 shows single nucleotide polymorphisms found in polynucleotide embodiments, along with allele frequencies in different human populations.

DESCRIPTION OF THE INVENTION

[0064] Before the present proteins, nucleic acids, and methods are described, it is understood that embodiments of the invention are not limited to the particular machines, instruments, materials, and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention.

[0065] As used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to “a host cell” includes a plurality of such host cells, and a reference to “an antibody” is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

[0066] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with various embodiments of the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

[0067] Definitions

[0068] “MDDT” refers to the amino acid sequences of substantially purified MDDT obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

[0069] The term “agonist” refers to a molecule which intensifies or mimics the biological activity of MDDT. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MDDT either by directly interacting with MDDT or by acting on components of the biological pathway in which MDDT participates.

[0070] An “allelic variant” is an alternative form of the gene encoding MDDT. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

[0071] “Altered” nucleic acid sequences encoding MDDT include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as MDDT or a polypeptide with at least one functional characteristic of MDDT. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding MDDT, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide encoding MDDT. The encoded protein may also be “altered,” and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent MDDT. Deliberate amino acid substitutions may be made on the basis of one or more similarities in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of MDDT is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

[0072] The terms “amino acid” and “amino acid sequence” can refer to an oligopeptide, a peptide, a polypeptide, or a protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. Where “amino acid sequence” is recited to refer to a sequence of a naturally occurring protein molecule, “amino acid sequence” and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

[0073] “Amplification” relates to the production of additional copies of a nucleic acid. Amplification may be carried out using polymerase chain reaction (PCR) technologies or other nucleic acid amplification technologies well known in the art.

[0074] The term “antagonist” refers to a molecule which inhibits or attenuates the biological activity of MDDT. Antagonists may include proteins such as antibodies, anticalins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of MDDT either by directly interacting with MDDT or by acting on components of the biological pathway in which MDDT participates.

[0075] The term “antibody” refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab′)₂, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind MDDT polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

[0076] The term “antigenic determinant” refers to that region of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

[0077] The term “aptamer” refers to a nucleic acid or oligonucleotide molecule that binds to a specific molecular target. Aptamers are derived from an in vitro evolutionary process (e.g., SELEX (Systematic Evolution of Ligands by EXponential Enrichment), described in U.S. Pat. No. 5,270,163), which selects for target-specific aptamer sequences from large combinatorial libraries. Aptamer compositions may be double-stranded or single-stranded, and may include deoxyribonucleotides, ribonucleotides, nucleotide derivatives, or other nucleotide-like molecules. The nucleotide components of an aptamer may have modified sugar groups (e.g., the 2′-OH group of a ribonucleotide may be replaced by 2′-F or 2′-NH₂), which may improve a desired property, e.g., resistance to nucleases or longer lifetime in blood. Aptamers may be conjugated to other molecules, e.g., a high molecular weight carrier to slow clearance of the aptamer from the circulatory system. Aptamers may be specifically cross-linked to their cognate ligands, e.g., by photo-activation of a cross-linker (Brody, E. N. and L. Gold (2000) J. Biotechnol. 74:5-13).

[0078] The term “intramer” refers to an aptamer which is expressed in vivo. For example, a vaccinia virus-based RNA expression system has been used to express specific RNA aptamers at high levels in the cytoplasm of leukocytes (Blind, M. et al. (1999) Proc. Natl. Acad. Sci. USA 96:3606-3610).

[0079] The term “spiegelmer” refers to an aptamer which includes L-DNA, L-RNA, or other left-handed nucleotide derivatives or nucleotide-like molecules. Aptamers containing left-handed nucleotides are resistant to degradation by naturally occurring enzymes, which normally act on substrates containing right-handed nucleotides.

[0080] The term “antisense” refers to any composition capable of base-pairing with the “sense” (coding) strand of a polynucleotide having a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2′-methoxyethyl sugars or 2′-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2′-deoxyuracil, or 7-deaza-2′-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation “negative” or “minus” can refer to the antisense strand, and the designation “positive” or “plus” can refer to the sense strand of a reference DNA molecule.

[0081] The term “biologically active” refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, “immunologically active” or “immunogenic” refers to the capability of the natural, recombinant, or synthetic MDDT, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

[0082] “Complementary” describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5′-AGT-3′ pairs with its complement, 3′-TCA-5′.

[0083] A “composition comprising a given polynucleotide” and a “composition comprising a given polypeptide” can refer to any composition containing the given polynucleotide or polypeptide. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotides encoding MDDT or fragments of MDDT may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

[0084] “Consensus sequence” refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems, Foster City Calif.) in the 5′ and/or the 3′ direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison Wis.) or Phrap (University of Washington, Seattle Wash.). Some sequences have been both extended and assembled to produce the consensus sequence.

[0085] “Conservative amino acid substitutions” are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions. Original Residue Conservative Substitution Ala Gly, Ser Arg His, Lys Asn Asp, Gln, His Asp Asn, Glu Cys Ala, Ser Gln Asn, Glu, His Glu Asp, Gln, His Gly Ala His Asn, Arg, Gln, Glu Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu, Ile Phe His, Met, Leu, Trp, Tyr Ser Cys, Thr Thr Ser, Val Trp Phe, Tyr Tyr His, Phe, Trp Val Ile, Leu, Thr

[0086] Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

[0087] A “deletion” refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

[0088] The term “derivative” refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

[0089] A “detectable label” refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

[0090] “Differential expression” refers to increased or upregulated; or decreased, downregulated, or absent gene or protein expression, determined by comparing at least two different samples. Such comparisons may be carried out between, for example, a treated and an untreated sample, or a diseased and a normal sample.

[0091] “Exon shuffling” refers to the recombination of different coding regions (exons). Since an exon may represent a structural or functional domain of the encoded protein, new proteins may be assembled through the novel reassortment of stable substructures, thus allowing acceleration of the evolution of new protein functions.

[0092] A “fragment” is a unique portion of MDDT or a polynucleotide encoding MDDT which can be identical in sequence to, but shorter in length than, the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from about 5 to about 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

[0093] A fragment of SEQ ID NO:57-112 can comprise a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:57-112, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:57-112 can be employed in one or more embodiments of methods of the invention, for example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:57-112 from related polynucleotides. The precise length of a fragment of SEQ ID NO:57-112 and the region of SEQ ID NO:57-112 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

[0094] A fragment of SEQ ID NO:1-56 is encoded by a fragment of SEQ ID NO:57-112. A fragment of SEQ ID NO:1-56 can comprise a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-56. For example, a fragment of SEQ ID NO:1-56 can be used as an immunogenic peptide for the development of antibodies that specifically recognize SEQ ID NO:1-56. The precise length of a fragment of SEQ ID NO:1-56 and the region of SEQ ID NO:1-56 to which the fragment corresponds can be determined based on the intended purpose for the fragment using one or more analytical methods described herein or otherwise known in the art.

[0095] A “full length” polynucleotide is one containing at least a translation initiation codon (e.g., methionine) followed by an open reading frame and a translation termination codon. A “full length” polynucleotide sequence encodes a “full length” polypeptide sequence.

[0096] “Homology” refers to sequence similarity or, interchangeably, sequence identity, between two or more polynucleotide sequences or two or more polypeptide sequences.

[0097] The terms “percent identity” and “% identity,” as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

[0098] Percent identity between polynucleotide sequences may be determined using one or more computer algorithms or programs known in the art or described herein. For example, percent identity can be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison Wis.). CLUSTAL V is described in Higgins, D. G. and P. M. Sharp (1989; CABIOS 5:151-153) and in Higgins, D. G. et al. (1992; CABIOS 8:189-191). For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and “diagonals saved”=4. The “weighted” residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polynucleotide sequences.

[0099] Alternatively, a suite of commonly used and freely available sequence comparison algorithms which can be used is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S. F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, Md., and on the Internet at http://www.ncbi.nlm.nih.gov/BLAST/. The BLAST software suite includes various sequence analysis programs including “blastn,” that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called “BLAST 2 Sequences” that is used for direct pairwise comparison of two nucleotide sequences. “BLAST 2 Sequences” can be accessed and used interactively at http://www.ncbi.nlmnih.gov/gorf/b12.html. The “BLAST 2 Sequences” tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

[0100] Matrix: BLOSUM62

[0101] Rewardfor match: 1

[0102] Penalty for mismatch: −2

[0103] Open Gap: 5 and Extension Gap: 2 penalties

[0104] Gap×drop-off 50

[0105] Expect: 10

[0106] Word Size: 11

[0107] Filter: on

[0108] Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0109] Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

[0110] The phrases “percent identity” and “% identity,” as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

[0111] Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and “diagonals saved”=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the “percent similarity” between aligned polypeptide sequence pairs.

[0112] Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the “BLAST 2 Sequences” tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

[0113] Matrix: BLOSUM62

[0114] Open Gap: 11 and Extension Gap: 1 penalties

[0115] Gap×drop-off: 50

[0116] Expect: 10

[0117] Word Size: 3

[0118] Filter: on

[0119] Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

[0120] “Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for chromosome replication, segregation and maintenance.

[0121] The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

[0122] “Hybridization” refers to the process by which a polynucleotide strand anneals with a complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e., binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68° C. in the presence of about 6×SSC, about 1% (w/v) SDS, and about 100 μg/ml sheared, denatured salmon sperm DNA.

[0123] Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5° C. to 20° C. lower than the thermal melting point (T_(m)) for the specific sequence at a defined ionic strength and pH. The T_(m) is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. An equation for calculating T_(m) and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.; specifically see volume 2, chapter 9.

[0124] High stringency conditions for hybridization between polynucleotides of the present invention include wash conditions of 68° C. in the presence of about 0.2×SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65° C., 60° C., 55° C., or 42° C. may be used. SSC concentration may be varied from about 0.1 to 2×SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 μg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

[0125] The term “hybridization complex” refers to a complex formed between two nucleic acids by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., Cot or Rot analysis) or formed between one nucleic acid present in solution and another nucleic acid immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

[0126] The words “insertion” and “addition” refer to changes in an amino acid or polynucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

[0127] “Immune response” can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytolines, chemoldnes, and other signaling molecules, which may affect cellular and systemic defense systems.

[0128] An “immunogenic fragment” is a polypeptide or oligopeptide fragment of MDDT which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term “immunogenic fragment” also includes any polypeptide or oligopeptide fragment of MDDT which is useful in any of the antibody production methods disclosed herein or known in the art.

[0129] The term “microarray” refers to an arrangement of a plurality of polynucleotides, polypeptides, antibodies, or other chemical compounds on a substrate.

[0130] The terms “element” and “array element” refer to a polynucleotide, polypeptide, antibody, or other chemical compound having a unique and defined position on a microarray.

[0131] The term “modulate” refers to a change in the activity of MDDT. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of MDDT.

[0132] The phrases “nucleic acid” and “nucleic acid sequence” refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

[0133] “Operably linked” refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

[0134] “Peptide nucleic acid” (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

[0135] “Post-translational modification” of an MDDT may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of MDDT.

[0136] “Probe” refers to nucleic acids encoding MDDT, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acids. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. “Primers” are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid, e.g., by the polymerase chain reaction (PCR).

[0137] Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

[0138] Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989; Molecular Cloning: A Laboratory Manual, 2^(nd) ed., vol. 1-3, Cold Spring Harbor Press, Plainview N.Y.), Ausubel, F. M. et al. (1999) Short Protocols in Molecular Biology, 4^(th) ed., John Wiley & Sons, New York N.Y.), and Innis, M. et al. (1990; PCR Protocols, A Guide to Methods and Applications, Academic Press, San Diego Calif.). PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge Mass.).

[0139] Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas Tex.) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 pmmer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge Mass.) allows the user to input a “mispriming library,” in which sequences to avoid as primer binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

[0140] A “recombinant nucleic acid” is a nucleic acid that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

[0141] Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be use to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

[0142] A “regulatory element” refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5′ and 3′ untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

[0143] “Reporter molecules” are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

[0144] An “RNA equivalent,” in reference to a DNA molecule, is composed of the same linear sequence of nucleotides as the reference DNA molecule with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0145] The term “sample” is used in its broadest sense. A sample suspected of containing MDDT, nucleic acids encoding MDDT, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

[0146] The terms “specific binding” and “specifically binding” refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope “A,” the presence of a polypeptide comprising the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

[0147] The term “substantially purified” refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably at least about 75% free, and most preferably at least about 90% free from other components with which they are naturally associated.

[0148] A “substitution” refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

[0149] “Substrate” refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

[0150] A “transcript image” or “expression profile” refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

[0151] “Transformation” describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term “transformed cells” includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

[0152] A “transgenic organism,” as used herein, is any organism, including but not limited to animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. In another embodiment, the nucleic acid can be introduced by infection with a recombinant viral vector, such as a lentiviral vector (Lois, C. et al. (2002) Science 295:868-872). The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

[0153] A “variant” of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length. A variant may be described as, for example, an “allelic” (as defined above), “splice,” “species,” or “polymorphic” variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotides that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass “single nucleotide polymorphisms” (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

[0154] A “variant” of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the “BLAST 2 Sequences” tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% or greater sequence identity over a certain defined length of one of the polypeptides.

[0155] The Invention

[0156] Various embodiments of the invention include new human molecules for disease detection and treatment (MDDT), the polynucleotides encoding MDDT, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, diseases treated with steroids and disorders caused by the metabolic response to treatment with steroids.

[0157] Table 1 summarizes the nomenclature for the full length polynucleotide and polypeptide embodiments of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown. Column 6 shows the Incyte ID numbers of physical, full length clones corresponding to polypeptide and polynucleotide embodiments. The full length clones encode polypeptides which have at least 95% sequence identity to the polypeptides shown in column 3.

[0158] Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for polypeptides of the invention. Column 3 shows the GenBank identification number (GenBank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability scores for the matches between each polypeptide and its homolog(s). Column 5 shows the annotation of the GenBank homolog(s) along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

[0159] Table 3 shows various structural features of the polypeptides of the invention. Columns 1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison Wis.). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

[0160] Together, Tables 2 and 3 summarize the properties of polypeptides of the invention, and these properties establish that the claimed polypeptides are molecules for disease detection and treatment. For example, SEQ ID NO:2 contains a potassium channel tetramerisation domain domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.)

[0161] In another example, SEQ ID NO:22 is 93% identical, from residue M1 to residue V1451, to mouse pecanex 1, which is the mouse homolog of Drosophila pecanex, a matemal-effect neurogenic protein (GenBank ID g665⁰377) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 0.0, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. Data from further BLAST analyses provide corroborative evidence that SEQ ID NO:22 is a pecanex 1 protein.

[0162] In another example, SEQ ID NO:31 is 33% identical, from residue R17 to residue G452, to Drosophila melanogaster Diablo (GenBank ID g7243777) as determined by the Basic Local Alignment Search-Tool (BLAST). (See Table 2.) The BLAST probability score is 2.9e-50, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:31 also contains a BTB-POZ protein interaction domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from BLIMPS and additional BLAST analyses provide further corroborative evidence that SEQ ID NO:31 is an apoptosis-associated protein.

[0163] In another example, SEQ ID NO:36 is 62% identical, from residue E84 to residue L370, to a human EVI-5 protein (GenBank ID g3093476) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.9e-90, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. Data from MOTIFS analysis provides further corroborative evidence that SEQ ID NO:36 is a protein with potential utility for disease detection or treatment.

[0164] In another example, SEQ ID NO:44 is 78% identical, from residue D224 to residue V838, and 98% identical, from residue M1 to residue W333, to human sporulation-induced transcript 4 (SIT4)-associated protein SAPLa (GenBank ID g11527201) as determined by the Basic Local Alignment Search Tool (BLAST). (See Table 2.) The BLAST probability score is 6.7e-250 for the first homologous section and 1.8e-171 for the second, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. Data from other BLAST analyses provide further corroborative evidence that SEQ ID NO:44 is a cycle cell phosphorylation sit4-associating protein (a protein which associates with the sit4 phosphatase in a cell cycle-dependent manner).

[0165] In another example, SEQ ID NO:47 is 52% identical, from residue F6 to residue L256, to a WD-40-containing Xenopus laevis protein that is upregulated by thyroid hormone (GenBank ID g1314316) as determined by the Basic Local Alignment Search Tool (BLAST). The BLAST probability score is 6.3e-73, which indicates the probability of obtaining the observed polypeptide sequence alignment by chance. SEQ ID NO:47 also contains a WD, G-beta repeat domain as determined by searching for statistically significant matches in the hidden Markov model (HMM)-based PFAM database of conserved protein family domains. (See Table 3.) Data from MOTIFS and PROFILESCAN analyses provide further corroborative evidence that SEQ ID NO:47 is a full-length human molecule for disease detection and treatment. SEQ ID NO:1, SEQ ID NO:3-21, SEQ ID NO:23-30, SEQ ID NO:32-35, SEQ ID NO:37-43, SEQ ID NO:45-46 and SEQ ID NO:48-56 were analyzed and annotated in a similar manner. The algorithms and parameters for the analysis of SEQ ID NO:1-56 are described in Table 7.

[0166] As shown in Table 4, the full length polynucleotide embodiments were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Column 1 lists the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:), the corresponding Incyte polynucleotide consensus sequence number (Incyte ID) for each polynucleotide of the invention, and the length of each polynucleotide sequence in basepairs. Column 2 shows the nucleotide start (5′) and stop (3′) positions of the cDNA and/or genomic sequences used to assemble the full length polynucleotide embodiments, and of fragments of the polynucleotides which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:57-112 or that distinguish between SEQ ID NO:57-112 and related polynucleotides.

[0167] The polynucleotide fragments described in Column 2 of Table 4 may refer specifically, for example, to Incyte cDNAs derived from tissue-specific cDNA libraries or from pooled cDNA libraries. Alternatively, the polynucleotide fragments described in column 2 may refer to GenBank cDNAs or ESTs which contributed to the assembly of the full length polynucleotides. In addition, the polynucleotide fragments described in column 2 may identify sequences derived from the ENSEMBL (The Sanger Centre, Cambridge, UK) database (i.e., those sequences including the designation “ENST”). Alternatively, the polynucleotide fragments described in column 2 may be derived from the NCBI RefSeq Nucleotide Sequence Records Database (ie., those sequences including the designation “NM” or “NT”) or the NCBI RefSeq Protein Sequence Records (i.e., those sequences including the designation “NP”). Alternatively, the polynucleotide fragments described in column 2 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an “exon stitching” algorithm. For example, a polynucleotide sequence identified as FL_XXXXXX_N_(1—)N_(2—)YYYYY_N_(3—)N₄ represents a “stitched” sequence in which XXXXXX is the identification number of the cluster of sequences to which the algorithm was applied, and YYYYY is the number of the prediction generated by the algorithm, and N_(1,2,3) . . . , if present, represent specific exons that may have been manually edited during analysis (See Example V). Alternatively, the polynucleotide fragments in colum 2 may refer to assemblages of exons brought together by an “exon-stretching” algorithm. For example, a polynucleotide sequence identified as FLXXXXXX_gAAAAA_gBBBB_(—1)_N is a “stretched” sequence, with XXXXXX being the Incyte project identification number, gAAAAA being the GenBank identification number of the human genomic sequence to which the “exon-stretching” algorithm was applied, gBBBBB being the GenBank identification number or NCBI RefSeq identification number of the nearest GenBank protein homolog, and N referring to specific exons (See Example V). In instances where a RefSeq sequence was used as a protein homolog for the “exon-stretching” algorithm, a RefSeq identifier (denoted by “NM,” “NP,” or “NT”) may be used in place of the GenBank identifier (ie., gBBBBB).

[0168] Alternatively, a prefix identifies component sequences that were hand-edited, predicted from genomic DNA sequences, or derived from a combination of sequence analysis methods. The following Table lists examples of component sequence prefixes and corresponding sequence analysis methods associated with the prefixes (see Example IV and Example V). Prefix Type of analysis and/or examples of programs GNN, Exon prediction from genomic sequences using, for GFG, example, GENSCAN (Stanford University, CA, USA) ENST or FGENES (Computer Genomics Group, The Sanger Centre, Cambridge, UK). GBI Hand-edited analysis of genomic sequences. FL Stitched or stretched genomic sequences (see Example V). INCY Full length transcript and exon prediction from mapping of EST sequences to the genome. Genomic location and EST composition data are combined to predict the exons and resulting transcript.

[0169] In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in Table 4 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

[0170] Table 5 shows the representative cDNA libraries for those full length polynucleotides which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotides. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

[0171] Table 8 shows single nucleotide polymorphisms (SNPs) found in polynucleotide embodiments, along with allele frequencies in different human populations. Columns 1 and 2 show the polynucleotide sequence identification number (SEQ ID NO:) and the corresponding Incyte project identification number (PID) for polynucleotides of the invention. Column 3 shows the Incyte identification number for the EST in which the SNP was detected (EST ID), and column 4 shows the identification number for the SNP(SNP ID). Column 5 shows the position within the EST sequence at which the SNP is located (EST SNP), and column 6 shows the position of the SNP within the full-length polynucleotide sequence (CB 1 SNP). Column 7 shows the allele found in the EST sequence. Columns 8 and 9 show the two alleles found at the SNP site. Column 10 shows the amino acid encoded by the codon including the SNP site, based upon the allele found in the EST. Columns 11-14 show the frequency of allele 1 in four different human populations. An entry of n/d (not detected) indicates that the frequency of allele 1 in the population was too low to be detected, while n/a (not available) indicates that the allele frequency was not determined for the population.

[0172] The invention also encompasses MDDT variants. A preferred MDDT variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the MDDT amino acid sequence, and which contains at least one functional or structural characteristic of MDDT.

[0173] Various embodiments also encompass polynucleotides which encode MDDT. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:57-112, which encodes MDDT. The polynucleotide sequences of SEQ ID NO:57-112, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

[0174] The invention also encompasses variants of a polynucleotide encoding MDDT. In particular, such a variant polynucleotide will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a polynucleotide encoding MDDT. A particular aspect of the invention encompasses a variant of a polynucleotide comprising a sequence selected from the group consisting of SEQ ID NO:57-112 which has at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:57-112. Any one of the polynucleotide variants described above can encode a polypeptide which contains at least one functional or structural characteristic of MDDT.

[0175] In addition, or in the alternative, a polynucleotide variant of the invention is a splice variant of a polynucleotide encoding MDDT. A splice variant may have portions which have significant sequence identity to a polynucleotide encoding MDDT, but will generally have a greater or lesser number of polynucleotides due to additions or deletions of blocks of sequence arising from alternate splicing of exons during mRNA processing. A splice variant may have less than about 70%, or alternatively less than about 60%, or alternatively less than about 50% polynucleotide sequence identity to a polynucleotide encoding MDDT over its entire length; however, portions of the splice variant will have at least about 70%, or alternatively at least about 85%, or alternatively at least about 95%, or alternatively 100% polynucleotide sequence identity to portions of the polynucleotide encoding MDDT. For example, a polynucleotide comprising a sequence of SEQ ID NO:112 and a polynucleotide comprising a sequence of SEQ ID NO:59 are splice variants of each other. Any one of the splice variants described above can encode a polypeptide which contains at least one functional or structural characteristic of MDDT.

[0176] It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding MDDT, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring MDDT, and all such variations are to be considered as being specifically disclosed.

[0177] Although polynucleotides which encode MDDT and its variants are generally capable of hybridizing to polynucleotides encoding naturally occurring MDDT under appropriately selected conditions of stringency, it may be advantageous to produce polynucleotides encoding MDDT or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding MDDT and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

[0178] The invention also encompasses production of polynucleotides which encode MDDT and MDDT derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic polynucleotide may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a polynucleotide encoding MDDT or any fragment thereof.

[0179] Embodiments of the invention can also include polynucleotides that are capable of hybridizing to the claimed polynucleotides, and, in particular, to those having the sequences shown in SEQ ID NO:57-112 and fragments thereof, under various conditions of stringency (Wahl, G. M. and S. L. Berger (1987) Methods Enzymol. 152:399407; Kimmel, A. R. (1987) Methods Enzymol. 152:507-511). Hybridization conditions, including annealing and wash conditions, are described in “Definitions.”

[0180] Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase L SEQUENASE (US Biochemical, Cleveland Ohio), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Biosciences, Piscataway N.J.), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Invitrogen, Carlsbad Calif.). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno Nev.), PTC200 thermal cycler (MJ Research, Watertown Mass.) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Amersham Biosciences), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art (Ausubel et al., supra, ch. 7; Meyers, R. A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York N.Y., pp. 856-853).

[0181] The nucleic acids encoding MDDT may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art (Parker, J. D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto Calif.) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth Minn.) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68° C. to 72° C.

[0182] When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5′ regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5′ non-transcribed regulatory regions.

[0183] Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

[0184] In another embodiment of the invention, polynucleotides or fragments thereof which encode MDDT may be cloned in recombinant DNA molecules that direct expression of MDDT, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other polynucleotides which encode substantially the same or a functionally equivalent polypeptides may be produced and used to express MDDT.

[0185] The polynucleotides of the invention can be engineered using methods generally known in the art in order to alter MDDT-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

[0186] The nucleotides of the present invention may be subjected t6 DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara Calif.; described in U.S. Pat. No. 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F. C. et al. (1999) Nat. Biotechnol. 17:259-264; and Crameri, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or improve the biological properties of MDDT, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of DNA shuffling and selection/screening. Thus, genetic diversity is created through “artificial” breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

[0187] In another embodiment, polynucleotides encoding MDDT may be synthesized, in whole or in part, using one or more chemical methods well known in the art (Caruthers, M. H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232). Alternatively, MDDT itself or a fragment thereof may be synthesized using chemical methods known in the art. For example, peptide synthesis can be performed using various solution-phase or solid-phase techniques (Creighton, T. (1984) Proteins. Structures and Molecular Properties, WH Freeman, New York N.Y., pp. 5560; Roberge, J. Y. et al. (1995) Science 269:202-204). Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of MDDT, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

[0188] The peptide may be substantially purified by preparative high performance liquid chromatography (Chiez, R. M. and F. Z. Regnier (1990) Methods Enzymol. 182:392-421). The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (Creighton, supra, pp. 28-53).

[0189] In order to express a biologically active MDDT, the polynucleotides encoding MDDT or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5′ and 3′ untranslated regions in the vector and in polynucleotides encoding MDDT. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of polynucleotides encoding MDDT. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where a polynucleotide sequence encoding MDDT and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

[0190] Methods which are well known to those skilled in the art may be used to construct expression vectors containing polynucleotides encoding MDDT and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination (Sambrook, J. et al. (1989) Molecular Cloning. A Laboratory Manual, Cold Spring Harbor Press, Plainview N.Y., ch. 4, 8, and 16-17; Ausubel et al., supra, ch. 1, 3, and 15).

[0191] A variety of expression vector/host systems may be utilized to contain and express polynucleotides encoding MDDT. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems (Sambrook, supra; Ausubel et al., supra; Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355). Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of polynucleotides to the targeted organ, tissue, or cell population (Di Nicola, M. et al. (1998) Cancer Gen. Ther. 5:350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90:6340-6344; Buller, R. M. et al. (1985) Nature 317:813-815; McGregor, D. P. et al. (1994) Mol. Imimunol. 31:219-226; Verma, I. M. and N. Somia (1997) Nature 389:239-242). The invention is not limited by the host cell employed.

[0192] In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotides encoding MDDT. For example, routine cloning, subcloning, and propagation of polynucleotides encoding MDDT can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla Calif.) or PSPORT1 plasmid (Invitrogen). Ligation of polynucleotides encoding MDDT into the vector's multiple cloning site disrupts the lacZ gene, allowing a calorimetric screening procedure for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence (Van Heeke, G. and S. M. Schuster (1989) J. Biol. Chem. 264:5503-5509). When large quantities of MDDT are needed, e.g. for the production of antibodies, vectors which direct high level expression of MDDT may be used. For example, vectors containing the strong, inducible SP6 or T7 bacteriophage promoter may be used.

[0193] Yeast expression systems may be used for production of MDDT. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign polynucleotide sequences into the host genome for stable propagation (Ausubel et al., supra; Bitter, G. A. et al. (1987) Methods Enzymol. 153:516-544; Scorer, C. A. et al. (1994) Bio/Technology 12:181-184).

[0194] Plant systems may also be used for expression of MDDT. Transcription of polynucleotides encoding MDDT may be driven by viral promoters, e.g., the ³⁵S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection (The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York N.Y., pp. 191-196).

[0195] In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, polynucleotides encoding MDDT may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses MDDT in host cells (Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

[0196] Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes (Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355).

[0197] For long term production of recombinant proteins in mammalian systems, stable expression of MDDT in cell lines is preferred. For example, polynucleotides encoding MDDT can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

[0198] Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in tk⁻ and apr⁻ cells, respectively (Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823). Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, dhfr confers resistance to methotrexate; neo confers resistance to the aminoglycosides neomycin and G418; and als and pat confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere arapin, F. et al. (1981) J. Mol. Biol. 150:1-14). Additional selectable genes have been described, e.g., trpB and hisD, which alter cellular requirements for metabolites (Hartman, S. C. and R. C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051). Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), P-glucuronidase and its substrate β-glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C. A. (1995) Methods Mol. Biol. 55:121-131).

[0199] Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding MDDT is inserted within a marker gene sequence, transformed cells containing polynucleotides encoding MDDT can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding MDDT under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

[0200] In general, host cells that contain the polynucleotide encoding MDDT and that express MDDT may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

[0201] Immunological methods for detecting and measuring the expression of MDDT using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on MDDT is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art (Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul Minn., Sect IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York N.Y.; Pound, J. D. (1998) Immunochemical Protocols, Humana Press, Totowa N.J.).

[0202] A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding MDDT include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide. Alternatively, polynucleotides encoding MDDT, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Biosciences, Promega (Madison Wis.), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

[0203] Host cells transformed with polynucleotides encoding MDDT may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode MDDT may be designed to contain signal sequences which direct secretion of MDDT through a prokaryotic or eukaryotic cell membrane.

[0204] In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted polynucleotides or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a “prepro” or “pro” form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HBEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas Va.) and may be chosen to ensure the correct modification and processing of the foreign protein.

[0205] In another embodiment of the invention, natural, modified, or recombinant polynucleotides encoding MDDT may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric MDDT protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of MDDT activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, c-myc, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, c-myc, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the MDDT encoding sequence and the heterologous protein sequence, so that MDDT may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel et al. (supra, ch. 10 and 16). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

[0206] In another embodiment, synthesis of radiolabeled MDDT may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, ³⁵S-methionine.

[0207] MDDT, fragments of MDDT, or variants of MDDT may be used to screen for compounds that specifically bind to MDDT. One or more test compounds may be screened for specific binding to MDDT. In various embodiments, 1, 2, 3, 4, 5, 10, 20, 50, 100, or 200 test compounds can be screened for specific binding to MDDT. Examples of test compounds can include antibodies, anticalins, oligonucleotides, proteins (e.g., ligands or receptors), or small molecules.

[0208] In related embodiments, variants of MDDT can be used to screen for binding of test compounds, such as antibodies, to MDDT, a variant of MDDT, or a combination of MDDT and/or one or more variants MDDT. In an embodiment, a variant of MDDT can be used to screen for compounds that bind to a variant of MDDT, but not to MDDT having the exact sequence of a sequence of SEQ ID NO:1-56. MDDT variants used to perform such screening can have a range of about 50% to about 99% sequence identity to MDDT, with various embodiments having 60%, 70%, 75%, 80%, 85%, 90%, and 95% sequence identity.

[0209] In an embodiment, a compound identified in a screen for specific binding to MDDT can be closely related to the natural ligand of MDDT, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner (Coligan, J. E. et al. (1991) Current Protocols in Immunology 1(2):Chapter 5). In another embodiment, the compound thus identified can be a natural ligand of a receptor MDDT (Howard, A. D. et al. (2001) Trends Pharmacol. Sci. 22: 132-140; Wise, A. et al. (2002) Drug Discovery Today 7:235-246).

[0210] In other embodiments, a compound identified in a screen for specific binding to MDDT can be closely related to the natural receptor to which MDDT binds, at least a fragment of the receptor, or a fragment of the receptor including all or a portion of the ligand binding site or binding pocket. For example, the compound may be a receptor for MDDT which is capable of propagating a signal, or a decoy receptor for MDDT which is not capable of propagating a signal (Ashkenazi, A. and V. M. Divit (1999) Curr. Opin. Cell Biol. 11:255-260; Mantovani, A. et al. (2001) Trends Immunol. 22:328-336). The compound can be rationally designed using known techniques. Examples of such techniques include those used to construct the compound etanercept (ENBREL; Immunex Corp., Seattle Wash.), which is efficacious for treating rheumatoid arthritis in humans. Etanercept is an engineered p75 tumor necrosis factor (TNF) receptor dimer linked to the Fc portion of human IgG1 (Taylor, P. C. et al. (2001) Curr. Opin. Immunol. 13:611-616).

[0211] In one embodiment, two or more antibodies having similar or, alternatively, different specificities can be screened for specific binding to MDDT, fragments of MDDT, or variants of MDDT. The binding specificity of the antibodies thus screened can thereby be selected to identify particular fragments or variants of MDDT. In one embodiment, an antibody can be selected such that its binding specificity allows for preferential identification of specific fragments or variants of MDDT. In another embodiment, an antibody can be selected such that its binding specificity allows for preferential diagnosis of a specific disease or condition having increased, decreased, or otherwise abnormal production of MDDT.

[0212] In an embodiment, anticalins can be screened for specific binding to MDDT, fragments of MDDT, or variants of MDDT. Anticalins are ligand-binding proteins that have been constructed based on a lipocalin scaffold (Weiss, G. A. and H. B. Lowman (2000) Chem. Biol. 7:R177-R184; Skerra, A. (2001) J. Biotechnol. 74:257-275). The protein architecture of lipocalins can include a beta-barrel having eight antiparallel beta-strands, which supports four loops at its open end. These loops form the natural ligand-binding site of the lipocalins, a site which can be re-engineered in vitro by amino acid substitutions to impart novel binding specificities. The amino acid substitutions can be made using methods known in the art or described herein, and can include conservative substitutions (e.g., substitutions that do not alter binding specificity) or substitutions that modestly, moderately, or significantly alter binding specificity.

[0213] In one embodiment, screening for compounds which specifically bind to, stimulate, or inhibit MDDT involves producing appropriate cells which express MDDT, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing MDDT or cell membrane fractions which contain MDDT are then contacted with a test compound and binding, stimulation, or inhibition of activity of either MDDT or the compound is analyzed.

[0214] An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with MDDT, either in solution or affixed to a solid support, and detecting the binding of MDDT to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support

[0215] An assay can be used to assess the ability of a compound to bind to its natural ligand and/or to inhibit the binding of its natural ligand to its natural receptors. Examples of such assays include radio-labeling assays such as those described in U.S. Pat. No. 5,914,236 and U.S. Pat. No. 6,372,724. In a related embodiment, one or more amino acid substitutions can be introduced into a polypeptide compound (such as a receptor) to improve or alter its ability to bind to its natural ligands (Matthews, D. J. and J. A. Wells. (1994) Chem. Biol. 1:25-30). In another related embodiment, one or more amino acid substitutions can be introduced into a polypeptide compound (such as a ligand) to improve or alter its ability to bind to its natural receptors (Cunningham, B. C. and J. A. Wells (1991) Proc. Natl. Acad. Sci. USA 88:3407-3411; Lowman, H. B. et al. (1991) J. Biol. Chem. 266:10982-10988).

[0216] MDDT, fragments of MDDT, or variants of MDDT may be used to screen for compounds that modulate the activity of MDDT. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for MDDT activity, wherein MDDT is combined with at least one test compound, and the activity of MDDT in the presence of a test compound is compared with the activity of MDDT in the absence of the test compound. A change in the activity of MDDT in the presence of the test compound is indicative of a compound that modulates the activity of MDDT. Alternatively, a test compound is combined with an in vitro or cell-free system comprising MDDT under conditions suitable for MDDT activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of MDDT may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

[0217] In another embodiment, polynucleotides encoding MDDT or their mammalian homologs may be “knocked out” in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease (see, e.g., U.S. Pat. No. 5,175,383 and U.S. Pat. No. 5,767,337). For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M. R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J. D. (1996) Clin. Invest. 97:1999-2002; Wagner, K. U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

[0218] Polynucleotides encoding MDDT may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J. A. et al. (1998) Science 282:1145-1147).

[0219] Polynucleotides encoding MDDT can also be used to create “knockin” humanized animals (pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding MDDT is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress MDDT, e.g., by secreting MDDT in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) Biotechnol. Annu. Rev. 4:55-74).

[0220] Therapeutics

[0221] Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of MDDT and molecules for disease detection and treatment. In particular, SEQ ID NO:110 shows co-expression with osteoporosis-relevant genes. In addition, examples of tissues expressing MDDT can be found in Table 6 and can also be found in Example XI. Therefore, MDDT appears to play a role in cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, diseases treated with steroids and disorders caused by the metabolic response to treatment with steroids. In the treatment of disorders associated with increased MDDT expression or activity, it is desirable to decrease the expression or activity of MDDT. In the treatment of disorders associated with decreased MDDT expression or activity, it is desirable to increase the expression or activity of MDDT.

[0222] Therefore, in one embodiment, MDDT or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCID), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helninthic infections, and trauma; a disease treated with a steroid and a disorder caused by the metabolic response to treatment with steroids, such as adenomatosis, cholestasis, cirrhosis, hemangioma, Henoch-Schonlein purpura, hepatitis, hepatocellular and metastatic carcinomas, idiopathic thrombocytopenic purpura, porphyria, sarcoidosis, and Wilson disease; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; and a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia. SEQ ID NO:2 can be used in the diagnosis and treatment of Tangier disease and SEQ ID NO: 5 can be used in the diagnosis and treatment of type II diabetes.

[0223] In another embodiment, a vector capable of expressing MDDT or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT including, but not limited to, those described above.

[0224] In a further embodiment, a composition comprising a substantially purified MDDT in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT including, but not limited to, those provided above.

[0225] In still another embodiment, an agonist which modulates the activity of MDDT may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of MDDT including, but not limited to, those listed above.

[0226] In a further embodiment, an antagonist of MDDT may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MDDT. Examples of such disorders include, but are not limited to, those cell proliferative, autoimmune/inflammatory, developmental, and neurological disorders, diseases treated with steroids and disorders caused by the metabolic response to treatment with steroids described above. In one aspect, an antibody which specifically binds MDDT may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express MDDT.

[0227] In an additional embodiment, a vector expressing the complement of the polynucleotide encoding MDDT may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of MDDT including, but not limited to, those described above.

[0228] In other embodiments, any protein, agonist, antagonist, antibody, complementary sequence, or vector embodiments may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

[0229] An antagonist of MDDT may be produced using methods which are generally known in the art. In particular, purified MDDT may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind MDDT. Antibodies to MDDT may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use. Single chain antibodies (e.g., from camels or llamas) may be potent enzyme inhibitors and may have advantages in the design of peptide mimetics, and in the development of immuno-adsorbents and biosensors (Muyldermans, S. (2001) J. Biotechnol. 74:277-302).

[0230] For the production of antibodies, various hosts including goats, rabbits, rats, mice, camels, dromedaries, llamas, humans, and others may be immunized by injection with MDDT or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

[0231] It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to MDDT have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of MDDT amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

[0232] Monoclonal antibodies to MDDT may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; Cole, S. P. et al. (1984) Mol. Cell Biol. 62:109-120).

[0233] In addition, techniques developed for the production of “chimeric antibodies,” such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used (Morrison, S. L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M. S. et al. (1984) Nature 312:604-608; Takeda, S. et al. (1985) Nature 314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce MDDT-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton, D. R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137).

[0234] Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

[0235] Antibody fragments which contain specific binding sites for MDDT may also be generated. For example, such fragments include, but are not limited to, F(ab)₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab)₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W. D. et al. (1989) Science 246:1275-1281).

[0236] Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between MDDT and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering MDDT epitopes is generally used, but a competitive binding assay may also be employed (Pound, supra).

[0237] Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for MDDT. Affinity is expressed as an association constant, K_(a), which is defined as the molar concentration of MDDT-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The K_(a) determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple MDDT epitopes, represents the average affinity, or avidity, of the antibodies for MDDT. The K_(a) determined for a preparation of monoclonal antibodies, which are monospecific for a particular MDDT epitope, represents a true measure of affinity. High-affinity antibody preparations with K_(a) ranging from about 10⁹ to 10¹² L/mole are preferred for use in immunoassays in which the MDDT-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with K_(a) ranging from about 10⁶ to 10⁷ L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of MDDT, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington D.C.; Liddell, J. E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York N.Y.).

[0238] The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of MDDT-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available (Catty, supra; Coligan et al., supra).

[0239] In another embodiment of the invention, polynucleotides encoding MDDT, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding MDDT. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding MDDT (Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press, Totawa N.J.).

[0240] In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein (Slater, J. E. et al. (1998) J. Allergy Clin. Immunol. 102:469475; Scanlon, K. J. et al. (1995) 9:1288-1296). Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors (Miller, A. D. (1990) Blood 76:271; Ausubel et al., supra; Uckert, W. and W. Walther (1994) Pharmacol. Ther. 63:323-347). Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art (Rossi, J. J. (1995) Br. Med. Bull. 51:217-225; Boado, R. J. et al. (1998) J. Pharm. Sci. 87:1308-1315; Morris, M. C. et al. (1997) Nucleic Acids Res. 25:2730-2736).

[0241] In another embodiment of the invention, polynucleotides encoding MDDT may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) Science 288:669-672), severe combined immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R. M. et al. (1995) Science 270:475480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R. G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, ILG. et al. (1995) Hum. Gene Therapy 6:667-703), thalassamias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R. G. (1995) Science 270:404410; Verma, I. M. and N. Somia (1997) Nature 389:239-242)), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparuin and Trypanosoma cruzz). In the case where a genetic deficiency in MDDT expression or regulation causes disease, the expression of MDDT from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

[0242] In a further embodiment of the invention, diseases or disorders caused by deficiencies in MDDT are treated by constructing mammalian expression vectors encoding MDDT and introducing these vectors by mechanical means into MDDT-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R. A. and W. F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J.-L. and H. Recipon (1998) Curr. Opin. Biotechnol. 9:445-450).

[0243] Expression vectors that may be effective for the expression of MDDT include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX, PCR2-TOPOTA vectors (Invitrogen, Carlsbad Calif.), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla Calif.), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto Calif.). MDDT may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or β-actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F. M. V. and H. M. Blau (1998) Curr. Opin. Biotechnol. 9:451456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter, or the RU486/mifepristone inducible promoter (Rossi, F. M. V. and H. M. Blau, supra)), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding MDDT from a normal individual.

[0244] Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F. L. and A. J. Eb (1973) Virology 52:456-467), or by electroporation (Neumann, E. et al. (1982) EMBO J. 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

[0245] In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to MDDT expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding MDDT under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus cis-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) Proc. Natl. Acad. Sci. USA 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) J. Virol. 61:1647-1650; Bender, M. A. et al. (1987) J. Virol. 61:1639-1646; Adam, M. A. and A. D. Miller (1988) J. Virol. 62:3802-3806; Dull, T. et al. (1998) J. Virol. 72:8463-8471; Zufferey, R. et al. (1998) J. Virol. 72:9873-9880). U.S. Pat. No. 5,910,434 to Rigg (“Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant”) discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference. Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4⁺ T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) J. Virol. 71:7020-7029; Bauer, G. et al. (1997) Blood 89:2259-2267; Bonyhadi, M. L. (1997) J. Virol. 71:4707-4716; Ranga, U. et al. (1998) Proc. Natl. Acad. Sci. USA 95:1201-1206; Su, L. (1997) Blood 89:2283-2290).

[0246] In an embodiment, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding MDDT to cells which have one or more genetic abnormalities with respect to the expression of MDDT. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas (Csete, M. E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Pat. No. 5,707,618 to Armentano (“Adenovirus vectors for gene therapy”), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P. A. et al. (1999; Annu. Rev. Nutr. 19:511-544) and Verma, I. M. and N. Somia (1997; Nature 18:389:239-242).

[0247] In another embodiment, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding MDDT to target cells which have one or more genetic abnormalities with respect to the expression of MDDT. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing MDDT to cells of the central nervous system, for which HSV has a tropism The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Pat. No. 5,804,413 to DeLuca (“Herpes simplex virus strains for gene transfer”), which is hereby incorporated by reference. U.S. Pat. No. 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W. F. et al. (1999; J. Virol. 73:519-532) and Xu, H. et al. (1994; Dev. Biol. 163:152-161). The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

[0248] In another embodiment, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding MDDT to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for MDDT into the alphavirus genome in place of the capsid-coding region results in the production of a large number of MDDT-coding RNAs and the synthesis of high levels of MDDT in vector transduced cells. While alphavirus infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S. A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of MDDT into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

[0249] Oligonucleotides derived from the transcription initiation site, e.g., between about positions −10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J. E. et al. (1994) in Huber, B. E. and B. L Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco N.Y., pp. 163-177). A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

[0250] Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of RNA molecules encoding MDDT.

[0251] Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

[0252] Complementary ribonucleic acid molecules and ribozymes may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA molecules encoding MDDT. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

[0253] RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5′ and/or 3′ ends of the molecule, or the use of phosphorothioate or 2′ O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

[0254] An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding MDDT. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, tmmscription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased MDDT expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding MDDT may be therapeutically useful, and in the treatment of disorders associated with decreased MDDT expression or activity, a compound which specifically promotes expression of the polynucleotide encoding MDDT may be therapeutically useful.

[0255] At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding MDDT is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an in vitro cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding MDDT are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding MDDT. The amount of hybridization may be quantified, thus forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Pat. No. 5,932,435; Arndt, G. M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M. L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruice, T. W. et al. (1997) U.S. Pat. No. 5,686,242; Bruice, T. W. et al. (2000) U.S. Pat. No. 6,022,691).

[0256] Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art (Goldman, C. K. et al. (1997) Nat. Biotechnol. 15:462-466).

[0257] Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

[0258] An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton Pa.). Such compositions may consist of MDDT, antibodies to MDDT, and mimetics, agonists, antagonists, or inhibitors of MDDT.

[0259] The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

[0260] Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins), recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J. S. et al., U.S. Pat. No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

[0261] Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

[0262] Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising MDDT or fragments thereof. For example, liposome preparations containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, MDDT or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S. R. et al. (1999) Science 285:1569-1572).

[0263] For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

[0264] A therapeutically effective dose refers to that amount of active ingredient, for example MDDT or fragments thereof, antibodies of MDDT, and agonists, antagonists or inhibitors of MDDT, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED₅₀ (the dose therapeutically effective in 50% of the population) or LD₅₀ (the dose lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the LD₅₀/ED₅₀ ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED₅₀ with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

[0265] The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

[0266] Normal dosage amounts may vary from about 0.1 μg to 100,000 μg, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

[0267] Diagnostics

[0268] In another embodiment, antibodies which specifically bind MDDT may be used for the diagnosis of disorders characterized by expression of MDDT, or in assays to monitor patients being treated with MDDT or agonists, antagonists, or inhibitors of MDDT. Antibodies useful for diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for MDDT include methods which utilize the antibody and a label to detect MDDT in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may be used.

[0269] A variety of protocols for measuring MDDT, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of MDDT expression. Normal or standard values for MDDT expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to MDDT under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of MDDT expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

[0270] In another embodiment of the invention, polynucleotides encoding MDDT may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotides, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of MDDT may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of MDDT, and to monitor regulation of MDDT levels during therapeutic intervention.

[0271] In one aspect, hybridization with PCR probes which are capable of detecting polynucleotides, including genomic sequences, encoding MDDT or closely related molecules may be used to identify nucleic acid sequences which encode MDDT. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5′ regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding MDDT, allelic variants, or related sequences.

[0272] Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the MDDT encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:57-112 or from genomic sequences including promoters, enhancers, and introns of the MDDT gene.

[0273] Means for producing specific hybridization probes for polynucleotides encoding MDDT include the cloning of polynucleotides encoding MDDT or MDDT derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ³²P or ³⁵S, or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

[0274] Polynucleotides encoding MDDT may be used for the diagnosis of disorders associated with expression of MDDT. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and heliminthic infections, and trauma; a disease treated with a steroid and a disorder caused by the metabolic response to treatment with steroids, such as adenomatosis, cholestasis, cirrhosis, hemangioma, Henoch-Schonlein purpura, hepatitis, hepatocellular and metastatic carcinomas, idiopathic thrombocytopenic purpura, porphyria, sarcoidosis, and Wilson disease; a developmental disorder such as renal tubular acidosis, anemia, Cushing's syndrome, achondroplastic dwarfism, Duchenne and Becker muscular dystrophy, epilepsy, gonadal dysgenesis, WAGR syndrome (Wilms' tumor, aniridia, genitourinary abnormalities, and mental retardation), Smith-Magenis syndrome, myelodysplastic syndrome, hereditary mucoepithelial dysplasia, hereditary keratodermas, hereditary neuropathies such as Charcot-Marie-Tooth disease and neurofibromatosis, hypothyroidism, hydrocephalus, seizure disorders such as Syndenham's chorea and cerebral palsy, spina bifida, anencephaly, craniorachischisis, congenital glaucoma, cataract, and sensorineural hearing loss; and a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmn-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system including Down syndrome, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathesia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia. SEQ ID NO:58, encoding SEQ ID NO:2, and SEQ ID NO:2 can be used in the diagnosis and treatment of Tangier disease and SEQ ID NO:61, encoding SEQ ID NO:5, and SEQ ID NO:5 can be used in the diagnosis and treatment of type II diabetes. Polynucleotides encoding MDDT may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered MDDT expression. Such qualitative or quantitative methods are well known in the art.

[0275] In a particular aspect, polynucleotides encoding MDDT may be used in assays that detect the presence of associated disorders, particularly those mentioned above. Polynucleotides complementary to sequences encoding MDDT may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of polynucleotides encoding MDDT in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

[0276] In order to provide a basis for the diagnosis of a disorder associated with expression of MDDT, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding MDDT, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

[0277] Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

[0278] With respect to cancer, the presence of an abnormal amount of transcript (either under- or overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier, thereby preventing the development or further progression of the cancer.

[0279] Additional diagnostic uses for oligonucleotides designed from the sequences encoding MDDT may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding MDDT, or a fragment of a polynucleotide complementary to the polynucleotide encoding MDDT, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

[0280] In a particular aspect, oligonucleotide primers derived from polynucleotides encoding MDDT may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from polynucleotides encoding MDDT are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In FSCCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed in silico SNP (is SNP), are capable of identifying polymorphisms by comparing the sequence of individual overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego Calif.).

[0281] SNPs may be used to study the genetic basis of human disease. For example, at least 16 common SNPs have been associated with non-insulin-dependent diabetes mellitus. SNPs are also useful for examining differences in disease outcomes in monogenic disorders, such as cystic fibrosis, sickle cell anemia, or chronic granulomatous disease. For example, variants in the mannose-binding lectin, MBL2, have been shown to be correlated with deleterious pulmonary outcomes in cystic fibrosis. SNPs also have utility in pharmacogenomics, the identification of genetic variants that influence a patient's response to a drug, such as life-threatening toxicity. For example, a variation in N-acetyl transferase is associated with a high incidence of peripheral neuropathy in response to the anti-tuberculosis drug isoniazid, while a variation in the core promoter of the ALOX5 gene results in diminished clinical response to treatment with an anti-asthma drug that targets the 5-lipoxygenase pathway. Analysis of the distribution of SNPs in different populations is useful for investigating genetic drift, mutation, recombination, and selection, as well as for tracing the origins of populations and their migrations (Taylor, J. G. et al. (2001) Trends Mol. Med. 7:507-512; Kwok, P.-Y. and Z. Gu (1999) Mol. Med. Today 5:538-543; Nowotny, P. et al. (2001) Curr. Opin. Neurobiol. 11:637-641).

[0282] Methods which may also be used to quantify the expression of MDDT include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves (Melby, P. C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem 212:229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or calorimetric response gives rapid quantitation.

[0283] In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotides described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

[0284] In another embodiment, MDDT, fragments of MDDT, or antibodies specific for MDDT may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

[0285] A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time (Seilhamer et al., “Comparative Gene Transcript Analysis,” U.S. Pat. No. 5,840,484; hereby expressly incorporated by reference herein). Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

[0286] Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

[0287] Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurning environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E. F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N. L. Anderson (2000) Toxicol. Lett. 112-113:467471). Ifa test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity (see, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released Feb. 29, 2000, available at http://www.niehs.nih.gov/oc/news/toxchip.htm). Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

[0288] In an embodiment, the toxicity of a test compound can be assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

[0289] Another embodiment relates to the use of the polypeptides disclosed herein to analyze the proteome of a tissue or cell type. The term proteome refers to the global pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, supra). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of interest. In some cases, further sequence data may be obtained for definitive protein identification.

[0290] A proteomic profile may also be generated using antibodies specific for MDDT to quantify the levels of MDDT expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueling, A. et al. (1999) Anal. Biochem. 270:103-111; Mendoze, L. G. et al. (1999) Biotechniques 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

[0291] Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N. L. and J. Seilhamer (1997) Electrophoresis 18:533-537), so proteome toxicant signatures may be useful in the analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

[0292] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

[0293] In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

[0294] Microarrays may be prepared, used, and analyzed using methods known in the art (Brennan, T. M. et al. (1995) U.S. Pat. No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R. A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; Heller, M. J. et al. (1997) U.S. Pat. No. 5,605,662). Various types of microarrays are well known and thoroughly described in Schena, M., ed. (1999; DNA Microarrays: A Practical Approach, Oxford University Press, London).

[0295] In another embodiment of the invention, nucleic acid sequences encoding MDDT may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries (Harrington, J. J. et al. (1997) Nat. Genet. 15:345-355; Price, C. M. (1993) Blood Rev. 7:127-134; Trask, B. J. (1991) Trends Genet. 7:149-154). Once mapped, the nucleic acid sequences may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP) (Lander, E. S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357).

[0296] Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data (Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968). Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) World Wide Web site. Correlation between the location of the gene encoding MDDT on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

[0297] In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation (Gatti, R. A. et al. (1988) Nature 336:577-580). The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

[0298] In another embodiment of the invention, MDDT, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between MDDT and the agent being tested may be measured.

[0299] Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest (Geysen, et al. (1984) PCT application WO84/03564). In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with MDDT, or fragments thereof, and washed. Bound MDDT is then detected by methods well known in the art. Purified MDDT can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

[0300] In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding MDDT specifically compete with a test compound for binding MDDT. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with MDDT.

[0301] In additional embodiments, the nucleotide sequences which encode MDDT may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

[0302] Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

[0303] The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/304,298, U.S. Ser. No. 60/305,324, U.S. Ser. No. 60/307,003, U.S. Ser. No. 60/308,185, U.S. Ser. No. 60/310,096, U.S. Ser. No. 60/311,551 and U.S. Ser. No. 60/363,649, are expressly incorporated by reference herein.

EXAMPLES

[0304] I. Construction of cDNA Libraries

[0305] Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.). Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Invitrogen), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

[0306] Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth Calif.), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin Tex.).

[0307] In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERSCRIPT plasmid system (Invitrogen), using the recommended procedures or similar methods known in the art (Ausubel et al., supra, ch. 5). Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Biosciences) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Invitrogen), PCDNA2.1 plasmid (Invitrogen, Carlsbad Calif.), PBK-CMV plasmid (Stratagene), PCR2-TOPOTA plasmid (Invitrogen), PCMV-ICIS plasmid (Stratagene), pIGEN (Incyte Genomics, Palo Alto Calif.), pRARE (Incyte Genomics), or pINCY (Incyte Genomics), or derivatives thereof. Recombinant plasmids were transformed into competent E. coli cells including XL1-Blue, XL1-BlueMRF, or SOIR from Stratagene or DH5α, DH10B, or ElectroMAX DH10B from Invitrogen.

[0308] II. Isolation of cDNA Clones

[0309] Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg Md.); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4° C.

[0310] Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V. B. (1994) Anal. Biochem 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene Oreg.) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

[0311] III. Sequencing and Analysis

[0312] Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Biosciences or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Amersham Biosciences); the ABI PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (Ausubel et al., supra, ch.

[0313] 7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

[0314] The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS, DOMO, PRODOM; PROTEOME databases with sequences from Homo sapiens, Rattus norvegicus, Mus musculus, Caenorhabditis elegans, Saccharomyces cerevisiae, Schizosaccharomyces pombe, and Candida albicans (Incyte Genomics, Palo Alto Calif.); hidden Markov model (HMM)-based protein family databases such as PFAM, INCY, and TIGRFAM (Haft, D. H. et al. (2001) Nucleic Acids Res. 29:4143); and HMM-based protein domain databases such as SMART (Schultz, J. et al. (1998) Proc. Natl. Acad. Sci. USA 95:5857-5864; Letunic, I. et al. (2002) Nucleic Acids Res. 30:242-244). (HMM is a probabilistic approach which analyzes consensus primary structures of gene families; see, for example, Eddy, S. R. (1996) Curr. Opin. Struct Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMER. The Incyte cDNA sequences were assembled to produce full length polynucleotide sequences. Alternatively, GenBank cDNAs, GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length polypeptide sequences. Alternatively, a polypeptide may begin at any of the methionine residues of the full length translated polypeptide. Full length polypeptide sequences were subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, the PROTEOME databases, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, hidden Markov model (HMM)-based protein family databases such as PFAM, INCY, and TIGRFAM; and HMM-based protein domain databases such as SMART. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco Calif.) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are generated using default parameters specified by the CLUSTAL algorithm as incorporated into the MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

[0315] Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and full length sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

[0316] The programs described above for the assembly and analysis of fill length polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:57-112. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 2.

[0317] IV. Identification and Editing of Coding Sequences from Genomic DNA

[0318] Putative molecules for disease detection and treatment were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94; Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode molecules for disease detection and treatment, the encoded polypeptides were analyzed by querying against PFAM models for molecules for disease detection and treatment. Potential molecules for disease detection and treatment were also identified by homology to Incyte cDNA sequences that had been annotated as molecules for disease detection and treatment. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Full length polynucleotide sequences were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example m. Alternatively, full length polynucleotide sequences were derived entirely from edited or unedited Genscan-predicted coding sequences.

[0319] V. Assembly of Genomic Sequence Data with cDNA Sequence Data

[0320] “Stitched” Sequences

[0321] Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example m were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then “stitched” together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpri public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

[0322] “Stretched” Sequences

[0323] Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example m were queried against public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore “stretched” or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

[0324] VI. Chromosomal Mapping of MDDT Encoding Polynucleotides

[0325] The sequences which were used to assemble SEQ ID NO:57-112 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:57-112 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO:, to that map location.

[0326] Map locations are represented by ranges, or intervals, of human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI “GeneMap'99” World Wide Web site (http://www.ncbi.nlm.nih.gov/genemap/), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

[0327] VII. Analysis of Polynucleotide Expression

[0328] Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook, supra, ch. 7; Ausubel et al., supra, ch. 4).

[0329] Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as: $\frac{{BLAST}{\quad \quad}{Score} \times {Percent}\quad {Identity}}{5 \times {minimum}\quad \left\{ {{{length}\left( {{Seq}.\quad 1} \right)},\quad {{length}\left( {{Seq}.\quad 2} \right)}} \right\}}$

[0330] The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and 4 for every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

[0331] Alternatively, polynucleotides encoding MDDT are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA encoding MDDT. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto Calif.).

[0332] VIII. Extension of MDDT Encoding Polynucleotides

[0333] Full length polynucleotides are produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5′ extension of the known fragment, and the other primer was synthesized to initiate 3′ extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68° C. to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

[0334] Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

[0335] High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing Mg²⁺, (NH₄)₂SO₄, and 2-mercaptoethanol, Taq DNA polymerase (Amersham Biosciences), ELONGASE enzyme (Invitrogen), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 57° C., 1 min; Step 4: 68° C., 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68° C., 5 min; Step 7: storage at 4° C.

[0336] The concentration of DNA in each well was determined by dispensing 100 μl PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene Oreg.) dissolved in 1×TE and 0.5 μl of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton Mass.), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5 μl to 10 μl aliquot of the reaction mixture was analyzed by electrophoresis on a 1% agarose gel to determine which reactions were successful in extending the sequence.

[0337] The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison Wis.), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Biosciences). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were religated using T4 ligase (New England Biolabs, Beverly Mass.) into pUC 18 vector (Amersham Biosciences), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent E. coli cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37° C. in 384-well plates in LB/2×carb liquid media.

[0338] The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Biosciences) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94° C., 3 min; Step 2: 94° C., 15 sec; Step 3: 60° C., 1 min; Step 4: 72° C., 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72° C., 5 min; Step 7: storage at 4° C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethysulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Biosciences) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosysterns).

[0339] In like manner, full length polynucleotides are verified using the above procedure or are used to obtain 5′ regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

[0340] IX. Identification of Single Nucleotide Polymorphisms in MDDT Encoding Polynucleotides

[0341] Common DNA sequence variants known as single nucleotide polymorphisms (SNPs) were identified in SEQ ID NO:57-112 using the LIFESEQ database (Incyte Genomics). Sequences from the same gene were clustered together and assembled as described in Example III, allowing the identification of all sequence variants in the gene. An algorithm consisting of a series of filters was used to distinguish SNPs from other sequence variants. Preliminary filters removed the majority of basecall errors by requiring a minimum Phred quality score of 15, and removed sequence alignment errors and errors resulting from improper trimming of vector sequences, chimeras, and splice variants. An automated procedure of advanced chromosome analysis analysed the original chromatogram files in the vicinity of the putative SNP. Clone error filters used statistically generated algorithms to identify errors introduced during laboratory processing, such as those caused by reverse transcriptase, polymerase, or somatic mutation. Clustering error filters used statistically generated algorithms to identify errors resulting from clustering of close homologs or pseudogenes, or due to contamination by non-human sequences. A final set of filters removed duplicates and SNPs found in immunoglobulins or T-cell receptors.

[0342] Certain SNPs were selected for further characterization by mass spectrometry using the high throughput MASSARRAY system (Sequenom, Inc.) to analyze allele frequencies at the SNP sites in four different human populations. The Caucasian population comprised 92 individuals (46 male, 46 female), including 83 from Utah, four French, three Venezualan, and two Amish individuals. The African population comprised 194 individuals (97 male, 97 female), all African Americans. The Hispanic population comprised 324 individuals (162 male, 162 female), all Mexican Hispanic. The Asian population comprised 126 individuals (64 male, 62 female) with a reported parental breakdown of 43% Chinese, 31% Japanese, 13% Korean, 5% Vietnamese, and 8% other Asian. Allele frequencies were first analyzed in the Caucasian population; in some cases those SNPs which showed no allelic variance in this population were not further tested in the other three populations.

[0343] X. Labeling and Use of Individual Hybridization Probes

[0344] Hybridization probes derived from SEQ ID NO:57-112 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 μmol of each oligomer, 250 μCi of [γ-³²P] adenosine triphosphate (Amersham Biosciences), and T4 polynucleotide kinase (DuPont NEN, Boston Mass.). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Biosciences). An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

[0345] The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham N.H.). Hybridization is carried out for 16 hours at 40° C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1×saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and compared.

[0346] XI. Microarrays

[0347] The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing; see, e.g., Baldeschweiler et al., supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porqus surface (Schena, M., ed. (1999) DNA Microarrays: A Practical Approach, Oxford University Press, London). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements (Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31).

[0348] Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorbtion and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

[0349] Tissue or Cell Sample Preparation

[0350] Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)⁺ RNA is purified using the oligo-(dT) cellulose method. Each poly(A)⁺ RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 μg/μl oligo-(dT) primer (21 mer), 1× first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Biosciences). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)⁺ RNA with GEMBRIGHI kits (Incyte). Specific control poly(A)+ RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C. for 2 hr, each reaction sample (one with Cy3 and another with CyS labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C. to the stop the reaction and degrade the RNA. Samples are purified using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto Calif.) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook N.Y.) and resuspended in 14 μl 5× SSC/0.2% SDS.

[0351] Microarray Preparation

[0352] Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5 μg. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Biosciences).

[0353] Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester Pa.), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110° C. oven.

[0354] Array elements are applied to the coated glass substrate using a procedure described in U.S. Pat. No. 5,807,522, incorporated herein by reference. 1 μl of the array element DNA, at an average concentration of 100 ng/μl, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

[0355] Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water. Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford Mass.) for 30 minutes at 60° C. followed by washes in 0.2% SDS and distilled water as before.

[0356] Hybridization

[0357] Hybridization reactions contain 9 μl of sample mixture consisting of 0.2 μg each of Cy3 and CyS labeled cDNA synthesis products in SX SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65° C. for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm² coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140 μl of 5×SSC in a corner of the chamber. The chamber containing the arrays is incubated for about 6.5 hours at 60° C. The arrays are washed for 10 min at 45° C. in a first wash buffer (1×SSC, 0.1% SDS), three times for 10 minutes each at 45° C. in a second wash buffer (0.1×SSC), and dried.

[0358] Detection

[0359] Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara Calif.) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20×microscope objective (Nikon, Inc., Melville N.Y.). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm×1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

[0360] In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater N.J.) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for CyS. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

[0361] The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

[0362] The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood Mass.) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

[0363] A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte). Array elements that exhibited at least about a two-fold change in expression, a signal-to-background ratio of at least 2.5, and an element spot size of at least 40% were identified as differentially expressed using the GEMTOOLS program (Incyte Genomics).

[0364] Expression

[0365] For example, SEQ ID NO:58 was downregulated by at least two-fold in five out of the eight endothelial cell lines treated with 10 ng/ml TNF-α within four hours. SEQ ID NO:58 was also down regulated in Tangier disease fibroblasts as compared to normal controls suggesting that SEQ ID NO:58, encoding SEQ ID NO:2, can be used for the diagnosis, prognosis or treatment of a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, and complications of thrombolysis, balloon angioplasty, vascular replacement, coronary artery bypass, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheurnatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, complications of cardiac transplantation, congenital lung anomalies, atelectasis, pulmonary congestion and edema, pulmonary embolism, pulmonary hemorrhage, pulmonary infarction, pulmonary hypertension, vascular sclerosis, obstructive pulmonary disease, restrictive pulmonary disease, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, bronchial asthma, bronchiectasis, bacterial pneumonia, viral and mycoplasmal pneumonia, lung abscess, pulmonary tuberculosis, diffuse interstitial diseases, pneumoconioses, sarcoidosis, idiopathic pulmonary fibrosis, desquamative interstitial pneumonitis, hypersensitivity pneumonitis, pulmonary eosinophilia bronchiolitis obliterans-organizing pneumonia, diffuse pulmonary hemorrhage syndromes, Goodpasture's syndromes, idiopathic pulmonary hemosiderosis, pulmonary involvement in collagen-vascular disorders, pulmonary alveolar proteinosis, lung tumors, inflammatory and noninflammatory pleural effusions, pneumothorax, pleural tumors, drug-induced lung disease, radiation-induced lung disease, and Tangier disease.

[0366] For example, SEQ ID NO:90 showed differential expression in treated versus non-treated C3A cells as determined by microarray analysis. The expression of SEQ ID NO:90 was decreased by at least two fold in C3A cells treated with 10 μM MAH for one to six hours and with 100 μM for one or six hours versus untreated C3A cells. SEQ ID NO:90 expression was also decreased by at least two-fold when C3A cells were treated for one to three hours with either 1 μM, 10 μM, or 100 μM bude when compared with untreated C3A cells. These experiments indicate that SEQ ID NO:90 was significantly under-expressed in C3A cells when tested with two steroid compounds, further establishing the utility of SEQ ID NO:90 as a diagnostic marker or as a potential therapeutic target for liver disorders associated with steroid therapy such as adenomatosis, cholestasis, cirrhosis, hemangioma, Henoch-Schonlein purpura, hepatitis, hepatocellular and metastatic carcinomas, idiopathic thrombocytopenic purpura, porphyria, sarcoidosis, and Wilson disease.

[0367] Human CD34 positive precursor cells were isolated by positive immunomagnetic selection from the leukapheresis of normal volunteer donors who had undergone G-CSF-induced stem cell mobilization. The purified CD34+ cells were cultured in vitro for 10 days in the presence of recombinant GM-CSF, Stem Cell Factor, TNF-alpha, TGF-beta1, and Flt3-Ligand. The resulting expanded cell population was enriched for cell cluster-forming immature dendritic cells (Lci) by sedimentation over a 7.5% BSA column at 1 g for 30 min. Immature dendritic cells were cultured for two additional days in the presence of the same combination of cytokines supplemented with LPS, IL-1beta, TNF-alpha, or double strand RNA. In addition, cluster-forming immature dendritic cells were disrupted by vigorous pipetting and cultured for two additional days in the presence of the same combination of cytokines without addition of any additional factor. The partially mature dendritic cells derived by mechanical disruption of cell clusters are characterized by the presence of intracellular rod-shaped structures called Birbeck's Granules. The dendritic cell population produced using this method was called Birbeck's Granule-positive dendritic cells, or BG.

[0368] CD34+ precursor cells were compared to immature dendritic cells (Lci); Lci were compared to mature dendritic cells derived in the presence of LPS, IL-1b, TNF-alpha, or double strand RNA; and undisturbed Lci (Clusters) were compared to BG. Array elements that exhibited about at least a two-fold change in expression and a signal intensity over 250 units, a signal-to-background ratio of at least 2.5, and an element spot size of at least 40% were identified as differentially expressed using the GEMTOOLS program (Incyte Genomics). SEQ ID NO:96, which contains a GTPase activating protein motif for Arf and a Rho GAP domain, showed at least a two-fold increased expression during the differentiation of dendritic cells when induced by simple mechanical disaggregation and a greater than two-fold expression during maturation of these cells when induced by TNF-alpha. TNF-alpha is a factor produced by many cell types in response to stress. In addition, mechanical disruption is a significant stress factor during organ transplantation. Further, these experiments indicate that SEQ ID NO:96 was significantly over-expressed during differentiation and maturation of human dendritic cells, further establishing the utility of SEQ ID NO:96 as a diagnostic marker or as a potential therapeutic target for organ transplant disorders.

[0369] For example, SEQ ID NO:110 showed differential expression in diseased versus normal tissue as determined by microarray analysis. Matched normal ovary and ovarian tumor tissue samples are provided by the Huntsman Cancer Institute, (Salt Lake City, Utah). The expression of MDDT was decreased in ovarian tumor cells relative to non-tumorous ovarian cells. Therefore, SEQ ID NO:110 is useful in diagnostic assays for ovarian cancer.

[0370] XII. Complementary Polynucleotides

[0371] Sequences complementary to the MDDT-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring MDDT. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of MDDT. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5′ sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the MDDT-encoding transcript.

[0372] XIII. Expression of MDDT

[0373] Expression and purification of MDDT is achieved using bacterial or virus-based expression systems. For expression of MDDT in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the trp-lac (tac) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the lac operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express MDDT upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of MDDT in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding MDDT by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus (Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945).

[0374] In most expression systems, MDDT is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Biosciences). Following purification, the GST moiety can be proteolytically cleaved from MDDT at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffiity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel et al. (supra, ch. 10 and 16). Purified MDDT obtained by these methods can be used directly in the assays shown in Examples XVI, and XVIII where applicable.

[0375] XIV. Functional Assays

[0376] MDDT function is assessed by expressing the sequences encoding MDDT at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT plasmid (Invitrogen, Carlsbad Calif.) and PCR3.1 plasmid (Invitrogen), both of which contain the cytomegalovirus promoter. 5-10 μg of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2 μg of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994; Flow Cytometry, Oxford, New York N.Y.).

[0377] The influence of MDDT on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding MDDT and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success N.Y.). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding MDDT and other genes of interest can be analyzed by northern analysis or microarray techniques.

[0378] XV. Production of MDDT Specific Antibodies

[0379] MDDT substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M. G. (1990) Methods Enzymol. 182:488-495), or other purification techniques, is used to immunize animals (e.g., rabbits, mice, etc.) and to produce antibodies using standard protocols.

[0380] Alternatively, the MDDT amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art (Ausubel et al., supra, ch. 11).

[0381] Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using FMOC chemistry and coupled to KLH (Sigma-Aldrich, St. Louis Mo.) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity (Ausubel et al., supra). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-MDDT activity by, for example, binding the peptide or MDDT to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

[0382] XVI. Purification of Naturally Occurring MDDT Using Specific Antibodies

[0383] Naturally occurring or recombinant MDDT is substantially purified by immunoaffinity chromatography using antibodies specific for MDDT. An immunoaffinity column is constructed by covalently coupling anti-MDDT antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Biosciences). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

[0384] Media containing MDDT are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of MDDT (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/MDDT binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and MDDT is collected.

[0385] XVII. Identification of Molecules Which Interact with MDDT

[0386] MDDT, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter reagent (Bolton, A. E. and W. M. Hunter (1973) Biochem. J. 133:529-539). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled MDDT, washed, and any wells with labeled MDDT complex are assayed. Data obtained using different concentrations of MDDT are used to calculate values for the number, affinity, and association of MDDT with the candidate molecules.

[0387] Alternatively, molecules interacting with MDDT are analyzed using the yeast two-hybrid system as described in Fields, S. and 0. Song (1989; Nature 340:245-246), or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech).

[0388] MDDT may also be used in the PATHCALLING process (CuraGen Corp., New Haven Conn.) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Pat. No. 6,057,101).

[0389] XVIII. Demonstration of MDDT Activity

[0390] Phorbol ester binding activity of MDDT is measured using an assay based on the fluorescent phorbol ester sapinotoxin-D (SAPD). Binding of SAPD to MDDT is quantified by measuring the resonance energy transfer from MDDT tryptophans to the 2-(N-methylamino)benzoyl fluorophore of the phorbol ester, as described by Slater et al. ((1996) J. Biol. Chem. 271:4627-4631).

[0391] Various modifications and variations of the described compositions, methods, and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. It will be appreciated that the invention provides novel and useful proteins, and their encoding polynucleotides, which can be used in the drug discovery process, as well as methods for using these compositions for the detection, diagnosis, and treatment of diseases and conditions. Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Nor should the description of such embodiments be considered exhaustive or limit the invention to the precise forms disclosed. Furthermore, elements from one embodiment can be readily recombined with elements from one or more other embodiments. Such combinations can form a number of embodiments within the scope of the invention. It is intended that the scope of the invention be defined by the following claims and their equivalents. TABLE 1 Incyte Incyte Polypeptide Incyte Polynucleotide Polynucleotide Incyte Full Length Project ID SEQ ID NO: Polypeptide ID SEQ ID NO: ID Clones 2867236 1 2867236CD1 57 2867236CB1 1536179CA2 1294096 2 1294096CD1 58 1294096CB1 7238537 3 7238537CD1 59 7238537CB1 90171762CA2, 90171778CA2, 90171786CA2, 90171870CA2, 90171886CA2, 90171894CA2, 90190048CA2, 90190116CA2, 90190124CA2, 90190132CA2 7494391 4 7494391CD1 60 7494391CB1 90140260CA2 6451054 5 6451054CD1 61 6451054CB1 7494592 6 7494592CD1 62 7494592CB1 5202657 7 5202657CD1 63 5202657CB1 3343965CA2 2013529 8 2013529CD1 64 2013529CB1 4010537CA2, 6300041CA2 3841351 9 3841351CD1 65 3841351CB1 152116 10 152116CD1 66 152116CB1 2381031 11 2381031CD1 67 2381031CB1 2381031CA2 2511371 12 2511371CD1 68 2511371CB1 8068623 13 8068623CD1 69 8068623CB1 677977 14 677977CD1 70 677977CB1 1661472 15 1661472CD1 71 1661472CB1 1748508 16 1748508CD1 72 1748508CB1 90132493CA2 2159545 17 2159545CD1 73 2159545CB1 8560269 18 8560269CD1 74 8560269CB1 8710302 19 8710302CD1 75 8710302CB1 6778214 20 6778214CD1 76 6778214CB1 258383 21 258383CD1 77 258383CB1 90140053CA2, 90140161CA2 2804937 22 2804937CD1 78 2804937CB1 7494915 23 7494915CD1 79 7494915CB1 2073751 24 2073751CD1 80 2073751CB1 3178841 25 3178841CD1 81 3178841CB1 3674807 26 3674807CD1 82 3674807CB1 3674807CA2 1794922 27 1794922CD1 83 1794922CB1 90144984CA2 1795509 28 1795509CD1 84 1795509CB1 690351CA2, 90131912CA2, 90131949CA2, 90131952CA2, 90131960CA2, 90131976CA2, 90131992CA2, 90132060CA2, 90132084CA2, 90132092CA2 2017180 29 2017180CD1 85 2017180CB1 2807727CA2 219442 30 219442CD1 86 219442CB1 2597459 31 2597459CD1 87 2597459CB1 90140160CA2 2783863 32 2783863CD1 88 2783863CB1 2902971 33 2902971CD1 89 2902971CB1 368660 34 368660CD1 90 368660CB1 90130001CA2 2804990 35 2804990CD1 91 2804990CB1 7616219CA2 168571 36 168571CD1 92 168571CB1 1286391 37 1286391CD1 93 1286391CB1 2007684 38 2007684CD1 94 2007684CB1 2227040 39 2227040CD1 95 2227040CB1 4346130 40 4346130CD1 96 4346130CB1 55117040 41 55117040CD1 97 55117040CB1 55117036CA2 7472392 42 7472392CD1 98 7472392CB1 6622373CA2 4028960 43 4028960CD1 99 4028960CB1 8227004 44 8227004CD1 100 8227004CB1 3279686CA2 3044763 45 3044763CD1 101 3044763CB1 90126287CA2 4044519 46 4044519CD1 102 4044519CB1 4044519CA2, 90106511CA2, 90106619CA2, 90106627CA2, 90106659CA2 71351918 47 71351918CD1 103 71351918CB1 8109363 48 8109363CD1 104 8109363CB1 3853651CA2, 6859649CA2 1272746 49 1272746CD1 105 1272746CB1 1839974 50 1839974CD1 106 1839974CB1 90120531CA2 1877336 51 1877336CD1 107 1877336CB1 2321054 52 2321054CD1 108 2321054CB1 1236972CA2, 1398127CA2, 2245649CA2, 2321054CA2, 90106305CA2, 90106337CA2, 90106353CA2, 90106361CA2, 90106369CA2, 90106377CA2, 90106385CA2, 90106393CA2, 90106405CA2, 90106429CA2, 90106437CA2, 90106469CA2, 90106493CA2 2796034 53 2796034CD1 109 2796034CB1 4413112 54 4413112CD1 110 4413112CB1 90108176CA2, 90172662CA2 7654832 55 7654832CD1 111 7654832CB1 90110764CA2, 90110788CA2, 90110880CA2 7503849 56 7503849CD1 112 7503849CB1

[0392] TABLE 2 GenBank ID NO: Polypeptide SEQ Incyte or PROTEOME Probability ID NO: Polypeptide ID ID NO: Score Annotation 1 2867236CD1 g11065721 3.50E−134 [Homo sapiens] 28 kD interferon responsive protein 4 7494391CD1 g13506808 5.70E−42 [Mus musculus] thymic stromal co-transporter Chen, C., et al., Biochim. Biophys. Acta 1493: 159-169 (2000) 7 5202657CD1 g3006139 7.90E−42 [Schizosaccharomyces pombe] hypothetical zf-C3HC4 zinc finger protein 15 1661472CD1 g6899934 1.90E−24 [Arabidopsis thaliana] putative zinc-finger protein 17 2159545CD1 g4650844 3.40E−120 [Homo sapiens] Kelch motif containing protein 18 8560269CD1 g18252514 1.00E−123 [Homo sapiens] hepatocellular carcinoma-associated antigen HCA557b 20 6778214CD1 g57671 8.90E−15 [Rattus norvegicus] ribonuclease inhibitor Kawanomoto, M., et al., Biochim. Biophys. Acta 1129: 335-338 (1992) 22 2804937CD1 g6650377 0 [Mus musculus] pecanex 1 23 7494915CD1 g2072953 1.60E−34 [Homo sapiens] putative p150 Sassaman, D. M. et al. (1997) Nature Genet. 16: 37-43 24 2073751CD1 g18652658 4.00E−17 [Schmidtea mediterranea] myosin heavy chain A 31 2597459CD1 g7243777 2.90E−50 [Drosophila melanogaster] Diablo 35 2804990CD1 g1196425 4.60E−28 [Homo sapiens] envelope protein Cohen, M. et al. (1985) Virology 147: 449-458 36 168571CD1 g3093476 6.90E−90 [Homo sapiens] EVI-5 homolog Liao, X. et al. (1997) Oncogene 14: 1023-1029 39 2227040CD1 g1799568 1.50E−80 [Homo sapiens] stac Suzuki H., et al. (1996) Biochem. Biophys. Res. Commun. 229: 902-909 40 4346130CD1 g15625572 0 [Homo sapiens] centaurin delta1 42 7472392CD1 g12853030 3.00E−81 [Mus musculus] Cyclic nucleotide-binding domain containing protein˜data source: Pfam, source key: PF00027, evidence: ISS˜putative 43 4028960CD1 g6063688 4.50E−102 [Homo sapiens] AMMECR1 Vitelli, F., et al., Genomics 55: 335-340 (1999) 44 8227004CD1 g11527201 6.70E−250 [Homo sapiens] sporulation-induced transcript 4-associated protein SAPLa Twells, R. C. J., et al., Genomics 72: 231-242 (2001) 47 71351918CD1 g1314316 6.30E−73 [Xenopus laevis] WD-40 motifs; up-regulated by thyroid hormone in tadpoles Brown, D. D., et al., Proc. Natl. Acad. Sci. U.S.A. 9: 1924-1929 (1996) 52 2321054CD1 g15278367 4.00E−52 [Homo sapiens] Similar to fasciculation and elongation protein zeta 2 (zygin II) 55 7654832CD1 g15420869 0 [Mus musculus] ankyrin repeat-containing SOCS box protein 5 Kile, B. T., et al., Mol. Cell. Biol. 21: 6189-6197 (2001)

[0393] TABLE 3 Amino Analytical SEQ Incyte Acid Potential Potential Methods ID Polypeptide Resi- Phosphorylation Glycosylation and NO: ID dues Sites Sites Signature Sequences, Domains and Motifs Databases 1 2867236CD1 246 S99 S212 T11 T26 N129 N201 T73 T111 T131 2 1294096CD1 325 S6 S25 S54 S142 N254 K+ channel tetramerisation domain: D34-Q134 HMMER_PFAM S151 S162 S204 S304 S316 T47 T51 T252 T267 Y119 3 7238537CD1 376 S34 S52 S96 S106 N152 N319 Cytosolic domain: S321-A376 TMHMMER S113 S118 S264 Transmembrane domain: T298-V320 S359 S373 T38 Non-cytosolic domain: M1-V297 T231 T286 4 7494391CD1 461 S48 S70 S93 S233 N38 N46 N53 Sugar transport proteins signature 1: L91-S107 MOTIFS S253 S440 S454 N143 N229 S459 T166 Y39 N251 Cytosolic domain: M1-V6, D96-K101, D157-R168, TMHMMER G219-E258, S319-D324, K374-L384, K437-R461 Transmembrane domain: E7-Y29, I78-S95, F102- F124, S134-V156, I169-I191, F196-L218, L259- F281, F296-F318, I325-T347, M351-S373, F385- Y407, F417-V436 Non-cytosolic domain: R30-D77, A125-A133, R192- G195, I282-V295, T348-M350, S408-G416 5 6451054CD1 168 S26 S28 S47 S80 N50 S85 S98 S113 T96 6 7494592CD1 832 S201 S363 S470 N586 S489 S557 S580 S658 S702 S785 S799 S818 T166 T228 T324 T352 T366 T371 T399 T545 T659 T734 Y430 7 5202657CD1 393 S28 S135 S180 N189 PROTEIN C29A3.03C CHROMOSOME II BLAST_(—) S190 Y35 Y218 ZINCFINGER NUCLEAR DNABINDING CODED PRODOM Y252 FOR BY PD024560: E158-F393 8 2013529CD1 280 S41 S77 S138 S144 N232 S159 S183 S193 S235 S252 S257 S272 T20 T155 T158 T178 9 3841351CD1 344 S5 S14 S15 S33 N217 S38 S169 T130 T173 T271 T276 10 152116CD1 405 S139 S163 S292 N147 S322 S346 S361 T10 T70 T151 T325 11 2381031CD1 185 S52 S56 S130 S134 N121 N141 S143 S145 S181 T60 12 2511371CD1 463 S8 S261 S300 S330 Trp-Asp (WD) repeat protein BL00678: S210-W220 BLIMPS_(—) T47 T88 T166 BLOCKS T313 WD domain, G-beta repeat: C186-R221, P343-D376, HMMER_PFAM P254-K290 13 8068623CD1 403 S85 S106 S164 TBC domain: E57-C268 HMMER_PFAM S389 T324 T364 Cytosolic domain: R261-T364 TMHMMER Transmembrane domain: L238-Y260, N365-V387 Non-cytosolic domain: M1-R237, K388-P403 14 677977CD1 574 S45 S57 S65 S79 N214 signal_cleavage: M1-A22 SPSCAN S80 S218 S234 S246 S340 S376 T53 T58 T519 Cell attachment sequence: R203-D205 MOTIFS 15 1661472CD1 731 S9 S100 S121 S156 N335 PROTEIN ZINC FINGER CONSERVED BLAST_(—) S160 S219 S264 CHROMOSOME IV COSMID CODED FOR BY C PRODOM S339 S340 S393 PD043678: D4-R101 S422 S450 S590 S625 S669 S672 T85 T222 T359 T377 T491 T561 T648 Y23 PROLINE-RICH PROTEIN DM03894|P05142|1- BLAST_DOMO 134: V460-P550 Zinc finger, C2H2 type, domain: C16-H37 MOTIFS 16 1748508CD1 299 S75 S117 S166 N42 N110 S206 T226 17 2159545CD1 620 S7 S32 S34 S127 N29 BTB/POZ domain: K51-F164 HMMER_PFAM S218 S297 S307 S354 S475 S522 S531 T70 T106 T311 T316 T390 T401 T448 T542 Y306 Kelch motif: R355-N400, R496-T541, K402-N447, HMMER_PFAM P449-G494, P543-S588, S307-N353 PROTEIN REPEAT MATRIX RING CANAL BLAST_(—) KELCH R12E2.1 C47D12.7 KIAA0132 KIAA0469 PRODOM PD001473: P166-L294 POZ DOMAIN BLAST_DOMO DM00509|Q04652|131-335: E65-L238 DM00509|A45773|130-334: E65-L238 DM00509|P21073|1-198: F60-Q243 18 8560269CD1 218 S68 S133 T55 T91 N28 N165 Leucine zipper pattern: L141-L162 MOTIFS T93 T151 19 8710302CD1 427 S22 S38 T118 T368 Cytosolic domain: R90-T115 TMHMMER Y331 Transmembrane domain: E67-L89, I116-F138 Non-cytosolic domain: M1-P66, R139-S427 20 6778214CD1 612 S50 S191 S232 N70 N168 N228 S359 S370 S388 N275 N360 S435 S473 S505 N416 S507 S509 S511 S590 S607 T47 T72 T144 T439 T478 21 258383CD1 458 S22 S38 S120 T149 Cytosolic domain: R90-K95, R170-Q299, S355-S458 TMHMMER T399 Y362 Transmembrane domain: E67-L89, F96-L115, I147- F169, L300-R322, I332-A354 Non-cytosolic domain: M1-P66, I116-T146, N323- I331 22 2804937CD1 1451 S14 S28 S168 S222 N201 N265 Cytosolic domain: M1-N116, R200-V219, G293- TMHMMER S367 S369 S483 N689 N830 H303, Q399-Y404 S490 S649 S691 N1092 N1172 Transmembrane domain: V117-F139, I177-S199, S768 S787 S821 N1182 N1344 F220-L242, L270-Y292, I304-S323, L376-L398, S822 S884 S885 N1370 V405-P422 S923 S944 S968 Non-cytosolic domain: R140-I176, L243-S269, R324- S978 S1045 S1093 D375, Q423-V1451 S1111 S1242 S1247 S1262 S1267 S1330 S1348 S1372 S1392 S1397 S1421 T637 T832 T977 T1438 Y446 Y562 Y635 Y845 Y1355 PROTEIN COSMID 30B8 KIAA0435 B0511.12 BLAST_(—) PECANEX DEVELOPMENTAL NEUROGENESIS PRODOM TRANSMEMBRANE GLYCOPROTEIN PD014553: N636-G1198 PROTEIN B0511.12 COSMID 30B8 PECANEX BLAST_(—) DEVELOPMENTAL NEUROGENESIS PRODOM TRANSMEMBRANE GLYCOPROTEIN REPEAT PD018553: L66-L287, S354-I471, S280-P359, G1148-N1178 PROTEIN COSMID 30B8 PECANEX BLAST_(—) DEVELOPMENTAL NEUROGENESIS PRODOM TRANSMEMBRANE GLYCOPROTEIN REPEAT B0511.12 PD025614: W1379-V1444, P1179-P1207 23 7494915CD1 184 S9 T24 T30 T36 N22 Reverse transcriptase (RNA-dependent DNA HMMER_PFAM T66 polymerase): R86-S159 Cytosolic domain: M1-L153 TMHMMER Transmembrane domain: F154-V176 Non-cytosolic domain: K177-H184 DNA RNADIRECTED POLYMERASE PUTATIVE BLAST_(—) P150 TRANSCRIPTASE REVERSE PROTEIN L1 PRODOM SEQUENCE PD002004: Q25-L88 TRANSCRIPTASE; REVERSE; ORF2; ENCODE; BLAST_DOMO DM01377|P08548|132-516: T24-M100 DM01377|P08547|132-516: Q25-M100 DM01377|I38588|130-517: Q25-M100 DM01377|S16783|1-259: Q18-M100 24 2073751CD1 407 S179 S273 S283 N247 PROTEIN COILED COIL CHAIN MYOSIN BLAST_(—) T61 T129 T213 REPEAT HEAVY ATPBINDING FILAMENT PRODOM T294 T306 T376 HEPTAD PD000002: E128-E366 (Pvalue = 2.3e−10) T379 T386 Y22 Leucine zipper pattern: L301-L322 MOTIFS 25 3178841CD1 261 S40 S56 S70 S140 HYPOTHETICAL 32.0 KD PROTEIN C09F5.2 IN BLAST_(—) S144 T234 CHROMOSOME III TRANSMEMBRANE PRODOM PD128096: V45-V183 Cytosolic domains: 1-72, 123-155, 227-261 TMHMMER Transmembrane domains: 79-90, 101-122, 156-178, 204-226 Non-cytosolic domains: 91-99, 179-203 26 3674807CD1 209 S197 T17 T187 N132 Signal peptide: M41-G90 SPSCAN 27 1794922CD1 333 S6 S17 S39 S65 N63 N295 MOTIFS S140 S174 S212 S241 T31 T217 T310 Y261 28 1795509CD1 257 T43 T168 Y105 COSMID E04F6 PD132304: F72-C254 BLAST_(—) PRODOM Cell attachment sequence: R78-D80 MOTIFS 29 2017180CD1 293 S5 S120 S135 S155 N273 N287 MOTIFS S251 S255 S279 S288 T27 T42 T107 T142 30 219442CD1 598 S28 S66 S71 S102 N195 N220 MOTIFS S149 S163 S180 N227 S186 S191 S215 S228 S263 S283 S287 S361 S365 S406 S439 S543 S561 S571 S584 T45 T67 T172 T185 T276 T290 T337 T472 T492 T545 31 2597459CD1 470 S3 S8 S23 S78 N25 N155 N325 BTB/POZ domain: D26-L139 HMMER_PFAM S177 S196 S201 S359 S377 S451 T157 T279 Y101 Y292 Y309 Kelch motif: G335-K385, C387-D433 HMMER_PFAM BTB Domain PF00651: A55-F67 BLIMPS_(—) PFAM PROTEIN DNA-BINDING ZINC FINGER METAL BLAST_(—) BINDING NUCLEAR ZINC FINGER PRODOM TRANSCRIPTION REGULATION CHROMOSOME PD000632: Q16-L139 POZ DOMAIN DM00509 BLAST_DOMO Q04652|131-335: S21-N218 A45773|130-334: S21-N218 P21073|1-198: S23-E216 S59069|1-171: H24-L135 32 2783863CD1 311 S39 S101 S133 N68 PROTEIN CHROMOSOME READING FRAME BLAST_(—) T136 ORF TRANSMEMBRANE COSMID D8035.34P PRODOM XV YOL002C PD005362: N68-S301 Cytosolic domains: 1-73, 129-140, 196-201, 257-275 TMHMMR Transmembrane domains: 74-96, 106-128, 141-163, 173-195, 202-224, 239-256, 276-298 Non-cytosolic domains: 97-105, 164-172, 225-238, 299-311 MEMBRANE; YOL002C; CHROMOSOME; BLAST_DOMO C30D11.11; DM02642 Q09749|49-323: T32-K302 Q09910|169-441: T32-V283 S62569|169-441: T32-V283 S61982|50-325: Y31-V283 33 2902971CD1 894 S9 S14 S17 S75 N106 N312 PROTEIN CHROMOSOME C30D11.09 I B0361.1 BLAST_(—) S86 S97 S113 S114 N596 N757 III PD033465: E673-K786 PRODOM S115 S141 S161 S169 S223 S267 S277 S293 S313 S327 S351 S372 S420 S431 S439 S454 S489 S536 S554 S580 S598 S705 S759 S792 S806 S868 T176 T278 T291 T323 T346 T409 T438 T581 T629 T635 T723 Y310 SPAC30D11.09; DM04663 BLAST_DOMO Q10945|1-144: I662-K786 Q09909|388-532: M672-W796 S62567|388-532: M672-W796 Cell attachment sequence: R425-D427 MOTIFS ATP/GTP-binding site motif A (P-loop): A622-T629 MOTIFS 34 368660CD1 653 S37 S69 S79 S135 N288 N508 N542 TPR Domain: V341-H374, A307-N340, C382-F415 HMMER_PFAM S225 S290 S303 S475 S482 S483 S512 S515 S516 S520 S582 S645 T373 T384 T414 T448 T453 T476 T601 T629 Cell attachment sequence: R125-D127 MOTIFS 35 2804990CD1 144 T16 N17 Cytosolic domain: 137-144 TMHMMR Transmembrane domain: 114-136 Non-cytosolic domain: 1-113 36 168571CD1 424 S88 S123 S124 N122 N311 signal_cleavage: M1-L24 SPSCAN S151 S179 S194 S258 S269 S364 S365 S386 S407 S409 T92 EVI5 HOMOLOG TRUNCATED EVI5 BLAST_(—) ECOTROPIC VIRAL INTEGRATION SITE PRODOM COSMID F01G12 PD075221: E84-P180 Protein kinases ATP-binding region signature: L370- MOTIFS K401 37 1286391CD1 1351 S187 S266 S311 N215 N235 Integrase core domain: R1062-L1130 HMMER_PFAM S320 S359 S360 N358 N543 S423 S486 S496 N1293 S556 S633 S657 S704 S884 S1000 S1204 S1262 S1274 S1296 S1345 T25 T74 T95 T124 T159 T230 T329 T392 T463 T642 T691 T940 T1015 T1079 T1215 POLPOLYPROTEIN BLAST_DOMO DM00159|S08405|760-943: H1009-A1139 DM00140|S52564|1-364: Y517-K670 Leucine zipper pattern: L837-L858 MOTIFS 38 2007684CD1 78 39 2227040CD1 411 S5 S39 S56 S84 N172 N218 Phorbol esters/diacylglycerol binding domain: H111- HMMER_PFAM S112 S122 S168 C161 S198 S224 S232 S234 S246 S249 S325 S372 S396 T82 T188 T207 T286 SH3 domain: Y295-V349 HMMER_PFAM Phorbol esters/diacylglycerol binding domain BLIMPS_(—) proteins BL00479: H111-G133, Q137-C152 BLOCKS Phorbol esters/diacylglycerol binding domain: R120- PROFILE- S213 SCAN Diacylglycerol/phorbol-ester binding signature BLMPS_(—) PR00008: H158-R170, V108-S122, C124-G133, PRINTS Q137-V148 STAC BLAST_(—) PD027304: Q347-I411 PRODOM PD032205: G163-G245 SRC HOMOLOGY 3 (SH3) DOMAIN BLAST_DOMO DM00025|S61138|55-108: Y297-Q347 Cytochrome c family heme-binding site signature: MOTIFS C124-Q129 Phorbol esters/diacylglycerol binding domain: H111- MOTIFS C161 40 4346130CD1 1704 S3 S165 S295 S323 N42 N167 N205 Putative GTP-ase activating protein for Arf: Y685- HMMER_PFAM S346 S350 S378 N231 N327 L807 S416 S424 S480 N694 N697 S677 S683 S696 N943 N1009 S699 S739 S781 N1572 S834 S911 S932 S977 S1124 S1165 S1172 S1194 S1211 S1404 S1428 S1435 S1476 S1477 S1487 S1510 S1582 S1593 S1604 T34 T83 T122 T155 T183 T190 T196 T312 T314 T357 T409 T411 T417 T437 T534 T548 T643 T663 T681 T791 T808 T919 T1011 T1096 T1105 T1215 T1279 T1369 T1423 T1524 T1639 T1656 PH domain: S1435-H1537, K483-K574, P588-A679, HMMER_PFAM I879-V1003 RhoGAP domain: P1129-E1282 HMMER_PFAM SAM domain (Sterile alpha motif): V4-L68 HMMER_PFAM HIV Rev interacting protein signature PR00405: BLIMPS_(—) N697-C716, C716-K733, V484-V505 PRINTS PROTEIN GTPASE DOMAIN AC PD00930: P1129- BLIMPS_(—) G1154, L1232-L1272 PRODOM PROTEIN ZINC FINGER NUCLEAR DNA BLAST_(—) BINDING PUTATIVE GTPASE ACTIVATING PRODOM FACTOR CHROMOSOME REPEAT PD002425: N694-E775 PROTEIN GTPASE DOMAIN SH2 ACTIVATION BLAST_(—) ZINC 3 KINASE SH3 PHOSPHATIDYLINOSITOL PRODOM REGULATORY PD000780: V1128-E1282 PH DOMAIN DM00470 BLAST_DOMO |S54307|1621-1845: K1125-E1301 |P34588|1-285: K1125-N1291 |A49307|566-842: T1096-Q1274 |P15882|109-331: I1107-T1275 41 55117040CD1 243 S13 S38 S53 S59 N50 N203 Ankyrin repeat: Q135-N167, K168-E200, Y201-Q230 HMMER_PFAM S75 T45 T171 Aldehyde ferredoxin oxid PF01314: A110-V122, R73- BLIMPS_(—) L103, A82-K114 PFAM 42 7472392CD1 248 S7 S57 S112 S137 S157 S175 S200 T12 T180 43 4028960CD1 310 S59 S277 S283 T98 N36 N63 N93 T141 T144 T184 N97 N297 T199 T269 44 8227004CD1 838 S11 S133 S202 N79 N210 N231 PROTEIN SIT4-ASSOCIATING BLAST_(—) S214 S304 S315 N261 N302 PHOSPHORYLATION CELL CYCLE SAP155 PRODOM S402 S417 S503 N358 N409 KIAA0685 SAP185 SAP190 SAP4 PD014556: D68- S582 S599 S604 N542 N552 E284 S616 S673 S687 N558 N647 S696 S700 S705 S742 S817 T15 T23 T171 T233 T274 T278 T282 T390 T411 T413 T472 T507 T512 T608 T614 T711 T751 T789 SIT4-ASSOCIATING PROTEIN SAP190 BLAST_DOMO DM03002|P40856|222-821: M92-N363 SIT4-ASSOCIAT1NG PROTEIN SAP185 BLAST_DOMO DM03002|P36123|229-825: E98-N363 45 3044763CD1 408 S25 S62 S68 S103 N257 N342 Leucine zipper pattern: L261-L282 MOTIFS S184 S286 S330 S344 S377 S392 T98 T131 T158 T213 Cytosolic domains: M1-G229, R290-R301, S377- TMHMMER S408 Transmembrane domains: L230-G252, T267-D289, N302-L324, I354-L376 Non-cytosolic domains: D253-K266, S325-Q353 46 4044519CD1 101 T89 Signal_cleavage: M1-S15 SPSCAN Signal Peptide: M1-S19, M1-T16, M31-S59 HMMER Cytosolic domains: M1-M31, E82-L101 TMHMMER Transmembrane domains: V32-L54, L64-L81 Non-cytosolic domain: N55-S63 47 71351918CD1 256 S26 S107 S174 WD domain, G-beta repeat: C32-D68, Q136-D171, HMMER_PFAM S194 S202 T35 T63 V179-Q212 T222 Non-cytosolic domain: M1-L256 TMHMMER Trp-Asp (WD-40) repeats signature: L44-A92 PROFILE- SCAN Trp-Asp containing, G-protein WD-40 repeats GENE BLAST_(—) 16 PD106308: R71-L256 PRODOM Trp-Asp (WD) repeats signature: V55-C69 MOTIFS 48 8109363CD1 104 Non-cytosolic domain: M1-G104 TMHMMER 49 1272746CD1 855 S27 S93 S159 S184 N132 N157 Non-cytosolic domain: M1-S855 TMHMMER S245 S287 S329 N254 N312 S593 S708 S726 N325 N486 S793 S811 S827 N592 N615 T18 T26 T35 T45 N623 N659 T128 T200 T202 N822 T319 T352 T438 T470 T601 T642 T807 50 1839974CD1 427 S254 S277 S321 N73 N258 N405 Fibronectin type III domain: L276-G364 HMMER_PFAM S334 S361 S365 T50T182T247 Y329 Non-cytosolic domain: M1-I427 TMHMMER Fibronectin type III repeat signature PR00014: S393- BLIMPS_(—) P402, G406-W416 PRINTS 51 1877336CD1 800 S58 S74 S252 S277 N272 N281 Non-cytosolic domain: M1-F800 TMHMMER S283 S306 S351 N411 N785 S380 S415 S424 S437 S439 S446 S491 S521 S534 S539 S605 S786 T208 T302 T313 T488 T553 T572 T747 T781 Y331 FIBRILLAR COLLAGEN CARBOXYL- BLAST_DOMO TERMINAL DM00019|S42886|221-377: G112-N237 52 2321054CD1 107 S87 T17 T62 Signal_cleavage: M1-A43 SPSCAN Non-cytosolic domain: M1-E24 TMHMMER Transmembrane domain: A25-A43 Cytosolic domain: K44-E107 53 2796034CD1 522 S10 S49 S77 S191 N59 N85 N120 Non-cytosolic domain: M1-Q522 TMHMMER S195 S204 S212 N487 N494 S335 S339 S344 S361 S371 S397 S443 S453 T72 T125 T138 T146 T228 T241 T245 T267 T318 T363 T496 54 4413112CD1 305 S28 S57 S98 S122 N44 N55 N130 Signal_cleavage: M1-S20 SPSCAN S238 S294 N148 Signal Peptide: M1-S20 HMMER Non-cytosolic domain: M1-T165 TMHMMER Transmembrane domain: I166-W188 Cytosolic domain: R189-H305 Leucine-rich repeat signature PR00019: L84-L97, BLIMPS_(—) V63-L76 PRINTS 55 7654832CD1 329 S2 S67 S150 S244 Signal_cleavage: M1-G46 SPSCAN S277 T121 Cytosolic domain: M1-T20 TMHMMER Transmembrane domain: I21-I43 Non-cytosolic domain: V44-R329 Ank repeat: Y232-T264, D102-I134, A69-L101, HMMER_PFAM D135-C167, S170-P199, H200-K231 56 7503849CD1 236 S34 S52 S96 S106 N152 Signal peptide: M18-A80 SPSCAN S113 S118 T38 T231

[0394] TABLE 4 Polynucleotide SEQ ID NO: / Incyte ID/Sequence Length Sequence Fragments 57/2867236CB1/ 1-222, 1-461, 1-464, 1-572, 4-516, 7-279, 12-266, 16-285, 23-278, 24-281, 24-522, 30-320, 31-309, 31-316, 34-172, 1485 34-327, 34-639, 42-282, 46-218, 46-335, 51-290, 51-342, 141-404, 141-405, 143-579, 182-471, 208-654, 208-684, 211-695, 217-453, 321-836, 335-910, 381-933, 390-996, 475-747, 475-762, 482-1009, 537-1153, 591-970, 717-993, 796-1090, 797-1382, 808-1485, 963-1280 58/1294096CB1/ 1-210, 1-383, 1-416, 1-508, 1-516, 1-6176, 33-443, 33-570, 228-695, 228-1034, 365-486, 495-1170, 511-962, 574- 6176 961, 647-975, 794-1062, 959-1554, 1000-1160, 1009-1246, 1009-1497, 1034-1327, 1075-1207, 1111-1292, 1170- 1258, 1250-1842, 1260-1540, 1261-1835, 1288-1927, 1292-1877, 1352-1518, 1417-1679, 1438-1085, 1446-1787, 1542-1841, 1697-1891, 1860-2146, 1872-1935, 1971-2491, 2021-2670, 2028-2623, 2108-2393, 2173-2698, 2174- 2729, 2179-2427, 2192-2528, 2194-2469, 2196-2775, 2198-2432, 2205-2471, 2206-2456, 2208-2458, 2211-2451, 2212-2465, 2226-2443, 2230-2787, 2242-2498, 2270-2481, 2281-2922, 2296-2933, 2310-2564, 2320-2575, 2327- 2614, 2329-2701, 2337-2663, 2350-2472, 2384-2671, 2384-3130, 2397-2558, 2397-2976, 2418-2677, 2450-2878, 2455-2608, 2470-2665, 2479-2725, 2480-2676, 2484-2768, 2496-3042, 2506-2905, 2509-2739, 2509-3040, 2512- 2772, 2563-3211, 2603-2902, 2665-2928, 2667-3092, 2673-3232, 2706-3159, 2711-3168, 2719-2972, 2726-3166, 2729-2927, 2738-3165, 2743-2840, 2744-3166, 2750-2997, 2763-3037, 2779-3309, 2780-3064, 2797-3413, 2822- 3091, 2829-3021, 2836-3285, 2843-3169, 2848-3438, 2852-3032, 2852-3209, 2856-3109, 2861-3546, 2881-3106, 2881-3375, 2890-3411, 2907-3364, 2910-3158, 2964-3435, 2993-3483, 2993-3597, 3009-3277, 3051-3494, 3056- 3286, 3069-3279, 3069-3583, 3071-3355, 3071-3660, 3098-3530, 3103-3348, 3126-3582, 3134-3337, 3140-3709, 3145-3396, 3174-3319, 3199-3388, 3199-3854, 3201-3770, 3204-3779, 3222-3627, 3250-3667, 3284-3920, 3308- 3625, 3336-3570, 3336-3594, 3336-3598, 3336-3601, 3336-3615, 3336-3617, 3336-3629, 3336-3631, 3336-3636, 3336-3669, 3342-3867, 3342-3957, 3342-3961, 3361-3965, 3370-3645, 3381-3575, 3381-3580, 3420-3832, 3435- 4105, 3460-3723, 3513-4121, 3519-3784, 3521-3985, 3542-3680, 3544-3775, 3559-4065, 3569-4170, 3576-3824, 3601-3810, 3625-3753, 3633-3852, 3639-4169, 3644-3940, 3651-4246, 3673-4260, 3682-3853, 3716-4031, 3720- 4094, 3720-4186, 3720-4194, 3721-4281, 3728-4206, 3728-4340, 3728-4427, 3749-4132, 3750-4001, 3750-4297, 3751-3880, 3759-4040, 3768-4266, 3778-4243, 3781-4065, 3783-4453, 3789-4049, 3796-4095, 3803-4392, 3820- 4049, 3820-4052, 3820-4106, 3835-4309, 3841-4163, 3841-4185, 3852-4098, 3853-4437, 3865-4082, 3865-4389, 3868-4165, 3892-4082, 3898-4136, 3899-4211, 3937-4467, 3940-4545, 3945-4098, 3954-4496, 3963-4183, 3973-4467, 3978-4383, 3987-4288, 3987-4535, 3991-4468, 3993-4595, 4004-4256, 4009-4482, 4011-4475, 4013- 4496, 4014-4292, 4017-4496, 4018-4481, 4020-4496, 4027-4496, 4028-4496, 4033-4480, 4037-4496, 4049-4496, 4050-4479, 4050-4496, 4054-4481, 4055-4481, 4057-4496, 4063-4481, 4067-4496, 4071-4480, 4077-4496, 4079- 4475, 4080-4480, 4088-4355, 4096-4480, 4099-4544, 4099-4580, 4107-4481, 4125-4421, 4130-4448, 4131-4486, 4136-4236, 4144-4481, 4145-4780, 4152-4421, 4162-4479, 4169-4480, 4169-4486, 4178-4464, 4180-4484, 4185- 4451, 4185-4544, 4185-4769, 4187-4402, 4192-4361, 4198-4476, 4224-4405, 4224-4445, 4237-4483, 4241-4496, 4249-4481, 4278-4715, 4283-4397, 4327-4587, 4370-4630, 4373-4627, 4402-4496, 4409-4717, 4449-4731, 4451- 4750, 4467-4618, 4468-4820, 4478-4720, 4478-5043, 4490-4908, 4492-4738, 4493-4740, 4497-5079, 4499-4646, 4503-4776, 4506-4737, 4525-4787, 4527-4755, 4552-5003, 4556-4852, 4561-4822, 4562-5252, 4564-5277, 4572- 4875, 4574-4841, 4591-5200, 4603-4856, 4604-4867, 4605-4849, 4605-4988, 4606-4864, 4610-4892, 4614-4818, 4614-5195, 4625-4875, 4625-4881, 4644-5326, 4649-4940, 4655-4824, 4657-5067, 4672-4965, 4677-5283, 4690-4934, 4694-4916, 4698-4976, 4700-4949, 4707-5179, 4715-4975, 4717-5277, 4727-4987, 4732-5006, 4732- 5009, 4743-4962, 4744-5327, 4749-5009, 4770-5078, 4780-5025, 4789-4995, 4798-5040, 4804-5290, 4823-4912, 4823-5407, 4824-4943, 4825-5077, 4829-5103, 4833-5086, 4855-5387, 4874-5558, 4912-5366, 4916-5718, 4919- 5475, 4987-5562, 4991-5497, 5003-5554, 5009-5551, 5015-5373, 5059-5359, 5087-5585, 5100-5412, 5117-5368, 5118-5354, 5123-5387, 5132-5378, 5132-5443, 5135-5600, 5136-5360, 5140-5388, 5159-5473, 5165-5390, 5166- 5424, 5169-5429, 5184-5409, 5189-5356, 5190-5680, 5205-5467, 5205-5505, 5206-5507, 5206-5759, 5213-5491, 5223-5507, 5227-5503, 5233-5953, 5236-5506, 5236-5734, 5238-5493, 5238-5507, 5248-5499, 5249-5575, 5255- 5376, 5267-5525, 5278-5587, 5279-5566, 5282-5555, 5286-5424, 5289-5901, 5290-5505, 5298-5566, 5301-5559, 5353-5640, 5354-5549, 5354-5597, 5354-5601, 5389-5912, 5412-5957, 5479-6039, 5544-5877, 5547-6168, 5574- 6129, 5591-5846, 5591-5990, 5591-6127, 5594-6062, 5599-6176, 5601-5849, 5603-6069, 5609-5864, 5609-5868, 5609-5925, 5609-5979, 5609-6133, 5611-5894, 5617-5868, 5619-5882, 5623-5862, 5632-5890, 5638-6176, 5645-5866, 5655-6169, 5659-5853, 5659-6082, 5664-5866, 5664-5911, 5671-5929, 5671-6063, 5671-6068, 5671- 6169, 5672-5929, 5673-5914, 5674-6169, 5682-6154, 5688-6169, 5689-5913, 5689-5961, 5689-5973, 5691-6095, 5692-6145, 5696-5948, 5697-6149, 5697-6169, 5699-5987, 5699-5993, 5703-6169, 5704-5982, 5704-6151, 5704- 6169, 5709-6166, 5710-5872, 5710-6170, 5712-5984, 5712-5995, 5712-6169, 5713-5872, 5716-6153, 5720-6176, 5729-6169, 5735-6145, 5745-6170, 5746-6169, 5749-5942, 5752-5994, 5752-6169, 5753-6022, 5753-6171, 5754- 6170, 5756-5999, 5756-6169, 5756-6174, 5757-6169, 5759-6169, 5759-6176, 5761-6169, 5762-6149, 5763-5996, 5764-6169, 5771-6035, 5771-6174, 5772-5994, 5775-5959, 5776-6016, 5780-6169, 5783-6061, 5783-6169, 5785- 6095, 5786-5991, 5786-6113, 5788-6169, 5789-6073, 5803-6071, 5805-6076, 5811-6173, 5812-6169, 5812-6176, 5814-6075, 5814-6142, 5814-6176, 5815-6174, 5816-6169, 5816-6171, 5817-6153, 5818-6169, 5819-6145, 5820- 6160, 5820-6173, 5820-6176, 5822-6176, 5824-6031, 5824-6169, 5824-6171, 5827-6149, 5830-6168, 5830-6169, 5832-6017, 5844-6170, 5846-6083, 5846-6095, 5846-6107, 5846-6170, 5850-6169, 5852-6152, 5852-6170, 5854-6095, 5861-6173, 5868-6169, 5874-6133, 5874-6169, 5881-6122, 5883-6136, 5887-6173, 5928-6162, 5928- 6176, 5931-6171, 5932-6133, 5935-6151, 5935-6162, 5935-6163, 5935-6174, 5937-6169, 5941-6166, 5941-6176, 5945-6166, 5957-6150, 5958-6119, 5958-6145, 5958-6154, 5962-6163, 5962-6166, 5963-6139, 5971-6147, 5971- 6176, 5973-6145, 5979-6175, 5989-6164, 5996-6137, 6005-6171, 6006-6151, 6006-6176, 6020-6169, 6022-6145, 6027-6142, 6051-6169, 6063-6169, 6087-6166, 6101-6169 59/7238537CB1/ 1-496, 13-568, 15-704, 16-417, 16-532, 17-371, 18-272, 18-325, 19-309, 20-571, 21-215, 25-288, 25-322, 27-288, 1944 32-623, 34-671, 35-287, 40-682, 41-638, 44-642, 54-372, 138-407, 147-380, 161-429, 204-838, 233-497, 233-767, 268-897, 297-829, 305-729, 310-664, 336-894, 338-586, 346-615, 352-938, 354-702, 369-771, 380-1045, 388-837, 394-1041, 428-710, 428-1061, 428-1206, 462-892, 472-896, 494-1232, 496-1077, 511-1063, 519-777, 527-797, 530- 772, 531-770, 548-1220, 558-1229, 559-1143, 561-1116, 561-1220, 578-1194, 584-1232, 586-864, 595-861, 603- 870, 634-1312, 662-1147, 681-1042, 681-1388, 686-1169, 703-1209, 710-1189, 723-1149, 731-1284, 741-1209, 744- 1175, 760-1324, 766-1079, 774-1188, 792-1051, 802-1160, 807-1052, 813-1120, 813-1386, 834-1191, 840-1129, 861-1318, 861-1439, 861-1470, 866-1128, 868-1403, 881-1117, 883-1122, 889-1516, 891-1156, 891-1168, 893- 1131, 894-1158, 896-1601, 904-1387, 908-1634, 915-1398, 924-1163, 924-1500, 924-1544, 930-1600, 931-1187, 931-1489, 934-1658, 938-1535, 942-1456, 947-1210, 951-1250, 957-1214, 959-1422, 967-1585, 970-1422, 976- 1226, 981-1419, 985-1418, 987-1704, 992-1520, 995-1259, 1003-1269, 1003-1567, 1005-1703, 1006-1585, 1010-1204, 1010-1263, 1010-1623, 1013-1303, 1014-1632, 1019-1354, 1024-1483, 1025-1545, 1031-1662, 1039- 1302, 1039-1418, 1039-1593, 1051-1698, 1052-1416, 1059-1300, 1063-1600, 1065-1422, 1066-1404, 1067-1464, 1073-1409, 1073-1593, 1074-1369, 1074-1419, 1075-1544, 1079-1323, 1081-1668, 1086-1544, 1088-1697, 1093- 1378, 1099-1544, 1101-1424, 1103-1544, 1110-1460, 1117-1462, 1128-1630, 1133-1703, 1135-1702, 1138-1617, 1140-1703, 1143-1550, 1145-1369, 1147-1544, 1153-1690, 1155-1702, 1157-1698, 1159-1696, 1171-1335, 1178- 1752, 1192-1544, 1200-1547, 1209-1540, 1213-1506, 1224-1928, 1236-1704, 1243-1704, 1247-1705, 1256-1703, 1256-1705, 1261-1705, 1263-1561, 1270-1704, 1273-1704, 1288-1705, 1290-1705, 1293-1696, 1293-1944, 1294- 1704, 1295-1704, 1297-1704, 1308-1703, 1308-1704, 1311-1568, 1315-1666, 1317-1704, 1318-1705, 1322-1705, 1324-1705, 1327-1627, 1327-1702, 1328-1704, 1332-1704, 1333-1704, 1334-1693, 1337-1696, 1344-1613, 1353- 1722, 1355-1650, 1362-1705, 1366-1654, 1366-1660, 1366-1704, 1372-1804, 1380-1704, 1386-1705, 1388-1645, 1389-1704, 1396-1704, 1403-1704, 1426-1682, 1480-1693, 1483-1704, 1494-1717, 1494-1737, 1542-1705 60/7494391CB1/ 1-669, 172-838, 295-743, 295-786, 295-843, 295-931, 295-934, 295-954, 295-1002, 295-1021, 299-774, 299-919, 1992 300-582, 300-1127, 346-1138, 347-974, 350-1163, 414-1050, 430-1203, 435-1167, 439-642, 444-517, 481-1162, 532-1242, 557-1282, 587-1396, 652-1310, 674-1162, 755-1546, 756-1560, 804-1044, 805-1586, 822-1464, 822- 1614, 838-1064, 883-1583, 922-1557, 924-1710, 961-1686, 964-1657, 965-1207, 990-1471, 1025-1312, 1025-1665, 1032-1842, 1033-1648, 1072-1643, 1075-1507, 1087-1921, 1099-1602, 1114-1555, 1121-1356, 1121-1475, 1134- 1474, 1156-1376, 1156-1825, 1161-1707, 1168-1893, 1190-1814, 1229-1870, 1255-1903, 1258-1769, 1266-1869, 1282-1575, 1300-1806, 1325-1992, 1347-1540 61/6451054CB1/ 1-24, 1-27, 1-36, 1-41, 1-42, 1-43, 1-53, 1-55, 1-64, 1-65, 1-71, 1-72, 1-75, 1-80, 1-83, 1-86, 1-88, 1-89, 1-90, 1-92, 3906 1-94, 1-95, 1-109, 1-117, 1-123, 1-130, 1-131, 1-139, 1-140, 1-170, 1-172, 1-186, 1-189, 1-190, 1-191, 1-193, 1-399, 5-189, 6-186, 7-189, 10-159, 14-151, 22-193, 29-193, 38-192, 38-193, 41-112, 44-189, 59-90, 71-193, 78-193, 79- 193, 86-193, 87-193, 91-192, 96-192, 122-193, 126-193, 127-193, 133-186, 139-192, 151-192, 153-191, 158-193, 162-193, 192-680, 192-728, 433-998, 433-1007, 433-1039, 433-1040, 444-668, 453-1350, 503-782, 573-1070, 573- 1166, 573-3748, 633-984, 633-1139, 639-1306, 666-1172, 683-950, 684-1132, 703-1346, 755-1518, 790-1294, 814- 1423, 867-1641, 869-1468, 909-1501, 996-1644, 1009-1598, 1025-1654, 1090-1117, 1103-1320, 1103-1610, 1105- 1535, 1105-1550, 1131-1438, 1136-1465, 1153-1704, 1158-1465, 1177-1419, 1178-1253, 1198-1709, 1201-1552, 1210-1552, 1224-1839, 1227-1486, 1239-1540, 1240-1540, 1249-1788, 1269-1821, 1292-1804, 1317-1499, 1332- 1556, 1426-2015, 1465-1953, 1471-1707, 1487-1693, 1509-2141, 1519-1798, 1520-1609, 1570-1912, 1593-2047, 1621-1891, 1631-2218, 1723-1882, 1726-2213, 1762-2341, 1764-2348, 1764-2431, 1765-2431, 1785-2431, 1816-2078, 1822-2074, 1843-2044, 1861-2292, 1874-2214, 1891-2776, 1921-2298, 1943-2431, 1969-2494, 1990- 2610, 2003-2306, 2011-2255, 2029-2290, 2029-2442, 2078-2299, 2079-2599, 2094-2558, 2121-2320, 2121-2323, 2127-2428, 2128-2336, 2128-2623, 2129-2857, 2136-2731, 2140-2430, 2155-2620, 2191-2846, 2198-2731, 2200- 2731, 2206-2460, 2210-2444, 2211-2367, 2217-3127, 2227-2447, 2243-2806, 2320-2898, 2325-2981, 2340-2767, 2354-2493, 2356-2466, 2358-2592, 2358-2740, 2373-2485, 2374-2561, 2374-2857, 2374-2892, 2378-2661, 2380- 2652, 2383-2656, 2394-2976, 2396-3005, 2430-3135, 2447-2699, 2447-2706, 2470-3044, 2473-2759, 2474-3022, 2482-3005, 2492-3007, 2498-2986, 2502-2946, 2503-2634, 2510-2706, 2510-3005, 2515-2964, 2516-2747, 2522- 3007, 2524-2768, 2527-2656, 2535-3028, 2555-2858, 2555-3132, 2555-3133, 2556-2825, 2559-2819, 2573-2795, 2593-2863, 2595-2857, 2598-2836, 2603-2876, 2603-2926, 2617-3043, 2619-2887, 2620-3067, 2623-2761, 2635- 3021, 2646-2908, 2649-3215, 2651-3260, 2652-3135, 2653-3065, 2659-3420, 2665-2946, 2679-3186, 2683-3348, 2684-3235, 2686-3166, 2687-3162, 2689-3174, 2711-2945, 2716-2983, 2732-2988, 2737-3247, 2739-3202, 2776-3348, 2783-3290, 2789-3052, 2790-3247, 2796-3045, 2799-3054, 2802-3423, 2830-3094, 2834-3460, 2846- 3098, 2847-3046, 2862-3145, 2866-3107, 2867-3029, 2869-3162, 2871-3253, 2871-3410, 2875-3131, 2891-3193, 2893-3193, 2900-3149, 2900-3494, 2901-3485, 2914-3137, 2922-3185, 2922-3381, 2925-3444, 2927-3495, 2932- 3584, 2947-3420, 2957-3233, 2959-3210, 2966-2998, 2991-3259, 2994-3597, 2997-3580, 3004-3264, 3013-3571, 3016-3181, 3023-3228, 3025-3299, 3025-3348, 3025-3662, 3026-3224, 3046-3308, 3051-3315, 3053-3526, 3057- 3562, 3059-3739, 3063-3300, 3079-3640, 3081-3742, 3096-3564, 3104-3748, 3105-3738, 3116-3737, 3119-3680, 3121-3358, 3127-3307, 3127-3647, 3128-3432, 3128-3701, 3129-3295, 3133-3513, 3145-3733, 3146-3739, 3156- 3365, 3156-3417, 3156-3427, 3156-3616, 3156-3738, 3175-3733, 3184-3635, 3188-3418, 3190-3742, 3193-3386, 3200-3407, 3200-3697, 3214-3457, 3214-3742, 3216-3738, 3227-3676, 3235-3691, 3246-3742, 3246-3743, 3247- 3746, 3255-3531, 3255-3748, 3256-3742, 3263-3491, 3263-3751, 3269-3536, 3274-3345, 3277-3396, 3277-3549, 3291-3748, 3292-3742, 3294-3748, 3296-3327, 3296-3703, 3296-3760, 3297-3742, 3298-3748, 3300-3548, 3300-3559, 3300-3743, 3300-3748, 3303-3748, 3306-3746, 3311-3748, 3314-3748, 3315-3748, 3321-3756, 3322- 3755, 3322-3760, 3331-3754, 3333-3760, 3342-3749, 3343-3746, 3344-3747, 3345-3616, 3346-3742, 3351-3750, 3360-3746, 3363-3748, 3371-3713, 3371-3748, 3372-3524, 3375-3741, 3377-3746, 3378-3748, 3382-3740, 3389- 3748, 3395-3674, 3397-3742, 3409-3664, 3410-3746, 3413-3746, 3417-3688, 3419-3711, 3423-3746, 3428-3760, 3440-3746, 3443-3748, 3450-3746, 3450-3748, 3455-3746, 3461-3732, 3469-3760, 3480-3681, 3482-3543, 3496- 3735, 3496-3748, 3499-3732, 3504-3733, 3504-3735, 3504-3747, 3504-3760, 3519-3742, 3528-3748, 3535-3748, 3585-3748, 3603-3735, 3609-3748, 3612-3748, 3614-3906, 3636-3748, 3665-3739 62/7494592CB1/ 1-234, 8-614, 30-557, 30-619, 31-226, 102-429, 127-689, 134-799, 150-400, 186-834, 238-571, 520-1276, 624- 3236 1216, 688-1195, 721-851, 792-1518, 821-1162, 835-1154, 905-1626, 916-1626, 922-1626, 943-1222, 953-1499, 1086-1616, 1112-1702, 1246-1665, 1251-1676, 1313-1858, 1441-1854, 1465-1919, 1477-1620, 1642-2180, 1697- 1860, 1716-2387, 1778-2128, 1796-2083, 1822-2371, 1846-2158, 1905-2422, 1973-2308, 2075-2187, 2092-2626, 2092-2631, 2094-2362, 2101-2662, 2191-2810, 2243-2655, 2506-2824, 2570-3236, 2572-2827 63/5202657CB1/ 1-237, 1-525, 2-270, 3-277, 3-300, 3-557, 3-567, 7-270, 7-275, 8-292, 8-529, 12-207, 12-248, 12-606, 26-274, 26- 1906 541, 27-276, 28-572, 29-306, 33-244, 33-330, 76-714, 119-450, 119-451, 125-371, 272-537, 296-556, 324-467, 553- 990, 555-813, 555-961, 557-812, 557-814, 571-812, 605-799, 608-860, 656-884, 661-927, 669-931, 712-959, 712- 976, 712-992, 713-980, 716-1007, 777-1048, 798-1050, 884-1405, 890-1120, 902-1175, 929-1294, 998-1533, 1018- 1432, 1037-1198, 1055-1230, 1061-1563, 1062-1283, 1064-1326, 1066-1342, 1068-1333, 1075-1396, 1079-1305, 1085-1345, 1085-1370, 1094-1347, 1102-1313, 1102-1321, 1102-1658, 1102-1789, 1139-1396, 1151-1648, 1177- 1403, 1183-1867, 1198-1894, 1205-1491, 1210-1827, 1226-1563, 1230-1834, 1237-1663, 1259-1874, 1264-1838, 1265-1544, 1268-1882, 1275-1566, 1284-1586, 1296-1516, 1303-1496, 1344-1583, 1346-1906, 1353-1874, 1359- 1594, 1366-1748, 1373-1635, 1375-1656, 1375-1851, 1378-1618, 1378-1619, 1393-1594, 1393-1631, 1393-1656, 1398-1751, 1425-1894, 1441-1898, 1446-1872, 1450-1906, 1455-1855, 1459-1891, 1462-1718, 1462-1878, 1467- 1864, 1475-1898, 1520-1793, 1520-1890, 1529-1878, 1536-1760, 1536-1823, 1558-1891, 1560-1890, 1587-1792, 1602-1870, 1606-1851, 1622-1872, 1636-1906, 1697-1906, 1708-1886, 1755-1891, 1776-1874 64/2013529CB1/ 1-153, 1-293, 1-303, 1-322, 1-383, 1-423, 1-469, 1-478, 1-483, 1-484, 1-490, 1-507, 1-560, 1-603, 1-611, 1-627, 1- 1347 654, 1-659, 1-660, 2-554, 2-630, 15-313, 15-636, 25-303, 25-328, 48-793, 64-554, 108-793, 183-441, 254-777, 279- 567, 282-556, 331-616, 341-1071, 350-604, 350-889, 374-591, 374-665, 413-610, 415-683, 455-1085, 517-848, 517- 924, 518-1149, 529-1098, 573-1203, 618-998, 634-1303, 647-1224, 675-1318, 681-895, 681-1040, 681-1057, 681- 1077, 681-1090, 681-1091, 681-1094, 681-1199, 681-1201, 681-1205, 681-1215, 681-1223, 681-1303, 681-1312, 684-1127, 684-1308, 751-1347, 761-1347, 771-1347, 816-1312, 908-1312, 916-1334, 929-1310, 1062-1347, 1089- 1310, 1128-1312, 1172-1310 65/3841351CB1/ 1-585, 1-1854, 21-594, 29-721, 31-630, 34-302, 46-582, 49-289, 74-312, 474-875, 632-884, 632-1014, 632-1230, 1854 632-1287, 675-1276, 761-1254, 814-1392, 850-1273, 864-1103, 904-1208, 906-1431, 945-1276, 949-1268, 1207- 1854, 1208-1608, 1316-1854, 1378-1603, 1410-1800, 1473-1560 66/152116CB1/ 1-568, 74-694, 81-697, 93-579, 105-775, 108-291, 239-902, 468-718, 468-869, 515-761, 579-838, 583-1327, 670- 1327 1289, 685-1291, 700-896, 872-1287 67/2381031CB1/ 1-225, 1-515, 1-604, 2-254, 3-272, 7-185, 7-266, 7-286, 7-290, 7-291, 7-294, 7-296, 8-207, 9-301, 11-307, 11-319, 627 15-264, 16-250, 17-278, 17-290, 17-295, 17-572, 18-246, 20-373, 22-301, 29-271, 29-287, 32-202, 32-257, 32-273, 32-291, 32-338, 32-343, 35-293, 35-295, 35-348, 37-194, 37-397, 37-452, 43-360, 51-327, 154-435, 155-617, 156- 433, 157-627, 158-607, 158-612, 162-378, 162-379, 164-615, 168-479, 169-627, 185-627, 188-606, 189-627, 204- 609, 223-607, 233-409, 254-615, 284-556, 292-573, 300-606, 344-529, 366-612, 418-627 68/2511371CB1/ 1-577, 237-1628, 328-691, 328-892, 334-925, 373-975, 496-1062, 557-1106, 686-855, 921-978, 1002-1634, 1053- 2564 1594, 1091-1766, 1102-1630, 1209-1827, 1210-1767, 1213-1642, 1213-1926, 1286-1943, 1305-1700, 1316-1945, 1336-1800, 1341-1981, 1341-2008, 1344-1908, 1345-1935, 1349-1899, 1464-2013, 1492-2061, 1503-1967, 1569- 2167, 1581-2170, 1662-2343, 1695-2351, 1746-2337, 1746-2400, 1750-2394, 1756-2418, 1772-2316, 1776-2497, 1902-2429, 1924-2453, 1930-2564 69/8068623CB1/ 1-1457, 1292-1820, 1292-1831, 1292-1843, 1292-1908, 1292-1933, 1305-2006, 1306-1967, 1307-1900, 1307-1942, 4134 1313-1790, 1319-1826, 1320-2234, 1322-1920, 1327-1889, 1331-1976, 1332-1610, 1352-1908, 1399-1856, 1439- 1929, 1485-1694, 1485-2040, 1501-1939, 1510-2089, 1516-2152, 1516-2156, 1516-2175, 1616-1985, 1695-1933, 1695-1942, 1738-1934, 1810-2017, 1810-2271, 1862-2339, 1882-2248, 1941-2478, 1961-2212, 1961-2214, 1970- 2218, 1975-2115, 1989-2719, 2009-2287, 2019-2457, 2019-2568, 2029-2269, 2046-2627, 2051-2697, 2055-2587, 2167-2434, 2185-2435, 2213-2829, 2258-2521, 2336-2525, 2408-2941, 2409-2620, 2430-2714, 2478-3024, 2547- 3147, 2670-2933, 2674-2921, 2674-3216, 2788-3037, 2867-3224, 2867-3445, 2908-3173, 2959-3159, 2959-3186, 2998-3252, 2998-3544, 3104-3358, 3195-3383, 3195-3432, 3285-3557, 3310-3502, 3368-3647, 3387-3642, 3410- 3598, 3491-3643, 3491-4021, 3499-3753, 3554-4134, 3610-3749, 3629-3859, 3652-3900, 3776-4011 70/677977CB1/ 1-1548, 464-1093, 467-1093, 482-1093, 496-1093, 502-1093, 504-1093, 506-1093, 513-1093, 515-1093, 528-1093, 2329 529-1093, 569-1093, 588-1093, 612-1088, 626-1093, 627-1093, 655-976, 678-1093, 694-1093, 903-1166, 927-1448, 1119-1860, 1161-1830, 1211-1741, 1253-1481, 1374-2024, 1378-1640, 1414-1546, 1414-1548, 1439-1704, 1461- 2042, 1467-1985, 1482-1548, 1512-1548, 1516-1548, 1519-1548, 1522-1548, 1548-1636, 1548-1733, 1548-1740, 1548-1763, 1548-1764, 1548-1788, 1548-2001, 1548-2080, 1548-2147, 1548-2195, 1548-2210, 1548-2220, 1548- 2329, 1578-1656, 1582-1851, 1585-2146, 1588-1849, 1588-2097 71/1661472CB1/ 1-389, 2-389, 4-26, 18-2925, 96-815, 118-777, 333-923, 366-622, 369-907, 482-1135, 536-1004, 573-812, 661- 2960 1021, 739-973, 739-1245, 743-1323, 774-1466, 793-1368, 882-1005, 927-1440, 964-1514, 1008-1582, 1035-1321, 1291-1719, 1305-1567, 1305-1721, 1369-1547, 1419-1666, 1419-1795, 1630-1685, 1675-2070, 1766-2529, 1781- 2148, 1781-2152, 1781-2164, 1781-2210, 1781-2221, 1781-2275, 1781-2292, 1781-2457, 1782-2446, 1799-2194, 1812-2291, 1839-2037, 1839-2318, 1843-2466, 1883-2459, 1893-2298, 1904-2271, 1935-2144, 1935-2150, 1939- 2197, 1941-2200, 1941-2541, 1941-2621, 1942-2327, 1949-2152, 1949-2206, 1994-2214, 1996-2151, 1997-2253, 2004-2298, 2005-2756, 2010-2248, 2028-2282, 2032-2262, 2032-2283, 2038-2258, 2038-2372, 2038-2489, 2039- 2723, 2046-2331, 2053-2544, 2055-2802, 2102-2744, 2111-2313, 2127-2345, 2127-2622, 2132-2914, 2140-2373, 2160-2754, 2161-2417, 2164-2392, 2166-2412, 2176-2445, 2203-2384, 2233-2883, 2239-2536, 2239-2548, 2259- 2497, 2270-2541, 2272-2520, 2285-2451, 2285-2761, 2306-2855, 2328-2760, 2341-2592, 2349-2619, 2349-2796, 2357-2810, 2372-2948, 2377-2628, 2385-2811, 2391-2811, 2403-2893, 2439-2857, 2443-2920, 2453-2926, 2468-2925, 2478-2921, 2483-2922, 2488-2960, 2497-2938, 2499-2923, 2500-2917, 2502-2920, 2504-2948, 2511- 2923, 2515-2923, 2520-2928, 2543-2926, 2549-2700, 2557-2920, 2568-2923, 2584-2934, 2595-2924, 2597-2914, 2726-2920, 2770-2924, 2773-2924 72/1748508CB1/ 1-523, 57-749, 89-761, 392-889, 473-739, 545-1327, 592-1314, 640-1337, 678-1404, 706-1471, 741-868, 860-1366, 2623 896-1143, 912-1385, 916-1156, 920-1172, 981-1578, 1067-1925, 1097-1796, 1150-1427, 1182-1797, 1240-1957, 1299-1529, 1322-1592, 1322-1603, 1322-1617, 1322-1737, 1322-1931, 1322-1962, 1345-1623, 1348-1770, 1352- 1619, 1353-1624, 1384-1750, 1384-1997, 1392-1661, 1439-1709, 1558-1769, 1558-1938, 1614-1899, 1725-2254, 1801-2046, 1859-2113, 1951-2195, 1951-2505, 1951-2603, 1953-2098, 1954-2495, 1956-2480, 1959-2116, 1963- 2501, 1963-2511, 1967-2209, 1980-2512, 1988-2601, 2010-2582, 2010-2613, 2046-2595, 2063-2584, 2064-2588, 2079-2616, 2085-2358, 2092-2257, 2098-2617, 2103-2502, 2106-2616, 2114-2616, 2122-2407, 2128-2592, 2138- 2592, 2141-2598, 2142-2595, 2142-2598, 2147-2599, 2148-2614, 2166-2616, 2167-2599, 2175-2307, 2182-2595, 2200-2595, 2201-2623, 2202-2595, 2207-2592, 2226-2597, 2229-2595, 2235-2505, 2244-2595, 2246-2616, 2263- 2595, 2264-2542, 2269-2565, 2288-2595, 2288-2597, 2297-2592, 2324-2578, 2344-2595, 2372-2615, 2424-2615, 2535-2599 73/2159545CB1/ 1-625, 1-695, 9-773, 46-2189, 275-1051, 343-822, 704-4518, 987-1569, 990-1563, 992-1230, 992-1443, 1029-1388, 4518 1260-1989, 1262-1572, 1263-1572, 1266-1569, 1266-1572, 1314-1570, 1363-1613, 1363-1912, 1520-2058, 1588- 2056, 1588-2086, 1590-1883, 1660-2224, 1736-2117, 1747-1939, 1781-2041, 1781-2324, 1798-2058, 1912-2216 74/8560269CB1/ 1-263, 1-272, 1-329, 65-281, 65-332, 67-209, 90-274, 90-389, 91-270, 132-788, 331-583, 346-802, 348-620, 358- 1238 949, 509-1075, 559-1024, 619-1030, 620-826, 620-879, 620-1031, 666-875, 666-1129, 678-1093, 736-1091, 764- 1057, 783-1107, 785-1045, 785-1078, 785-1088, 918-1184, 1020-1238 75/8710302CB1/ 1-226, 82-368, 96-381, 125-423, 180-915, 184-395, 188-437, 189-379, 481-984, 493-989, 499-917, 500-980, 550- 1771 869, 558-991, 561-973, 561-991, 563-991, 565-1159, 569-1250, 606-1103, 667-1226, 688-1356, 714-974, 714-1216, 718-989, 771-1028, 844-1142, 846-1402, 914-1493, 943-1371, 1032-1571, 1041-1598, 1041-1623, 1091-1369, 1091- 1372, 1091-1700, 1110-1383, 1154-1723, 1158-1444, 1273-1771, 1327-1598, 1330-1616 76/6778214CB1/ 1-143, 60-830, 148-772, 165-441, 182-425, 207-373, 217-893, 342-479, 381-851, 400-885, 404-851, 407-764, 415- 2909 886, 420-851, 431-851, 432-867, 438-1047, 455-851, 475-882, 501-851, 515-851, 541-851, 550-813, 551-859, 568- 851, 580-844, 621-880, 694-875, 871-1537, 882-1105, 883-1469, 884-1313, 888-1480, 891-1318, 891-1326, 891- 1348, 891-1575, 911-1111, 911-1312, 914-1221, 925-1362, 925-1394, 1001-1290, 1066-1374, 1088-1243, 1113- 1296, 1171-1645, 1213-1326, 1319-1556, 1319-1878, 1319-1919, 1351-1921, 1357-1592, 1376-1867, 1390-1921, 1406-1646, 1430-1671, 1478-1725, 1502-1701, 1522-1921, 1558-1917, 1560-1746, 1560-1921, 1587-1795, 1695- 1921, 1841-2143, 1847-1921, 1922-2129, 1922-2425, 2000-2203, 2009-2249, 2016-2218, 2016-2313, 2019-2155, 2055-2290, 2096-2381, 2166-2394, 2204-2485, 2204-2486, 2204-2795, 2208-2440, 2208-2444, 2241-2443, 2246- 2488, 2246-2831, 2286-2909 77/258383CB1/ 1-226, 82-368, 82-513, 82-520, 82-540, 82-557, 82-571, 82-575, 82-610, 82-613, 82-619, 82-626, 82-628, 82-676, 2216 82-734, 83-468, 83-571, 83-634, 88-548, 90-219, 96-381, 98-616, 122-423, 125-562, 168-785, 177-846, 182-513, 184-395, 188-437, 188-723, 188-748, 189-379, 189-663, 189-768, 201-747, 202-1007, 221-578, 234-785, 267-708, 354-910, 388-1073, 397-978, 411-979, 423-964, 437-928, 438-1036, 471-807, 480-1043, 529-962, 537-1184, 560- 1084, 574-1077, 592-1010, 593-1073, 651-1084, 654-1066, 654-1084, 656-1084, 658-1252, 662-1343, 699-1196, 760-1319, 781-1449, 807-1067, 807-1309, 811-1082, 864-1121, 937-1235, 939-1495, 1007-1586, 1036-1464, 1072- 1356, 1110-1417, 1125-1664, 1134-1691, 1134-1716, 1184-1462, 1184-1465, 1184-1793, 1203-1476, 1233-1424, 1247-1816, 1251-1537, 1366-1929, 1420-1691, 1423-1709, 1595-2216, 1643-2062, 1645-2216, 1669-2216, 1735- 2216 78/2804937CB1/ 1-841, 4-671, 292-843, 292-847, 294-643, 329-4681, 436-801, 605-894, 1232-1669, 1471-1741, 1950-2226, 1950- 5320 2439, 1950-2443, 1950-2520, 1950-2524, 2113-2740, 2115-2775, 2120-2793, 2213-2798, 2260-2857, 2323-2857, 2347-2870, 2383-3024, 2398-3079, 2429-3142, 2456-3035, 2459-3079, 2508-2838, 2532-3079, 2572-3160, 2599- 3079, 2607-3209, 2607-3232, 2620-3219, 2697-3259, 2701-2879, 2701-2994, 2701-3340, 2763-2817, 2779-3422, 2804-3070, 2811-3035, 2831-3243, 2831-3417, 2844-3133, 2861-3369, 2900-3064, 2914-3500, 2974-3256, 3001- 3609, 3021-3595, 3032-3535, 3060-3333, 3060-3553, 3065-3337, 3065-3565, 3085-3670, 3087-3678, 3094-3607, 3118-3607, 3118-3727, 3119-3762, 3129-3619, 3130-3693, 3135-3726, 3165-3841, 3166-3623, 3166-3766, 3214- 3444, 3219-3809, 3223-3819, 3235-3715, 3240-3879, 3264-3710, 3305-3845, 3306-3820, 3329-3979, 3336-3792, 3339-3972, 3342-4018, 3369-4032, 3370-3890, 3405-3946, 3422-3639, 3432-3927, 3447-3706, 3471-4052, 3471- 4124, 3493-4138, 3494-4126, 3496-4105, 3501-3762, 3501-3921, 3502-4028, 3503-4076, 3523-4138, 3556-3829, 3557-3772, 3569-4175, 3578-4188, 3591-3850, 3617-4269, 3621-3827, 3626-4175, 3637-3955, 3643-4208, 3647-4203, 3659-4214, 3663-4155, 3663-4275, 3678-4011, 3682-3950, 3682-4088, 3682-4214, 3695-4268, 3701- 4230, 3704-4293, 3717-3955, 3717-4286, 3726-4266, 3731-4312, 3734-4345, 3737-4355, 3749-4344, 3750-4006, 3750-4331, 3751-4011, 3756-4343, 3763-4293, 3780-4272, 3780-4450, 3781-4316, 3786-4056, 3807-4196, 3808- 3905, 3809-4469, 3810-4368, 3813-4209, 3816-4344, 3821-4013, 3824-4305, 3831-4422, 3832-4360, 3848-4565, 3855-4565, 3857-4401, 3863-4151, 3863-4216, 3863-4323, 3868-4458, 3870-4509, 3871-4565, 3883-4415, 3886- 4495, 3908-4535, 3914-4470, 3915-4384, 3924-4507, 3925-4182, 3934-4236, 3935-4427, 3937-4200, 3942-4356, 3942-4479, 3943-4218, 3946-4232, 3947-4591, 3948-4462, 3948-4591, 3952-4196, 3955-4129, 3961-4547, 3963- 4514, 3967-4606, 3974-4608, 3978-4440, 3994-4458, 3997-4385, 3997-4619, 3998-4458, 4007-4470, 4009-4517, 4014-4509, 4017-4625, 4017-4682, 4021-4449, 4029-4599, 4039-4646, 4061-4094, 4062-4609, 4067-4366, 4074- 4584, 4076-4659, 4081-4349, 4086-4313, 4086-4589, 4097-4659, 4120-4551, 4122-4741, 4124-4716, 4125-4591, 4135-4670, 4136-4645, 4137-4683, 4142-4709, 4146-4372, 4146-4634, 4146-4692, 4146-4729, 4147-4396, 4153- 4715, 4162-4679, 4164-4706, 4169-4639, 4169-4699, 4172-4686, 4180-4403, 4186-4718, 4188-4810, 4192-4842, 4211-4753, 4230-4681, 4244-4672, 4245-4836, 4258-4729, 4263-4622, 4263-4854, 4264-4699, 4275-4830, 4276- 4885, 4280-4888, 4288-4534, 4288-4723, 4288-4938, 4289-4895, 4297-4429, 4300-4871, 4312-4657, 4315-4760, 4315-4914, 4327-4753, 4327-4806, 4338-4888, 4340-4761, 4340-4903, 4355-4590, 4357-4565, 4361-4899, 4364- 5013, 4374-4899, 4389-4894, 4389-4898, 4390-4903, 4393-4964, 4399-4648, 4399-4895, 4406-4719, 4416-4654, 4416-4664, 4416-4879, 4421-4899, 4434-4902, 4438-4903, 4448-4978, 4471-4903, 4475-5125, 4477-4836, 4494- 4853, 4494-4958, 4496-4903, 4502-4901, 4503-4914, 4507-4903, 4510-4902, 4568-4974, 4570-4762, 4573-4903, 4575-4805, 4614-4898, 4651-4903, 4720-4943, 4720-4964, 4722-4893, 4867-5130, 4953-5320, 5018-5269, 5104- 5320, 5134-5320, 5155-5320 79/7494915CB1/ 1-653, 51-602 653 80/2073751CB1/ 1-415, 14-312, 14-367, 14-496, 14-507, 14-510, 14-559, 14-560, 19-268, 19-463, 54-340, 62-542, 81-564, 102-560, 1794 110-941, 111-372, 117-369, 117-599, 120-326, 191-508, 199-709, 239-550, 252-731, 532-599, 600-658, 788-1715, 790-1227, 792-1044, 1051-1229, 1082-1227, 1266-1794, 1280-1583, 1395-1544, 1716-1794 81/3178841CB1/ 1-282, 1-510, 8-281, 53-404, 55-518, 55-519, 58-501, 73-519, 78-447, 86-348, 90-501, 97-886, 115-515, 120-324, 2691 120-446, 120-519, 130-519, 136-387, 136-694, 148-519, 152-519, 160-515, 163-517, 163-519, 168-466, 179-464, 202-510, 265-954, 267-469, 467-1036, 485-1029, 512-970, 514-1021, 515-1164, 516-907, 516-981, 517-1116, 518- 1067, 521-905, 521-906, 521-931, 521-946, 521-991, 521-997, 521-1021, 521-1022, 521-1023, 521-1036, 521-1041, 521-1047, 521-1050, 521-1059, 521-1066, 521-1082, 521-1089, 521-1113, 521-1115, 521-1126, 521-1128, 521- 1130, 521-1136, 521-1145, 521-1154, 521-1158, 521-1167, 521-1172, 522-1116, 527-1206, 530-871, 530-1209, 543- 815, 543-921, 547-867, 547-977, 559-1076, 561-929, 585-1217, 599-882, 613-1267, 619-885, 620-1194, 647-1261, 653-1303, 673-1310, 692-1369, 698-1123, 720-1378, 733-1476, 734-889, 738-1379, 744-1025, 764-1217, 770-1470, 789-985, 793-1470, 794-1304, 800-1055, 813-1416, 834-1496, 871-1568, 883-1152, 883-1163, 883-1649, 905-1471, 925-1475, 937-1203, 1011-1630, 1012-1589, 1031-1512, 1054-1639, 1066-1719, 1120-1606, 1120-1755, 1156- 1396, 1157-1755, 1159-1431, 1177-1755, 1184-1388, 1238-1733, 1247-1737, 1248-1805, 1273-1512, 1273-1519, 1273-1527, 1273-1528, 1303-1769, 1346-1906, 1357-1525, 1361-1755, 1430-1727, 1453- 1966, 1459-1762, 1466-1755, 1492-2116, 1499-1784, 1501-1805, 1544-2110, 1565-1947, 1580-1967, 1582-1816, 1588-1765, 1605-1771, 1622-2150, 1631-2200, 1655-2263, 1672-1961, 1672-2161, 1717-2229, 1718-1921, 1718- 2180, 1730-2225, 1749-2302, 1749-2382, 1751-2005, 1751-2007, 1766-1992, 1776-2037, 1803-2200, 1822-2083, 1856-2292, 1869-2440, 1918-2081, 1939-2549, 1949-2601, 1953-2601, 1968-2397, 1989-2574, 2004-2394, 2009- 2536, 2043-2332, 2067-2346, 2068-2333, 2068-2425, 2069-2318, 2069-2417, 2074-2327, 2083-2341, 2112-2378, 2112-2648, 2112-2687, 2132-2442, 2136-2682, 2151-2662, 2167-2380, 2187-2691, 2200-2462, 2207-2486, 2234- 2531, 2238-2467, 2417-2579 82/3674807CB1/ 1-290, 1-436, 1-453, 1-456, 1-488, 1-491, 1-524, 1-558, 1-563, 1-581, 1-591, 1-598, 1-600, 1-613, 1-641, 1-652, 1- 2056 686, 1-754, 2-575, 41-736, 58-502, 83-748, 105-854, 126-911, 133-395, 157-874, 167-650, 197-807, 226-703, 230- 807, 265-716, 323-891, 388-1071, 406-708, 417-1080, 440-1053, 441-682, 443-1099, 444-1024, 445-1075, 497-850, 504-1064, 527-1165, 547-1182, 573-1124, 631-1179, 635-1204, 636-1165, 660-1163, 664-1218, 688-864, 716-1206, 719-1339, 723-1023, 752-1255, 759-1295, 771-1325, 773-1382, 778-1378, 795-1382, 800-1455, 804-1354, 811- 1272, 823-1461, 834-1202, 837-1525, 845-1438, 846-1296, 850-1224, 857-1058, 866-983, 866-1282, 866-1362, 918- 1530, 976-1553, 983-1497, 1009-1446, 1046-1509, 1251-1882, 1388-1888, 1424-1711, 1721-2056, 1754-2056, 1807- 2056 83/1794922CB1/ 1-283, 1-407, 169-592, 169-957, 579-972, 838-1488, 850-1634, 896-1138, 896-1385, 1031-1642, 1084-1347, 1084- 2275 1544, 1166-1411, 1357-1649, 1357-1662, 1417-2118, 1459-1655, 1459-1722, 1464-1719, 1464-1996, 1472-2167, 1574-2254, 1575-1878, 1643-1791, 1684-2275, 1739-1994, 1739-2183, 1739-2199, 1765-2246, 1808-2266, 1810- 2269, 1816-2265, 1821-2257, 1825-2275, 1844-2265, 1876-2266, 1926-2265, 2042-2275 84/1795509CB1/ 1-282, 1-284, 62-313, 71-271, 72-325, 72-512, 72-826, 100-415, 108-345, 145-648, 167-555, 238-443, 238-943, 240- 1219 788, 293-552, 322-845, 337-887, 370-887, 397-685, 443-683, 443-921, 443-943, 469-694, 499-1096, 512-745, 526- 717, 530-845, 571-1009, 574-1034, 575-889, 579-1038, 579-1051, 579-1061, 583-1052, 584-845, 651-878, 661- 1210, 661-1219, 668-1219, 674-1190, 677-845, 740-1208, 859-1219, 944-1206 85/2017180CB1/ 1-264, 1-305, 1-447, 6-433, 7-515, 7-517, 9-330, 11-615, 15-308, 16-235, 16-293, 18-211, 18-279, 18-295, 20-665, 1015 21-224, 22-375, 26-718, 33-259, 35-300, 35-812, 36-290, 39-504, 40-334, 51-328, 52-287, 52-747, 58-317, 72-686, 79-527, 80-344, 114-677, 145-308, 174-444, 196-465, 228-463, 252-753, 362-768, 439-717, 459-1015, 479-748, 520- 657, 527-1012, 557-862, 602-884, 673-1012, 703-994, 706-987, 722-964, 725-976, 725-1015, 731-999, 743-991 86/219442CB1/ 1-408, 1-416, 1-460, 2-384, 4-297, 7-283, 118-745, 158-447, 350-855, 376-855, 381-612, 394-664, 419-855, 441- 2392 855, 493-659, 525-1114, 592-855, 629-1263, 635-953, 665-1113, 774-1133, 801-998, 820-1269, 883-1239, 913- 1150, 916-1044, 937-1114, 963-1061, 963-1115, 1035-1269, 1096-1628, 1120-1616, 1437-1941, 1617-2266, 1619- 1890, 1668-1976, 1691-2045, 1707-2253, 1713-2392, 1787-2080, 1798-2096, 1816-1946, 1818-2392, 1836-2392, 1879-2345, 1901-2392, 1935-2328, 1939-2392, 1944-2328, 1953-2059, 1964-2382 87/2597459CB1/ 1-578, 148-611, 404-1009, 421-824, 427-884, 432-612, 517-1000, 643-847, 643-909, 643-1098, 643-1123, 643- 1799 1130, 643-1136, 643-1139, 643-1143, 643-1149, 643-1150, 643-1164, 643-1169, 643-1178, 643-1180, 643-1181, 643-1182, 643-1189, 643-1200, 643-1210, 643-1219, 643-1249, 643-1277, 643-1290, 674-1283, 701-1279, 705- 1413, 755-1305, 898-1080, 966-1231, 966-1425, 1018-1711, 1019-1588, 1022-1409, 1052-1630, 1066-1552, 1069- 1442, 1119-1713, 1133-1696, 1145-1555, 1165-1754, 1190-1795, 1194-1767, 1202-1743, 1251-1761, 1255-1381, 1262-1789, 1262-1799, 1283-1799, 1314-1440, 1314-1767, 1379-1634, 1384-1599, 1384-1799, 1437-1706, 1444- 1727 88/2783863CB1/ 1-556, 227-772, 270-767, 279-574, 279-823, 279-909, 300-863, 387-977, 468-959, 600-1232, 884-1201, 884-1341, 3718 884-1455, 927-1069, 962-1117, 962-1562, 985-1742, 1007-1525, 1007-1592, 1045-1763, 1066-1448, 1088-1339, 1171-2106, 1183-1451, 1183-1742, 1189-1967, 1250-1897, 1267-1954, 1296-2124, 1301-1449, 1433-2059, 1466- 2059, 1560-2297, 1571-1823, 1571-1828, 1606-2363, 1625-1911, 1658-2015, 1664-1905, 1664-1919, 1664-2146, 1676-2352, 1681-1994, 1683-2031, 1686-2246, 1839-2104, 1846-2049, 1850-2069, 1856-2826, 1870-2666, 2056- 2233, 2113-2365, 2216-2491, 2218-2823, 2241-2473, 2256-2834, 2256-2881, 2266-2546, 2298-2564, 2330-2618, 2336-2618, 2341-2784, 2363-2604, 2377-2897, 2387-2902, 2402-2646, 2402-2671, 2402-2954, 2450-2733, 2456- 2875, 2503-2721, 2512-2973, 2627-2889, 2644-2908, 2741-2973, 2755-3289, 2816-3209, 2836-3387, 2847-3655, 2895-3151, 2896-3466, 2912-3158, 2945-3180, 2970-3262, 2971-3224, 2985-3710, 2987-3274, 3063-3718, 3064- 3675, 3106-3636, 3116-3710, 3117-3695, 3139-3704, 3143-3712, 3192-3700, 3200-3496, 3201-3712, 3215-3664, 3227-3699, 3228-3645, 3248-3711, 3249-3711, 3252-3710, 3258-3710, 3305-3665, 3356-3599, 3356-3696, 3356- 3710, 3372-3707, 3407-3594, 3407-3605, 3407-3707, 3413-3664, 3426-3711, 3429-3707 89/2902971CB1/ 1-105, 1-622, 1-644, 2-200, 2-285, 2-287, 2-821, 4-273, 8-232, 8-254, 8-256, 8-282, 8-635, 13-251, 16-236, 18-138, 3250 18-284, 18-303, 18-313, 19-812, 29-673, 34-231, 34-232, 34-282, 34-842, 43-482, 61-274, 64-266, 65-266, 68-266, 102-650, 200-274, 208-258, 276-582, 327-501, 575-1157, 665-838, 665-1384, 784-932, 803-1417, 848-1665, 855- 1472, 908-1530, 1013-1615, 1030-1345, 1041-1266, 1123-1527, 1157-1611, 1160-1737, 1293-1535, 1403-1721, 1450-2069, 1466-1710, 1631-1749, 1631-2071, 1700-1983, 1739-2028, 1739-2180, 1809-2254, 1844-2278, 1897- 2310, 1959-2199, 1959-2477, 1959-2491, 1971-2250, 2001-2477, 2043-2477, 2043-2516, 2050-2477, 2063-2477, 2165-2362, 2165-2603, 2165-2783, 2285-2980, 2363-2748, 2364-2975, 2394-2659, 2467-3133, 2477-3163, 2478- 2936, 2478-2978, 2536-2807, 2604-2987, 2623-2875, 2623-2907, 2623-2911, 2623-2924, 2625-2944, 2678-3224, 2698-3219, 2755-3204, 2766-3237, 2775-3250, 2789-3062, 2789-3217, 2789-3222, 2792-3245, 2801-3242, 2812- 3237, 2828-3237, 2845-3235, 2849-3228, 2897-3231, 2923-3131, 2953-3250 90/368660CB1/ 1-584, 4-273, 7-286, 33-410, 34-790, 35-811, 41-548, 529-1215, 530-935, 584-1232, 648-1227, 653-1394, 654- 2295 1118, 684-1187, 795-1048, 923-1158, 928-1227, 928-1415, 958-1196, 1016-1265, 1017-1325, 1038-1309, 1163- 1368, 1172-1542, 1388-1705, 1473-1557, 1477-1691, 1482-1774, 1485-2117, 1489-1747, 1526-2130, 1569-1748, 1658-2186, 1712-1917, 1712-1931, 1712-1934, 1712-1936, 1712-1947, 1712-1965, 1712-1982, 1714-2190, 1720- 1853, 1728-2295, 1740-1996, 1754-2252, 1777-1984, 1779-2042, 1791-2051, 1853-2031, 1863-1997, 1920-2293, 1922-2295 91/2804990CB1/ 1-738, 1-780, 210-758, 214-1734, 414-722, 484-517, 495-743, 498-884, 518-801, 641-1240, 679-975, 735-1131, 743- 1777 1234, 763-1285, 847-1458, 868-1191, 918-1186, 973-1353, 1041-1348, 1041-1452, 1094-1432, 1154-1594, 1202- 1395, 1214-1614, 1214-1718, 1218-1688, 1218-1710, 1218-1747, 1222-1487, 1222-1689, 1222-1746, 1253-1478, 1255-1777, 1266-1720, 1270-1594, 1271-1594, 1273-1594, 1279-1550, 1282-1552 92/168571CB1/ 1-564, 1-591, 50-722, 177-780, 382-983, 404-661, 426-1056, 444-979, 543-1149, 599-1147, 648-1148, 682-1146, 3181 687-1146, 689-1139, 909-1605, 1150-1412, 1150-1567, 1150-1611, 1152-1417, 1157-1765, 1159-1624, 1159-1666, 1159-1759, 1159-1760, 1168-1625, 1196-1449, 1216-1550, 1291-1505, 1291-1541, 1322-1737, 1331-1542, 1579- 1793, 1601-1967, 1707-2028, 1717-1942, 1781-2282, 1800-2145, 1836-2063, 1839-2077, 1839-2409, 1865-2430, 1875-2369, 1952-2369, 1960-2574, 1960-2593, 1961-2169, 1968-2611, 1971-2361, 1975-2558, 1979-2167, 1999- 2656, 2019-2298, 2021-2406, 2021-2476, 2022-2241, 2022-2559, 2062-2304, 2079-2271, 2112-2382, 2128-2715, 2133-2685, 2160-2672, 2185-2509, 2204-2808, 2222-2644, 2223-2814, 2293-2571, 2303-2523, 2305-2868, 2329- 2576, 2334-2606, 2335-2628, 2341-2856, 2379-2693, 2417-2638, 2425-2727, 2472-2896, 2494-3097, 2495-2724, 2500-2696, 2500-2772, 2500-2781, 2500-2835, 2500-3078, 2501-2773, 2504-3008, 2519-3171, 2540-2851, 2544- 2861, 2565-2827, 2567-2786, 2579-3101, 2583-2744, 2586-2885, 2586-3094, 2588-3102, 2602-2863, 2607-2859, 2648-2863, 2649-2814, 2664-3165, 2671-3161, 2708-3002, 2749-3094, 2800-3180, 2821-3098, 2821-3116, 2902- 3149, 3025-3181 93/1286391CB1/ 1-650, 1-2676, 152-347, 266-860, 266-968, 362-528, 442-4155, 634-1105, 660-901, 823-1005, 823-1263, 1004- 5987 1581, 1104-1337, 1126-1735, 1207-1630, 1229-1926, 1324-2013, 1415-1659, 1415-1728, 1838-2104, 1872-2353, 1959-2529, 2093-2721, 2111-2647, 2132-2438, 2177-2678, 2233-2705, 2331-3122, 2352-2542, 2447-2678, 2491- 3289, 2537-3129, 2704-3268, 2729-3009, 2729-3192, 2729-3194, 2729-3279, 2729-3292, 2805-3377, 2822-3285, 2875-3573, 2893-3549, 3028-3710, 3060-3611, 3079-3290, 3114-3527, 3256-3902, 3281-3856, 3297-3848, 3331- 3838, 3336-3851, 3364-3863, 3438-3903, 3439-4143, 3545-4169, 3603-4056, 3603-4252, 3698-4456, 3701-4276, 3742-4452, 3743-4167, 3743-4326, 3743-4360, 3743-4365, 3743-4411, 3743-4424, 3743-4427, 3743-4458, 3743- 4487, 3747-3967, 3763-4251, 3780-4419, 3790-4053, 3790-4220, 3804-4498, 3807-4424, 3887-4391, 3888-4502, 3894-4451, 3896-4502, 3928-4074, 3928-4156, 3928-4499, 3930-4380, 3933-4609, 3961-4662, 3986-4244, 3991- 4459, 3992-4629, 3999-4529, 4025-4577, 4054-4691, 4054-4709, 4145-4184, 4193-4757, 4350-4878, 4350-5055, 4350-5067, 4351-5002, 4490-5197, 4490-5265, 4532-5209, 4545-5117, 4563-5157, 4592-5083, 4646-5278, 4650-5278, 4652-5315, 4683-5357, 4684-5339, 4709-5193, 4715-5341, 4720-5399, 4731-5400, 4732-5395, 4744- 5220, 4756-5348, 4763-5378, 4785-5413, 4788-5078, 4788-5267, 4788-5281, 4788-5309, 4788-5383, 4788-5472, 4788-5491, 4789-5386, 4789-5395, 4791-5425, 4792-5440, 4798-5064, 4798-5363, 4799-5383, 4799-5491, 4799- 5584, 4800-5349, 4801-5607, 4818-5087, 4823-5300, 4831-5288, 4844-5125, 4844-5320, 4845-5032, 4861-5409, 4897-5514, 4898-5493, 4899-5527, 4906-5384, 4910-5163, 4910-5578, 4914-5480, 4914-5493, 4915-5158, 4915- 5503, 4920-5527, 4921-5496, 4936-5650, 4939-5221, 4942-5449, 4946-5535, 4949-5559, 4950-5527, 4954-5455, 4954-5536, 4956-5501, 4964-5597, 4965-5565, 4967-5599, 4980-5564, 4999-5483, 5001-5457, 5002-5527, 5018- 5556, 5021-5274, 5024-5534, 5040-5564, 5042-5514, 5061-5522, 5068-5539, 5070-5696, 5140-5371, 5232-5942, 5311-5977, 5327-5981, 5331-5987, 5333-5977, 5336-5955, 5485-5987, 5572-5981, 5629-5743, 5629-5920, 5684- 5905, 5688-5920, 5753-5965, 5766-5920 94/2007684CB1/ 1-275, 1-536, 23-227, 55-580, 250-765, 345-610, 420-765, 451-759, 452-613, 474-613 765 95/2227040CB1/ 1-418, 123-418, 162-484, 167-671, 187-391, 428-651, 524-764, 524-769, 524-1060, 552-667, 601-952, 797-1050, 2674 797-1336, 840-1091, 1023-1444, 1034-1555, 1104-1684, 1149-1369, 1149-1626, 1301-1416, 1310-1545, 1318- 1546, 1506-2099, 1661-2031, 1662-1944, 1677-2331, 1705-1968, 1771-2277, 1799-2106, 1901-2385, 1936-2142, 1936-2190, 1936-2208, 1941-2209, 1944-2242, 1944-2247, 1944-2400, 1945-2150, 1968-2192, 1968-2474, 2002- 2233, 2035-2674, 2039-2295, 2064-2401, 2071-2639, 2083-2256, 2097-2248, 2101-2671, 2160-2419, 2166-2330, 2166-2377, 2168-2389, 2278-2377, 2290-2377 96/4346130CB1/ 1-479, 2-493, 2-533, 2-535, 2-561, 21-272, 24-400, 30-558, 32-402, 37-480, 179-705, 471-800, 492-789, 536-672, 5920 536-910, 536-1141, 784-1423, 860-1379, 971-1215, 971-1226, 971-1358, 971-1565, 1053-1324, 1137-1485, 1349- 1817, 1368-1624, 1368-1841, 1435-1987, 1435-2009, 1561-2121, 1588-1817, 1590-2121, 1600-1817, 1720-1817, 1722-1817, 1768-2170, 2013-2504, 2079-2317, 2079-2346, 2079-2398, 2155-2682, 2155-2738, 2310-5524, 2373- 2857, 2451-2684, 2544-3072, 2771-3257, 2948-3187, 3369-4024, 3537-4052, 4366-4776, 4377-4732, 4378-4682, 4413-4693, 4752-5051, 4919-5161, 4945-5574, 5013-5385, 5055-5646, 5070-5319, 5241-5501, 5303-5864, 5392- 5780, 5392-5802, 5393-5627, 5431-5684, 5431-5920, 5433-5837, 5469-5873 97/55117040CB1/ 1-341, 1-347, 1-385, 1-418, 1-560, 1-661, 4-661, 5-661, 58-637, 89-157, 89-167, 89-171, 114-823, 200-268, 200- 1689 282, 201-282, 225-268, 325-877, 805-1689, 817-1532 98/7472392CB1/ 1-157, 1-158, 1-195, 1-333, 1-364, 1-438, 1-508, 1-510, 1-513, 1-546, 1-620, 1-624, 1-657, 1-684, 1-721, 1-735, 1- 1314 744, 1-764, 1-831, 1-912, 1-1048, 1-1307, 4-548, 14-811, 20-661, 24-920, 76-1044, 80-141, 231-778, 231-782, 342- 761, 502-1031, 536-1035, 536-1314, 561-657, 576-973, 648-788 99/4028960CB1/ 1-824, 11-856, 19-545, 97-209, 115-790, 174-777, 174-850, 187-655, 209-534, 396-678, 434-650, 434-950, 657- 3322 935, 657-1053, 783-1046, 783-1383, 834-970, 879-1067, 885-1496, 945-1592, 1071-1491, 1176-1337, 1234-1892, 1284-1663, 1293-1801, 1314-1534, 1320-1704, 1341-1953, 1454-1760, 1684-1919, 1684-1920, 1684-1933, 1684- 2140, 1690-2148, 1850-2042, 1873-2116, 1875-2098, 1890-2348, 1963-2703, 2027-2518, 2043-2329, 2101-2324, 2127-2372, 2137-2776, 2169-2577, 2218-2493, 2322-2911, 2324-2491, 2336-2994, 2344-2558, 2395-2924, 2403- 3035, 2409-2592, 2414-2978, 2415-2688, 2496-2757, 2498-2724, 2505-3038, 2529-2864, 2536-2980, 2562-2692, 2632-3052, 2654-3051, 2743-3233, 2767-3227, 2784-3224, 2787-2921, 2794-3016, 2808-3218, 2817-3050, 2906- 3322 100/8227004CB1/ 1-250, 1-434, 1-492, 1-611, 1-612, 1-676, 1-860, 100-900, 114-772, 238-680, 247-879, 273-494, 288-685, 341-1108, 3621 396-813, 402-813, 425-1104, 467-1245, 507-1224, 526-896, 650-1364, 655-1231, 656-1302, 661-1301, 668-1423, 671-1042, 679-1258, 711-1301, 760-1301, 763-1131, 782-1542, 787-1323, 794-1224, 818-1271, 852-1355, 874- 1462, 904-1036, 916-1301, 961-1624, 980-1454, 1011-1397, 1025-1592, 1028-1255, 1031-1728, 1065-1298, 1065- 1605, 1149-1842, 1168-1548, 1202-1682, 1209-2160, 1217-1697, 1229-1757, 1282-1511, 1313-1804, 1334-2037, 1362-2087, 1372-1967, 1400-2375, 1407-2144, 1497-2162, 1621-2285, 1627-2092, 1627-2569, 1629-2068, 1630- 2318, 1652-1880, 1673-2409, 1683-2354, 1708-1979, 1733-1995, 1742-2449, 1743-2000, 1745-2189, 1746-2419, 1751-2439, 1751-2497, 1759-2530, 1792-2108, 1795-2614, 1816-2097, 1834-2105, 1845-2598, 1893-2144, 1893- 2485, 1903-2586, 1904-2715, 1904-2732, 1949-2203, 1951-2207, 1975-2296, 1977-2878, 1979-2214, 1980-2645, 1989-2407, 1996-2256, 1999-2668, 2006-2722, 2025-2560, 2032-2514, 2046-2745, 2061-2540, 2079-2707, 2094- 2348, 2094-2895, 2106-2296, 2106-2510, 2109-2289, 2109-2597, 2112-2372, 2119-2385, 2138-2789, 2150-2447, 2174-2333, 2188-2889, 2195-2841, 2209-2802, 2216-2546, 2251-2596, 2251-2604, 2272-2527, 2296- 2583, 2297-2575, 2312-2811, 2321-2574, 2335-2664, 2343-2950, 2350-2865, 2351-2879, 2353-2827, 2355-2567, 2363-2759, 2390-2588, 2394-2664, 2421-2920, 2426-2740, 2427-2942, 2447-2862, 2458-2846, 2462-3141, 2466- 2720, 2470-3192, 2483-2699, 2483-2997, 2798-3256, 2859-3106, 2908-3175, 2921-3178, 3049-3309, 3049-3621 101/3044763CB1/ 1-283, 41-819, 66-368, 88-204, 215-856, 218-734, 303-647, 389-661, 421-706, 465-713, 482-1060, 490-610, 490- 2704 952, 511-1108, 516-1026, 569-1199, 576-1240, 585-1112, 673-1246, 677-1221, 697-974, 732-978, 742-1290, 755- 1049, 780-1430, 824-997, 844-1079, 872-1392, 913-1188, 946-1561, 979-1529, 1035-1304, 1035-1755, 1035-1818, 1039-1294, 1056-1207, 1056-1290, 1076-1758, 1111-1489, 1113-1375, 1117-1433, 1147-1515, 1162-1458, 1166- 1744, 1171-1427, 1172-1518, 1173-1393, 1191-1461, 1208-1511, 1217-1365, 1227-1537, 1249-1800, 1273-1923, 1290-1513, 1296-1547, 1302-1495, 1321-1409, 1324-1798, 1332-1627, 1341-1494, 1341-1623, 1343-1818, 1363- 1682, 1363-1886, 1380-1649, 1388-1631, 1390-1635, 1390-1822, 1392-1911, 1397-1818, 1400-1818, 1402-1734, 1419-1791, 1420-1799, 1429-1818, 1438-1714, 1460-1646, 1461-1677, 1503-1918, 1511-1897, 1522-1608, 1556- 1799, 1571-1818, 1577-2418, 1596-1818, 1637-1918, 1643-1878, 1658-1808, 1658-1818, 1660-2116, 1754-1860, 1757-1813, 1757-1818, 1760-1918, 2110-2704 102/4044519CB1/ 1-146, 1-291, 1-490, 1-574, 1-583, 1-598, 1-627, 1-631, 1-657, 1-679, 1-680, 1-808, 92-804, 98-820, 159-495, 479- 1345 1252, 509-1289, 615-1345, 674-1329, 684-1341, 764-1342 103/71351918CB1/ 1-246, 27-253, 29-80, 30-304, 33-278, 33-376, 33-561, 34-225, 36-571, 38-280, 43-324, 60-315, 61-286, 169-738, 1607 308-578, 419-947, 423-659, 424-695, 441-1112, 444-972, 466-994, 468-793, 478-829, 490-798, 498-1124, 506-725, 512-1016, 516-946, 519-791, 545-1040, 547-997, 565-1145, 568-849, 570-813, 570-956, 571-965, 576-736, 579- 1111, 581-1028, 582-1167, 587-1142, 588-1208, 595-1145, 595-1378, 596-857, 600-1109, 614-1186, 624-1220, 628- 848, 633-1213, 638-1225, 640-1172, 641-1244, 648-822, 648-1403, 649-955, 659-756, 672-1106, 676-1403, 678- 949, 680-1192, 683-931, 684-1206, 684-1228, 693-976, 699-1040, 700-960, 711-1305, 715-1263, 726-1304, 730- 987, 730-1358, 742-1339, 748-1399, 757-1264, 760-1244, 770-992, 771-1131, 787-1301, 788-1014, 796-1301, 798- 1336, 814-1374, 825-1536, 832-1068, 838-1396, 843-1044, 846-1093, 846-1482, 858-1114, 860-1494, 866-1149, 866-1428, 867-1306, 875-1471, 876-1120, 878-1146, 879-1238, 883-1528, 890-1533, 893-1090, 897-1393, 899- 1127, 899-1546, 900-1203, 904-1281, 917-1364, 918-1430, 928-1371, 930-1544, 937-1540, 949-1444, 952-1414, 952-1537, 955-1527, 956-1081, 963-1533, 988-1106, 990-1264, 999-1540, 1003-1459, 1006-1539, 1014-1473, 1015-1415, 1025-1288, 1028-1543, 1028-1550, 1030-1539, 1043-1527, 1046-1317, 1047-1358, 1047- 1367, 1047-1607, 1050-1546, 1051-1475, 1058-1353, 1070-1316 104/8109363CB1/ 1-521, 125-498, 246-543, 268-746, 315-549, 367-885, 403-1139, 464-717, 634-903, 662-1255, 704-925, 742-1371, 2622 845-1124, 864-1385, 966-1471, 1041-1444, 1045-1444, 1105-1415, 1105-1618, 1320-1624, 1320-1888, 1361-1648, 1373-1884, 1448-1688, 1556-1811, 1584-2049, 1591-1840, 1596-2174, 1690-1962, 1697-1956, 1697-2207, 1701- 1826, 1772-2051, 1790-2055, 1935-2190, 1937-2617, 2003-2253, 2003-2302, 2003-2490, 2010-2236, 2010-2309, 2011-2622, 2012-2593, 2052-2318, 2063-2292, 2063-2296, 2087-2622, 2094-2616, 2096-2340, 2161-2424, 2254- 2510 105/1272746CB1/ 1-214, 1-254, 1-595, 3-267, 7-248, 41-267, 46-275, 154-268, 202-394, 202-775, 202-841, 207-392, 207-534, 207- 3489 918, 340-632, 340-866, 401-1133, 463-1095, 506-1225, 592-864, 746-1357, 748-1382, 772-1095, 929-1193, 954- 1410, 959-1425, 1059-1554, 1064-1421, 1166-1419, 1336-1669, 1449-1951, 1493-2128, 1519-1968, 1519-2004, 1519-2045, 1519-2055, 1519-2096, 1519-2113, 1519-2155, 1519-2161, 1519-2202, 1520-2009, 1521-1786, 1560- 2144, 1569-2178, 1625-2247, 1642-1783, 1663-1912, 1700-2520, 1710-2140, 1734-2263, 1813-2446, 1860-2519, 1880-2572, 1937-2098, 1951-2552, 1953-2706, 1955-2186, 1955-2219, 1955-2641, 1955-2763, 1956-2325, 1959- 2420, 1965-2559, 1976-2243, 1982-2480, 1994-2072, 2023-2579, 2024-2647, 2031-2642, 2052-2697, 2053-2742, 2126-2775, 2127-2699, 2135-2420, 2139-2833, 2173-2730, 2177-2840, 2182-2783, 2183-2869, 2215-2456, 2215- 2830, 2229-2785, 2236-2935, 2242-2935, 2246-2852, 2256-3027, 2257-2763, 2288-2848, 2294-2924, 2296-2932, 2301-2525, 2314-2824, 2322-2524, 2322-2792, 2324-2935, 2341-2935, 2344-2914, 2354-2935, 2358-2935, 2373- 2932, 2379-2932, 2382-2935, 2384-2918, 2386-2599, 2386-2935, 2389-2935, 2391-3001, 2397-2693, 2413-2639, 2422-2935, 2424-2935, 2431-2679, 2443-3079, 2449-2935, 2468-3177, 2477-2941, 2487-2856, 2495-2935, 2499- 2932, 2516-2932, 2524-3136, 2526-2932, 2530-2938, 2558-2935, 2561-2935, 2609-3294, 2620-3315, 2621-2940, 2624-2907, 2648-2773, 2658-3455, 2674-3489, 2708-3463, 2756-3191, 2768-2977, 2768-3252, 2768-3265, 2768- 3267, 2768-3278, 2768-3288, 2768-3372, 2830-3068, 2830-3195, 2833-3452, 2867-3421, 2889-3431, 2916-3366, 2941-3196, 2962-3443, 2977-3197, 2992-3444, 3020-3285, 3105-3349, 3105-3434, 3105-3452, 3122-3330, 3125- 3443, 3126-3449, 3137-3306, 3228-3443, 3230-3443, 3305-3449 106/1839974CB1/ 1-747, 1-757, 24-624, 25-529, 25-530, 87-694, 150-944, 179-571, 313-528, 458-1022, 469-1197, 588-930, 820- 2269 1097, 893-1455, 1174-1547, 1174-1604, 1179-1519, 1362-1636, 1447-1743, 1513-1804, 1521-1764, 1654-2269, 1658-1892, 1658-2148, 1661-2231, 1812-2269, 1905-2103, 1912-2175, 1949-2240, 2008-2098 107/1877336CB1/ 1-194, 1-197, 1-399, 3-412, 4-295, 7-222, 9-240, 13-569, 13-608, 15-558, 15-642, 17-218, 19-628, 25-277, 25-549, 3075 33-305, 34-614, 38-621, 43-698, 102-510, 103-770, 103-800, 112-738, 137-754, 138-429, 144-664, 173-730, 241- 514, 259-535, 262-614, 262-662, 286-594, 421-648, 573-1015, 641-1229, 691-1147, 713-942, 725-1421, 757-1368, 803-1368, 806-1309, 820-1492, 835-1360, 835-1368, 837-1459, 840-1325, 844-1339, 872-1439, 877-1464, 883- 1467, 889-1366, 893-1557, 895-1366, 898-1370, 926-1593, 959-1455, 971-1387, 1007-1678, 1014-1567, 1045- 1572, 1075-1707, 1097-1225, 1104-1471, 1104-1662, 1104-1698, 1106-1800, 1154-1653, 1156-1735, 1160-1850, 1176-1709, 1176-1859, 1177-1806, 1180-1801, 1183-1718, 1196-1800, 1215-1736, 1224-1878, 1252-1897, 1265- 1829, 1272-1801, 1283-1639, 1291-1815, 1295-1830, 1314-1866, 1316-1807, 1318-1861, 1319-1795, 1319-1908, 1325-1836, 1335-1848, 1335-1851, 1338-1941, 1340-1905, 1346-1784, 1347-1867, 1355-1820, 1359-1851, 1363- 1859, 1379-1947, 1384-1891, 1406-1927, 1417-1902, 1436-2104, 1500-2058, 1519-1981, 1520-2025, 1520-2034, 1521-1859, 1521-1860, 1526-2061, 1528-2160, 1529-2025, 1548-2212, 1557-2158, 1562-2158, 1567-2301, 1591-2113, 1598-2183, 1606-2125, 1610-2247, 1612-2157, 1612-2186, 1628-2291, 1647-2255, 1675-2326, 1684- 2069, 1684-2301, 1687-2349, 1699-2148, 1700-2215, 1700-2252, 1704-2212, 1705-2205, 1705-2360, 1738-2370, 1743-2076, 1750-1776, 1752-2278, 1762-2337, 1763-2190, 1763-2285, 1764-2236, 1777-2503, 1791-2295, 1793- 2186, 1794-2364, 1800-2361, 1805-2226, 1815-2085, 1819-2382, 1831-2323, 1842-2302, 1873-2325, 1988-2212, 2005-2608, 2039-2706, 2085-2673, 2323-2357, 2365-2695, 2397-2962, 2402-2686, 2418-2677, 2419-2999, 2420- 2670, 2430-2668, 2448-2678, 2449-2612, 2457-2660, 2603-2663, 2702-2789, 2704-3056, 2716-2984, 2723-3056, 2729-3057, 2736-2912, 2738-2981, 2762-2981, 2762-2997, 2769-2974, 2769-3013, 2769-3027, 2777-3057, 2784- 3024, 2785-3058, 2789-3029, 2801-3018, 2811-3056, 2811-3075, 2822-3049, 2823-3049, 2829-3055, 2831-3075, 2833-3039, 2834-3059, 2845-3058, 2851-3061, 2851-3075, 2852-3027, 2852-3046, 2861-3075, 2865-3059, 2865- 3075, 2867-3037, 2868-3075, 2876-3046, 2876-3056, 2876-3059, 2876-3073, 2877-3056, 2878-3039, 2879-3058, 2881-2987, 2883-3063, 2885-3032, 2885-3075, 2887-3056, 2887-3058, 2887-3059, 2887-3073, 2887-3075, 2890-2989, 2892-3058, 2894-3075, 2895-3042, 2908-3060, 2949-3075, 2998-3057, 2998-3060, 2998-3063, 2998- 3064, 2999-3075 108/2321054CB1/ 1-96, 1-109, 1-134, 1-273, 100-364, 100-637, 100-656, 100-691, 100-700, 100-831, 100-834, 100-848, 101-453, 132- 849 842, 174-823, 200-731, 200-784, 213-780, 246-833, 273-573, 278-849, 287-796, 297-831, 323-537, 323-553, 334- 838, 355-642, 360-587, 361-696, 382-652, 554-776 109/2796034CB1/ 1-790, 49-773, 85-773, 118-773, 300-773, 326-773, 498-773, 544-799, 563-804, 608-810, 709-1077, 801-1077, 947- 2659 1142, 958-1273, 958-1538, 991-1142, 1008-1219, 1262-2658, 1263-1551, 1408-1997, 1479-1860, 1715-2350, 2017- 2618, 2156-2306, 2187-2659 110/4413112CB1/ 1-268, 1-289, 1-622, 10-245, 10-254, 10-358, 10-433, 10-438, 15-263, 367-623, 367-779, 367-816, 367-884, 367- 2205 889, 367-897, 367-942, 367-944, 367-947, 367-955, 367-1001, 367-1010, 367-1026, 367-1064, 367-1089, 370-982, 372-464, 382-1075, 458-737, 458-1128, 653-1316, 713-981, 769-1212, 802-1467, 823-1343, 901-1468, 949-1164, 949-1167, 950-1323, 964-1578, 1031-1397, 1034-1650, 1040-1500, 1094-1394, 1129-1804, 1310-1503, 1362-1621, 1416-1512, 1436-1691, 1462-1667, 1462-1717, 1462-1964, 1467-1778, 1478-1619, 1504-1800, 1545-1912, 1611- 1837, 1611-2115, 1657-1911, 1703-2205, 1762-2018 111/7654832CB1/ 1-391, 1-567, 29-488, 29-678, 97-699, 104-846, 115-227, 153-627, 153-680, 153-684, 153-726, 153-769, 153-776, 3042 648-942, 649-814, 649-1187, 713-1409, 733-1267, 951-1546, 1107-1800, 1207-1869, 1207-1901, 1207-1938, 1207- 1945, 1207-1947, 1207-1981, 1207-1982, 1207-1987, 1207-1994, 1207-1996, 1207-1999, 1208-1938, 1208-1943, 1208-2086, 1274-2012, 1600-1872, 1668-1940, 1668-2141, 1668-2353, 1669-2432, 1819-2113, 1858-2031, 2050- 2567, 2051-2327, 2120-2973, 2121-2428, 2135-2973, 2139-2975, 2311-2951, 2393-3009, 2412-3042, 2416-3042, 2423-2949, 2439-3039, 2446-2973, 2460-3009, 2483-2728, 2552-2800, 2559-3042, 2630-2862, 2770-3027 112/7503849CB1/ 1-214, 1-216, 1-249, 1-273, 1-293, 2-239, 4-783, 6-301, 6-343, 8-2112, 10-556, 13-311, 14-303, 14-495, 16-264, 16- 2112 633, 17-295, 18-248, 18-269, 18-605, 18-707, 19-252, 19-258, 19-287, 19-536, 19-712, 20-272, 20-374, 21-268, 21- 292, 21-328, 21-337, 21-343, 21-444, 22-325, 22-416, 22-703, 23-298, 23-540, 23-641, 24-219, 24-456, 25-687, 25- 709, 27-335, 28-304, 29-597, 35-626, 37-665, 37-674, 38-538, 38-704, 39-570, 39-625, 40-631, 40-645, 41-685, 41- 784, 42-657, 42-757, 43-301, 45-592, 48-630, 48-708, 51-344, 51-418, 51-421, 53-337, 57-489, 58-386, 59-340, 60- 311, 61-418, 62-307, 67-387, 89-333, 115-735, 139-404, 141-338, 141-410, 145-383, 164-440, 165-386, 167-414, 180-464, 186-546, 186-607, 211-466, 218-413, 218-721, 219-539, 220-688, 221-310, 221-446, 230-520, 230-556, 232-485, 235-531, 236-770, 239-874, 278-497, 288-765, 297-748, 314-737, 329-508, 334-580, 384-510, 531-1073, 563-833, 656-945, 674-907, 698-1310, 882-1475, 948-1177, 950-1399, 969-1314, 980-1554, 1012-1252, 1016-1515, 1028-1678, 1030-1298, 1035-1615, 1045-1301, 1047-1501, 1048-1284, 1048-1344, 1056-1684, 1058-1328, 1058- 1330, 1058-1336, 1060-1298, 1062-1799, 1066-1582, 1080-1643, 1083-1800, 1091-1668, 1091-1712, 1092-1335, 1098-1657, 1101-1826, 1109-1560, 1109-1624, 1126-1590, 1134-1753, 1137-1590, 1148-1587, 1152- 1586, 1153-1715, 1159-1762, 1168-1314, 1170-1437, 1170-1735, 1172-1789, 1172-1871, 1177-1431, 1177-1474, 1177-1791, 1179-1651, 1190-1636, 1192-1713, 1204-1466, 1205-1628, 1206-1470, 1206-1586, 1219-1584, 1221- 1489, 1225-1628, 1226-1468, 1232-1590, 1234-1467, 1234-1632, 1240-1590, 1240-1800, 1241-1497, 1241-1537, 1241-1587, 1242-1712, 1244-1485, 1246-1427, 1246-1491, 1248-1836, 1249-1708, 1249-1873, 1253-1712, 1255- 1865, 1260-1546, 1266-1712, 1268-1592, 1268-1873, 1270-1497, 1270-1712, 1275-1717, 1275-1718, 1277-1647, 1284-1541, 1295-1826, 1298-1873, 1299-1873, 1300-1715, 1300-1871, 1300-1873, 1302-1873, 1303-1710, 1303- 1785, 1307-1871, 1308-1870, 1316-1536, 1316-1868, 1319-1718, 1321-1858, 1324-1590, 1324-1864, 1325-1866, 1343-1872, 1344-1463, 1345-1583, 1360-1586, 1360-1715, 1379-1676, 1382-1873, 1402-1873, 1415-1873, 1424- 1494, 1424-1873, 1428-1590, 1428-1729, 1428-1873, 1429-1873, 1441-1712, 1441-1872, 1453-1673, 1456-1873, 1458-1873, 1461-2112, 1462-1873, 1463-1872, 1464-1850, 1464-1873, 1476-1871, 1476-1872, 1479-1736, 1483- 1834, 1490-1570, 1490-1873, 1493-1811, 1496-1872, 1502-1861, 1520-1796, 1521-1820, 1528-1658, 1530-1873, 1533-1873, 1534-1822, 1534-1830, 1534-1872, 1548-1872, 1554-1873, 1556-1813, 1557-1872, 1563-1704, 1564- 1872, 1571-1872, 1573-1873, 1599-1868, 1601-1844, 1601-1845, 1624-1873, 1701-1873, 1748-1859, 1814-1864

[0395] TABLE 5 Polynucleotide Incyte Representative SEQ ID NO: Project ID: Library 57 2867236CB1 KIDNNOT20 58 1294096CB1 PROSTUS23 59 7238537CB1 BRAITUT03 60 7494391CB1 SINTNOT18 61 6451054CB1 CORPNOT02 62 7494592CB1 UTRSTMR01 63 5202657CB1 HEARFET01 64 2013529CB1 TESTNOT03 65 3841351CB1 LIVRNOT21 66 152116CB1 BRAITDR02 67 2381031CB1 PROSBPS05 68 2511371CB1 CONUTUT01 69 8068623CB1 TONSDIC01 70 677977CB1 BRABDIE02 71 1661472CB1 MLP000032 72 1748508CB1 PROSNON01 73 2159545CB1 PLACFEB01 74 8560269CB1 NEUTFMT01 75 8710302CB1 THYMNOE02 76 6778214CB1 THYRTUT03 77 258383CB1 BRSTNOT17 78 2804937CB1 STOMTDE01 80 2073751CB1 TLYMUNT01 81 3178841CB1 UTRSTUE01 82 3674807CB1 PLACNOT07 83 1794922CB1 PROSTUT05 84 1795509CB1 PROSTUT05 85 2017180CB1 BLADTUT08 86 219442CB1 THYMNOT05 87 2597459CB1 BRACNOK02 88 2783863CB1 BRAHTDR03 89 2902971CB1 BRAYDIN03 90 368660CB1 BRSTNOT01 91 2804990CB1 BRAITUT02 92 168571CB1 BRAUNOR01 93 1286391CB1 MENITUT03 94 2007684CB1 LUNGNON03 95 2227040CB1 BRSTNOT03 96 4346130CB1 BRAUNOR01 98 7472392CB1 BRALNON02 99 4028960CB1 KIDNFEC01 100 8227004CB1 PROSNOT19 101 3044763CB1 HEAANOT01 102 4044519CB1 LUNGNOT35 103 71351918CB1 BRSTTUT01 104 8109363CB1 BRAINOT19 105 1272746CB1 TESTTUT02 106 1839974CB1 OVARDIR01 107 1877336CB1 ADRETUR01 108 2321054CB1 BRSTNOT13 109 2796034CB1 LUNGDIN02 110 4413112CB1 MONOTXT01 111 7654832CB1 BLADTUT06 112 7503849CB1 KIDNNOT09

[0396] TABLE 6 Library Vector Library Description ADRETUR01 PCDNA2.1 This random primed library was constructed using RNA isolated from left upper pole, adrenal gland tumor tissue removed from a 52-year-old Caucasian male during nephroureterectomy and local destruction of renal lesion. Pathology indicated grade 3 adrenal cortical carcinoma forming a mass that infiltrated almost the whole adrenal parenchyma and extended to adjacent adipose tissue. A metastatic tumor nodule was identified in the hilar region. The renal vein was infiltrated by tumor and the neoplastic process was present at the resection margin of the renal vein. Fragments of adrenal cortical carcinoma and thrombus were found in the inferior vena cava. Patient history included abnormal weight loss. Family history included skin cancer, type I diabetes, and neurotic depression. BLADTUT06 pINCY Library was constructed using RNA isolated from bladder tumor tissue removed from the posterior bladder wall of a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, and gastrostomy. Pathology indicated grade 3 transitional cell carcinoma in the left lateral bladder wall. The remaining bladder showed marked cystitis with scattered microscopic foci of transitional cell carcinoma in situ. Patient history included angina, emphysema and tobacco use. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes. BLADTUT08 pINCY Library was constructed using RNA isolated from bladder tumor tissue removed from a 72- year-old Caucasian male during a radical cystectomy and prostatectomy. Pathology indicated an invasive grade 3 (of 3) transitional cell carcinoma in the right bladder base. Patient history included pure hypercholesterolemia and tobacco abuse. Family history included myocardial infarction, cerebrovascular disease, and brain cancer. BRABDIE02 pINCY This 5′ biased random primed library was constructed using RNA isolated from diseased cerebellum tissue removed from the brain of a 57-year-old Caucasian male who died from a cerebrovascular accident. Serologies were negative. Patient history included Huntington's disease, emphysema, and tobacco abuse (3-4 packs per day, for 40 years). BRACNOK02 PSPORT1 This amplified and normalized library was constructed using RNA isolated from posterior cingulate tissue removed from an 85-year-old Caucasian female who died from myocardial infarction and retroperitoneal hemorrhage. Pathology indicated atherosclerosis, moderate to severe, involving the circle of Willis, middle cerebral, basilar and vertebral arteries; infarction, remote, left dentate nucleus; and amyloid plaque deposition consistent with age. There was mild to moderate leptomeningeal fibrosis, especially over the convexity of the frontal lobe. There was mild generalized atrophy involving all lobes. The white matter was mildly thinned. Cortical thickness in the temporal lobes, both maximal and minimal, was slightly reduced. The substantia nigra pars compacta appeared mildly depigmented. Patient history included COPD, hypertension, and recurrent deep venous thrombosis. 6.4 million independent clones from this amplified library were normalized in one round using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6 (1996): 791. BRAHTDR03 PCDNA2.1 This random primed library was constructed using RNA isolated from archaecortex, anterior hippocampus tissue removed from a 55-year-old Caucasian female who died from cholangio- carcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver. BRAINOT19 pINCY Library was constructed using RNA isolated from diseased brain tissue removed from the left frontal lobe of a 27-year-old Caucasian male during a brain lobectomy. Pathology indicated a focal deep white matter lesion, characterized by marked gliosis, calcifi- cations, and hemosiderin-laden macrophages, consistent with a remote perinatal injury. This tissue also showed mild to moderate generalized gliosis, predominantly subpial and subcortical, consistent with chronic seizure disorder. The left temporal lobe, including the mesial temporal structures, showed focal, marked pyramidal cell loss and gliosis in hippocampal sector CA1, consistent with mesial temporal sclerosis. GFAP was positive for astrocytes. The patient presented with intractable epilepsy, focal epilepsy, hemiplegia, and an unspecified brain injury. Patient history included cerebral palsy, abnormality of gait, and depressive disorder. Family history included brain cancer. BRAITDR02 PCDNA2.1 This random primed library was constructed using RNA isolated from allocortex, neocortex, anterior and frontal cingulate tissue removed from a 55-year-old Caucasian female who died from cholangiocarcinoma. Pathology indicated mild meningeal fibrosis predominately over the convexities, scattered axonal spheroids in the white matter of the cingulate cortex and the thalamus, and a few scattered neurofibrillary tangles in the entorhinal cortex and the periaqueductal gray region. Pathology for the associated tumor tissue indicated well-differentiated cholangiocarcinoma of the liver with residual or relapsed tumor. Patient history included cholangiocarcinoma, post-operative Budd-Chiari syndrome, biliary ascites, hydrothorax, dehydration, malnutrition, oliguria and acute renal failure. Previous surgeries included cholecystectomy and resection of 85% of the liver. BRAITUT02 PSPORT1 Library was constructed using RNA isolated from brain tumor tissue removed from the frontal lobe of a 58-year-old Caucasian male during excision of a cerebral meningeal lesion. Pathology indicated a grade 2 metastatic hypernephroma. Patient history included a grade 2 renal cell carcinoma, insomnia, and chronic airway obstruction. Family history included a malignant neoplasm of the kidney. BRAITUT03 PSPORT1 Library was constructed using RNA isolated from brain tumor tissue removed from the left frontal lobe of a 17-year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a grade 4 fibrillary giant and small-cell astrocytoma. Family history included benign hypertension and cerebrovascular disease. BRALNON02 pINCY This thalamus tissue library was constructed from 4.24 million independent clones from a thalamus tissue library. Starting RNA was made from thalamus tissue removed from a 35-year- old Caucasian male who died from cardiac failure. Pathology indicated moderate leptomeningeal fibrosis and multiple microinfarctions of the cerebral neocortex. Microscopically, the cerebral hemisphere revealed moderate fibrosis of the leptomeninges with focal calcifications. There was evidence of shrunken and slightly eosinophilic pyramidal neurons throughout the cerebral hemispheres. Scattered throughout the cerebral cortex, there were multiple small microscopic areas of cavitation with surrounding gliosis. Patient history included dilated cardiomyopathy, congestive heart failure, cardiomegaly and an enlarged spleen and liver. The library was normalized in two rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research (1996) 6: 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. BRAUNOR01 pINCY This random primed library was constructed using RNA isolated from striatum, globus pallidus and posterior putamen tissue removed from an 81-year-old Caucasian female who died from a hemorrhage and ruptured thoracic aorta due to atherosclerosis. Pathology indicated moderate atherosclerosis involving the internal carotids, bilaterally; microscopic infarcts of the frontal cortex and hippocampus; and scattered diffuse amyloid plaques and neurofibrillary tangles, consistent with age. Grossly, the leptomeninges showed only mild thickening and hyalinization along the superior sagittal sinus. The remainder of the leptomeninges was thin and contained some congested blood vessels. Mild atrophy was found mostly in the frontal poles and lobes, and temporal lobes, bilaterally. Microscopically, there were pairs of Alzheimer type II astrocytes within the deep layers of the neocortex. There was increased satellitosis around neurons in the deep gray matter in the middle frontal cortex. The amygdala contained rare diffuse plaques and neurofibrillary tangles. The posterior hippocampus contained a microscopic area of cystic cavitation with hemosiderin-laden macrophages surrounded by reactive gliosis. Patient history included sepsis, cholangitis, post-operative atelectasis, pneumonia CAD, cardiomegaly due to left ventricular hypertrophy, splenomegaly, arteriolonephrosclerosis, nodular colloidal goiter, emphysema, CHF, hypothyroidism, and peripheral vascular disease. BRAYDIN03 pINCY This normalized library was constructed from 6.7 million independent clones from a brain tissue library. Starting RNA was made from RNA isolated from diseased hypothalamus tissue removed from a 57-year-old Caucasian male who died from a cerebrovascular accident. Patient history included Huntington's disease and emphysema. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228 and Bonaldo et al., Genome Research (1996) 6: 791, except that a significantly longer (48-hours/round) reannealing hybridization was used. The library was linearized and recircularized to select for insert containing clones. BRSTNOT01 PBLUESCRIPT Library was constructed using RNA isolated from the breast tissue of a 56-year-old Caucasian female who died in a motor vehicle accident. BRSTNOT03 PSPORT1 Library was constructed using RNA isolated from diseased breast tissue removed from a 54- year-old Caucasian female during a bilateral radical mastectomy. Pathology for the associated tumor tissue indicated residual invasive grade 3 mammary ductal adenocarcinoma. Patient history included kidney infection and condyloma acuminatum. Family history included benign hypertension, hyperlipidemia and a malignant neoplasm of the colon. BRSTNOT13 pINCY Library was constructed using RNA isolated from breast tissue removed from a 36-year-old Caucasian female during bilateral simple mastectomy. Patient history included a breast neoplasm, depressive disorder, hyperlipidemia, and a chronic stomach ulcer. Family history included a cardiovascular and cerebrovascular disease; hyperlipidemia; skin, breast, esophageal, bladder, and bone cancer; and Hodgkin's lymphoma. BRSTNOT17 pINCY Library was constructed using RNA isolated from breast tissue removed from a 46-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology for the associated tumor tissue indicated invasive grade 3, nuclear grade 2 adenocarcinoma, ductal type. An intraductal carcinoma component, non-comedo, comprised approximately 50% of the neoplasm, including the lactiferous ducts. Angiolymphatic involvement was present, and metastatic adenocarcinoma was present in 7 of 10 axillary lymph nodes. The largest nodal metastasis measured 3 cm, and focal extracapsular extension was identified. Family history included atherosclerotic coronary artery disease, type II diabetes, cerebrovascular disease, and depressive disorder. BRSTTUT01 PSPORT1 Library was constructed using RNA isolated from breast tumor tissue removed from a 55-year- old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated invasive grade 4 mammary adenocarcinoma of mixed lobular and ductal type, extensively involving the left breast. The tumor was identified in the deep dermis near the lactiferous ducts with extracapsular extension. Seven mid and low and five high axillary lymph nodes were positive for tumor. Proliferative fibrocysytic changes were characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Patient history included atrial tachycardia, blood in the stool, and a benign breast neoplasm. Family history included benign hypertension, atherosclerotic coronary artery disease, cerebrovascular disease, and depressive disorder. CONUTUT01 pINCY Library was constructed using RNA isolated from sigmoid mesentery tumor tissue obtained from a 61-year-old female during a total abdominal hysterectomy and bilateral salpingo- oophorectomy with regional lymph node excision. Pathology indicated a metastatic grade 4 malignant mixed mullerian tumor present in the sigmoid mesentery at two sites. CORPNOT02 pINCY Library was constructed using RNA isolated from diseased corpus callosum tissue removed from the brain of a 74-year-old Caucasian male who died from Alzheimer's disease. HEAANOT01 pINCY Library was constructed using RNA isolated from right coronary and right circumflex coronary artery tissue removed from the explanted heart of a 46-year-old Caucasian male during a heart transplantation. Patient history included myocardial infarction from total occlusion of the left anterior descending coronary artery, atherosclerotic coronary artery disease, hyperlipidemia, myocardial ischemia, dilated cardiomyopathy, left ventricular dysfunction, and tobacco abuse. Previous surgeries included cardiac catheterization. Family history included atherosclerotic coronary artery disease. HEARFET01 pINCY Library was constructed using RNA isolated from heart tissue removed from a Hispanic male fetus, who died at 18 weeks' gestation. KIDNFEC01 PBLUESCRIPT Library was constructed using RNA isolated from kidney tissue removed from a pool of twelve Caucasian male and female fetuses that were spontaneously aborted at 19-23 weeks' gestation. KIDNNOT09 pINCY Library was constructed using RNA isolated from the kidney tissue of a Caucasian male fetus, who died at 23 weeks' gestation. KIDNNOT20 pINCY Library was constructed using RNA isolated from left kidney tissue removed from a 43-year- old Caucasian male during nephroureterectomy, regional lymph node excision, and unilateral left adrenalectomy. Pathology for the associated tumor tissue indicated a grade 2 renal cell carcinoma. Family history included atherosclerotic coronary artery disease. LIVRNOT21 pINCY Library was constructed using RNA isolated from liver tissue removed from a 29-year-old Caucasian male who died from massive head injury due to a motor vehicle accident. Serology was positive for cytomegalovirus. LUNGDIN02 pINCY This normalized lung tissue library was constructed from 7.6 million independent clones from a diseased lung tissue library. Starting RNA was made from RNA isolated from diseased lung tissue. Pathology indicated ideopathic pulmonary disease. The library was normalized in 2 rounds using conditions adapted from Soares et al., PNAS (1994) 91: 9228-9232 and Bonaldo et al., Genome Research 6 (1996): 791, except that a significantly longer (48 hours/round) reannealing hybridization was used. LUNGNON03 PSPORT1 This normalized library was constructed from 2.56 million independent clones from a lung tissue library. RNA was made from lung tissue removed from the left lobe of a 58-year-old Caucasian male during a segmental lung resection. Pathology for the associated tumor tissue indicated a metastatic grade 3 (of 4) osteosarcoma. Patient history included soft tissue cancer, secondary cancer of the lung, prostate cancer, and an acute duodenal ulcer with hemorrhage. Patient also received radiation therapy to the retroperitoneum. Family history included prostate cancer, breast cancer, and acute leukemia. The normalization and hybridization conditions were adapted from Scares et al., PNAS (1994) 91: 9228; Swaroop et al., NAR (1991) 19: 1954; and Bonaldo et al., Genome Research (1996) 6: 791. LUNGNOT35 pINCY Library was constructed using RNA isolated from lung tissue removed from a 62-year-old Caucasian female. Pathology for the associated tumor tissue indicated a grade 1 spindle cell carcinoid forming a nodule. Patient history included depression, thrombophlebitis, and hyperlipidemia. Family history included cerebrovascular disease, atherosclerotic coronary artery disease, breast cancer, colon cancer, type II diabetes, and malignant skin melanoma. MENITUT03 pINCY Library was constructed using RNA isolated from brain meningioma tissue removed from a 35- year-old Caucasian female during excision of a cerebral meningeal lesion. Pathology indicated a benign neoplasm in the right cerebellopontine angle of the brain. Patient history included hypothyroidism. Family history included myocardial infarction and breast cancer. MLP000032 PCR2-TOPOTA Library was constructed using pooled cDNA from different donors. cDNA was generated using mRNA isolated from the following: aorta, cerebellum, lymph nodes, muscle, tonsil (lymphoid hyperplasia), bladder tumor (invasive grade 3 transitional cell carcinoma.), breast (proliferative fibrocystic changes without atypia characterized by epithelial ductal hyperplasia, testicle tumor (embryonal carcinoma), spleen, ovary, parathyroid, ileum, breast skin, sigmoid colon, penis tumor (fungating invasive grade 4 squamous cell carcinoma), fetal lung,, breast, fetal small intestine, fetal liver, fetal pancreas, fetal lung, fetal skin, fetal penis, fetal bone, fetal ribs, frontal brain tumor (grade 4 gemistocytic astrocytoma), ovary (stromal hyperthecosis), bladder, bladder tumor (invasive grade 3 transitional cell carcinoma), stomach, lymph node tumor (metastatic basaloid squamous cell carcinoma), tonsil (reactive lymphoid hyperplasia), periosteum from the tibia, fetal brain, fetal spleen, uterus tumor, endometrial (grade 3 adenosquamous carcinoma), seminal vesicle, liver, aorta, adrenal gland, lymph node (metastatic grade 3 squamous cell carcinoma), glossal muscle, esophagus, esophagus tumor (invasive grade 3 adenocarcinoma), ileum, pancreas, soft tissue tumor from the skull (grade 3 ependymoma), transverse colon, (benign familial polyposis), rectum tumor (grade 3 colonic adenocarcinoma), rib tumor, (metastatic grade 3 osteosarcoma), lung, heart, placenta, thymus, stomach, spleen (splenomegaly with congestion), uterus, cervix (mild chronic cervicitis with focal squamous metaplasia), spleen tumor (malignant lymphoma, diffuse large cell type, B-cell phenotype with abundant reactive T-cells and marked granulomatous response), umbilical cord blood mononuclear cells, upper lobe lung tumor, (grade 3 squamous cell carcinoma), endometrium (secretory phase), liver, liver tumor (metastatic grade 2 neuroendocrine carcinoma), colon, umbilical cord blood, Th1 cells, nonactivated, umbilical cord blood, Th2 cells, nonactivated, coronary artery endothelial cells (untreated), coronary artery smooth muscle cells, (untreated), coronary artery smooth muscle cells (treated with TNF & IL-1 10 ng/ml each for 20 hours), bladder (mild chronic cystitis), epiglottis, breast skin, small intestine, fetal prostate stroma fibroblasts, prostate epithelial cells (PrEC cells), fetal adrenal glands, fetal liver, kidney transformed embryonal cell line (293-EBNA) (untreated), kidney transformed embryonal cell line (293-EBNA) (treated with 5Aza-2deoxycytidine for 72 hours), mammary epithelial cells, (HMEC cells), peripheral blood monocytes (treated with IL-10 at time 0, 10 ng/ml, LPS was added at 1 hour at 5 ng/ml. Incubation 24 hours), peripheral blood monocytes (treated with anti-IL-10 at time 0, 10 ng/ml, LPS was added at 1 hour at 5 ng/ml. Incubation 24 hours), spinal cord, base of medulla (Huntington's chorea), thigh and arm muscle (ALS), breast skin fibroblast (untreated), breast skin fibroblast (treated with 9CIS Retinoic Acid 1 μM for 20 hours), breast skin fibroblast (treated with TNF-alpha & IL-1 beta, 10 ng/ml each for 20 hours), fetal liver mast cells, hematopoietic (Mast cells prepared from human fetal liver hematopoietic progenitor cells (CD34+ stem cells) cultured in the presence of hIL-6 and hSCF for 18 days), epithelial layer of colon, bronchial epithelial cells (treated for 20 hours with 20% smoke conditioned media), lymph node, pooled peripheral blood mononuclear cells (untreated), pooled brain segments: striatum, globus pallidus and posterior putamen (Alzheimer's Disease), pituitary gland, umbilical cord blood, CD34+ derived dendritic cells (treated with SCF, GM-CSF & TNF alpha, 13 days), umbilical cord blood, CD34+ derived dendritic cells (treated with SCF, GM-CSF & TNF alpha, 13 days followed by PMA/Ionomycin for 5 hours), small intestine, rectum, bone marrow neuroblastoma cell line (SH-SY5Y cells, treated with 6-Hydroxydopamine 100 uM for 8 hours), bone marrow, neuroblastoma cell line (SH-SY5Y cells, untreated), brain segments from one donor: amygdala, entorhinal cortex, globus pallidus, substantia innominata, striatum, dorsal caudate nucleus, dorsal putamen, ventral nucleus accumbens, archaecortex (hippocampus anterior and posterior), thalamus, nucleus raphe magnus, periaqueductal gray, midbrain, substantia nigra, and dentate nucleus, pineal gland (Alzheimer's Disease), preadipocytes (untreated), preadipocytes (treated with a peroxisome proliferator-activated receptor gamma agonist, 1 microM, 4 hours), pooled prostate (adenofibromatous hyperplasia), pooled kidney, pooled adipocytes (untreated), pooled adipocytes (treated with human insulin), pooled mesentaric and abdomenal fat, pooled adrenal glands, pooled thyroid (normal and adenomatous hyperplasia), pooled spleen (normal and with changes consistent with idiopathic thrombocytopenic purpura), pooled right and left breast, pooled lung, pooled nasal polyps, pooled fat, pooled synovium (normal and rhumatoid arthritis), pooled brain (meningioma, gemistocytic astrocytoma. and Alzheimer's disease), pooled fetal colon, pooled colon: ascending, descending (chronic ulcerative colitis), and rectal tumor (adenocarcinoma), pooled esophagus, normal and tumor (invasive grade 3 adenocarcinoma), pooled breast skin fibroblast (one treated w/9CIS Retinoic Acid and the other with TNF-alpha & IL-1 beta), pooled gallbladder (acute necrotizing cholecystitis with cholelithiasis (clinically hydrops), acute hemorrhagic cholecystitis with cholelithiasis, chronic cholecystitis and cholelithiasis), pooled fetal heart, (Patau's and fetal demise), pooled neurogenic tumor cell line, SK-N-MC, (neuroepitelioma, metastasis to supra-orbital area, untreated) and neuron, NT-2 cell line, (treated with mouse leptin at 1 μg/ml and 9cis retinoic acid at 3.3 μM for 6 days), pooled ovary (normal and polycystic ovarian disease), pooled prostate, (adenofibromatous hyperplasia), pooled seminal vesicle, pooled small intestine, pooled fetal small intestine, pooled stomach and fetal stomach, prostate epithelial cells, pooled testis (normal and embryonal carcinoma), pooled uterus, pooled uterus tumor (grade 3 adenosquamous carcinoma and leiomyoma), pooled uterus, endometrium, and myometrium, (normal and adenomatous hyperplasia with squamous metaplasia and focal atypia), pooled brain: (temporal lobe meningioma, cerebellum and hippocampus (Alzheimer's Disease), pooled skin, fetal lung, adrenal tumor (adrenal cortical carcinoma), prostate tumor (adenocarcinoma), fetal heart, fetal small intestine, ovary tumor (mucinous cystadenoma), ovary, ovary tumor (transitional cell carcinoma), disease prostate (adenofibromatous hyperplasia), fetal colon, uterus tumor (leiomyoma), temporal brain, submandibular gland, colon tumor (adenocarcinoma), ascending and transverse colon, ovary tumor (endometrioid carcinoma), lung tumor (squamous cell carcinoma), fetal brain, fetal lung, ureter tumor (transitional cell carcinoma), untreated HNT cells, para-aortic soft tissue, testis, seminal vesicle, diseased ovary (endometriosis), temporal lobe, myometrium, diseased gallbladder (cholecystitis, cholelithiasis), placenta, breast tumor (ductal adenocarcinoma), breast, lung tumor (liposarcoma), endometrium, abdominal fat, cervical spine dorsal root ganglion, thoracic spine dorsal root ganglion, diseased thyroid (adenomatous hyperplasia), liver, kidney, fetal liver, NT-2 cells (treated with mouse leptin and 9cis RA), K562 cells (treated with 9cis RA), cerebellum, corpus callosum, hypothalamus, fetal brain astrocytes (treated with TNFa and IL-1b), inferior parietal cortex, posterior hippocampus, pons, thalamus, C3A cells (untreated), C3A cells (treated with 3-methylcholanthrene), testis, colon epithelial layer, pooled prostate, pooled liver, substantia nigra, thigh muscle, rib bone, fallopian tube tumor (endometrioid and serous adenocarcinoma), diseased lung (idiopathic pulmonary disease), cingulate anterior allocortex and neocortex, cingulate posterior allocortex, auditory neocortex, frontal neocortex, orbital inferior neocortex, parietal superior neocortex, visual primary neocortex, dentate nucleus, posterior cingulate, cerebellum, vermis, inferior temporal cortex, medulla, posterior parietal cortex, colon polyp, pooled breast, anterior and posterior hippocampus, mesenteric and abdominal fat, pooled esophagus, pooled fetal kidney, pooled fetal liver, ileum, small intestine, pooled gallbladder, frontal and superior temporal cortex, pooled ovary, pooled endometrium, pooled prostate, pooled kidney, fetal femur, sacrum tumor (giant cell tumor), pooled kidney and kidney tumor (renal cell carcinoma clear-cell type), pooled liver and liver tumor (neuroendocrine carcinoma), pooled fetal liver, pooled lung, fetal pancreas, pancreas, parotid gland, parotid tumor (sebaceous lymphadenoma), retroperitoneal and suprglottic soft tissue, spleen, fetal spleen, spleen tumor (malignant lymphoma), diseased spleen (idiopathic thrombocytopenic purpura), parathyroid, thyroid, thymus, tonsil ureter tumor (transitional cell carcinoma), pooled adrenal gland and adrenal tumor (pheochromocytoma), pooled lymph node tumor (Hodgkin's disease and metastatic adenocarcinoma), pooled neck and calf muscles, and pooled bladder MONOTXT01 pINCY Library was constructed using RNA isolated from treated monocytes from peripheral blood obtained from a 42-year-old female. The cells were treated with anti IL-10 and LPS. NEUTFMT01 PBLUESCRIPT Library was constructed using total RNA isolated from peripheral blood granulocytes collected by density gradient centrifugation through Ficoll-Hypaque. The cells were isolated from buffy coat units obtained from unrelated male and female donors. Cells were cultured in 10 nM fMLP for 30 minutes, lysed in GuSCN, and spun through CsCl to obtain RNA for library construction. Because this library was made from total RNA, it has an unusually high proportion of unique singleton sequences, which may not all come from polyA RNA species. OVARDIR01 PCDNA2.1 This random primed library was constructed using RNA isolated from right ovary tissue removed from a 45-year-old Caucasian female during total abdominal hysterectomy, bilateral salpingo-oophorectomy, vaginal suspension and fixation, and incidental appendectomy. Pathology indicated stromal hyperthecosis of the right and left ovaries. Pathology for the matched tumor tissue indicated a dermoid cyst (benign cystic teratoma) in the left ovary. Multiple (3) intramural leiomyomata were identified. The cervix showed squamous metaplasia. Patient history included metrorrhagia, female stress incontinence, alopecia, depressive disorder, pneumonia, normal delivery, and deficiency anemia. Family history included benign hypertension, atherosclerotic coronary artery disease, hyperlipidemia, and primary tuberculous complex. PLACFEB01 pINCY Library was constructed using pooled cDNA from two different donors. cDNA was generated using RNA isolated from placenta tissue removed from a Caucasian fetus (donor A), who died after 16 weeks' gestation from fetal demise and hydrocephalus; and a Caucasian male fetus (donor B), who died after 18 weeks' gestation from fetal demise. Patient history included umbilical cord wrapped around the head (3 times) and the shoulders (1 time) in donor A. Serology was positive for anti-CMV in donor A. Family history included multiple pregnancies and live births, and an abortion in donor A. PLACNOT07 pINCY Library was constructed using RNA isolated from placental tissue removed from a Caucasian fetus, who died after 16 weeks' gestation from fetal demise and hydrocephalus. Serology was positive for anti-CMV (cytomegalovirus). PROSBPS05 pINCY This subtracted prostate tissue library was constructed using 4.48 × 10e5 clones from diseased prostate tissue and was subjected to two rounds of subtraction hybridization with 1.56 million clones from a breast tissue library. The starting library for subtraction was constructed using RNA isolated from diseased prostate tissue removed from a 70-year-old Caucasian male during a radical prostatectomy and closed prostatic biopsy. Pathology indicated benign prostatic hypertrophy. Pathology for the matched tumor tissue indicated adenocarcinoma. The patient presented with elevated prostate specific antigen and induration. Patient history included benign hypertension, gastrointestinal bleed, cardiac dysrhythmia, cardiac arrest, hyperlipidemia, alcohol abuse and fractured mandible. Previous surgeries included splenectomy, cholecystectomy and inguinal hernia repair. Patient medications included Verapamil and antacids. Family history included benign hypertension, myocardial infarction and coronary atherosclerosis in the mother; tobacco abuse and lung cancer in the father; tobacco abuse, cerebrovascular accident and lung cancer in the sibling(s). The hybridization probe for subtraction was derived from a similarly constructed library from RNA isolated from nontumorous breast tissue from a different donor. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR 19 (1991): 1954 and Bonaldo, et al. Genome Research 6 (1996): 791. PROSNON01 PSPORT1 This normalized prostate library was constructed from 4.4 M independent clones from a prostate library. Starting RNA was made from prostate tissue removed from a 28-year-old Caucasian male who died from a self-inflicted gunshot wound. The normalization and hybridization conditions were adapted from Soares, M. B. et al. (1994) Proc. Natl. Acad. Sci. USA 91: 9228-9232, using a longer (19 hour) reannealing hybridization period. PROSNOT19 pINCY Library was constructed using RNA isolated from diseased prostate tissue removed from a 59- year-old Caucasian male during a radical prostatectomy with regional lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated an adenocarcinoma (Gleason grade 3 + 3). The patient presented with elevated prostate-specific antigen (PSA). Patient history included colon diverticuli, asbestosis, and thrombophlebitis. Previous surgeries included a partial colectomy. Family history included benign hypertension, multiple myeloma, hyperlipidemia and rheumatoid arthritis. PROSTUS23 pINCY This subtracted prostate tumor library was constructed using 10 million clones from a pooled prostate tumor library that was subjected to 2 rounds of subtractive hybridization with 10 million clones from a pooled prostate tissue library. The starting library for subtraction was constructed by pooling equal numbers of clones from 4 prostate tumor libraries using mRNA isolated from prostate tumor removed from Caucasian males at ages 58 (A), 61 (B), 66 (C), and 68 (D) during prostatectomy with lymph node excision. Pathology indicated adenocarcinoma in all donors. History included elevated PSA, induration and tobacco abuse in donor A; elevated PSA, induration, prostate hyperplasia, renal failure, osteoarthritis, renal artery stenosis, benign HTN, thrombocytopenia, hyperlipidemia, tobacco/alcohol abuse and hepatitis C (carrier) in donor B; elevated PSA, induration, and tobacco abuse in donor C; and elevated PSA, induration, hypercholesterolemia, and kidney calculus in donor D. The hybridization probe for subtraction was constructed by pooling equal numbers of cDNA clones from 3 prostate tissue libraries derived from prostate tissue, prostate epithelial cells, and fibroblasts from prostate stroma from 3 different donors. Subtractive hybridization conditions were based on the methodologies of Swaroop et al., NAR 19 (1991): 1954 and Bonaldo, et al. Genome Research 6 (1996): 791. PROSTUT05 PSPORT1 Library was constructed using RNA isolated from prostate tumor tissue removed from a 69- year-old Caucasian male during a radical prostatectomy. Pathology indicated adenocarcinoma (Gleason grade 3 + 4). Adenofibromatous hyperplasia was also present. Family history included congestive heart failure, multiple myeloma, hyperlipidemia, and rheumatoid arthritis. SINTNOT18 pINCY Library was constructed using RNA isolated from small intestine tissue obtained from a 59- year-old male. STOMTDE01 PCDNA2.1 This 5′ biased random primed library was constructed using RNA isolated from stomach tissue removed from a 61-year-old Caucasian male during a partial esophagectomy, proximal gastrectomy, pyloromyotomy, and regional lymph node excision. Pathology for the associated tumor indicated an invasive grade 3 adenocarcinoma in the esophagus, extending distally to involve the gastroesophageal junction. The tumor extended through the muscularis to involve periesophageal and perigastric soft tissues. One perigastric and two periesophageal lymph nodes were positive for tumor. There were multiple perigastric and periesophageal tumor implants. The patient presented with deficiency anemia and myelodysplasia. Patient history included hyperlipidemia, and tobacco and alcohol abuse in remission. Previous surgeries included adenotonsillectomy, rhinoplasty, vasectomy, and hemorrhoidectomy. A previous bone marrow aspiration found the marrow to be hypercellular for age and had a cellularity-to-fat ratio of 95:5. The marrow was focally densely fibrotic. Granulocytic precursors were slightly increased with normal maturation. The estimate of blast cells was greater than 5%. Megakaryocytes were increased and appeared atypical in clusters. Storage cells and granulomata were absent. Patient medications included Epoetin, Danocrine, Berocca Plus tablets, Selenium, vitamin B6 phosphate, vitamins E & C, and beta carotene. Family history included alcohol abuse, atherosclerotic coronary artery disease, type II diabetes, chronic liver disease, and primary cardiomyopathy in the father; and benign hypertension and cerebrovascular disease in the mother. TESTNOT03 PBLUESCRIPT Library was constructed using RNA isolated from testicular tissue removed from a 37-year- old Caucasian male, who died from liver disease. Patient history included cirrhosis, jaundice, and liver failure. TESTTUT02 pINCY Library was constructed using RNA isolated from testicular tumor removed from a 31-year-old Caucasian male during unilateral orchiectomy. Pathology indicated embryonal carcinoma. THYMNOE02 PCDNA2.1 This 5′ biased random primed library was constructed using RNA isolated from thymus tissue removed from a 3-year-old Hispanic male during a thymectomy and closure of a patent ductus arteriosus. The patient presented with severe pulmonary stenosis and cyanosis. Patient history included a cardiac catheterization and echocardiogram. Previous surgeries included Blalock-Taussig shunt and pulmonary valvotomy. The patient was not taking any medications. Family history included benign hypertension, osteoarthritis, depressive disorder, and extrinsic asthma in the grandparent(s). THYMNOT05 pINCY Library was constructed using RNA isolated from thymus tissue removed from a 3-year-old Hispanic male during a thymectomy and closure of a patent ductus arteriosus. The patient presented with severe pulmonary stenosis and cyanosis. Patient history included a cardiac catheterization and echocardiogram. Previous surgeries included Blalock-Taussig shunt and pulmonary valvotomy. The patient was not taking any medications. Family history included benign hypertension, osteoarthritis, depressive disorder, and extrinsic asthma in the grandparent(s). THYRTUT03 pINCY Library was constructed using RNA isolated from benign thyroid tumor tissue removed from a 17-year-old Caucasian male during a thyroidectomy. Pathology indicated encapsulated follicular adenoma forming a circumscribed mass. TLYMUNT01 pINCY Library was constructed using RNA isolated from resting allogenic T-lymphocyte tissue removed from an adult (40-50-year old) Caucasian male. TONSDIC01 PSPORT1 This large size fractionated library was constructed using pooled cDNA from two donors. cDNA was generated using mRNA isolated from diseased left tonsil tissue removed from a 6- year-old Caucasian male (donor A) during adenotonsillectomy and from diseased right tonsil tissue removed from a 9-year-old Caucasian female (donor B) during adenotonsillectomy. Pathology indicated reactive lymphoid hyperplasia, bilaterally (A) and lymphoid hyperplasia (B). The patients presented with sleep apnea (A) and hypertrophy of tonsils, cough, and unspecified nasal and sinus disease (B). Patient history included a bacterial infection (A). Previous surgeries included myringotomy with tube insertion (A). Donor A was not taking any medications and donor B was taking Vancenase. Family history included benign hypertension, myocardial infarction, and atherosclerotic coronary artery disease in the grandparent(s) of donor A; and extrinsic asthma and unspecified allergy in the mother; unspecified allergy in the father; benign hypertension, deficiency anemia, osteoarthritis, extrinsic asthma and unspecified allergy in the grandparent(s) of donor B. UTRSTMR01 pINCY Library was constructed using RNA isolated from uterine myometrial tissue removed from a 41- year-old Caucasian female during a vaginal hysterectomy. The endometrium was secretory and contained fragments of endometrial polyps. Pathology for associated tumor tissue indicated uterine leiomyoma. Patient history included ventral hernia and a benign ovarian neoplasm. UTRSTUE01 PCDNA2.1 This 5′ biased random primed library was constructed using RNA isolated from uterus tumor tissue removed a 37-year-old Black female during myomectomy, dilation and curettage, right fimbrial region biopsy, and incidental appendectomy. Pathology indicated multiple (12) uterine leiomyomata. A fimbrial cyst was identified. The patient presented with deficiency anemia, an umbilical hernia, and premenopausal menorrhagia. Patient history included premenopausal menorrhagia and sarcoidosis of the lung. Previous surgeries included hysteroscopy, dilation and curettage, and an endoscopic lung biopsy. Patient medications included Chromagen and Claritin. Family history included acute myocardial infarction and atherosclerotic coronary artery disease in the father.

[0397] TABLE 7 Parameter Program Description Reference Threshold ABI A program that removes vector sequences and masks Applied Biosystems, Foster City, CA. FACTURA ambiguous bases in nucleic acid sequences. ABI/ A Fast Data Finder useful in comparing and Applied Biosystems, Foster City, CA; Mismatch <50% PARACEL FDF annotating amino acid or nucleic acid sequences. Paracel Inc., Pasadena, CA. ABI A program that assembles nucleic acid sequences. Applied Biosystems, Foster City, CA. AutoAssembler BLAST A Basic Local Alignment Search Tool useful in Altschul, S. F. et al. (1990) J. Mol. Biol. ESTs: Probability sequence similarity search for amino acid and nucleic 215: 403-410; Altschul, S. F. et al. (1997) value = 1.0E−8 acid sequences. BLAST includes five functions: Nucleic Acids Res. 25: 3389-3402. or less blastp, blastn, blastx, tblastn, and tblastx. Full Length sequences: Probability value = 1.0E−10 or less FASTA A Pearson and Lipman algorithm that searches for Pearson, W. R. and D. J. Lipman (1988) Proc. ESTs: fasta E similarity between a query sequence and a group of Natl. Acad Sci. USA 85: 2444-2448; Pearson, value = 1.06E−6 sequences of the same type. FASTA comprises as W. R. (1990) Methods Enzymol. 183: 63-98; Assembled ESTs: least five functions: fasta, tfasta, fastx, tfastx, and and Smith, T. F. and M. S. Waterman (1981) fasta Identity = ssearch. Adv. Appl. Math. 2: 482-489. 95% or greater and Match length = 200 bases or greater; fastx E value = 1.0E−8 or less Full Length sequences: fastx score = 100 or greater BLIMPS A BLocks IMProved Searcher that matches a Henikoff, S. and J. G. Henikoff (1991) Probability value = sequence against those in BLOCKS, PRINTS, Nucleic Acids Res. 19: 6565-6572; Henikoff, 1.0E−3 or less DOMO, PRODOM, and PFAM databases to search J. G. and S. Henikoff (1996) Methods for gene families, sequence homology, and structural Enzymol. 266: 88-105; and Attwood, T. K. et fingerprint regions. al. (1997) J. Chem. Inf. Comput. Sci. 37: 417- 424. HMMER An algorithm for searching a query sequence against Krogh, A. et al. (1994) J. Mol. Biol. PFAM, INCY, SMART hidden Markov model (HMM)-based databases of 235: 1501-1531; Sonnhammer, E. L. L. et al. or TIGRFAM hits: protein family consensus sequences, such as PFAM, (1988) Nucleic Acids Res. 26: 320-322; Probability value = INCY, SMART and TIGRFAM. Durbin, R. et al. (1998) Our World View, in 1.0E−3 or less a Nutshell, Cambridge Univ. Press, pp. 1- Signal peptide 350. hits: Score = 0 or greater ProfileScan An algorithm that searches for structural and Gribskov, M. et al. (1988) CABIOS 4: 61-66; Normalized quality sequence motifs in protein sequences that match Gribskov, M. et al. (1989) Methods score ≧ GCG- sequence patterns defined in Prosite. Enzymol. 183: 146-159; Bairoch, A. et al. specified “HIGH” (1997) Nucleic Acids Res. 25: 217-221. value for that particular Prosite motif. Generally, score = 1.4-2.1. Phred A base-calling algorithm that examines automated Ewing, B. et al. (1998) Genome Res. 8: 175- sequencer traces with high sensitivity and probability. 185; Ewing, B. and P. Green (1998) Genome Res. 8: 186-194. Phrap A Phils Revised Assembly Program including Smith, T. F. and M. S. Waterman (1981) Adv. Score = 120 SWAT and CrossMatch, programs based on efficient Appl. Math. 2: 482-489; Smith, T. F. and or greater; implementation of the Smith-Waterman algorithm, M. S. Waterman (1981) J. Mol. Biol. 147: 195- Match useful in searching sequence homology and 197; and Green, P., University of length = 56 assembling DNA sequences. Washington, Seattle, WA. or greater Consed A graphical tool for viewing and editing Phrap Gordon, D. et al. (1998) Genome Res. 8: 195- assemblies. 202. SPScan A weight matrix analysis program that scans protein Nielson, H. et al. (1997) Protein Engineering Score = 3.5 sequences for the presence of secretory signal 10: 1-6; Claverie, J. M. and S. Audic (1997) or greater peptides. CABIOS 12: 431-439. TMAP A program that uses weight matrices to delineate Persson, B. and P. Argos (1994) J. Mol. Biol. transmembrane segments on protein sequences and 237: 182-192; Persson, B. and P. Argos determine orientation. (1996) Protein Sci. 5: 363-371. TMHMMER A program that uses a hidden Markov model (HMM) Sonnhammer, E. L. et al. (1998) Proc. Sixth to delineate transmembrane segments on protein Intl. Conf. on Intelligent Systems for Mol. sequences and determine orientation. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182. Motifs A program that searches amino acid sequences for Bairoch, A. et al. (1997) Nucleic Acids Res. patterns that matched those defined in Prosite. 25: 217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.

[0398] TABLE 8 Asian Hispanic SEQ EST Al- Al- Caucasian African Allele 1 Allele 1 ID EST CB1 Al- lele lele Allele 1 Allele 1 fre- fre- NO: PID EST ID SNP ID SNP SNP lele 1 2 Amino Acid frequency frequency quency quency 112 7503849 1339126H1 SNP00112738 151 315 A G A T80 n/a n/a n/a n/a 112 7503849 1376303H1 SNP00009519 85 38 C C A noncoding n/a n/a n/a n/a 112 7503849 1376303H1 SNP00037704 88 35 G G A noncoding n/a n/a n/a n/a 112 7503849 1422323H1 SNP00061236 167 384 T C T stop103 n/d n/d n/d n/d 112 7503849 1520683H1 SNP00009519 131 39 C C A noncoding n/a n/a n/a n/a 112 7503849 1520683H1 SNP00037704 134 36 G G A noncoding n/a n/a n/a n/a 112 7503849 2211818H1 SNP00097061 219 1021 C C T noncoding n/a n/a n/a n/a 112 7503849 2346103H1 SNP00037704 106 27 G G A noncoding n/a n/a n/a n/a 112 7503849 2497486H1 SNP00009519 84 41 C C A noncoding n/a n/a n/a n/a 112 7503849 2497486H1 SNP00037704 87 38 G G A noncoding n/a n/a n/a n/a 112 7503849 2688833H1 SNP00009519 103 42 C C A noncoding n/a n/a n/a n/a 112 7503849 2688833H1 SNP00037704 106 39 G G A noncoding n/a n/a n/a n/a 112 7503849 2691537H1 SNP00009519 228 106 G G T R10 n/a n/a n/a n/a 112 7503849 2691537H1 SNP00037704 225 109 C C T P11 n/a n/a n/a n/a 112 7503849 2984764H1 SNP00037704 84 100 C C T P8 n/a n/a n/a n/a 112 7503849 2998532H1 SNP00092683 42 1103 C C T noncoding n/a n/a n/a n/a 112 7503849 3083817H1 SNP00092683 97 1102 T C T noncoding n/a n/a n/a n/a 112 7503849 3083817H1 SNP00097061 15 1020 C C T noncoding n/a n/a n/a n/a 112 7503849 3163442H1 SNP00097061 252 1015 C C T noncoding n/a n/a n/a n/a 112 7503849 3184509H1 SNP00009519 79 94 G G T G6 n/a n/a n/a n/a 112 7503849 3184509H1 SNP00037704 82 97 C C T P7 n/a n/a n/a n/a 112 7503849 3184509H1 SNP00112738 288 305 G G A S76 n/a n/a n/a n/a 112 7503849 3319727H1 SNP00092683 71 1101 C C T noncoding n/a n/a n/a n/a 112 7503849 3360460H1 SNP00009519 85 44 C C A noncoding n/a n/a n/a n/a 112 7503849 3501445H1 SNP00009519 97 102 T G T C9 n/a n/a n/a n/a 112 7503849 3692522H1 SNP00061236 202 381 C C T P102 n/d n/d n/d n/d 112 7503849 3748594H1 SNP00112738 84 313 A G A H79 n/a n/a n/a n/a 112 7503849 3777748H1 SNP00112738 239 291 G G A G72 n/a n/a n/a n/a 112 7503849 3877579H1 SNP00009519 47 96 T G T S7 n/a n/a n/a n/a 112 7503849 4205658H1 SNP00061236 49 382 C C T A102 n/d n/d n/d n/d 112 7503849 4541534H1 SNP00112739 225 609 C C T H178 n/d n/d n/d n/d 112 7503849 4575407H1 SNP00092683 54 1100 C C T noncoding n/a n/a n/a n/a 112 7503849 4640189H1 SNP00112739 206 611 C C T Y178 n/d n/d n/d n/d 112 7503849 4916293H1 SNP00092683 43 1099 C C T noncoding n/a n/a n/a n/a 112 7503849 4956713H1 SNP00097061 8 1019 C C T noncoding n/a n/a n/a n/a 112 7503849 5026038H1 SNP00112739 75 602 C C T R175 n/d n/d n/d n/d 112 7503849 5206042H1 SNP00097061 135 851 C C T noncoding n/a n/a n/a n/a 112 7503849 5872016H1 SNP00061236 159 375 C C T L100 n/d n/d n/d n/d 112 7503849 6732363H1 SNP00112740 410 627 C C T L184 n/a n/a n/a n/a

[0399]

1 112 1 246 PRT Homo sapiens misc_feature Incyte ID No 2867236CD1 1 Met Val Val Asp Phe Trp Thr Trp Glu Gln Thr Phe Gln Glu Leu 1 5 10 15 Ile Gln Glu Ala Lys Pro Arg Ala Thr Trp Thr Leu Lys Leu Asp 20 25 30 Gly Asn Leu Gln Leu Asp Cys Leu Ala Gln Gly Trp Lys Gln Tyr 35 40 45 Gln Gln Arg Ala Phe Gly Trp Phe Arg Cys Ser Ser Cys Gln Arg 50 55 60 Ser Trp Ala Ser Ala Gln Val Gln Ile Leu Cys His Thr Tyr Trp 65 70 75 Glu His Trp Thr Ser Gln Gly Gln Val Arg Met Arg Leu Phe Gly 80 85 90 Gln Arg Cys Gln Lys Cys Ser Trp Ser Gln Tyr Glu Met Pro Glu 95 100 105 Phe Ser Ser Asp Ser Thr Met Arg Ile Leu Ser Asn Leu Val Gln 110 115 120 His Ile Leu Lys Lys Tyr Tyr Gly Asn Gly Thr Arg Lys Ser Pro 125 130 135 Glu Met Pro Val Ile Leu Glu Val Ser Leu Glu Gly Ser His Asp 140 145 150 Thr Ala Asn Cys Glu Ala Cys Thr Leu Gly Ile Cys Gly Gln Gly 155 160 165 Leu Lys Ser Tyr Met Thr Lys Pro Ser Lys Ser Leu Leu Pro His 170 175 180 Leu Lys Thr Gly Asn Ser Ser Pro Gly Ile Gly Ala Val Tyr Leu 185 190 195 Ala Asn Gln Ala Lys Asn Gln Ser Ala Glu Ala Lys Glu Ala Lys 200 205 210 Gly Ser Gly Tyr Glu Lys Leu Gly Pro Ser Arg Asp Pro Asp Pro 215 220 225 Leu Asn Ile Cys Val Phe Ile Leu Leu Leu Val Phe Ile Val Val 230 235 240 Lys Cys Phe Thr Ser Glu 245 2 325 PRT Homo sapiens misc_feature Incyte ID No 1294096CD1 2 Met Ala Leu Ala Asp Ser Thr Arg Gly Leu Pro Asn Gly Gly Gly 1 5 10 15 Gly Gly Gly Gly Ser Gly Ser Ser Ser Ser Ser Ala Glu Pro Pro 20 25 30 Leu Phe Pro Asp Ile Val Glu Leu Asn Val Gly Gly Gln Val Tyr 35 40 45 Val Thr Arg Arg Cys Thr Val Val Ser Val Pro Asp Ser Leu Leu 50 55 60 Trp Arg Met Phe Thr Gln Gln Gln Pro Gln Glu Leu Ala Arg Asp 65 70 75 Ser Lys Gly Arg Phe Phe Leu Asp Arg Asp Gly Phe Leu Phe Arg 80 85 90 Tyr Ile Leu Asp Tyr Leu Arg Asp Leu Gln Leu Val Leu Pro Asp 95 100 105 Tyr Phe Pro Glu Arg Ser Arg Leu Gln Arg Glu Ala Glu Tyr Phe 110 115 120 Glu Leu Pro Glu Leu Val Arg Arg Leu Gly Ala Pro Gln Gln Pro 125 130 135 Gly Pro Gly Pro Pro Pro Ser Arg Arg Gly Val His Lys Glu Gly 140 145 150 Ser Leu Gly Asp Glu Leu Leu Pro Leu Gly Tyr Ser Glu Pro Glu 155 160 165 Gln Gln Glu Gly Ala Ser Ala Gly Ala Pro Ser Pro Thr Leu Glu 170 175 180 Leu Ala Ser Arg Ser Pro Ser Gly Gly Ala Ala Gly Pro Leu Leu 185 190 195 Thr Pro Ser Gln Ser Leu Asp Gly Ser Arg Arg Ser Gly Tyr Ile 200 205 210 Thr Ile Gly Tyr Arg Gly Ser Tyr Thr Ile Gly Arg Asp Ala Gln 215 220 225 Ala Asp Ala Lys Phe Arg Arg Val Ala Arg Ile Thr Val Cys Gly 230 235 240 Lys Thr Ser Leu Ala Lys Glu Val Phe Gly Asp Thr Leu Asn Glu 245 250 255 Ser Arg Asp Pro Asp Arg Pro Pro Glu Arg Tyr Thr Ser Arg Tyr 260 265 270 Tyr Leu Lys Phe Asn Phe Leu Glu Gln Ala Phe Asp Lys Leu Ser 275 280 285 Glu Ser Gly Phe His Met Val Ala Cys Ser Ser Thr Gly Thr Cys 290 295 300 Ala Phe Ala Ser Ser Thr Asp Gln Ser Glu Asp Lys Ile Trp Thr 305 310 315 Ser Tyr Thr Glu Tyr Val Phe Cys Arg Glu 320 325 3 376 PRT Homo sapiens misc_feature Incyte ID No 7238537CD1 3 Met Ala Arg Gly Pro Gly Pro Leu Gly Arg Pro Arg Pro Asp Thr 1 5 10 15 Val Ala Met Pro Lys Arg Gly Lys Arg Leu Lys Phe Arg Ala His 20 25 30 Asp Ala Cys Ser Gly Arg Val Thr Val Ala Asp Tyr Ala Asn Ser 35 40 45 Asp Pro Ala Val Val Arg Ser Gly Arg Val Lys Lys Ala Val Ala 50 55 60 Asn Ala Val Gln Gln Glu Val Lys Ser Leu Cys Gly Leu Glu Ala 65 70 75 Ser Gln Val Pro Ala Glu Glu Ala Leu Ser Gly Ala Gly Glu Pro 80 85 90 Cys Asp Ile Ile Asp Ser Ser Asp Glu Met Asp Ala Gln Glu Glu 95 100 105 Ser Ile His Glu Arg Thr Val Ser Arg Lys Lys Lys Ser Lys Arg 110 115 120 His Lys Glu Glu Leu Asp Gly Ala Gly Gly Glu Glu Tyr Pro Met 125 130 135 Asp Ile Trp Leu Leu Leu Ala Ser Tyr Ile Arg Pro Glu Asp Ile 140 145 150 Val Asn Phe Ser Leu Ile Cys Lys Asn Ala Trp Thr Val Thr Cys 155 160 165 Thr Ala Ala Phe Trp Thr Arg Leu Tyr Arg Arg His Tyr Thr Leu 170 175 180 Asp Ala Ser Leu Pro Leu Arg Leu Arg Pro Glu Ser Met Glu Lys 185 190 195 Leu Arg Cys Leu Arg Ala Cys Val Ile Arg Ser Leu Tyr His Met 200 205 210 Tyr Glu Pro Phe Ala Ala Arg Ile Ser Lys Asn Pro Ala Ile Pro 215 220 225 Glu Ser Thr Pro Ser Thr Leu Lys Asn Ser Lys Cys Leu Leu Phe 230 235 240 Trp Cys Arg Lys Ile Val Gly Asn Arg Gln Glu Pro Met Trp Glu 245 250 255 Phe Asn Phe Lys Phe Lys Lys Gln Ser Pro Arg Leu Lys Ser Lys 260 265 270 Cys Thr Gly Gly Leu Gln Pro Pro Val Gln Tyr Glu Asp Val His 275 280 285 Thr Asn Pro Asp Gln Asp Cys Cys Leu Leu Gln Val Thr Thr Leu 290 295 300 Asn Phe Ile Phe Ile Pro Ile Val Met Gly Met Ile Phe Thr Leu 305 310 315 Phe Thr Ile Asn Val Ser Thr Asp Met Arg His His Arg Val Arg 320 325 330 Leu Val Phe Gln Asp Ser Pro Val His Gly Gly Arg Lys Leu Arg 335 340 345 Ser Glu Gln Gly Val Gln Val Ile Leu Asp Pro Val His Ser Val 350 355 360 Arg Leu Phe Asp Trp Trp His Pro Gln Tyr Pro Phe Ser Leu Arg 365 370 375 Ala 4 461 PRT Homo sapiens misc_feature Incyte ID No 7494391CD1 4 Met Lys Ile Leu Phe Val Glu Pro Ala Ile Phe Leu Ser Ala Phe 1 5 10 15 Ala Met Thr Leu Thr Gly Pro Leu Thr Thr Gln Tyr Val Tyr Arg 20 25 30 Arg Ile Trp Glu Glu Thr Gly Asn Tyr Thr Phe Ser Ser Asp Ser 35 40 45 Asn Ile Ser Glu Cys Glu Lys Asn Lys Ser Ser Pro Ile Phe Ala 50 55 60 Phe Gln Glu Glu Val Gln Lys Lys Val Ser Arg Phe Asn Leu Gln 65 70 75 Met Asp Ile Ser Gly Leu Ile Pro Gly Leu Val Ser Thr Phe Ile 80 85 90 Leu Leu Ser Ile Ser Asp His Tyr Gly Arg Lys Phe Pro Met Ile 95 100 105 Leu Ser Ser Val Gly Ala Leu Ala Thr Ser Val Trp Leu Cys Leu 110 115 120 Leu Cys Tyr Phe Ala Phe Pro Phe Gln Leu Leu Ile Ala Ser Thr 125 130 135 Phe Ile Gly Ala Phe Cys Gly Asn Tyr Thr Thr Phe Trp Gly Ala 140 145 150 Cys Phe Ala Tyr Ile Val Asp Gln Cys Lys Glu His Lys Gln Lys 155 160 165 Thr Ile Arg Ile Ala Ile Ile Asp Phe Leu Leu Gly Leu Val Thr 170 175 180 Gly Leu Thr Gly Leu Ser Ser Gly Tyr Phe Ile Arg Glu Leu Gly 185 190 195 Phe Glu Trp Ser Phe Leu Ile Ile Ala Val Ser Leu Ala Val Asn 200 205 210 Leu Ile Tyr Ile Leu Phe Phe Leu Gly Asp Pro Val Lys Glu Cys 215 220 225 Ser Ser Gln Asn Val Thr Met Ser Cys Ser Glu Gly Phe Lys Asn 230 235 240 Leu Phe Tyr Arg Thr Tyr Met Leu Phe Lys Asn Ala Ser Gly Lys 245 250 255 Arg Arg Phe Leu Leu Cys Leu Leu Leu Phe Thr Val Ile Thr Tyr 260 265 270 Phe Phe Val Val Ile Gly Ile Ala Pro Ile Phe Ile Leu Tyr Glu 275 280 285 Leu Asp Ser Pro Leu Cys Trp Asn Glu Val Phe Ile Gly Tyr Gly 290 295 300 Ser Ala Leu Gly Ser Ala Ser Phe Leu Thr Ser Phe Leu Gly Ile 305 310 315 Trp Leu Phe Ser Tyr Cys Met Glu Asp Ile His Met Ala Phe Ile 320 325 330 Gly Ile Phe Thr Thr Met Thr Gly Met Ala Met Thr Ala Phe Ala 335 340 345 Ser Thr Thr Leu Met Met Phe Leu Ala Arg Val Pro Phe Leu Phe 350 355 360 Thr Ile Val Pro Phe Ser Val Leu Arg Ser Met Leu Ser Lys Val 365 370 375 Val Arg Ser Thr Glu Gln Gly Thr Leu Phe Ala Cys Ile Ala Phe 380 385 390 Leu Glu Thr Leu Gly Gly Val Thr Ala Val Ser Thr Phe Asn Gly 395 400 405 Ile Tyr Ser Ala Thr Val Ala Trp Tyr Pro Gly Phe Thr Phe Leu 410 415 420 Leu Ser Ala Gly Leu Leu Leu Leu Pro Ala Ile Ser Leu Cys Val 425 430 435 Val Lys Cys Thr Ser Trp Asn Glu Gly Ser Tyr Glu Leu Leu Ile 440 445 450 Gln Glu Glu Ser Ser Glu Asp Ala Ser Asp Arg 455 460 5 168 PRT Homo sapiens misc_feature Incyte ID No 6451054CD1 5 Met Met Glu Glu Ile Asp Arg Phe Gln Val Pro Thr Ala His Ser 1 5 10 15 Glu Met Gln Pro Leu Asp Pro Ala Ala Ala Ser Ile Ser Asp Gly 20 25 30 Asp Cys Asp Ala Arg Glu Glu Lys Gln Arg Glu Leu Ala Arg Lys 35 40 45 Gly Ser Leu Lys Asn Gly Ser Met Gly Ser Pro Val Asn Gln Gln 50 55 60 Pro Lys Lys Asn Asn Val Met Ala Arg Thr Arg Leu Val Val Pro 65 70 75 Asn Lys Gly Tyr Ser Ser Leu Asp Gln Ser Pro Asp Glu Lys Pro 80 85 90 Leu Val Ala Leu Asp Thr Asp Ser Asp Asp Asp Phe Asp Met Ser 95 100 105 Arg Tyr Ser Ser Ser Gly Tyr Ser Ser Ala Glu Gln Ile Asn Gln 110 115 120 Asp Leu Asn Ile Gln Leu Leu Lys Asp Gly Tyr Arg Leu Asp Glu 125 130 135 Ile Pro Asp Asp Glu Asp Leu Asp Leu Ile Pro Pro Lys Ser Val 140 145 150 Asn Pro Thr Cys Met Cys Cys Gln Ala Thr Ser Ser Thr Ala Cys 155 160 165 His Ile Gln 6 832 PRT Homo sapiens misc_feature Incyte ID No 7494592CD1 6 Met Met Glu Glu Glu Glu Leu Glu Phe Val Glu Glu Leu Glu Ala 1 5 10 15 Val Leu Gln Leu Thr Pro Glu Val Gln Leu Ala Ile Glu Gln Val 20 25 30 Phe Pro Ser Gln Asp Pro Leu Asp Arg Ala Asp Phe Asn Ala Val 35 40 45 Glu Tyr Ile Asn Thr Leu Phe Pro Thr Glu Gln Ser Leu Ala Asn 50 55 60 Ile Asp Glu Val Val Asn Lys Ile Arg Leu Lys Ile Arg Arg Leu 65 70 75 Asp Asp Asn Ile Arg Thr Val Val Arg Gly Gln Thr Asn Val Gly 80 85 90 Gln Asp Gly Arg Gln Ala Leu Glu Glu Ala Gln Lys Ala Ile Gln 95 100 105 Gln Leu Phe Gly Lys Ile Lys Asp Ile Lys Asp Lys Ala Glu Lys 110 115 120 Ser Glu Gln Met Val Lys Glu Ile Thr Arg Asp Ile Lys Gln Leu 125 130 135 Asp His Ala Lys Arg His Leu Thr Thr Ser Ile Thr Thr Leu Asn 140 145 150 His Leu His Met Leu Ala Gly Gly Val Asp Ser Leu Glu Ala Met 155 160 165 Thr Arg Arg Arg Gln Tyr Gly Glu Val Ala Asn Leu Leu Gln Gly 170 175 180 Val Met Asn Val Leu Glu His Phe His Lys Tyr Met Gly Ile Pro 185 190 195 Gln Ile Arg Gln Leu Ser Glu Arg Val Lys Ala Ala Gln Thr Glu 200 205 210 Leu Gly Gln Gln Ile Leu Ala Asp Phe Glu Glu Ala Phe Pro Ser 215 220 225 Gln Gly Thr Lys Arg Pro Gly Gly Pro Ser Asn Val Leu Arg Asp 230 235 240 Ala Cys Leu Val Ala Asn Ile Leu Asp Pro Arg Ile Lys Gln Glu 245 250 255 Ile Ile Lys Lys Phe Ile Lys Gln His Leu Ser Glu Tyr Leu Val 260 265 270 Leu Phe Gln Glu Asn Gln Asp Val Ala Trp Leu Asp Lys Ile Asp 275 280 285 Arg Arg Tyr Ala Trp Ile Lys Arg Gln Leu Val Asp Tyr Glu Glu 290 295 300 Lys Tyr Gly Arg Met Phe Pro Arg Glu Trp Cys Met Ala Glu Arg 305 310 315 Ile Ala Val Glu Phe Cys His Val Thr Arg Ala Glu Leu Ala Lys 320 325 330 Ile Met Arg Thr Arg Ala Lys Glu Ile Glu Val Lys Leu Leu Leu 335 340 345 Phe Ala Ile Gln Arg Thr Thr Asn Phe Glu Gly Phe Leu Ala Lys 350 355 360 Arg Phe Ser Gly Cys Thr Leu Thr Asp Gly Thr Leu Lys Lys Leu 365 370 375 Glu Ser Pro Pro Pro Ser Thr Asn Pro Phe Leu Glu Asp Glu Pro 380 385 390 Thr Pro Glu Met Glu Glu Leu Ala Thr Glu Lys Gly Asp Leu Asp 395 400 405 Gln Pro Lys Lys Pro Lys Ala Pro Asp Asn Pro Phe His Gly Ile 410 415 420 Val Ser Lys Cys Phe Glu Pro His Leu Tyr Val Tyr Ile Glu Ser 425 430 435 Gln Asp Lys Asn Leu Gly Glu Leu Ile Asp Arg Phe Val Ala Asp 440 445 450 Phe Lys Ala Gln Gly Pro Pro Lys Pro Asn Thr Asp Glu Gly Gly 455 460 465 Ala Val Leu Pro Ser Cys Ala Asp Leu Phe Val Tyr Tyr Lys Lys 470 475 480 Cys Met Val Gln Cys Ser Gln Leu Ser Thr Gly Glu Pro Met Ile 485 490 495 Ala Leu Thr Thr Ile Phe Gln Lys Tyr Leu Arg Glu Tyr Ala Trp 500 505 510 Lys Ile Leu Ser Gly Asn Leu Pro Lys Thr Thr Thr Ser Ser Gly 515 520 525 Gly Leu Thr Ile Ser Ser Leu Leu Lys Glu Lys Glu Gly Ser Glu 530 535 540 Val Ala Lys Phe Thr Leu Glu Glu Leu Cys Leu Ile Cys Asn Ile 545 550 555 Leu Ser Thr Ala Glu Tyr Cys Leu Ala Thr Thr Gln Gln Leu Glu 560 565 570 Glu Lys Leu Lys Glu Lys Val Asp Val Ser Leu Ile Glu Arg Ile 575 580 585 Asn Leu Thr Gly Glu Met Asp Thr Phe Ser Thr Val Ile Ser Ser 590 595 600 Ser Ile Gln Leu Leu Val Gln Asp Leu Asp Ala Ala Cys Asp Pro 605 610 615 Ala Leu Thr Ala Met Ser Lys Met Gln Trp Gln Asn Val Glu His 620 625 630 Val Gly Asp Gln Ser Pro Tyr Val Thr Ser Val Ile Leu His Ile 635 640 645 Lys Gln Asn Val Pro Ile Ile Arg Asp Asn Leu Ala Ser Thr Arg 650 655 660 Lys Tyr Phe Thr Gln Phe Cys Val Lys Phe Ala Asn Ser Phe Ile 665 670 675 Pro Lys Phe Ile Thr His Leu Phe Lys Cys Lys Pro Ile Ser Met 680 685 690 Val Gly Ala Glu Gln Leu Leu Leu Asp Thr His Ser Leu Lys Met 695 700 705 Val Leu Leu Asp Leu Pro Ser Ile Ser Ser Gln Val Val Arg Lys 710 715 720 Ala Pro Ala Ser Tyr Thr Lys Ile Val Val Lys Gly Met Thr Arg 725 730 735 Ala Glu Met Ile Leu Lys Val Val Met Ala Pro His Glu Pro Leu 740 745 750 Val Val Phe Val Asp Asn Tyr Ile Lys Leu Leu Thr Asp Cys Asn 755 760 765 Thr Glu Thr Phe Gln Lys Ile Leu Asp Met Lys Gly Leu Lys Arg 770 775 780 Ser Glu Gln Ser Ser Met Leu Glu Leu Leu Arg Gln Arg Leu Pro 785 790 795 Ala Pro Pro Ser Gly Ala Glu Ser Ser Gly Ser Leu Ser Leu Thr 800 805 810 Ala Pro Thr Pro Glu Gln Glu Ser Ser Arg Ile Arg Lys Leu Glu 815 820 825 Lys Leu Ile Lys Lys Arg Leu 830 7 393 PRT Homo sapiens misc_feature Incyte ID No 5202657CD1 7 Met Glu Gln Cys Ala Cys Val Glu Arg Glu Leu Asp Lys Val Leu 1 5 10 15 Gln Lys Phe Leu Thr Tyr Gly Gln His Cys Glu Arg Ser Leu Glu 20 25 30 Glu Leu Leu His Tyr Val Gly Gln Leu Arg Ala Glu Leu Ala Ser 35 40 45 Ala Ala Leu Gln Gly Thr Pro Leu Ser Ala Thr Leu Ser Leu Val 50 55 60 Met Ser Gln Cys Cys Arg Lys Ile Lys Asp Thr Val Gln Lys Leu 65 70 75 Ala Ser Asp His Lys Asp Ile His Ser Ser Val Ser Arg Val Gly 80 85 90 Lys Ala Ile Asp Arg Asn Phe Asp Ser Glu Ile Cys Gly Val Val 95 100 105 Ser Asp Ala Val Trp Asp Ala Arg Glu Gln Gln Gln Gln Ile Leu 110 115 120 Gln Met Ala Ile Val Glu His Leu Tyr Gln Gln Gly Met Leu Ser 125 130 135 Val Ala Glu Glu Leu Cys Gln Glu Ser Thr Leu Asn Val Asp Leu 140 145 150 Asp Phe Lys Gln Pro Phe Leu Glu Leu Asn Arg Ile Leu Glu Ala 155 160 165 Leu His Glu Gln Asp Leu Gly Pro Ala Leu Glu Trp Ala Val Ser 170 175 180 His Arg Gln Arg Leu Leu Glu Leu Asn Ser Ser Leu Glu Phe Lys 185 190 195 Leu His Arg Leu His Phe Ile Arg Leu Leu Ala Gly Gly Pro Ala 200 205 210 Lys Gln Leu Glu Ala Leu Ser Tyr Ala Arg His Phe Gln Pro Phe 215 220 225 Ala Arg Leu His Gln Arg Glu Ile Gln Val Met Met Gly Ser Leu 230 235 240 Val Tyr Leu Arg Leu Gly Leu Glu Lys Ser Pro Tyr Cys His Leu 245 250 255 Leu Asp Ser Ser His Trp Ala Glu Ile Cys Glu Thr Phe Thr Arg 260 265 270 Asp Ala Cys Ser Leu Leu Gly Leu Ser Val Glu Ser Pro Leu Ser 275 280 285 Val Ser Phe Ala Ser Gly Cys Val Ala Leu Pro Val Leu Met Asn 290 295 300 Ile Lys Ala Val Ile Glu Gln Arg Gln Cys Thr Gly Val Trp Asn 305 310 315 His Lys Asp Glu Leu Pro Ile Glu Ile Glu Leu Gly Met Lys Cys 320 325 330 Trp Tyr His Ser Val Phe Ala Cys Pro Ile Leu Arg Gln Gln Thr 335 340 345 Ser Asp Ser Asn Pro Pro Ile Lys Leu Ile Cys Gly His Val Ile 350 355 360 Ser Arg Asp Ala Leu Asn Lys Leu Ile Asn Gly Gly Lys Leu Lys 365 370 375 Cys Pro Tyr Cys Pro Met Glu Gln Asn Pro Ala Asp Gly Lys Arg 380 385 390 Ile Ile Phe 8 280 PRT Homo sapiens misc_feature Incyte ID No 2013529CD1 8 Met Ala Thr Glu Ala Pro Val Asn Ile Ala Pro Pro Glu Cys Ser 1 5 10 15 Thr Val Val Ser Thr Ala Val Asp Ser Leu Ile Trp Gln Pro Asn 20 25 30 Ser Leu Asn Met His Met Ile Arg Pro Lys Ser Ala Lys Gly Arg 35 40 45 Thr Arg Pro Ser Leu Gln Lys Ser Gln Gly Val Glu Val Cys Ala 50 55 60 His His Ile Pro Ser Pro Pro Pro Ala Ile Pro Tyr Glu Leu Pro 65 70 75 Ser Ser Gln Lys Pro Gly Ala Cys Ala Pro Lys Ser Pro Asn Gln 80 85 90 Gly Ala Ser Asp Glu Ile Pro Glu Leu Gln Gln Gln Val Pro Thr 95 100 105 Gly Ala Ser Ser Ser Leu Asn Lys Tyr Pro Val Leu Pro Ser Ile 110 115 120 Asn Arg Lys Asn Leu Glu Glu Glu Ala Val Glu Thr Val Ala Lys 125 130 135 Lys Ala Ser Ser Leu Gln Leu Ser Ser Ile Arg Ala Leu Tyr Gln 140 145 150 Asp Glu Thr Gly Thr Met Lys Thr Ser Glu Glu Asp Ser Arg Ala 155 160 165 Arg Ala Cys Ala Val Glu Arg Lys Phe Ile Val Arg Thr Lys Lys 170 175 180 Gln Gly Ser Ser Arg Ala Gly Asn Leu Glu Glu Pro Ser Asp Gln 185 190 195 Glu Pro Arg Leu Leu Leu Ala Val Arg Ser Pro Thr Gly Gln Arg 200 205 210 Phe Val Arg His Phe Arg Pro Thr Asp Asp Leu Gln Thr Ile Val 215 220 225 Ala Val Ala Glu Gln Lys Asn Lys Thr Ser Tyr Arg His Cys Ser 230 235 240 Ile Glu Thr Met Glu Val Pro Arg Arg Arg Phe Ser Asp Leu Thr 245 250 255 Lys Ser Leu Gln Glu Cys Arg Ile Pro His Lys Ser Val Leu Gly 260 265 270 Ile Ser Leu Glu Asp Gly Glu Gly Trp Pro 275 280 9 344 PRT Homo sapiens misc_feature Incyte ID No 3841351CD1 9 Met Asp Ser Tyr Ser Ala Pro Glu Ser Thr Pro Ser Ala Ser Ser 1 5 10 15 Arg Pro Glu Asp Tyr Phe Ile Gly Ala Thr Pro Leu Gln Lys Arg 20 25 30 Leu Glu Ser Val Arg Lys Gln Ser Ser Phe Ile Leu Thr Pro Pro 35 40 45 Arg Arg Lys Ile Pro Gln Cys Ser Gln Leu Gln Glu Asp Val Asp 50 55 60 Pro Gln Lys Val Ala Phe Leu Leu His Lys Gln Trp Thr Leu Tyr 65 70 75 Ser Leu Thr Pro Leu Tyr Lys Phe Ser Tyr Ser Asn Leu Lys Glu 80 85 90 Tyr Ser Arg Leu Leu Asn Ala Phe Ile Val Ala Glu Lys Gln Lys 95 100 105 Gly Leu Ala Val Glu Val Gly Glu Asp Phe Asn Ile Lys Val Ile 110 115 120 Phe Ser Thr Leu Leu Gly Met Lys Gly Thr Gln Arg Asp Pro Glu 125 130 135 Ala Phe Leu Val Gln Ile Val Ser Lys Ser Gln Leu Pro Ser Glu 140 145 150 Asn Arg Glu Gly Lys Val Leu Trp Thr Gly Trp Phe Cys Cys Val 155 160 165 Phe Gly Asp Ser Leu Leu Glu Thr Val Ser Glu Asp Phe Thr Cys 170 175 180 Leu Pro Leu Phe Leu Ala Asn Gly Ala Glu Ser Asn Thr Ala Ile 185 190 195 Ile Gly Thr Trp Phe Gln Lys Thr Phe Asp Cys Tyr Phe Ser Pro 200 205 210 Leu Ala Ile Asn Ala Phe Asn Leu Ser Trp Met Ala Ala Met Trp 215 220 225 Thr Ala Cys Lys Met Asp His Tyr Val Ala Thr Thr Glu Phe Leu 230 235 240 Trp Ser Val Pro Cys Ser Pro Gln Ser Leu Asp Ile Ser Phe Ala 245 250 255 Ile His Pro Glu Asp Ala Lys Ala Leu Trp Asp Ser Val His Lys 260 265 270 Thr Pro Gly Glu Val Thr Gln Glu Glu Val Asp Leu Phe Met Asp 275 280 285 Cys Leu Tyr Ser His Phe His Arg His Phe Lys Ile His Leu Ser 290 295 300 Ala Thr Arg Leu Val Arg Val Ser Thr Ser Val Ala Ser Ala His 305 310 315 Thr Asp Gly Lys Ile Lys Ile Leu Cys His Lys Tyr Leu Ile Gly 320 325 330 Val Leu Ala Tyr Leu Thr Glu Leu Ala Ile Phe Gln Ile Glu 335 340 10 405 PRT Homo sapiens misc_feature Incyte ID No 152116CD1 10 Met Glu Pro Gly Ala Gly Gly Arg Asn Thr Ala Arg Ala Gln Arg 1 5 10 15 Ala Gly Ser Pro Asn Thr Pro Pro Pro Arg Glu Gln Glu Arg Lys 20 25 30 Leu Glu Gln Glu Lys Leu Ser Gly Val Val Lys Ser Val His Arg 35 40 45 Arg Leu Arg Lys Lys Tyr Arg Glu Val Gly Asp Phe Asp Lys Ile 50 55 60 Trp Arg Glu His Cys Glu Asp Glu Glu Thr Leu Cys Glu Tyr Ala 65 70 75 Val Ala Met Lys Asn Leu Ala Asp Asn His Trp Ala Lys Thr Cys 80 85 90 Glu Gly Glu Gly Arg Ile Glu Trp Cys Cys Ser Val Cys Arg Glu 95 100 105 Tyr Phe Gln Asn Gly Gly Lys Arg Lys Ala Leu Glu Lys Asp Glu 110 115 120 Lys Arg Ala Val Leu Ala Thr Lys Thr Thr Pro Ala Leu Asn Met 125 130 135 His Glu Ser Ser Gln Leu Glu Gly His Leu Thr Asn Leu Ser Phe 140 145 150 Thr Asn Pro Glu Phe Ile Thr Glu Leu Leu Gln Ala Ser Gly Lys 155 160 165 Ile Arg Leu Leu Asp Val Gly Ser Cys Phe Asn Pro Phe Leu Lys 170 175 180 Phe Glu Glu Phe Leu Thr Val Gly Ile Asp Ile Val Pro Ala Val 185 190 195 Glu Ser Val Tyr Lys Cys Asp Phe Leu Asn Leu Gln Leu Gln Gln 200 205 210 Pro Leu Gln Leu Ala Gln Asp Ala Ile Asp Ala Phe Leu Lys Gln 215 220 225 Leu Lys Asn Pro Ile Asp Ser Leu Pro Gly Glu Leu Phe His Val 230 235 240 Val Val Phe Ser Leu Leu Leu Ser Tyr Phe Pro Ser Pro Tyr Gln 245 250 255 Arg Trp Ile Cys Cys Lys Lys Ala His Glu Leu Leu Val Leu Asn 260 265 270 Gly Leu Leu Leu Ile Ile Thr Pro Asp Ser Ser His Gln Asn Arg 275 280 285 His Ala Met Met Met Lys Ser Trp Lys Ile Ala Ile Glu Ser Leu 290 295 300 Gly Phe Lys Arg Phe Lys Tyr Ser Lys Phe Ser His Met His Leu 305 310 315 Met Ala Phe Arg Lys Ile Ser Leu Lys Thr Thr Ser Asp Leu Val 320 325 330 Ser Arg Asn Tyr Pro Gly Met Leu Tyr Ile Pro Gln Asp Phe Asn 335 340 345 Ser Ile Glu Asp Glu Glu Tyr Ser Asn Pro Ser Cys Tyr Val Arg 350 355 360 Ser Asp Ile Glu Asp Glu Gln Leu Ala Tyr Gly Phe Thr Glu Leu 365 370 375 Pro Asp Ala Pro Tyr Asp Ser Asp Ser Gly Glu Ser Gln Ala Ser 380 385 390 Ser Ile Pro Phe Tyr Glu Leu Glu Asp Pro Ile Leu Leu Leu Ser 395 400 405 11 185 PRT Homo sapiens misc_feature Incyte ID No 2381031CD1 11 Met Glu Val His Gly Lys Pro Lys Ala Ser Pro Ser Cys Ser Ser 1 5 10 15 Pro Thr Arg Asp Ser Ser Gly Val Pro Val Ser Lys Glu Leu Leu 20 25 30 Thr Ala Gly Ser Asp Gly Arg Gly Gly Ile Trp Asp Arg Leu Leu 35 40 45 Ile Asn Ser Gln Pro Lys Ser Arg Lys Thr Ser Thr Leu Gln Thr 50 55 60 Val Arg Ile Glu Arg Ser Pro Leu Leu Asp Gln Val Gln Thr Phe 65 70 75 Leu Pro Gln Met Ala Arg Ala Asn Glu Lys Leu Arg Lys Glu Met 80 85 90 Ala Ala Ala Pro Pro Gly Arg Phe Asn Ile Glu Asn Ile Asp Gly 95 100 105 Pro His Ser Lys Val Ile Gln Met Asp Val Ala Leu Phe Glu Met 110 115 120 Asn Gln Ser Asp Ser Lys Glu Val Asp Ser Ser Glu Glu Ser Ser 125 130 135 Gln Asp Ser Ser Glu Asn Ser Ser Glu Ser Glu Asp Glu Asp Asp 140 145 150 Ser Ile Pro Ser Glu Val Thr Ile Asp Asn Ile Lys Leu Pro Asn 155 160 165 Ser Glu Gly Gly Lys Gly Lys Ile Glu Val Leu Asp Ser Pro Ala 170 175 180 Ser Lys Lys Lys Lys 185 12 463 PRT Homo sapiens misc_feature Incyte ID No 2511371CD1 12 Met Ala Gln Gln Gln Thr Gly Ser Arg Lys Arg Lys Ala Pro Ala 1 5 10 15 Val Glu Ala Asp Ala Glu Ser Ser Pro Ser Gln Gly Leu Ala Ala 20 25 30 Ala Asp Gly Glu Gly Pro Leu Leu Leu Lys Arg Gln Arg Arg Pro 35 40 45 Ala Thr Tyr Arg Ser Met Ala His Tyr Leu Lys Val Arg Glu Val 50 55 60 Gly Gly Trp Gly Pro Ala Arg Leu Gln Gly Phe Asp Gly Glu Leu 65 70 75 Arg Gly Tyr Ala Val Gln Arg Leu Pro Glu Leu Leu Thr Glu Arg 80 85 90 Gln Leu Glu Leu Gly Thr Val Asn Lys Val Phe Ala Ser Gln Trp 95 100 105 Leu Asn Ser Arg Gln Val Val Cys Gly Thr Lys Cys Asn Thr Leu 110 115 120 Phe Val Val Asp Val Glu Ser Gly His Ile Ala Arg Ile Pro Leu 125 130 135 Leu Arg Asp Ser Glu Ala Arg Leu Ala Gln Asp Gln Gln Gly Cys 140 145 150 Gly Ile His Ala Ile Glu Leu Asn Pro Ser Lys Thr Leu Leu Ala 155 160 165 Thr Gly Gly Glu Asn Pro Asn Ser Leu Ala Ile Tyr Gln Leu Pro 170 175 180 Ser Leu Asp Pro Leu Cys Leu Gly Asp Arg His Gly His Lys Asp 185 190 195 Trp Ile Phe Ala Val Ala Trp Leu Ser Asp Thr Val Ala Val Ser 200 205 210 Gly Ser Arg Asp Gly Thr Val Ala Leu Trp Arg Met Asp Pro Asp 215 220 225 Lys Phe Asp Asp Thr Val Ala Trp His Ser Glu Val Gly Leu Pro 230 235 240 Val Tyr Ala His Ile Arg Pro Arg Asp Val Glu Ala Ile Pro Arg 245 250 255 Ala Ile Ile Asn Pro Ser Asn Arg Lys Val Arg Ala Leu Ala Cys 260 265 270 Gly Gly Lys Asn Gln Glu Leu Gly Ala Val Ser Leu Asp Gly Tyr 275 280 285 Phe His Leu Trp Lys Ala Gly Ser Ala Leu Ser Arg Leu Leu Ser 290 295 300 Ile Arg Leu Pro Tyr Phe Arg Asp Asn Val Cys Leu Thr Tyr Cys 305 310 315 Asp Asp Met Ser Val Tyr Ala Val Gly Ser His Ser His Val Ser 320 325 330 Phe Leu Asp Leu Arg Gln Asp Gln Gln Asn Ile Arg Pro Leu Cys 335 340 345 Ser Arg Glu Gly Gly Thr Gly Val Arg Ser Leu Ser Phe Tyr Arg 350 355 360 His Ile Ile Thr Val Gly Thr Gly Gln Gly Ser Leu Leu Phe Tyr 365 370 375 Asp Val Arg Ala Gln Lys Phe Leu Glu Glu Arg Ala Ser Ala Thr 380 385 390 Leu Glu Ser Ser Ser Gly Pro Ala Arg Arg Lys Leu Arg Leu Ala 395 400 405 Cys Gly Arg Gly Trp Leu Asn His Asn Asp Phe Trp Val Asn Tyr 410 415 420 Phe Gly Gly Met Glu Val Phe Pro Asn Ala Leu Tyr Thr His Cys 425 430 435 Tyr Asn Trp Pro Glu Met Lys Leu Phe Val Ala Gly Gly Pro Leu 440 445 450 Pro Ala Gly Leu His Gly Asn Tyr Ala Gly Leu Trp Ser 455 460 13 403 PRT Homo sapiens misc_feature Incyte ID No 8068623CD1 13 Met Ala Leu Arg Ser Ala Gln Gly Asp Gly Pro Thr Ser Gly His 1 5 10 15 Trp Asp Gly Gly Ala Glu Lys Ala Asp Phe Asn Ala Lys Arg Lys 20 25 30 Lys Lys Val Ala Glu Ile His Gln Ala Leu Asn Ser Asp Pro Thr 35 40 45 Asp Val Ala Ala Leu Arg Arg Met Ala Ile Ser Glu Gly Gly Leu 50 55 60 Leu Thr Asp Glu Ile Arg Arg Lys Val Trp Pro Lys Leu Leu Asn 65 70 75 Val Asn Ala Asn Asp Pro Pro Pro Ile Ser Gly Lys Asn Leu Arg 80 85 90 Gln Met Ser Lys Asp Tyr Gln Gln Val Leu Leu Asp Val Arg Arg 95 100 105 Ser Leu Arg Arg Phe Pro Pro Gly Met Pro Glu Glu Gln Arg Glu 110 115 120 Gly Leu Gln Glu Glu Leu Ile Asp Ile Ile Leu Leu Ile Leu Glu 125 130 135 Arg Asn Pro Gln Leu His Tyr Tyr Gln Gly Tyr His Asp Ile Val 140 145 150 Val Thr Phe Leu Leu Val Val Gly Glu Arg Leu Ala Thr Ser Leu 155 160 165 Val Glu Lys Leu Ser Thr His His Leu Arg Asp Phe Met Asp Pro 170 175 180 Thr Met Asp Asn Thr Lys His Ile Leu Asn Tyr Leu Met Pro Ile 185 190 195 Ile Asp Gln Val Asn Pro Glu Leu His Asp Phe Met Gln Ser Ala 200 205 210 Glu Val Gly Thr Ile Phe Ala Leu Ser Trp Leu Ile Thr Trp Phe 215 220 225 Gly His Val Leu Ser Asp Phe Arg His Val Val Arg Leu Tyr Asp 230 235 240 Phe Phe Leu Ala Cys His Pro Leu Met Pro Ile Tyr Phe Ala Ala 245 250 255 Val Ile Val Leu Tyr Arg Glu Gln Glu Val Leu Asp Cys Asp Cys 260 265 270 Asp Met Ala Ser Val His His Leu Leu Ser Gln Ile Pro Gln Asp 275 280 285 Leu Pro Tyr Glu Thr Leu Ile Ser Arg Ala Gly Asp Leu Phe Val 290 295 300 Gln Phe Pro Pro Ser Glu Leu Ala Arg Glu Ala Ala Ala Gln Gln 305 310 315 Gln Ala Glu Arg Thr Ala Ala Ser Thr Phe Lys Asp Phe Glu Leu 320 325 330 Ala Ser Ala Gln Gln Arg Pro Asp Met Val Leu Arg Gln Arg Phe 335 340 345 Arg Gly Leu Leu Arg Pro Glu Asp Arg Thr Lys Asp Val Leu Thr 350 355 360 Lys Pro Arg Thr Asn Arg Phe Val Lys Leu Ala Val Met Gly Leu 365 370 375 Thr Val Ala Leu Gly Ala Ala Ala Leu Ala Val Val Lys Ser Ala 380 385 390 Leu Glu Trp Ala Pro Lys Phe Gln Leu Gln Leu Phe Pro 395 400 14 574 PRT Homo sapiens misc_feature Incyte ID No 677977CD1 14 Met Gly Gly Glu Arg Lys Ala Gln Thr Cys Ala Ala Thr Phe Ser 1 5 10 15 Val Pro Ala Arg Ala Cys Ala Ala Gly Ser Arg Thr Met Pro Thr 20 25 30 Cys Ala Gly Ser Trp Ser Ser Trp Ala Val Arg Trp Ala Leu Ser 35 40 45 Ala Arg Arg Cys Gly Trp Pro Thr Arg Arg Arg Ser Thr Ala Pro 50 55 60 Cys Thr Pro Gly Ser Trp Arg Cys Ala Thr Thr Gly Cys Arg Cys 65 70 75 Leu Ala Arg Ser Ser Arg Arg Ser Arg Gly Leu Arg Ala Pro Asp 80 85 90 Leu Arg Ala Arg Val His Leu Gln Gly Gln Pro Arg Leu Val Leu 95 100 105 Ala Leu Ala Glu Ala Pro Arg His Leu Gln Pro Ala Leu Leu Arg 110 115 120 Arg Gly Gly Pro Pro Ala Pro Ser Pro Ala Pro Gly Pro Pro Val 125 130 135 Lys Glu Glu Pro Ala Leu Pro Ser Gly Ala Gly Pro Leu Pro Asp 140 145 150 Arg Ala Pro Ala Pro Pro Pro Pro Ala Glu Gly Gly Tyr Gly Asp 155 160 165 Glu Gln Ile Tyr Ser Ala Ser Val Thr Gly Leu Tyr Trp Lys Leu 170 175 180 Leu Pro Glu Gln Ala Ala Pro Pro Gly Ala Gly Asp Pro Gly Ala 185 190 195 Gly Gly Cys Gly Arg Arg Trp Arg Gly Asp Arg Val Thr Val Leu 200 205 210 Leu Ala Ala Asn Leu Thr Gly Ser His Lys Leu Lys Pro Leu Val 215 220 225 Ile Gly Arg Leu Pro Asp Pro Pro Ser Leu Arg His His Asn Gln 230 235 240 Asp Lys Phe Pro Ala Ser Tyr Arg Tyr Ser Pro Asp Ala Trp Leu 245 250 255 Ser Arg Pro Leu Leu Arg Gly Trp Phe Phe Glu Glu Phe Val Pro 260 265 270 Gly Val Lys Arg Tyr Leu Arg Arg Ser Cys Leu Gln Gln Lys Ala 275 280 285 Val Leu Leu Val Ala His Pro Pro Cys Pro Ser Pro Ala Ala Ser 290 295 300 Met Pro Ala Leu Asp Ser Glu Asp Ala Pro Val Arg Cys Arg Pro 305 310 315 Glu Pro Leu Gly Pro Pro Glu Glu Leu Gln Thr Pro Asp Gly Ala 320 325 330 Val Arg Val Leu Phe Leu Ser Lys Gly Ser Ser Arg Ala His Ile 335 340 345 Pro Glu Pro Val Glu Gln Gly Val Val Ala Ala Phe Lys Gln Leu 350 355 360 Tyr Lys Arg Glu Leu Leu Arg Leu Ala Val Ser Cys Ala Ser Gly 365 370 375 Ser Pro Leu Asp Phe Met Arg Ser Phe Met Leu Lys Asp Met Leu 380 385 390 Tyr Leu Ala Gly Leu Ser Trp Asp Leu Val Gln Ala Gly Ser Ile 395 400 405 Glu Arg Cys Trp Leu Leu Gly Leu Arg Ala Ala Phe Glu Pro Arg 410 415 420 Pro Gly Glu Asp Ser Ala Gly Gln Pro Ala Gln Ala Glu Glu Ala 425 430 435 Ala Glu His Ser Arg Val Leu Ser Asp Leu Thr His Leu Ala Ala 440 445 450 Leu Ala Tyr Lys Cys Leu Ala Pro Glu Glu Val Ala Glu Trp Leu 455 460 465 His Leu Asp Asp Asp Gly Ala Ser Leu Pro Ser Ala Met Gly Gly 470 475 480 Gly Glu Asp Glu Glu Glu Ala Thr Asp Tyr Gly Gly Thr Ser Ser 485 490 495 Leu Pro Ser Ala Ile Gly Gly Gly Glu Asp Glu Glu Glu Ala Thr 500 505 510 Asp Tyr Gly Gly Thr Ser Val Pro Thr Ala Gly Glu Ala Val Arg 515 520 525 Gly Leu Glu Thr Ala Leu Arg Trp Leu Glu Asn Gln Asp Pro Arg 530 535 540 Glu Val Gly Pro Leu Arg Leu Val Gln Leu Arg Ser Leu Ile Ser 545 550 555 Met Ala Arg Arg Leu Gly Gly Ile Gly His Thr Pro Ala Gly Pro 560 565 570 Tyr Asp Gly Val 15 731 PRT Homo sapiens misc_feature Incyte ID No 1661472CD1 15 Met Gln Gly Asp Pro Asp Asp Thr Ser His Arg Gly His Pro Leu 1 5 10 15 Cys Lys Phe Cys Asp Glu Arg Tyr Leu Asp Asn Asp Glu Leu Leu 20 25 30 Lys His Leu Arg Arg Asp His Tyr Phe Cys His Phe Cys Asp Ser 35 40 45 Asp Gly Ala Gln Asp Tyr Tyr Ser Asp Tyr Ala Tyr Leu Arg Glu 50 55 60 His Phe Arg Glu Lys His Phe Leu Cys Glu Glu Gly Arg Cys Ser 65 70 75 Thr Glu Gln Phe Thr His Ala Phe Arg Thr Glu Ile Asp Leu Lys 80 85 90 Ala His Arg Thr Ala Cys His Ser Arg Ser Arg Ala Glu Ala Arg 95 100 105 Gln Asn Arg His Ile Asp Leu Gln Phe Ser Tyr Ala Pro Arg His 110 115 120 Ser Arg Arg Asn Glu Gly Val Val Gly Gly Glu Asp Tyr Glu Glu 125 130 135 Val Asp Arg Tyr Ser Arg Gln Gly Arg Val Ala Arg Ala Gly Thr 140 145 150 Arg Gly Ala Gln Gln Ser Arg Arg Gly Ser Trp Arg Tyr Lys Arg 155 160 165 Glu Glu Glu Asp Arg Glu Val Ala Ala Ala Val Arg Ala Ser Val 170 175 180 Ala Ala Gln Gln Gln Glu Glu Ala Arg Arg Ser Glu Asp Gln Glu 185 190 195 Glu Gly Gly Arg Pro Lys Lys Glu Glu Ala Ala Ala Arg Gly Pro 200 205 210 Glu Asp Pro Arg Gly Pro Arg Arg Ser Pro Arg Thr Gln Gly Glu 215 220 225 Gly Pro Gly Pro Lys Glu Thr Ser Thr Asn Gly Pro Val Ser Gln 230 235 240 Glu Ala Phe Ser Val Thr Gly Pro Ala Ala Pro Gly Cys Val Gly 245 250 255 Val Pro Gly Ala Leu Pro Pro Pro Ser Pro Lys Leu Lys Asp Glu 260 265 270 Asp Phe Pro Ser Leu Ser Ala Ser Thr Ser Ser Ser Cys Ser Thr 275 280 285 Ala Ala Thr Pro Gly Pro Val Gly Leu Ala Leu Pro Tyr Ala Ile 290 295 300 Pro Ala Arg Gly Arg Ser Ala Phe Gln Glu Glu Asp Phe Pro Ala 305 310 315 Leu Val Ser Ser Val Pro Lys Pro Gly Thr Ala Pro Thr Ser Leu 320 325 330 Val Ser Ala Trp Asn Ser Ser Ser Ser Ser Lys Lys Val Ala Gln 335 340 345 Pro Pro Leu Ser Ala Gln Ala Thr Gly Ser Gly Gln Pro Thr Arg 350 355 360 Lys Ala Gly Lys Gly Ser Arg Gly Gly Arg Lys Gly Gly Pro Pro 365 370 375 Phe Thr Gln Glu Glu Glu Glu Asp Gly Gly Pro Ala Leu Gln Glu 380 385 390 Leu Leu Ser Thr Arg Pro Thr Gly Ser Val Ser Ser Thr Leu Gly 395 400 405 Leu Ala Ser Ile Gln Pro Ser Lys Val Gly Lys Lys Lys Lys Val 410 415 420 Gly Ser Glu Lys Pro Gly Thr Thr Leu Pro Gln Pro Pro Pro Ala 425 430 435 Thr Cys Pro Pro Gly Ala Leu Gln Ala Pro Glu Ala Pro Ala Ser 440 445 450 Arg Ala Glu Gly Pro Val Ala Val Val Val Asn Gly His Thr Glu 455 460 465 Gly Pro Ala Pro Ala Arg Ser Ala Pro Lys Glu Pro Pro Gly Leu 470 475 480 Pro Arg Pro Leu Gly Ser Phe Pro Cys Pro Thr Pro Gln Glu Asp 485 490 495 Phe Pro Ala Leu Gly Gly Pro Cys Pro Pro Arg Met Pro Pro Pro 500 505 510 Pro Gly Phe Ser Ala Val Val Leu Leu Lys Gly Thr Pro Pro Pro 515 520 525 Pro Pro Pro Gly Leu Val Pro Pro Ile Ser Lys Pro Pro Pro Gly 530 535 540 Phe Ser Gly Leu Leu Pro Ser Pro His Pro Ala Ser Val Pro Ser 545 550 555 Pro Ala Thr Thr Thr Thr Thr Lys Ala Pro Arg Leu Leu Pro Ala 560 565 570 Pro Arg Ala Tyr Leu Val Pro Glu Asn Phe Arg Glu Arg Asn Leu 575 580 585 Gln Leu Ile Gln Ser Ile Arg Asp Phe Leu Gln Ser Asp Glu Ala 590 595 600 Arg Phe Ser Glu Phe Lys Ser His Ser Gly Glu Phe Arg Gln Gly 605 610 615 Leu Ile Ser Ala Ala Gln Tyr Tyr Lys Ser Cys Arg Asp Leu Leu 620 625 630 Gly Glu Asn Phe Gln Lys Val Phe Asn Glu Leu Leu Val Leu Leu 635 640 645 Pro Asp Thr Ala Lys Gln Gln Glu Leu Leu Ser Ala His Thr Asp 650 655 660 Phe Cys Asn Arg Glu Lys Pro Leu Ser Thr Lys Ser Lys Lys Asn 665 670 675 Lys Lys Ser Ala Trp Gln Ala Thr Thr Gln Gln Ala Gly Leu Asp 680 685 690 Cys Arg Val Cys Pro Thr Cys Gln Gln Val Leu Ala His Gly Asp 695 700 705 Ala Ser Ser His Gln Ala Leu His Ala Ala Arg Asp Asp Asp Phe 710 715 720 Pro Ser Leu Gln Ala Ile Ala Arg Ile Ile Thr 725 730 16 299 PRT Homo sapiens misc_feature Incyte ID No 1748508CD1 16 Met Glu Thr Tyr Phe Val Glu Ile Ile Leu Cys Lys Tyr Val Phe 1 5 10 15 Asn Thr Tyr Phe Ile Phe Leu Thr Phe Gln Asn Tyr His Glu Ile 20 25 30 Met Thr Arg His Pro Glu Asn Tyr Gln Trp Glu Asn Trp Ser Leu 35 40 45 Glu Asn Val Ala Thr Ile Leu Ala His Arg Phe Pro Asn Ser Tyr 50 55 60 Ile Trp Val Ile Lys Cys Ser Arg Met His Leu His Lys Phe Ser 65 70 75 Cys Tyr Asp Asn Phe Val Lys Ser Asn Met Phe Gly Ala Pro Glu 80 85 90 His Asn Thr Asp Phe Gly Ala Phe Lys His Leu Tyr Met Leu Leu 95 100 105 Val Asn Ala Phe Asn Leu Ser Gln Asn Ser Leu Ser Lys Lys Ser 110 115 120 Leu Asn Val Trp Asn Lys Asp Ser Ile Ala Ser Asn Cys Arg Ser 125 130 135 Ser Pro Ser His Thr Thr Asn Gly Cys Gln Gly Glu Lys Val Arg 140 145 150 Thr Cys Glu Lys Ser Asp Glu Ser Ala Met Ser Phe Tyr Pro Pro 155 160 165 Ser Leu Asn Asp Ala Ser Phe Thr Leu Ile Gly Phe Ser Lys Gly 170 175 180 Cys Val Val Leu Asn Gln Leu Leu Phe Glu Leu Lys Glu Ala Lys 185 190 195 Lys Asp Lys Asn Ile Asp Ala Phe Ile Lys Ser Ile Arg Thr Met 200 205 210 Tyr Trp Leu Asp Gly Gly His Ser Gly Gly Ser Asn Thr Trp Val 215 220 225 Thr Tyr Pro Glu Val Leu Lys Glu Phe Ala Gln Thr Gly Ile Ile 230 235 240 Val His Thr His Val Thr Pro Tyr Gln Val Arg Asp Pro Met Arg 245 250 255 Ser Trp Ile Gly Lys Glu His Lys Lys Phe Val Gln Ile Leu Gly 260 265 270 Asp Leu Gly Met Gln Val Thr Ser Gln Ile His Phe Thr Lys Glu 275 280 285 Ala Pro Ser Ile Glu Asn His Phe Arg Val His Glu Val Phe 290 295 17 620 PRT Homo sapiens misc_feature Incyte ID No 2159545CD1 17 Met Ala Ser Asp Ser Met Ser Ser Lys Gln Ala Arg Asn His Ile 1 5 10 15 Thr Lys Gly Lys Arg Gln Gln Gln His Gln Gln Ile Lys Asn Arg 20 25 30 Ser Ser Ile Ser Asp Gly Asp Gly Glu Asp Ser Phe Ile Phe Glu 35 40 45 Ala Asn Glu Ala Trp Lys Asp Phe His Gly Ser Leu Leu Arg Phe 50 55 60 Tyr Glu Asn Gly Glu Leu Cys Asp Val Thr Leu Lys Val Gly Ser 65 70 75 Lys Leu Ile Ser Cys His Lys Leu Val Leu Ala Cys Val Ile Pro 80 85 90 Tyr Phe Arg Ala Met Phe Leu Ser Glu Met Ala Glu Ala Lys Gln 95 100 105 Thr Leu Ile Glu Ile Arg Asp Phe Asp Gly Asp Ala Ile Glu Asp 110 115 120 Leu Val Lys Phe Val Tyr Ser Ser Arg Leu Thr Leu Thr Val Asp 125 130 135 Asn Val Gln Pro Leu Leu Tyr Ala Ala Cys Ile Leu Gln Val Glu 140 145 150 Leu Val Ala Arg Ala Cys Cys Glu Tyr Met Lys Leu His Phe His 155 160 165 Pro Ser Asn Cys Leu Ala Val Arg Ala Phe Ala Glu Ser His Asn 170 175 180 Arg Ile Asp Leu Met Asp Met Ala Asp Gln Tyr Ala Cys Asp His 185 190 195 Phe Thr Glu Val Val Glu Cys Glu Asp Phe Val Ser Val Ser Pro 200 205 210 Gln His Leu His Lys Leu Leu Ser Ser Ser Asp Leu Asn Ile Glu 215 220 225 Asn Glu Lys Gln Val Tyr Asn Ala Ala Ile Lys Trp Leu Leu Ala 230 235 240 Asn Pro Gln His His Ser Lys Trp Leu Asp Glu Thr Leu Ala Gln 245 250 255 Val Arg Leu Pro Leu Leu Pro Val Asp Phe Leu Met Gly Val Val 260 265 270 Ala Lys Glu Gln Ile Val Lys Gln Asn Leu Lys Cys Arg Asp Leu 275 280 285 Leu Asp Glu Ala Arg Asn Tyr His Leu His Leu Ser Ser Arg Ala 290 295 300 Val Pro Asp Phe Glu Tyr Ser Ile Arg Thr Thr Pro Arg Lys His 305 310 315 Thr Ala Gly Val Leu Phe Cys Val Gly Gly Arg Gly Gly Ser Gly 320 325 330 Asp Pro Phe Arg Ser Ile Glu Cys Tyr Ser Ile Asn Lys Asn Ser 335 340 345 Trp Phe Phe Gly Pro Glu Met Asn Ser Arg Arg Arg His Val Gly 350 355 360 Val Ile Ser Val Glu Gly Lys Val Tyr Ala Val Gly Gly His Asp 365 370 375 Gly Asn Glu His Leu Gly Ser Met Glu Met Phe Asp Pro Leu Thr 380 385 390 Asn Lys Trp Met Met Lys Ala Ser Met Asn Thr Lys Arg Arg Gly 395 400 405 Ile Ala Leu Ala Ser Leu Gly Gly Pro Ile Tyr Ala Ile Gly Gly 410 415 420 Leu Asp Asp Asn Thr Cys Phe Asn Asp Val Glu Arg Tyr Asp Ile 425 430 435 Glu Ser Asp Gln Trp Ser Thr Val Ala Pro Met Asn Thr Pro Arg 440 445 450 Gly Gly Val Gly Ser Val Ala Leu Val Asn His Val Tyr Ala Val 455 460 465 Gly Gly Asn Asp Gly Met Ala Ser Leu Ser Ser Val Glu Arg Tyr 470 475 480 Asp Pro His Leu Asp Lys Trp Ile Glu Val Lys Glu Met Gly Gln 485 490 495 Arg Arg Ala Gly Asn Gly Val Ser Lys Leu His Gly Cys Leu Tyr 500 505 510 Val Val Gly Gly Phe Asp Asp Asn Ser Pro Leu Ser Ser Val Glu 515 520 525 Arg Tyr Asp Pro Arg Ser Asn Lys Trp Asp Tyr Val Ala Ala Leu 530 535 540 Thr Thr Pro Arg Gly Gly Val Gly Ile Ala Thr Val Met Gly Lys 545 550 555 Ile Phe Ala Val Gly Gly His Asn Gly Asn Ala Tyr Leu Asn Thr 560 565 570 Val Glu Ala Phe Asp Pro Val Leu Asn Arg Trp Glu Leu Val Gly 575 580 585 Ser Val Ser His Cys Arg Ala Gly Ala Gly Val Ala Val Cys Ser 590 595 600 Cys Leu Thr Ser Gln Ile Arg Asp Val Gly His Gly Ser Asn Asn 605 610 615 Val Val Asp Cys Met 620 18 218 PRT Homo sapiens misc_feature Incyte ID No 8560269CD1 18 Met Ala Leu Val Pro Tyr Glu Glu Thr Thr Glu Phe Gly Leu Gln 1 5 10 15 Lys Phe His Lys Pro Leu Ala Thr Phe Ser Phe Ala Asn His Thr 20 25 30 Ile Gln Ile Arg Gln Asp Trp Arg His Leu Gly Val Ala Ala Val 35 40 45 Val Trp Asp Ala Ala Ile Val Leu Ser Thr Tyr Leu Glu Met Gly 50 55 60 Ala Val Glu Leu Arg Gly Arg Ser Ala Val Glu Leu Gly Ala Gly 65 70 75 Thr Gly Leu Val Gly Ile Val Ala Ala Leu Leu Gly Ala His Val 80 85 90 Thr Ile Thr Asp Arg Lys Val Ala Leu Glu Phe Leu Lys Ser Asn 95 100 105 Val Gln Ala Asn Leu Pro Pro His Ile Gln Thr Lys Thr Val Val 110 115 120 Lys Glu Leu Thr Trp Gly Gln Asn Leu Gly Ser Phe Ser Pro Gly 125 130 135 Glu Phe Asp Leu Ile Leu Gly Ala Asp Ile Ile Tyr Leu Glu Glu 140 145 150 Thr Phe Thr Asp Leu Leu Gln Thr Leu Glu His Leu Cys Ser Asn 155 160 165 His Ser Val Ile Leu Leu Ala Cys Arg Ile Arg Tyr Glu Arg Asp 170 175 180 Asn Asn Phe Leu Ala Met Leu Glu Arg Gln Phe Ile Val Arg Lys 185 190 195 Val His Tyr Asp Pro Glu Lys Asp Val His Ile Tyr Glu Ala Gln 200 205 210 Lys Arg Asn Gln Lys Glu Asp Leu 215 19 427 PRT Homo sapiens misc_feature Incyte ID No 8710302CD1 19 Met Ala Ala Leu Ser Lys Ser Ile Pro His Asn Cys Tyr Glu Ile 1 5 10 15 Gly His Thr Trp His Pro Ser Cys Arg Val Ser Phe Leu Gln Ile 20 25 30 Thr Gly Gly Ala Leu Glu Glu Ser Leu Lys Ile Tyr Ala Pro Leu 35 40 45 Tyr Leu Ile Ala Ala Ile Leu Arg Lys Arg Lys Leu Asp Tyr Tyr 50 55 60 Leu His Lys Leu Leu Pro Glu Ile Leu Gln Ser Ala Ser Phe Leu 65 70 75 Thr Ala Asn Gly Ala Leu Tyr Met Ala Phe Phe Cys Ile Leu Arg 80 85 90 Arg Gly Leu Leu Thr Ile Tyr Met Ala Asn Leu Ala Thr Glu Thr 95 100 105 Leu Phe Arg Met Gly Val Ala Arg Gly Thr Ile Thr Thr Leu Arg 110 115 120 Asn Gly Glu Val Leu Leu Phe Cys Ile Thr Ala Ala Met Tyr Met 125 130 135 Phe Phe Phe Arg Cys Lys Asp Gly Leu Lys Gly Phe Thr Phe Ser 140 145 150 Ala Leu Arg Phe Ile Val Gly Lys Glu Glu Ile Pro Thr His Ser 155 160 165 Phe Ser Pro Glu Ala Ala Tyr Ala Lys Val Glu Gln Lys Arg Glu 170 175 180 Gln His Glu Glu Lys Pro Arg Arg Met Asn Met Ile Gly Leu Val 185 190 195 Arg Lys Phe Val Asp Ser Ile Cys Lys His Gly Pro Arg His Arg 200 205 210 Cys Cys Lys His Tyr Glu Asp Asn Cys Ile Ser Tyr Cys Ile Lys 215 220 225 Gly Phe Ile Arg Met Phe Ser Val Gly Tyr Leu Ile Gln Cys Cys 230 235 240 Leu Arg Ile Pro Ser Ala Phe Arg His Leu Phe Thr Gln Pro Ser 245 250 255 Arg Leu Leu Ser Leu Phe Tyr Asn Lys Glu Asn Phe Gln Leu Gly 260 265 270 Ala Phe Leu Gly Ser Phe Val Ser Ile Tyr Lys Gly Thr Ser Cys 275 280 285 Phe Leu Arg Trp Ile Arg Asn Leu Asp Asp Glu Leu His Ala Ile 290 295 300 Ile Ala Gly Phe Leu Ala Gly Ile Ser Met Met Phe Tyr Lys Ser 305 310 315 Thr Thr Ile Ser Met Tyr Leu Ala Ser Lys Leu Val Glu Thr Met 320 325 330 Tyr Phe Lys Gly Ile Glu Ala Gly Lys Val Pro Tyr Phe Pro His 335 340 345 Ala Asp Thr Ile Ile Tyr Ser Ile Ser Thr Ala Ile Cys Phe Gln 350 355 360 Ala Ala Val Met Glu Val Gln Thr Leu Arg Pro Ser Tyr Trp Lys 365 370 375 Phe Leu Leu Arg Leu Thr Lys Gly Lys Phe Ala Val Met Asn Arg 380 385 390 Lys Val Leu Asp Val Phe Gly Thr Gly Ala Ser Lys His Phe Gln 395 400 405 Asp Phe Ile Pro Arg Leu Asp Pro Arg Tyr Thr Thr Val Thr Pro 410 415 420 Glu Leu Pro Thr Glu Phe Ser 425 20 612 PRT Homo sapiens misc_feature Incyte ID No 6778214CD1 20 Met Glu Ile Ala Pro Gln Glu Ala Pro Pro Val Pro Gly Ala Asp 1 5 10 15 Gly Asp Ile Glu Glu Ala Pro Ala Glu Ala Gly Ser Pro Ser Pro 20 25 30 Ala Ser Pro Pro Ala Asp Gly Arg Leu Lys Ala Ala Ala Lys Arg 35 40 45 Val Thr Phe Pro Ser Asp Glu Asp Ile Val Ser Gly Ala Val Glu 50 55 60 Pro Lys Asp Pro Trp Arg His Ala Gln Asn Val Thr Val Asp Glu 65 70 75 Val Ile Gly Ala Tyr Lys Gln Ala Cys Gln Lys Leu Asn Cys Arg 80 85 90 Gln Ile Pro Lys Leu Leu Arg Gln Leu Gln Glu Phe Thr Asp Leu 95 100 105 Gly His Arg Leu Asp Cys Leu Asp Leu Lys Gly Glu Lys Leu Asp 110 115 120 Tyr Lys Thr Cys Glu Ala Leu Glu Glu Val Phe Lys Arg Leu Gln 125 130 135 Phe Lys Val Val Asp Leu Glu Gln Thr Asn Leu Asp Glu Asp Gly 140 145 150 Ala Ser Ala Leu Phe Asp Met Ile Glu Tyr Tyr Glu Ser Ala Thr 155 160 165 His Leu Asn Ile Ser Phe Asn Lys His Ile Gly Thr Arg Gly Trp 170 175 180 Gln Ala Ala Ala His Met Met Arg Lys Thr Ser Cys Leu Gln Tyr 185 190 195 Leu Asp Ala Arg Asn Thr Pro Leu Leu Asp His Ser Ala Pro Phe 200 205 210 Val Ala Arg Ala Leu Arg Ile Arg Ser Ser Leu Ala Val Leu His 215 220 225 Leu Glu Asn Ala Ser Leu Ser Gly Arg Pro Leu Met Leu Leu Ala 230 235 240 Thr Ala Leu Lys Met Asn Met Asn Leu Arg Glu Leu Tyr Leu Ala 245 250 255 Asp Asn Lys Leu Asn Gly Leu Gln Asp Ser Ala Gln Leu Gly Asn 260 265 270 Leu Leu Lys Phe Asn Cys Ser Leu Gln Ile Leu Asp Leu Arg Asn 275 280 285 Asn His Val Leu Asp Ser Gly Leu Ala Tyr Ile Cys Glu Gly Leu 290 295 300 Lys Glu Gln Arg Lys Gly Leu Val Thr Leu Val Leu Trp Asn Asn 305 310 315 Gln Leu Thr His Thr Gly Met Ala Phe Leu Gly Met Thr Leu Pro 320 325 330 His Thr Gln Ser Leu Glu Thr Leu Asn Leu Gly His Asn Pro Ile 335 340 345 Gly Asn Glu Gly Val Arg His Leu Lys Asn Gly Leu Ile Ser Asn 350 355 360 Arg Ser Val Leu Arg Leu Gly Leu Ala Ser Thr Lys Leu Thr Cys 365 370 375 Glu Gly Ala Val Ala Val Ala Glu Phe Ile Ala Glu Ser Pro Arg 380 385 390 Leu Leu Arg Leu Asp Leu Arg Glu Asn Glu Ile Lys Thr Gly Gly 395 400 405 Leu Met Ala Leu Ser Leu Ala Leu Lys Val Asn His Ser Leu Leu 410 415 420 Arg Leu Asp Leu Asp Arg Glu Pro Lys Lys Glu Ala Val Lys Ser 425 430 435 Phe Ile Glu Thr Gln Lys Ala Leu Leu Ala Glu Ile Gln Asn Gly 440 445 450 Cys Lys Arg Asn Leu Val Leu Ala Arg Glu Arg Glu Glu Lys Glu 455 460 465 Gln Pro Pro Gln Leu Ser Ala Ser Met Pro Glu Thr Thr Ala Thr 470 475 480 Glu Pro Gln Pro Asp Asp Glu Pro Ala Ala Gly Val Gln Asn Gly 485 490 495 Ala Pro Ser Pro Ala Pro Ser Pro Asp Ser Asp Ser Asp Ser Asp 500 505 510 Ser Asp Gly Glu Glu Glu Glu Glu Glu Glu Gly Glu Arg Asp Glu 515 520 525 Thr Pro Ser Gly Ala Ile Asp Thr Arg Asp Thr Gly Ser Ser Glu 530 535 540 Pro Gln Pro Pro Pro Glu Pro Pro Arg Ser Gly Pro Pro Leu Pro 545 550 555 Asn Gly Leu Lys Pro Glu Phe Ala Leu Ala Leu Pro Pro Glu Pro 560 565 570 Pro Pro Gly Pro Glu Val Lys Gly Gly Ser Cys Gly Leu Glu His 575 580 585 Glu Leu Ser Cys Ser Lys Asn Glu Lys Glu Leu Glu Glu Leu Leu 590 595 600 Leu Glu Ala Ser Gln Glu Ser Gly Gln Glu Thr Leu 605 610 21 458 PRT Homo sapiens misc_feature Incyte ID No 258383CD1 21 Met Ala Ala Leu Ser Lys Ser Ile Pro His Asn Cys Tyr Glu Ile 1 5 10 15 Gly His Thr Trp His Pro Ser Cys Arg Val Ser Phe Leu Gln Ile 20 25 30 Thr Gly Gly Ala Leu Glu Glu Ser Leu Lys Ile Tyr Ala Pro Leu 35 40 45 Tyr Leu Ile Ala Ala Ile Leu Arg Lys Arg Lys Leu Asp Tyr Tyr 50 55 60 Leu His Lys Leu Leu Pro Glu Ile Leu Gln Ser Ala Ser Phe Leu 65 70 75 Thr Ala Asn Gly Ala Leu Tyr Met Ala Phe Phe Cys Ile Leu Arg 80 85 90 Lys Ile Leu Gly Lys Phe Tyr Ser Trp Thr Pro Gly Phe Gly Ala 95 100 105 Ala Leu Pro Ala Ser Tyr Val Ala Ile Leu Ile Glu Arg Lys Ser 110 115 120 Arg Arg Gly Leu Leu Thr Ile Tyr Met Ala Asn Leu Ala Thr Glu 125 130 135 Thr Leu Phe Arg Met Gly Val Ala Arg Gly Thr Ile Thr Thr Leu 140 145 150 Arg Asn Gly Glu Val Leu Leu Phe Cys Ile Thr Ala Ala Met Tyr 155 160 165 Met Phe Phe Phe Arg Cys Lys Asp Gly Leu Lys Gly Phe Thr Phe 170 175 180 Ser Ala Leu Arg Phe Ile Val Gly Lys Glu Glu Ile Pro Thr His 185 190 195 Ser Phe Ser Pro Glu Ala Ala Tyr Ala Lys Val Glu Gln Lys Arg 200 205 210 Glu Gln His Glu Glu Lys Pro Arg Arg Met Asn Met Ile Gly Leu 215 220 225 Val Arg Lys Phe Val Asp Ser Ile Cys Lys His Gly Pro Arg His 230 235 240 Arg Cys Cys Lys His Tyr Glu Asp Asn Cys Ile Ser Tyr Cys Ile 245 250 255 Lys Gly Phe Ile Arg Met Phe Ser Val Gly Tyr Leu Ile Gln Cys 260 265 270 Cys Leu Arg Ile Pro Ser Ala Phe Arg His Leu Phe Thr Gln Pro 275 280 285 Ser Arg Leu Leu Ser Leu Phe Tyr Asn Lys Glu Asn Phe Gln Leu 290 295 300 Gly Ala Phe Leu Gly Ser Phe Val Ser Ile Tyr Lys Gly Thr Ser 305 310 315 Cys Phe Leu Arg Trp Ile Arg Asn Leu Asp Asp Glu Leu His Ala 320 325 330 Ile Ile Ala Gly Phe Leu Ala Gly Ile Ser Met Met Phe Tyr Lys 335 340 345 Ser Thr Thr Ile Ser Met Tyr Leu Ala Ser Lys Leu Val Glu Thr 350 355 360 Met Tyr Phe Lys Gly Ile Glu Ala Gly Lys Val Pro Tyr Phe Pro 365 370 375 His Ala Asp Thr Ile Ile Tyr Ser Ile Ser Thr Ala Ile Cys Phe 380 385 390 Gln Ala Ala Val Met Glu Val Gln Thr Leu Arg Pro Ser Tyr Trp 395 400 405 Lys Phe Leu Leu Arg Leu Thr Lys Gly Lys Phe Ala Val Met Asn 410 415 420 Arg Lys Val Leu Asp Val Phe Gly Thr Gly Ala Ser Lys His Phe 425 430 435 Gln Asp Phe Ile Pro Arg Leu Asp Pro Arg Tyr Thr Thr Val Thr 440 445 450 Pro Glu Leu Pro Thr Glu Phe Ser 455 22 1451 PRT Homo sapiens misc_feature Incyte ID No 2804937CD1 22 Met Ser Leu Val Asn Phe Glu Pro Ala Ala Arg Arg Ala Ser Asn 1 5 10 15 Ile Cys Asp Thr Asp Ser His Val Ser Ser Ser Thr Ser Val Arg 20 25 30 Phe Tyr Pro His Asp Val Leu Ser Leu Pro Gln Ile Arg Leu Asn 35 40 45 Arg Leu Leu Thr Ile Asp Thr Asp Leu Leu Glu Gln Gln Asp Ile 50 55 60 Asp Leu Ser Pro Asp Leu Ala Ala Thr Tyr Gly Pro Thr Glu Glu 65 70 75 Ala Ala Gln Lys Val Lys His Tyr Tyr Arg Phe Trp Ile Leu Pro 80 85 90 Gln Leu Trp Ile Gly Ile Asn Phe Asp Arg Leu Thr Leu Leu Ala 95 100 105 Leu Phe Asp Arg Asn Arg Glu Ile Leu Glu Asn Val Leu Ala Val 110 115 120 Ile Leu Ala Ile Leu Val Ala Phe Leu Gly Ser Ile Leu Leu Ile 125 130 135 Gln Gly Phe Phe Arg Asp Ile Trp Val Phe Gln Phe Cys Leu Val 140 145 150 Ile Ala Ser Cys Gln Tyr Ser Leu Leu Lys Ser Val Gln Pro Asp 155 160 165 Ser Ser Ser Pro Arg His Gly His Asn Arg Ile Ile Ala Tyr Ser 170 175 180 Arg Pro Val Tyr Phe Cys Ile Cys Cys Gly Leu Ile Trp Leu Leu 185 190 195 Asp Tyr Gly Ser Arg Asn Leu Thr Ala Thr Lys Phe Lys Leu Tyr 200 205 210 Gly Ile Thr Phe Thr Asn Pro Leu Val Phe Ile Ser Ala Arg Asp 215 220 225 Leu Val Ile Val Phe Thr Leu Cys Phe Pro Ile Val Phe Phe Ile 230 235 240 Gly Leu Leu Pro Gln Val Asn Thr Phe Val Met Tyr Leu Cys Glu 245 250 255 Gln Leu Asp Ile His Ile Phe Gly Gly Asn Ala Thr Thr Ser Leu 260 265 270 Leu Ala Ala Leu Tyr Ser Phe Ile Cys Ser Ile Val Ala Val Ala 275 280 285 Leu Leu Tyr Gly Leu Cys Tyr Gly Ala Leu Lys Asp Ser Trp Asp 290 295 300 Gly Gln His Ile Pro Val Leu Phe Ser Ile Phe Cys Gly Leu Leu 305 310 315 Val Ala Val Ser Tyr His Leu Ser Arg Gln Ser Ser Asp Pro Ser 320 325 330 Val Leu Phe Ser Leu Val Gln Ser Lys Ile Phe Pro Lys Thr Glu 335 340 345 Glu Lys Asn Pro Glu Asp Pro Leu Ser Glu Val Lys Asp Pro Leu 350 355 360 Pro Glu Lys Leu Arg Asn Ser Val Ser Glu Arg Leu Gln Ser Asp 365 370 375 Leu Val Val Cys Ile Val Ile Gly Val Leu Tyr Phe Ala Ile His 380 385 390 Val Ser Thr Val Phe Thr Val Leu Gln Pro Ala Leu Lys Tyr Val 395 400 405 Leu Tyr Thr Leu Val Gly Phe Val Gly Phe Val Thr His Tyr Val 410 415 420 Leu Pro Gln Val Arg Lys Gln Leu Pro Trp His Cys Phe Ser His 425 430 435 Pro Leu Leu Lys Thr Leu Glu Tyr Asn Gln Tyr Glu Val Arg Asn 440 445 450 Ala Ala Thr Met Met Trp Phe Glu Lys Leu His Val Trp Leu Leu 455 460 465 Phe Val Glu Lys Asn Ile Ile Tyr Pro Leu Ile Val Leu Asn Glu 470 475 480 Leu Ser Ser Ser Ala Glu Thr Ile Ala Ser Pro Lys Lys Leu Asn 485 490 495 Thr Glu Leu Gly Ala Leu Met Ile Thr Val Ala Gly Leu Lys Leu 500 505 510 Leu Arg Ser Ser Phe Ser Ser Pro Thr Tyr Gln Tyr Val Thr Val 515 520 525 Ile Phe Thr Val Leu Phe Phe Lys Phe Asp Tyr Glu Ala Phe Ser 530 535 540 Glu Thr Met Leu Leu Asp Leu Phe Phe Met Ser Ile Leu Phe Asn 545 550 555 Lys Leu Trp Glu Leu Leu Tyr Lys Leu Gln Phe Val Tyr Thr Tyr 560 565 570 Ile Ala Pro Trp Gln Ile Thr Trp Gly Ser Ala Phe His Ala Phe 575 580 585 Ala Gln Pro Phe Ala Val Pro His Ser Ala Met Leu Phe Ile Gln 590 595 600 Ala Ala Val Ser Ala Phe Phe Ser Thr Pro Leu Asn Pro Phe Leu 605 610 615 Gly Ser Ala Ile Phe Ile Thr Ser Tyr Val Arg Pro Val Lys Phe 620 625 630 Trp Glu Arg Asp Tyr Asn Thr Lys Arg Val Asp His Ser Asn Thr 635 640 645 Arg Leu Ala Ser Gln Leu Asp Arg Asn Pro Gly Ser Asp Asp Asn 650 655 660 Asn Leu Asn Ser Ile Phe Tyr Glu His Leu Thr Arg Ser Leu Gln 665 670 675 His Ser Leu Cys Gly Asp Leu Leu Leu Gly Arg Trp Gly Asn Tyr 680 685 690 Ser Thr Gly Asp Cys Phe Ile Leu Ala Ser Asp Tyr Leu Asn Ala 695 700 705 Leu Val His Leu Ile Glu Ile Gly Asn Gly Leu Val Thr Phe Gln 710 715 720 Leu Arg Gly Leu Glu Phe Arg Gly Thr Tyr Cys Gln Gln Arg Glu 725 730 735 Val Glu Ala Ile Thr Glu Gly Val Glu Glu Asp Glu Gly Phe Cys 740 745 750 Cys Cys Glu Pro Gly His Ile Pro His Met Leu Ser Phe Asn Ala 755 760 765 Ala Phe Ser Gln Arg Trp Leu Ala Trp Glu Val Ile Val Thr Lys 770 775 780 Tyr Ile Leu Glu Gly Tyr Ser Ile Thr Asp Asn Ser Ala Ala Ser 785 790 795 Met Leu Gln Val Phe Asp Leu Arg Lys Val Leu Thr Thr Tyr Tyr 800 805 810 Val Lys Gly Ile Ile Tyr Tyr Val Thr Thr Ser Ser Lys Leu Glu 815 820 825 Glu Trp Leu Ala Asn Glu Thr Met Gln Glu Gly Leu Arg Leu Cys 830 835 840 Ala Asp Arg Asn Tyr Val Asp Val Asp Pro Thr Phe Asn Pro Asn 845 850 855 Ile Asp Glu Asp Tyr Asp His Arg Leu Ala Gly Ile Ser Arg Glu 860 865 870 Ser Phe Cys Val Ile Tyr Leu Asn Trp Ile Glu Tyr Cys Ser Ser 875 880 885 Arg Arg Ala Lys Pro Val Asp Val Asp Lys Asp Ser Ser Leu Val 890 895 900 Thr Leu Cys Tyr Gly Leu Cys Val Leu Gly Arg Arg Ala Leu Gly 905 910 915 Thr Ala Ser His His Met Ser Ser Asn Leu Glu Ser Phe Leu Tyr 920 925 930 Gly Leu His Ala Leu Phe Lys Gly Asp Phe Arg Ile Ser Ser Ile 935 940 945 Arg Asp Glu Trp Ile Phe Ala Asp Met Glu Leu Leu Arg Lys Val 950 955 960 Val Val Pro Gly Ile Arg Met Ser Ile Lys Leu His Gln Asp His 965 970 975 Phe Thr Ser Pro Asp Glu Tyr Asp Asp Pro Thr Val Leu Tyr Glu 980 985 990 Ala Ile Val Ser His Glu Lys Asn Leu Val Ile Ala His Glu Gly 995 1000 1005 Asp Pro Ala Trp Arg Ser Ala Val Leu Ala Asn Ser Pro Ser Leu 1010 1015 1020 Leu Ala Leu Arg His Val Met Asp Asp Gly Thr Asn Glu Tyr Lys 1025 1030 1035 Ile Ile Met Leu Asn Arg Arg Tyr Leu Ser Phe Arg Val Ile Lys 1040 1045 1050 Val Asn Lys Glu Cys Val Arg Gly Leu Trp Ala Gly Gln Gln Gln 1055 1060 1065 Glu Leu Val Phe Leu Arg Asn Arg Asn Pro Glu Arg Gly Ser Ile 1070 1075 1080 Gln Asn Ala Lys Gln Ala Leu Arg Asn Met Ile Asn Ser Ser Cys 1085 1090 1095 Asp Gln Pro Ile Gly Tyr Pro Ile Phe Val Ser Pro Leu Thr Thr 1100 1105 1110 Ser Tyr Ser Asp Ser His Glu Gln Leu Lys Asp Ile Leu Gly Gly 1115 1120 1125 Pro Ile Ser Leu Gly Asn Ile Arg Asn Phe Ile Val Ser Thr Trp 1130 1135 1140 His Arg Leu Arg Lys Gly Cys Gly Ala Gly Cys Asn Ser Gly Gly 1145 1150 1155 Asn Ile Glu Asp Ser Asp Thr Gly Gly Gly Thr Ser Cys Thr Gly 1160 1165 1170 Asn Asn Ala Thr Thr Ala Asn Asn Pro His Ser Asn Val Thr Gln 1175 1180 1185 Gly Ser Ile Gly Asn Pro Gly Gln Gly Ser Gly Thr Gly Leu His 1190 1195 1200 Pro Pro Val Thr Ser Tyr Pro Pro Thr Leu Gly Thr Ser His Ser 1205 1210 1215 Ser His Ser Val Gln Ser Gly Leu Val Arg Gln Ser Pro Ala Arg 1220 1225 1230 Ala Ser Val Ala Ser Gln Ser Ser Tyr Cys Tyr Ser Ser Arg His 1235 1240 1245 Ser Ser Leu Arg Met Ser Thr Thr Gly Phe Val Pro Cys Arg Arg 1250 1255 1260 Ser Ser Thr Ser Gln Ile Ser Leu Arg Asn Leu Pro Ser Ser Ile 1265 1270 1275 Gln Ser Arg Leu Ser Met Val Asn Gln Met Glu Pro Ser Gly Gln 1280 1285 1290 Ser Gly Leu Ala Cys Val Gln His Gly Leu Pro Ser Ser Ser Ser 1295 1300 1305 Ser Ser Gln Ser Ile Pro Ala Cys Lys His His Thr Leu Val Gly 1310 1315 1320 Phe Leu Ala Thr Glu Gly Gly Gln Ser Ser Ala Thr Asp Ala Gln 1325 1330 1335 Pro Gly Asn Thr Leu Ser Pro Ala Asn Asn Ser His Ser Arg Lys 1340 1345 1350 Ala Glu Val Ile Tyr Arg Val Gln Ile Val Asp Pro Ser Gln Ile 1355 1360 1365 Leu Glu Gly Ile Asn Leu Ser Lys Arg Lys Glu Leu Gln Trp Pro 1370 1375 1380 Asp Glu Gly Ile Arg Leu Lys Ala Gly Arg Asn Ser Trp Lys Asp 1385 1390 1395 Trp Ser Pro Gln Glu Gly Met Glu Gly His Val Ile His Arg Trp 1400 1405 1410 Val Pro Cys Ser Arg Asp Pro Gly Thr Arg Ser His Ile Asp Lys 1415 1420 1425 Ala Val Leu Leu Val Gln Ile Asp Asp Lys Tyr Val Thr Val Ile 1430 1435 1440 Glu Thr Gly Val Leu Glu Leu Gly Ala Glu Val 1445 1450 23 184 PRT Homo sapiens misc_feature Incyte ID No 7494915CD1 23 Met Met Pro Gly Glu Lys Lys Gln Ser Gly Ser Gln Gln Gln Asn 1 5 10 15 Asn Gly Gln Ala Ser Lys Asn Arg Thr Gln Lys Glu Ile Val Thr 20 25 30 Gln Lys Arg Pro Ile Thr Ser Asn Glu Ile Glu Leu Val Val Lys 35 40 45 Lys Lys Leu Pro Arg Glu Lys Gly Pro Gly Pro Asp Gly Phe Ile 50 55 60 Ala Glu Phe Phe Arg Thr Val Lys Glu Glu Leu Glu Pro Thr Leu 65 70 75 Leu Lys Leu Phe Gln Lys Ile Glu Arg Glu Arg Ile Leu Pro Asn 80 85 90 Thr Phe Tyr Gly Val Ser Ile Thr Leu Met Pro Lys Pro Glu Lys 95 100 105 Asp Thr Thr Ala Thr Thr Thr Thr Thr Thr Thr Asn Tyr Arg Pro 110 115 120 Thr Ser Leu Met Asn Val Asp Ser Lys Ile Leu Asn Lys Ile Leu 125 130 135 Ala Asn Gln Ile Gln Pro His Ile Lys Lys Ile Ile His His Asn 140 145 150 Gln Lys Leu Phe Ser Leu Ile Arg Ser His Leu Ser Ile Leu Ala 155 160 165 Phe Val Ala Ile Ala Phe Gly Val Leu Asp Val Lys Pro Leu Pro 170 175 180 Ile Pro Met His 24 407 PRT Homo sapiens misc_feature Incyte ID No 2073751CD1 24 Met Ala Ala Glu Ile Asp Phe Leu Arg Glu Gln Asn Arg Arg Leu 1 5 10 15 Asn Glu Asp Phe Arg Arg Tyr Gln Met Glu Ser Phe Ser Lys Tyr 20 25 30 Ser Ser Val Gln Lys Ala Val Cys Gln Gly Glu Gly Asp Asp Thr 35 40 45 Phe Glu Asn Leu Val Phe Asp Gln Ser Phe Leu Ala Pro Leu Val 50 55 60 Thr Glu Tyr Asp Lys His Leu Gly Glu Leu Asn Gly Gln Leu Lys 65 70 75 Tyr Tyr Gln Lys Gln Val Gly Glu Met Lys Leu Gln Phe Glu Asn 80 85 90 Val Ile Lys Glu Asn Glu Arg Leu His Ser Glu Leu Lys Asp Ala 95 100 105 Val Glu Lys Lys Leu Glu Ala Phe Pro Leu Gly Thr Glu Val Gly 110 115 120 Thr Asp Ile Tyr Ala Asp Asp Glu Thr Val Arg Asn Leu Gln Glu 125 130 135 Gln Leu Gln Leu Ala Asn Gln Glu Lys Thr Gln Ala Val Glu Leu 140 145 150 Trp Gln Thr Val Ser Gln Glu Leu Asp Arg Leu His Lys Leu Tyr 155 160 165 Gln Glu His Met Thr Glu Ala Gln Ile His Val Phe Glu Ser Gln 170 175 180 Lys Gln Lys Asp Gln Leu Phe Asp Phe Gln Gln Leu Thr Lys Gln 185 190 195 Leu His Val Thr Asn Glu Asn Met Glu Val Thr Asn Gln Gln Phe 200 205 210 Leu Lys Thr Val Thr Glu Gln Ser Val Ile Ile Glu Gln Leu Arg 215 220 225 Lys Lys Leu Arg Gln Ala Lys Leu Glu Leu Arg Val Ala Val Ala 230 235 240 Lys Val Glu Glu Leu Thr Asn Val Thr Glu Asp Leu Gln Gly Gln 245 250 255 Met Lys Lys Lys Glu Lys Asp Val Val Ser Ala His Gly Arg Glu 260 265 270 Glu Ala Ser Asp Arg Arg Leu Gln Gln Leu Gln Ser Ser Ile Lys 275 280 285 Gln Leu Glu Ile Arg Leu Cys Val Thr Ile Gln Glu Ala Asn Gln 290 295 300 Leu Arg Thr Glu Asn Thr His Leu Glu Lys Gln Thr Arg Glu Leu 305 310 315 Gln Ala Lys Cys Asn Glu Leu Glu Asn Glu Arg Tyr Glu Ala Ile 320 325 330 Val Arg Ala Arg Asn Ser Met Gln Leu Leu Glu Glu Ala Asn Leu 335 340 345 Gln Lys Ser Gln Ala Leu Leu Glu Glu Lys Gln Lys Glu Glu Asp 350 355 360 Ile Glu Lys Met Lys Glu Thr Val Ser Arg Phe Val Gln Asp Ala 365 370 375 Thr Ile Arg Thr Lys Lys Glu Val Ala Asn Thr Lys Lys Gln Cys 380 385 390 Asn Ile Gln Ile Ser Arg Leu Thr Glu Glu Leu Ser Ala Leu Gln 395 400 405 Met Glu 25 261 PRT Homo sapiens misc_feature Incyte ID No 3178841CD1 25 Met Thr Cys Leu Ala Pro Thr Met Ser Ala Glu Leu Asn Val Pro 1 5 10 15 Ile Asp Pro Ser Ala Pro Ala Cys Pro Glu Pro Gly His Lys Gly 20 25 30 Met Asp Tyr Arg Asp Trp Val Arg Arg Ser Tyr Leu Glu Leu Val 35 40 45 Thr Ser Asn His His Ser Val Gln Ala Leu Ser Trp Arg Lys Leu 50 55 60 Tyr Leu Ser Arg Ala Lys Leu Lys Ala Ser Ser Arg Thr Ser Ala 65 70 75 Leu Leu Ser Gly Phe Ala Met Val Ala Met Val Glu Val Gln Leu 80 85 90 Glu Thr Gln Tyr Gln Tyr Pro Arg Pro Leu Leu Ile Ala Phe Ser 95 100 105 Ala Cys Thr Thr Val Leu Val Ala Val His Leu Phe Ala Leu Leu 110 115 120 Ile Ser Thr Cys Ile Leu Pro Asn Val Glu Ala Val Ser Asn Ile 125 130 135 His Asn Leu Asn Ser Ile Ser Glu Ser Pro His Glu Arg Met His 140 145 150 Pro Tyr Ile Glu Leu Ala Trp Gly Phe Ser Thr Val Leu Gly Ile 155 160 165 Leu Leu Phe Leu Ala Glu Val Val Leu Leu Cys Trp Ile Lys Phe 170 175 180 Leu Pro Val Asp Ala Arg Arg Gln Pro Gly Pro Pro Pro Gly Pro 185 190 195 Gly Ser His Thr Gly Trp Gln Ala Ala Leu Val Ser Thr Ile Ile 200 205 210 Met Val Pro Val Gly Leu Ile Phe Val Val Phe Thr Ile His Phe 215 220 225 Tyr Arg Ser Leu Val Arg His Lys Thr Glu Arg His Asn Arg Glu 230 235 240 Ile Glu Glu Leu His Lys Leu Lys Val Gln Leu Asp Gly His Glu 245 250 255 Arg Ser Leu Gln Val Leu 260 26 209 PRT Homo sapiens misc_feature Incyte ID No 3674807CD1 26 Met Ala Thr Ile Ala Ala Ala Ala Phe Glu Ala Leu Met Asp Gly 1 5 10 15 Val Thr Cys Trp Asp Val Pro Arg Gly Pro Ile Pro Ser Glu Leu 20 25 30 Leu Leu Ile Gly Glu Ala Ala Phe Pro Val Met Val Asn Asp Lys 35 40 45 Gly Gln Val Leu Ile Ala Ala Ser Ser Tyr Gly Arg Gly Arg Leu 50 55 60 Val Val Val Ser His Glu Gly Tyr Leu Ser His Ala Gly Leu Ala 65 70 75 Pro Phe Leu Leu Asn Ala Val Ser Trp Leu Cys Pro Cys Pro Gly 80 85 90 Ala Pro Val Gly Val His Pro Ser Leu Ala Pro Leu Val Asn Ile 95 100 105 Leu Gln Asp Ala Gly Leu Glu Ala Gln Val Lys Pro Glu Pro Gly 110 115 120 Glu Pro Leu Gly Val Tyr Cys Ile Asn Ala Tyr Asn Asp Thr Leu 125 130 135 Thr Ala Thr Leu Ile Gln Phe Val Lys His Gly Gly Gly Leu Leu 140 145 150 Ile Gly Gly Gln Ala Trp Tyr Trp Ala Ser Gln His Gly Pro Asp 155 160 165 Lys Val Leu Ser Arg Phe Pro Gly Asn Lys Val Thr Ser Val Ala 170 175 180 Gly Val Tyr Phe Thr Asp Thr Tyr Gly Asp Arg Asp Arg Phe Lys 185 190 195 Val Ser Lys Lys Val Pro Lys Ile Pro Leu His Val Arg Arg 200 205 27 333 PRT Homo sapiens misc_feature Incyte ID No 1794922CD1 27 Met Lys Met Asp Val Ser Val Arg Ala Ala Gly Cys Ser Asp Asp 1 5 10 15 Leu Ser Ser Gly Glu Ala Asp Val Asp Pro Lys Leu Leu Glu Leu 20 25 30 Thr Ala Asp Glu Glu Lys Cys Arg Ser Ile Arg Arg Gln Tyr Arg 35 40 45 Gln Leu Met Tyr Cys Val Arg Gln Asn Arg Glu Asp Ile Val Ser 50 55 60 Ser Ala Asn Asn Ser Leu Thr Glu Ala Leu Glu Glu Ala Asn Val 65 70 75 Leu Phe Asp Gly Val Ser Arg Thr Arg Glu Ala Ala Leu Asp Ala 80 85 90 Arg Phe Leu Val Met Ala Ser Asp Leu Gly Lys Glu Lys Ala Lys 95 100 105 Gln Leu Asn Ser Asp Met Asn Phe Phe Asn Gln Leu Ala Phe Cys 110 115 120 Asp Phe Leu Phe Leu Phe Val Gly Leu Asn Trp Met Glu Gly Asp 125 130 135 Pro Asp Lys Leu Ser Asp Cys Asp Asp Ser Ile Ala Leu Ser Phe 140 145 150 Trp Lys Ala Ile Glu Lys Glu Ala Thr Ser Trp Met Val Lys Ala 155 160 165 Glu Thr Phe His Phe Val Phe Gly Ser Phe Lys Leu Glu Arg Ser 170 175 180 Ala Pro Lys Pro Arg Leu Glu His Gln Lys Lys Val Arg Lys Met 185 190 195 Glu Glu Asn Gly Asn Met Pro Thr Lys Leu Gln Lys Leu Asp Leu 200 205 210 Ser Ser Tyr Pro Glu Ala Thr Glu Lys Asn Val Glu Arg Ile Leu 215 220 225 Gly Leu Leu Gln Thr Tyr Phe Arg Lys Tyr Pro Asp Thr Pro Val 230 235 240 Ser Tyr Phe Glu Phe Val Ile Asp Pro Asn Ser Phe Ser Arg Thr 245 250 255 Val Glu Asn Ile Phe Tyr Val Ser Phe Ile Val Arg Asp Gly Phe 260 265 270 Ala Arg Ile Arg Leu Asp Glu Asp Arg Leu Pro Ile Leu Glu Pro 275 280 285 Met Asn Val Asn Gln Met Gly Glu Gly Asn Asp Ser Ser Cys His 290 295 300 Gly Arg Lys Gln Gly Val Ile Ser Leu Thr Leu Gln Glu Trp Lys 305 310 315 Asn Ile Val Ala Ala Phe Glu Ile Ser Glu Ala Met Ile Thr Tyr 320 325 330 Ser Ser Tyr 28 257 PRT Homo sapiens misc_feature Incyte ID No 1795509CD1 28 Met Val Ala Glu Lys Glu Thr Leu Ser Leu Asn Lys Cys Pro Asp 1 5 10 15 Lys Met Pro Lys Arg Thr Lys Leu Leu Ala Gln Gln Pro Leu Pro 20 25 30 Val His Gln Pro His Ser Leu Val Ser Glu Gly Phe Thr Val Lys 35 40 45 Ala Met Met Lys Asn Ser Val Val Arg Gly Pro Pro Ala Ala Gly 50 55 60 Ala Phe Lys Glu Arg Pro Thr Lys Pro Thr Ala Phe Arg Lys Phe 65 70 75 Tyr Glu Arg Gly Asp Phe Pro Ile Ala Leu Glu His Asp Ser Lys 80 85 90 Gly Asn Lys Ile Ala Trp Lys Val Glu Ile Glu Lys Leu Asp Tyr 95 100 105 His His Tyr Leu Pro Leu Phe Phe Asp Gly Leu Cys Glu Met Thr 110 115 120 Phe Pro Tyr Glu Phe Phe Ala Arg Gln Gly Ile His Asp Met Leu 125 130 135 Glu His Gly Gly Asn Lys Ile Leu Pro Val Leu Pro Gln Leu Ile 140 145 150 Ile Pro Ile Lys Asn Ala Leu Asn Leu Arg Asn Arg Gln Val Ile 155 160 165 Cys Val Thr Leu Lys Val Leu Gln His Leu Val Val Ser Ala Glu 170 175 180 Met Val Gly Lys Ala Leu Val Pro Tyr Tyr Arg Gln Ile Leu Pro 185 190 195 Val Leu Asn Ile Phe Lys Asn Met Asn Val Asn Ser Gly Asp Gly 200 205 210 Ile Asp Tyr Ser Gln Gln Lys Arg Glu Asn Ile Gly Asp Leu Ile 215 220 225 Gln Glu Thr Leu Glu Ala Phe Glu Arg Tyr Gly Gly Glu Asn Ala 230 235 240 Phe Ile Asn Ile Lys Tyr Val Val Pro Thr Tyr Glu Ser Cys Leu 245 250 255 Leu Asn 29 293 PRT Homo sapiens misc_feature Incyte ID No 2017180CD1 29 Met Arg Val Asp Ser Ser Ala Asp Pro Thr Met Ser Gln Glu Gln 1 5 10 15 Gly Pro Gly Ser Ser Thr Pro Pro Ser Ser Pro Thr Leu Leu Asp 20 25 30 Ala Leu Leu Gln Asn Leu Tyr Asp Phe Gly Gly Thr Glu Gly Glu 35 40 45 Thr Glu Gln Lys Lys Ile Ile Lys Lys Arg Glu Asn Lys Lys Arg 50 55 60 Asp Val Met Ala Ser Ala Ala Leu Ala Ala Glu Pro Ser Pro Leu 65 70 75 Pro Gly Ser Leu Ile Arg Gly Gln Arg Lys Ser Ala Ser Ser Phe 80 85 90 Phe Lys Glu Leu Arg Glu Glu Arg His Cys Ala Pro Ser Gly Thr 95 100 105 Pro Thr Gly Pro Glu Ile Leu Ala Ala Ala Val Pro Pro Ser Ser 110 115 120 Leu Lys Asn Asn Arg Glu Gln Val Glu Val Val Glu Phe His Ser 125 130 135 Asn Lys Lys Arg Lys Leu Thr Pro Asp His Asn Lys Asn Thr Lys 140 145 150 Gln Ala Asn Pro Ser Val Leu Glu Arg Asp Val Asp Thr Gln Glu 155 160 165 Phe Asn Leu Glu Lys Ala Arg Leu Glu Val His Arg Phe Gly Ile 170 175 180 Thr Gly Tyr Gly Lys Gly Lys Glu Arg Ile Leu Glu Gln Glu Arg 185 190 195 Ala Ile Met Leu Gly Ala Lys Pro Pro Lys Lys Ser Tyr Val Asn 200 205 210 Tyr Lys Val Leu Gln Glu Gln Ile Lys Glu Lys Lys Ala Ala Lys 215 220 225 Glu Glu Glu Lys Arg Leu Ala Gln Glu Thr Asp Ile Phe Lys Lys 230 235 240 Lys Lys Arg Lys Gly Gln Glu Asp Arg Lys Ser Lys Lys Lys Ser 245 250 255 Ala Pro Ser Ile Leu Ser Asn Gly Arg Ile Gly Gln Val Gly Lys 260 265 270 Phe Lys Asn Gly Thr Leu Ile Leu Ser Pro Val Asp Ile Lys Lys 275 280 285 Ile Asn Ser Ser Arg Val Ala Lys 290 30 598 PRT Homo sapiens misc_feature Incyte ID No 219442CD1 30 Met Ala Ala Ser Val Thr Asn Ala Val Pro Pro His Asn Phe Lys 1 5 10 15 Ser Gln Glu Val Thr Pro Ala Cys Leu Asp Gly Lys Ser Leu Arg 20 25 30 Ala Gly Ile Thr Glu Val Lys Glu Pro Ser Val Thr Ser Pro Thr 35 40 45 Pro Ser Asp Ile Gln Gln Asn Lys Gly Leu Pro Lys Pro Glu Phe 50 55 60 Arg Phe Lys Gly Gln Ser Thr Lys Ser Asp Ser Ala Glu Asp Tyr 65 70 75 Leu Leu Trp Lys Arg Leu Gln Gly Val Ser Ala Ala Cys Pro Ala 80 85 90 Pro Ser Ser Ala Ala His Gln Leu Glu His Leu Ser Ala Lys Leu 95 100 105 Gln Lys Ile Asp Glu Gln Leu Leu Ala Ile Gln Asn Ile Ala Glu 110 115 120 Asn Ile Glu Gln Asp Phe Pro Lys Pro Glu Met Leu Asp Leu His 125 130 135 Cys Asp Lys Ile Gly Pro Val Asp His Ile Glu Phe Ser Ser Gly 140 145 150 Pro Glu Phe Lys Lys Thr Leu Ala Ser Lys Thr Ile Ser Ile Ser 155 160 165 Glu Glu Val Arg Phe Leu Thr His Met Asp Glu Glu Asp Gln Ser 170 175 180 Asp Lys Lys Glu Thr Ser Glu Pro Glu Phe Ser Ile Thr Glu Asn 185 190 195 Tyr Ser Gly Gln Lys Thr Cys Val Phe Pro Thr Ala Asp Ser Ala 200 205 210 Val Ser Leu Ser Ser Ser Ser Asp Gln Asn Thr Thr Ser Pro Gly 215 220 225 Met Asn Ser Ser Asp Glu Leu Cys Glu Ser Val Ser Val His Pro 230 235 240 Leu Gln Met Thr Gly Leu Thr Asp Ile Ala Asp Ile Ile Asp Asp 245 250 255 Leu Ile Ile Lys Asp Gly Val Ser Ser Glu Glu Leu Gly Leu Thr 260 265 270 Glu Gln Ala Met Gly Thr Ser Arg Ile Gln His Tyr Ser Gly Arg 275 280 285 His Ser Gln Arg Thr Asp Lys Glu Arg Arg Glu Ile Gln Ala Trp 290 295 300 Met Lys Arg Lys Arg Lys Glu Arg Met Ala Lys Tyr Leu Asn Glu 305 310 315 Leu Ala Glu Lys Arg Gly Gln Glu His Asp Pro Phe Cys Pro Arg 320 325 330 Ser Asn Pro Leu Tyr Met Thr Ser Arg Glu Ile Arg Leu Arg Gln 335 340 345 Lys Met Lys His Glu Lys Asp Arg Leu Leu Leu Ser Glu His Tyr 350 355 360 Ser Arg Arg Ile Ser Gln Ala Tyr Gly Leu Met Asn Glu Leu Leu 365 370 375 Ser Glu Ser Val Gln Leu Pro Thr Leu Pro Gln Lys Pro Leu Pro 380 385 390 Asn Lys Pro Ser Pro Thr Gln Ser Ser Ser Cys Gln His Cys Pro 395 400 405 Ser Pro Arg Gly Glu Asn Gln His Gly His Ser Phe Leu Ile Asn 410 415 420 Arg Pro Gly Lys Val Lys Tyr Met Ser Lys Pro Ser Tyr Ile His 425 430 435 Lys Arg Lys Ser Phe Gly Gln Pro Gln Gly Ser Pro Trp Pro His 440 445 450 Gly Thr Ala Thr Phe Thr Ile Gln Lys Lys Ala Gly Gly Ala Lys 455 460 465 Ala Ala Val Arg Lys Ala Thr Gln Ser Pro Val Thr Phe Gln Lys 470 475 480 Gly Ser Asn Ala Pro Cys His Ser Leu Gln His Thr Lys Lys His 485 490 495 Gly Ser Ala Gly Leu Ala Pro Gln Thr Lys Gln Val Cys Val Glu 500 505 510 Tyr Glu Arg Glu Glu Thr Val Val Ser Pro Trp Thr Ile Pro Ser 515 520 525 Glu Ile His Lys Ile Leu His Glu Ser His Asn Ser Leu Leu Gln 530 535 540 Asp Leu Ser Pro Thr Glu Glu Glu Glu Pro Glu His Pro Phe Gly 545 550 555 Val Gly Gly Val Asp Ser Val Ser Glu Ser Thr Gly Ser Ile Leu 560 565 570 Ser Lys Leu Asp Trp Asn Ala Ile Glu Asp Met Val Ala Ser Val 575 580 585 Glu Asp Gln Gly Leu Ser Val His Trp Ala Leu Asp Leu 590 595 31 470 PRT Homo sapiens misc_feature Incyte ID No 2597459CD1 31 Met Pro Ser Glu Arg Cys Leu Ser Ile Gln Glu Met Leu Thr Gly 1 5 10 15 Gln Arg Leu Cys His Ser Glu Ser His Asn Asp Ser Val Leu Ala 20 25 30 Ala Leu Asn Gln Gln Arg Ser Asp Gly Ile Leu Cys Asp Ile Thr 35 40 45 Leu Ile Ala Glu Glu Gln Lys Phe His Ala His Lys Ala Val Leu 50 55 60 Ala Ala Cys Ser Asp Tyr Phe Arg Ala Met Phe Ser Leu Cys Met 65 70 75 Val Glu Ser Gly Ala Asp Glu Val Asn Leu His Gly Val Thr Ser 80 85 90 Leu Gly Leu Lys Gln Ala Leu Glu Phe Ala Tyr Thr Gly Gln Ile 95 100 105 Leu Leu Glu Pro Gly Val Ile Gln Asp Val Leu Ala Ala Gly Ser 110 115 120 His Leu Gln Leu Leu Glu Leu Leu Asn Leu Cys Ser His Tyr Leu 125 130 135 Ile Gln Glu Leu Asn Ser Phe Asn Tyr Leu Asp Leu Tyr Arg Leu 140 145 150 Ala Asp Leu Phe Asn Leu Thr Leu Leu Glu Lys Ala Val Ile Asp 155 160 165 Phe Leu Val Lys His Leu Ser Glu Leu Leu Lys Ser Arg Pro Glu 170 175 180 Glu Val Leu Thr Leu Pro Tyr Cys Leu Leu Gln Glu Val Leu Lys 185 190 195 Ser Asp Arg Leu Thr Ser Leu Ser Glu Glu Gln Ile Trp Gln Leu 200 205 210 Ala Val Arg Trp Leu Glu His Asn Cys His Tyr Gln Tyr Met Asp 215 220 225 Glu Leu Leu Gln Tyr Ile Arg Phe Gly Leu Met Asp Val Asp Thr 230 235 240 Leu His Thr Val Ala Leu Ser His Pro Leu Val Gln Ala Ser Glu 245 250 255 Thr Ala Thr Ala Leu Val Asn Glu Ala Leu Glu Tyr His Gln Ser 260 265 270 Ile Tyr Ala Gln Pro Val Trp Gln Thr Arg Arg Thr Lys Pro Arg 275 280 285 Phe Gln Ser Asp Thr Leu Tyr Ile Ile Gly Gly Lys Lys Arg Glu 290 295 300 Val Cys Lys Val Lys Glu Leu Arg Tyr Phe Asn Pro Val Asp Gln 305 310 315 Glu Asn Ala Leu Ile Ala Ala Ile Ala Asn Trp Ser Glu Leu Ala 320 325 330 Pro Met Pro Val Gly Arg Ser His His Cys Val Ala Val Met Gly 335 340 345 Asp Phe Leu Phe Val Ala Gly Gly Glu Val Glu His Ala Ser Gly 350 355 360 Arg Thr Cys Ala Val Arg Thr Ala Cys Arg Tyr Asp Pro Arg Ser 365 370 375 Asn Ser Trp Ala Glu Ile Ala Pro Met Lys Asn Cys Arg Glu His 380 385 390 Phe Val Leu Gly Ala Met Glu Glu Tyr Leu Tyr Ala Val Gly Gly 395 400 405 Arg Asn Glu Leu Arg Gln Val Leu Pro Thr Val Glu Arg Tyr Cys 410 415 420 Pro Lys Lys Asn Lys Trp Thr Phe Val Gln Ser Phe Asp Arg Ser 425 430 435 Leu Ser Cys His Ala Gly Tyr Val Ala Asp Gly Leu Leu Trp Ile 440 445 450 Ser Gly Arg Thr Tyr Leu Met Leu Asp Leu Ser Lys His Thr Phe 455 460 465 Ile Val Val Tyr Ile 470 32 311 PRT Homo sapiens misc_feature Incyte ID No 2783863CD1 32 Met His Gln Lys Leu Leu Lys Ser Ala His Tyr Ile Glu Leu Gly 1 5 10 15 Ser Tyr Gln Tyr Trp Pro Val Leu Val Pro Arg Gly Ile Arg Leu 20 25 30 Tyr Thr Tyr Glu Gln Ile Pro Gly Ser Leu Lys Asp Asn Pro Tyr 35 40 45 Ile Thr Asp Gly Tyr Arg Ala Tyr Leu Pro Ser Arg Leu Cys Ile 50 55 60 Lys Ser Leu Phe Ile Leu Ser Asn Glu Thr Val Asn Ile Trp Ser 65 70 75 His Leu Leu Gly Phe Phe Leu Phe Phe Thr Leu Gly Ile Tyr Asp 80 85 90 Met Thr Ser Val Leu Pro Ser Ala Ser Ala Ser Arg Glu Asp Phe 95 100 105 Val Ile Cys Ser Ile Cys Leu Phe Cys Phe Gln Val Cys Met Leu 110 115 120 Cys Ser Val Gly Tyr His Leu Phe Ser Cys His Arg Ser Glu Lys 125 130 135 Thr Cys Arg Arg Trp Met Ala Leu Asp Tyr Ala Gly Ile Ser Ile 140 145 150 Gly Ile Leu Gly Cys Tyr Val Ser Gly Val Phe Tyr Ala Phe Tyr 155 160 165 Cys Asn Asn Tyr Trp Arg Gln Val Tyr Leu Ile Thr Val Leu Ala 170 175 180 Met Ile Leu Ala Val Phe Phe Ala Gln Ile His Pro Asn Tyr Leu 185 190 195 Thr Gln Gln Trp Gln Arg Leu Arg Ser Ile Ile Phe Cys Ser Val 200 205 210 Ser Gly Tyr Gly Val Ile Pro Thr Leu His Trp Val Trp Leu Asn 215 220 225 Gly Gly Ile Gly Ala Pro Ile Val Gln Asp Phe Ala Pro Arg Val 230 235 240 Ile Val Met Tyr Met Ile Ala Leu Leu Ala Phe Leu Phe Tyr Ile 245 250 255 Ser Lys Val Pro Glu Arg Tyr Phe Pro Gly Gln Leu Asn Tyr Leu 260 265 270 Gly Ser Ser His Gln Ile Trp His Ile Leu Ala Val Val Met Leu 275 280 285 Tyr Trp Trp His Gln Ser Thr Val Tyr Val Met Gln Tyr Arg His 290 295 300 Ser Lys Pro Cys Pro Asp Tyr Val Ser His Leu 305 310 33 894 PRT Homo sapiens misc_feature Incyte ID No 2902971CD1 33 Met Ala Thr Ser Met Ala Ala Ala Ser Gly Arg Phe Glu Ser Ala 1 5 10 15 Lys Ser Ile Glu Glu Arg Lys Glu Gln Thr Arg Asn Ala Arg Ala 20 25 30 Glu Val Leu Arg Gln Ala Lys Ala Asn Phe Glu Lys Glu Glu Arg 35 40 45 Arg Lys Glu Leu Lys Arg Leu Arg Gly Glu Asp Thr Trp Met Leu 50 55 60 Pro Asp Val Asn Glu Arg Ile Glu Gln Phe Ser Gln Glu His Ser 65 70 75 Val Lys Lys Lys Lys Lys Lys Asp Lys His Ser Lys Lys Ala Lys 80 85 90 Lys Glu Lys Lys Lys Lys Ser Lys Lys Gln Lys Tyr Glu Lys Asn 95 100 105 Asn Glu Ser Ser Asp Ser Ser Ser Ser Ser Glu Asp Glu Trp Val 110 115 120 Glu Ala Val Pro Ser Gln Thr Pro Asp Lys Glu Lys Ala Trp Lys 125 130 135 Val Lys Asp Glu Lys Ser Gly Lys Asp Asp Thr Gln Ile Ile Lys 140 145 150 Arg Asp Glu Trp Met Thr Val Asp Phe Met Ser Val Lys Thr Val 155 160 165 Ser Ser Ser Ser Leu Lys Ala Glu Lys Glu Thr Met Arg Lys Ile 170 175 180 Glu Gln Glu Lys Asn Gln Ala Leu Glu Gln Ser Lys Leu Met Glu 185 190 195 Arg Glu Leu Asn Pro Tyr Trp Lys Asp Gly Gly Thr Gly Leu Pro 200 205 210 Pro Glu Asp Cys Ser Val Ser Ser Ile Thr Lys Val Ser Val Val 215 220 225 Glu Asp Gly Gly Leu Ser Trp Leu Arg Lys Ser Tyr Leu Arg Met 230 235 240 Lys Glu Gln Ala Glu Lys Gln Ser Arg Asn Phe Glu Asp Ile Val 245 250 255 Ala Glu Arg Tyr Gly Ser Met Glu Ile Phe Gln Ser Lys Leu Glu 260 265 270 Asp Ala Glu Lys Ala Ala Ser Thr Lys Glu Asp Tyr Arg Arg Glu 275 280 285 Arg Trp Arg Lys Pro Thr Tyr Ser Asp Lys Ala Gln Asn Cys Gln 290 295 300 Glu Ser Arg Glu Ser Asp Leu Val Lys Tyr Gly Asn Ser Ser Arg 305 310 315 Asp Arg Tyr Ala Thr Thr Asp Thr Ala Lys Asn Ser Asn Asn Glu 320 325 330 Lys Phe Ile Gly Asp Glu Lys Asp Lys Arg Pro Gly Ser Leu Glu 335 340 345 Thr Cys Arg Arg Glu Ser Asn Pro Arg Gln Asn Gln Glu Phe Ser 350 355 360 Phe Gly Asn Leu Arg Ala Lys Phe Leu Arg Pro Ser Asp Asp Glu 365 370 375 Glu Leu Ser Phe His Ser Lys Gly Arg Lys Phe Glu Pro Leu Ser 380 385 390 Ser Ser Ser Ala Leu Val Ala Gln Gly Ser Leu Cys Ser Gly Phe 395 400 405 Arg Lys Pro Thr Lys Asn Ser Glu Glu Arg Leu Thr Ser Trp Ser 410 415 420 Arg Ser Asp Gly Arg Gly Asp Lys Lys His Ser Asn Gln Lys Pro 425 430 435 Ser Glu Thr Ser Thr Asp Glu Tyr Gln His Val Pro Glu Asp Pro 440 445 450 Arg Glu Lys Ser Gln Asp Glu Val Leu Arg Asp Asp Pro Pro Lys 455 460 465 Lys Glu His Leu Arg Asp Thr Lys Ser Thr Phe Ala Gly Ser Pro 470 475 480 Glu Arg Glu Ser Ile His Ile Leu Ser Val Asp Glu Lys Asn Lys 485 490 495 Leu Gly Ala Lys Ile Ile Lys Ala Glu Met Met Gly Asn Met Glu 500 505 510 Leu Ala Glu Gln Leu Lys Val Gln Leu Glu Lys Ala Asn Lys Phe 515 520 525 Lys Glu Thr Ile Thr Gln Ile Pro Lys Lys Ser Gly Val Glu Asn 530 535 540 Glu Asp Gln Gln Glu Val Ile Leu Val Arg Thr Asp Gln Ser Gly 545 550 555 Arg Val Trp Pro Val Asn Thr Pro Gly Lys Ser Leu Glu Ser Gln 560 565 570 Gly Gly Arg Arg Lys Arg Gln Met Val Ser Thr His Glu Glu Arg 575 580 585 Glu Arg Val Arg Tyr Phe His Asp Asp Asp Asn Leu Ser Leu Asn 590 595 600 Asp Leu Val Lys Asn Glu Lys Met Gly Thr Ala Glu Asn Gln Asn 605 610 615 Lys Leu Phe Met Arg Met Ala Ser Lys Phe Met Gly Lys Thr Asp 620 625 630 Gly Asp Tyr Tyr Thr Leu Asp Asp Met Phe Val Ser Lys Ala Ala 635 640 645 Glu Arg Glu Arg Leu Gly Glu Glu Glu Glu Asn Gln Arg Lys Lys 650 655 660 Ala Ile Ala Glu His Arg Ser Leu Ala Ala Gln Met Glu Lys Cys 665 670 675 Leu Tyr Cys Phe Asp Ser Ser Gln Phe Pro Lys His Leu Ile Val 680 685 690 Ala Ile Gly Val Lys Val Tyr Leu Cys Leu Pro Asn Val Arg Ser 695 700 705 Leu Thr Glu Gly His Cys Leu Ile Val Pro Leu Gln His His Arg 710 715 720 Ala Ala Thr Leu Leu Asp Glu Asp Ile Trp Glu Glu Ile Gln Met 725 730 735 Phe Arg Lys Ser Leu Val Lys Met Phe Glu Asp Lys Gly Leu Asp 740 745 750 Cys Ile Phe Leu Glu Thr Asn Met Ser Met Lys Lys Gln Tyr His 755 760 765 Met Val Tyr Glu Cys Ile Pro Leu Pro Lys Glu Val Gly Asp Met 770 775 780 Ala Pro Ile Tyr Phe Lys Lys Ala Ile Met Glu Ser Asp Glu Glu 785 790 795 Trp Ser Met Asn Lys Lys Leu Met Asp Leu Ser Ser Lys Asp Ile 800 805 810 Arg Lys Ser Val Pro Arg Gly Leu Pro Tyr Phe Ser Val Asp Phe 815 820 825 Gly Leu His Gly Gly Phe Ala His Val Ile Glu Asp Gln His Lys 830 835 840 Phe Pro His Tyr Phe Gly Lys Glu Ile Ile Gly Gly Met Leu Asp 845 850 855 Ile Glu Pro Arg Leu Trp Arg Lys Gly Ile Arg Glu Ser Phe Glu 860 865 870 Asp Gln Arg Lys Lys Ala Leu Gln Phe Ala Gln Trp Trp Lys Pro 875 880 885 Tyr Asp Phe Thr Lys Ser Lys Asn Tyr 890 34 653 PRT Homo sapiens misc_feature Incyte ID No 368660CD1 34 Met Asp Arg Asp Leu Leu Arg Gln Ser Leu Asn Cys His Gly Ser 1 5 10 15 Ser Leu Leu Ser Leu Leu Arg Ser Glu Gln Gln Asp Asn Pro His 20 25 30 Phe Arg Ser Leu Leu Gly Ser Ala Ala Glu Pro Ala Arg Gly Pro 35 40 45 Pro Pro Gln His Pro Leu Gln Gly Arg Lys Glu Lys Arg Val Asp 50 55 60 Asn Ile Glu Ile Gln Lys Phe Ile Ser Lys Lys Ala Asp Leu Leu 65 70 75 Phe Ala Leu Ser Trp Lys Ser Asp Ala Pro Ala Thr Ser Glu Ile 80 85 90 Asn Glu Asp Ser Glu Asp His Tyr Ala Ile Met Pro Pro Leu Glu 95 100 105 Gln Phe Met Glu Ile Pro Ser Met Asp Arg Arg Glu Leu Phe Phe 110 115 120 Arg Asp Ile Glu Arg Gly Asp Ile Val Ile Gly Arg Ile Ser Ser 125 130 135 Ile Arg Glu Phe Gly Phe Phe Met Val Leu Ile Cys Leu Gly Ser 140 145 150 Gly Ile Met Arg Asp Ile Ala His Leu Glu Ile Thr Ala Leu Cys 155 160 165 Pro Leu Arg Asp Val Pro Ser His Ser Asn His Gly Asp Pro Leu 170 175 180 Ser Tyr Tyr Gln Thr Gly Asp Ile Ile Arg Ala Gly Ile Lys Asp 185 190 195 Ile Asp Arg Tyr His Glu Lys Leu Ala Val Ser Leu Tyr Ser Ser 200 205 210 Ser Leu Pro Pro His Leu Ser Gly Ile Lys Leu Gly Val Ile Ser 215 220 225 Ser Glu Glu Leu Pro Leu Tyr Tyr Arg Arg Ser Val Glu Leu Asn 230 235 240 Ser Asn Ser Leu Glu Ser Tyr Glu Asn Val Met Gln Ser Ser Leu 245 250 255 Gly Phe Val Asn Pro Gly Val Val Glu Phe Leu Leu Glu Lys Leu 260 265 270 Gly Ile Asp Glu Ser Asn Pro Pro Ser Leu Met Arg Gly Leu Gln 275 280 285 Ser Lys Asn Phe Ser Glu Asp Asp Phe Ala Ser Ala Leu Arg Lys 290 295 300 Lys Gln Ser Ala Ser Trp Ala Leu Lys Cys Val Lys Ile Gly Val 305 310 315 Asp Tyr Phe Lys Val Gly Arg His Val Asp Ala Met Asn Glu Tyr 320 325 330 Asn Lys Ala Leu Glu Ile Asp Lys Gln Asn Val Glu Ala Leu Val 335 340 345 Ala Arg Gly Ala Leu Tyr Ala Thr Lys Gly Ser Leu Asn Lys Ala 350 355 360 Ile Glu Asp Phe Glu Leu Ala Leu Glu Asn Cys Pro Thr His Arg 365 370 375 Asn Ala Arg Lys Tyr Leu Cys Gln Thr Leu Val Glu Arg Gly Gly 380 385 390 Gln Leu Glu Glu Glu Glu Lys Phe Leu Asn Ala Glu Ser Tyr Tyr 395 400 405 Lys Lys Ala Leu Ala Leu Asp Glu Thr Phe Lys Asp Ala Glu Asp 410 415 420 Ala Leu Gln Lys Leu His Lys Tyr Met Gln Lys Ser Leu Glu Leu 425 430 435 Arg Glu Lys Gln Ala Glu Lys Glu Glu Lys Gln Lys Thr Lys Lys 440 445 450 Ile Glu Thr Ser Ala Glu Lys Leu Arg Asn Val Leu Lys Glu Glu 455 460 465 Lys Arg Leu Lys Lys Lys Arg Arg Lys Ser Thr Ser Ser Ser Ser 470 475 480 Val Ser Ser Ala Asp Glu Ser Val Ser Ser Ser Ser Ser Ser Ser 485 490 495 Ser Ser Gly His Lys Arg His Lys Lys His Lys Arg Asn Arg Ser 500 505 510 Glu Ser Ser Arg Ser Ser Arg Arg His Ser Ser Arg Ala Ser Ser 515 520 525 Asn Gln Ile Asp Gln Asn Arg Lys Asp Glu Cys Tyr Pro Val Pro 530 535 540 Ala Asn Thr Ser Ala Ser Phe Leu Asn His Lys Gln Glu Val Glu 545 550 555 Lys Leu Leu Gly Lys Gln Asp Arg Leu Gln Tyr Glu Lys Thr Gln 560 565 570 Ile Lys Glu Lys Asp Arg Cys Pro Leu Ser Ser Ser Ser Leu Glu 575 580 585 Ile Pro Asp Asp Phe Gly Val Tyr Ser Tyr Leu Phe Lys Lys Leu 590 595 600 Thr Ile Lys Gln Pro Gln Ala Gly Pro Ser Gly Asp Ile Pro Glu 605 610 615 Glu Gly Ile Val Ile Ile Asp Asp Ser Ser Ile His Val Thr Asp 620 625 630 Pro Glu Asp Leu Gln Val Gly Gln Asp Met Glu Val Glu Asp Ser 635 640 645 Gly Ile Asp Asp Pro Asp His Gly 650 35 144 PRT Homo sapiens misc_feature Incyte ID No 2804990CD1 35 Met Leu Asn Arg Ile Ile Trp Leu Gln Ala Val Leu Glu Ile Ile 1 5 10 15 Thr Asn Lys Thr Thr Gln Ala Leu Thr Val Leu Ala Trp Gln Glu 20 25 30 Thr Leu Met Arg Asn Ala Ile Tyr Gln Asn Arg Leu Ala Leu Asp 35 40 45 Tyr Leu Leu Ala Ala Glu Gly Gly Val Cys Glu Lys Phe Asp Leu 50 55 60 Thr Asn Tyr Cys Leu His Ile Asp Asp Gln Gly Gln Val Val Glu 65 70 75 Asp Ile Val Lys Asp Ile Thr Lys Leu Ala His Ala Pro Val Gln 80 85 90 Val Trp His Gly Leu Asn Leu Gly Ala Met Phe Gly Asn Trp Phe 95 100 105 Pro Ala Ile Gly Gly Phe Lys Thr Leu Ile Ile Arg Val Ile Ile 110 115 120 Val Ile Gly Thr Cys Leu Leu Leu Pro Cys Leu Ile Pro Val Phe 125 130 135 Leu Gln Met Ile Lys Asn Phe Val Ala 140 36 424 PRT Homo sapiens misc_feature Incyte ID No 168571CD1 36 Met Ser Pro Leu Cys Ser Leu Cys Gln Glu Gly Ser Trp Thr Gly 1 5 10 15 Pro Ala Ala Trp Met Pro Gly Pro Leu Gly Pro Glu His Gln Gly 20 25 30 Val Gln Pro Arg Thr Pro Gln Ala Trp Ala Pro Leu Pro Ala Glu 35 40 45 Gly Leu Trp Gly Ala Arg Gly Glu Ala Ser Arg His Gly Gly Cys 50 55 60 Pro Ser Pro Ser His Gly Leu Gly Pro His Ala Ala Leu Cys Leu 65 70 75 Pro Gln Glu Asn Pro Arg Leu Thr Glu Asp Phe Val Ser His Leu 80 85 90 Glu Thr Glu Leu Glu Gln Ser Arg Leu Arg Glu Thr Glu Thr Leu 95 100 105 Gly Ala Leu Arg Glu Met Gln Asp Lys Val Leu Asp Met Glu Lys 110 115 120 Arg Asn Ser Ser Leu Pro Asp Glu Asn Asn Val Ala Gln Leu Gln 125 130 135 Glu Glu Leu Lys Ala Leu Lys Val Arg Glu Gly Gln Ala Val Ala 140 145 150 Ser Thr Arg Glu Leu Lys Leu Gln Leu Gln Glu Leu Ser Asp Thr 155 160 165 Trp Gln Ala His Leu Ala Arg Gly Gly Arg Trp Lys Glu Ser Pro 170 175 180 Arg Lys Leu Val Val Gly Glu Leu Gln Asp Glu Leu Met Ser Val 185 190 195 Arg Leu Arg Glu Ala Gln Ala Leu Ala Glu Gly Arg Glu Leu Arg 200 205 210 Gln Arg Val Val Glu Leu Glu Thr Gln Asp His Ile His Arg Asn 215 220 225 Leu Leu Asn Arg Val Glu Ala Glu Arg Ala Ala Leu Gln Glu Lys 230 235 240 Leu Gln Tyr Leu Ala Ala Gln Asn Lys Gly Leu Gln Thr Gln Leu 245 250 255 Ser Glu Ser Arg Arg Lys Gln Ala Glu Ala Glu Cys Lys Ser Lys 260 265 270 Glu Glu Val Met Ala Val Arg Leu Arg Glu Ala Asp Ser Met Ala 275 280 285 Ala Val Ala Glu Met Arg Gln Arg Ile Ala Glu Leu Glu Ile Gln 290 295 300 Arg Glu Glu Gly Arg Ile Gln Gly Gln Leu Asn His Ser Asp Ser 305 310 315 Ser Gln Tyr Ile Arg Glu Leu Lys Asp Gln Ile Glu Glu Leu Lys 320 325 330 Ala Glu Val Arg Leu Leu Lys Gly Pro Pro Pro Phe Glu Asp Pro 335 340 345 Leu Ala Phe Asp Gly Leu Ser Leu Ala Arg His Leu Asp Glu Asp 350 355 360 Ser Leu Pro Ser Ser Asp Glu Glu Leu Leu Gly Val Gly Val Gly 365 370 375 Ala Ala Leu Gln Asp Ala Leu Tyr Pro Leu Ser Pro Arg Asp Ala 380 385 390 Arg Phe Phe Arg Arg Leu Glu Arg Pro Ala Lys Asp Ser Glu Gly 395 400 405 Ser Ser Asp Ser Asp Ala Asp Glu Leu Ala Ala Pro Tyr Ser Gln 410 415 420 Gly Leu Asp Asn 37 1351 PRT Homo sapiens misc_feature Incyte ID No 1286391CD1 37 Met Ala Ala Ala Val Pro Lys Ala Glu Asn Pro Ser Arg Thr Gln 1 5 10 15 Val Pro Ser Ala Ala Pro Lys Leu Pro Thr Ser Arg Met Met Leu 20 25 30 Ala Val His Thr Glu Pro Ala Ala Pro Glu Val Pro Leu Ala Pro 35 40 45 Thr Lys Pro Thr Ala Gln Leu Met Ala Thr Ala Gln Lys Thr Val 50 55 60 Val Asn Gln Pro Val Leu Val Ala Gln Val Glu Pro Thr Thr Pro 65 70 75 Lys Thr Pro Gln Ala Gln Lys Met Pro Val Ala Lys Thr Ser Pro 80 85 90 Ala Gly Pro Lys Thr Pro Lys Ala Gln Ala Gly Pro Ala Ala Thr 95 100 105 Val Ser Lys Ala Pro Ala Ala Ser Lys Ala Pro Ala Ala Pro Lys 110 115 120 Val Pro Val Thr Pro Arg Val Ser Arg Ala Pro Lys Thr Pro Ala 125 130 135 Ala Gln Lys Val Pro Thr Asp Ala Gly Pro Thr Leu Asp Val Ala 140 145 150 Arg Leu Leu Ser Glu Val Gln Pro Thr Ser Arg Ala Ser Val Ser 155 160 165 Leu Leu Lys Gly Gln Gly Gln Ala Gly Arg Gln Gly Pro Gln Ser 170 175 180 Ser Gly Thr Leu Ala Leu Ser Ser Lys His Gln Phe Gln Met Glu 185 190 195 Gly Leu Leu Gly Ala Trp Glu Gly Ala Pro Arg Gln Pro Pro Arg 200 205 210 His Leu Gln Ala Asn Ser Thr Val Thr Ser Phe Gln Arg Tyr His 215 220 225 Glu Ala Leu Asn Thr Pro Phe Glu Leu Asn Leu Ser Gly Glu Pro 230 235 240 Gly Asn Gln Gly Leu Arg Arg Val Val Ile Asp Gly Ser Ser Val 245 250 255 Ala Met Val His Gly Leu Gln His Phe Phe Ser Cys Arg Gly Ile 260 265 270 Ala Met Ala Val Gln Phe Phe Trp Asn Arg Gly His Arg Glu Val 275 280 285 Thr Val Phe Val Pro Thr Trp Gln Leu Lys Lys Asn Arg Arg Val 290 295 300 Arg Glu Ser His Phe Leu Thr Lys Leu His Ser Leu Lys Met Leu 305 310 315 Ser Ile Thr Pro Ser Gln Leu Glu Asn Gly Lys Lys Ile Thr Thr 320 325 330 Tyr Asp Tyr Arg Phe Met Val Lys Leu Ala Glu Glu Thr Asp Gly 335 340 345 Ile Ile Val Thr Asn Glu Gln Ile His Ile Leu Met Asn Ser Ser 350 355 360 Lys Lys Leu Met Val Lys Asp Arg Leu Leu Pro Phe Thr Phe Ala 365 370 375 Gly Asn Leu Phe Met Val Pro Asp Asp Pro Leu Gly Arg Asp Gly 380 385 390 Pro Thr Leu Asp Glu Phe Leu Lys Lys Pro Asn Arg Leu Asp Thr 395 400 405 Asp Ile Gly Asn Phe Leu Lys Val Trp Lys Thr Leu Pro Pro Ser 410 415 420 Ser Ala Ser Val Thr Glu Leu Ser Asp Asp Ala Asp Ser Gly Pro 425 430 435 Leu Glu Ser Leu Pro Asn Met Glu Glu Val Arg Glu Glu Lys Glu 440 445 450 Glu Arg Gln Asp Glu Glu Gln Arg Gln Gly Gln Gly Thr Gln Lys 455 460 465 Ala Ala Glu Glu Asp Asp Leu Asp Ser Ser Leu Ala Ser Val Phe 470 475 480 Arg Val Glu Cys Pro Ser Leu Ser Glu Glu Ile Leu Arg Cys Leu 485 490 495 Ser Leu His Asp Pro Pro Asp Gly Ala Leu Asp Ile Asp Leu Leu 500 505 510 Pro Gly Ala Ala Ser Pro Tyr Leu Gly Ile Pro Trp Asp Gly Lys 515 520 525 Ala Pro Cys Gln Gln Val Leu Ala His Leu Ala Gln Leu Thr Ile 530 535 540 Pro Ser Asn Phe Thr Ala Leu Ser Phe Phe Met Gly Phe Met Asp 545 550 555 Ser His Arg Asp Ala Ile Pro Asp Tyr Glu Ala Leu Val Gly Pro 560 565 570 Leu His Ser Leu Leu Lys Gln Lys Pro Asp Trp Gln Trp Asp Gln 575 580 585 Glu His Glu Glu Ala Phe Leu Ala Leu Lys Arg Ala Leu Val Ser 590 595 600 Ala Leu Cys Leu Met Ala Pro Asn Ser Gln Leu Pro Phe Arg Leu 605 610 615 Glu Val Thr Val Ser His Val Ala Leu Thr Ala Ile Leu His Gln 620 625 630 Glu His Ser Gly Arg Lys His Pro Ile Ala Tyr Thr Ser Lys Pro 635 640 645 Leu Leu Pro Asp Glu Glu Ser Gln Gly Pro Gln Ser Gly Gly Asp 650 655 660 Ser Pro Tyr Ala Val Ala Trp Ala Leu Lys His Phe Ser Arg Cys 665 670 675 Ile Gly Asp Thr Pro Val Val Leu Asp Leu Ser Tyr Ala Ser Arg 680 685 690 Thr Thr Ala Asp Pro Glu Val Arg Glu Gly Arg Arg Val Ser Lys 695 700 705 Ala Trp Leu Ile Arg Trp Ser Leu Leu Val Gln Asp Lys Gly Lys 710 715 720 Arg Ala Leu Glu Leu Ala Leu Leu Gln Gly Leu Leu Gly Glu Asn 725 730 735 Arg Leu Leu Thr Pro Ala Ala Ser Met Pro Arg Phe Phe Gln Val 740 745 750 Leu Pro Pro Phe Ser Asp Leu Ser Thr Phe Val Cys Ile His Met 755 760 765 Ser Gly Tyr Cys Phe Tyr Arg Glu Asp Glu Trp Cys Ala Gly Phe 770 775 780 Gly Leu Tyr Val Leu Ser Pro Thr Ser Pro Pro Val Ser Leu Ser 785 790 795 Phe Ser Cys Ser Pro Tyr Thr Pro Thr Tyr Ala His Leu Ala Ala 800 805 810 Val Ala Cys Gly Leu Glu Arg Phe Gly Gln Ser Pro Leu Pro Val 815 820 825 Val Phe Leu Thr His Cys Asn Trp Ile Phe Ser Leu Leu Trp Glu 830 835 840 Leu Leu Pro Leu Trp Arg Ala Arg Gly Phe Leu Ser Ser Asp Gly 845 850 855 Ala Pro Leu Pro His Pro Ser Leu Leu Ser Tyr Ile Ile Ser Leu 860 865 870 Thr Ser Gly Leu Ser Ser Leu Pro Phe Ile Tyr Arg Thr Ser Tyr 875 880 885 Arg Gly Ser Leu Phe Ala Val Thr Val Asp Thr Leu Ala Lys Gln 890 895 900 Gly Ala Gln Gly Gly Gly Gln Trp Trp Ser Leu Pro Lys Asp Val 905 910 915 Pro Ala Pro Thr Val Ser Pro His Ala Met Gly Lys Arg Pro Asn 920 925 930 Leu Leu Ala Leu Gln Leu Ser Asp Ser Thr Leu Ala Asp Ile Ile 935 940 945 Ala Arg Leu Gln Ala Gly Gln Lys Leu Ser Gly Ser Ser Pro Phe 950 955 960 Ser Ser Ala Phe Asn Ser Leu Ser Leu Asp Lys Glu Ser Gly Leu 965 970 975 Leu Met Phe Lys Gly Asp Lys Lys Pro Arg Val Trp Val Val Pro 980 985 990 Thr Gln Leu Arg Arg Asp Leu Ile Phe Ser Val His Asp Ile Pro 995 1000 1005 Leu Gly Ala His Gln Arg Pro Glu Glu Thr Tyr Lys Lys Leu Arg 1010 1015 1020 Leu Leu Gly Trp Trp Pro Gly Met Gln Glu His Val Lys Asp Tyr 1025 1030 1035 Cys Arg Ser Cys Leu Phe Cys Ile Pro Arg Asn Leu Ile Gly Ser 1040 1045 1050 Glu Leu Lys Val Ile Glu Ser Pro Trp Pro Leu Arg Ser Thr Ala 1055 1060 1065 Pro Trp Ser Asn Leu Gln Ile Glu Val Val Gly Pro Val Thr Ile 1070 1075 1080 Ser Glu Glu Gly His Lys His Val Leu Ile Val Ala Asp Pro Asn 1085 1090 1095 Thr Arg Trp Val Glu Ala Phe Pro Leu Lys Pro Tyr Thr His Thr 1100 1105 1110 Ala Val Ala Gln Val Leu Leu Gln His Val Phe Ala Arg Trp Gly 1115 1120 1125 Val Pro Val Arg Leu Glu Ala Ala Gln Gly Pro Gln Phe Ala Arg 1130 1135 1140 His Val Leu Val Ser Cys Gly Leu Ala Leu Gly Ala Gln Val Ala 1145 1150 1155 Ser Leu Ser Arg Asp Leu Gln Phe Pro Cys Leu Thr Ser Ser Gly 1160 1165 1170 Ala Tyr Trp Glu Phe Lys Arg Ala Leu Lys Glu Phe Ile Phe Leu 1175 1180 1185 His Gly Lys Lys Trp Ala Ala Ser Leu Pro Leu Leu His Leu Ala 1190 1195 1200 Phe Arg Ala Ser Ser Thr Asp Ala Thr Pro Phe Lys Val Leu Thr 1205 1210 1215 Gly Gly Glu Ser Arg Leu Thr Glu Pro Leu Trp Trp Glu Met Ser 1220 1225 1230 Ser Ala Asn Ile Glu Gly Leu Lys Met Asp Val Phe Leu Leu Gln 1235 1240 1245 Leu Val Gly Glu Leu Leu Glu Leu His Trp Arg Val Ala Asp Lys 1250 1255 1260 Ala Ser Glu Lys Ala Glu Asn Arg Arg Phe Lys Arg Glu Ser Gln 1265 1270 1275 Glu Lys Glu Trp Asn Val Gly Asp Gln Val Leu Leu Leu Ser Leu 1280 1285 1290 Pro Arg Asn Gly Ser Ser Ala Lys Trp Val Gly Pro Phe Tyr Ile 1295 1300 1305 Gly Asp Arg Leu Ser Leu Ser Leu Tyr Arg Ile Trp Gly Phe Pro 1310 1315 1320 Thr Pro Glu Lys Leu Gly Cys Ile Tyr Pro Ser Ser Leu Met Lys 1325 1330 1335 Ala Phe Ala Lys Ser Gly Thr Pro Leu Ser Phe Lys Val Leu Glu 1340 1345 1350 Gln 38 78 PRT Homo sapiens misc_feature Incyte ID No 2007684CD1 38 Met Gln Glu Met Val Arg Glu Leu Trp Met Trp Asn Val Glu Glu 1 5 10 15 Glu Glu His Glu Val Gly Ile Cys Thr Trp Gly Gly Gln His Cys 20 25 30 Gly Cys Pro Ala Lys Ser Leu Pro Gly Pro His Pro Gly Gly Val 35 40 45 Ser Ala Pro Gln Ser Ala Ser Gln Leu Met Val Lys Leu Leu Val 50 55 60 Trp Gln Lys Ser Val His Lys Leu Arg Lys Leu Leu Glu Lys Thr 65 70 75 Glu Asn Tyr 39 411 PRT Homo sapiens misc_feature Incyte ID No 2227040CD1 39 Met Thr Glu Met Ser Glu Lys Glu Asn Glu Pro Asp Asp Ala Ala 1 5 10 15 Thr His Ser Pro Pro Gly Thr Val Ser Ala Leu Gln Glu Thr Lys 20 25 30 Leu Gln Arg Phe Lys Arg Ser Leu Ser Leu Lys Thr Ile Leu Arg 35 40 45 Ser Lys Ser Leu Glu Asn Phe Phe Leu Arg Ser Gly Ser Glu Leu 50 55 60 Lys Cys Pro Thr Glu Val Leu Leu Thr Pro Pro Thr Pro Leu Pro 65 70 75 Pro Pro Ser Pro Pro Pro Thr Ala Ser Asp Arg Gly Leu Ala Thr 80 85 90 Pro Ser Pro Ser Pro Cys Pro Val Pro Arg Pro Leu Ala Ala Leu 95 100 105 Lys Pro Val Thr Leu His Ser Phe Gln Glu His Val Phe Lys Arg 110 115 120 Ala Ser Pro Cys Glu Leu Cys His Gln Leu Ile Val Gly Asn Ser 125 130 135 Lys Gln Gly Leu Arg Cys Lys Met Cys Lys Val Ser Val His Leu 140 145 150 Trp Cys Ser Glu Glu Ile Ser His Gln Gln Cys Pro Gly Lys Thr 155 160 165 Ser Thr Ser Phe Arg Arg Asn Phe Ser Ser Pro Leu Leu Val His 170 175 180 Glu Pro Pro Pro Val Cys Ala Thr Ser Lys Glu Ser Pro Pro Thr 185 190 195 Gly Asp Ser Gly Lys Val Asp Pro Val Tyr Glu Thr Leu Arg Tyr 200 205 210 Gly Thr Ser Leu Ala Leu Met Asn Arg Ser Ser Phe Ser Ser Thr 215 220 225 Ser Glu Ser Pro Thr Arg Ser Leu Ser Glu Arg Asp Glu Leu Thr 230 235 240 Glu Asp Gly Glu Gly Ser Ile Arg Ser Ser Glu Glu Gly Pro Gly 245 250 255 Asp Ser Ala Ser Pro Val Phe Thr Ala Pro Ala Glu Ser Glu Gly 260 265 270 Pro Gly Pro Glu Glu Lys Ser Pro Gly Gln Gln Leu Pro Lys Ala 275 280 285 Thr Leu Arg Lys Asp Val Gly Pro Met Tyr Ser Tyr Val Ala Leu 290 295 300 Tyr Lys Phe Leu Pro Gln Glu Asn Asn Asp Leu Ala Leu Gln Pro 305 310 315 Gly Asp Arg Ile Met Leu Val Asp Asp Ser Asn Glu Asp Trp Trp 320 325 330 Lys Gly Lys Ile Gly Asp Arg Val Gly Phe Phe Pro Ala Asn Phe 335 340 345 Val Gln Arg Val Arg Pro Gly Glu Asn Val Trp Arg Cys Cys Gln 350 355 360 Pro Phe Ser Gly Asn Lys Glu Gln Gly Tyr Met Ser Leu Lys Glu 365 370 375 Asn Gln Ile Cys Val Gly Val Gly Arg Ser Lys Asp Ala Asp Gly 380 385 390 Phe Ile Arg Val Ser Ser Gly Lys Lys Arg Gly Leu Val Pro Val 395 400 405 Asp Ala Leu Thr Glu Ile 410 40 1704 PRT Homo sapiens misc_feature Incyte ID No 4346130CD1 40 Met Ser Ser Val Ser Glu Val Asn Val Asp Ile Lys Asp Phe Leu 1 5 10 15 Met Ser Ile Asn Leu Glu Gln Tyr Leu Leu His Phe His Glu Ser 20 25 30 Gly Phe Thr Thr Val Lys Asp Cys Ala Ala Ile Asn Asp Ser Leu 35 40 45 Leu Gln Lys Ile Gly Ile Ser Pro Thr Gly His Arg Arg Arg Ile 50 55 60 Leu Lys Gln Leu Gln Ile Ile Leu Ser Lys Met Gln Asp Ile Pro 65 70 75 Ile Tyr Ala Asn Val His Lys Thr Lys Lys Asn Asp Asp Pro Ser 80 85 90 Lys Asp Tyr His Val Pro Ser Ser Asp Gln Asn Ile Cys Ile Glu 95 100 105 Leu Ser Asn Ser Gly Ser Val Gln Thr Ser Ser Pro Pro Gln Leu 110 115 120 Glu Thr Val Arg Lys Asn Leu Glu Asp Ser Asp Ala Ser Val Glu 125 130 135 Arg Ser Gln Tyr Pro Gln Ser Asp Asp Lys Leu Ser Pro Pro Lys 140 145 150 Arg Asp Phe Pro Thr Ala Glu Glu Pro His Leu Asn Leu Gly Ser 155 160 165 Leu Asn Asp Ser Leu Phe Gly Ser Asp Asn Ile Lys Ile Glu Ser 170 175 180 Leu Ile Thr Lys Lys Thr Val Asp His Thr Val Glu Glu Gln Gln 185 190 195 Thr Glu Lys Val Lys Leu Ile Thr Glu Asn Leu Ser Lys Leu Pro 200 205 210 Asn Ala Asp Ser Glu Cys Leu Ser Phe Val Gly Cys Ser Thr Ser 215 220 225 Gly Thr Asn Ser Gly Asn Gly Thr Asn Gly Leu Leu Glu Gly Ser 230 235 240 Pro Pro Ser Pro Phe Phe Lys Phe Gln Gly Glu Met Ile Val Asn 245 250 255 Asp Leu Tyr Val Pro Ser Ser Pro Ile Leu Ala Pro Val Arg Ser 260 265 270 Arg Ser Lys Leu Val Ser Arg Pro Ser Arg Ser Phe Leu Leu Arg 275 280 285 His Arg Pro Val Pro Glu Ile Pro Gly Ser Thr Lys Gly Val Ser 290 295 300 Gly Ser Tyr Phe Arg Glu Arg Arg Asn Val Ala Thr Ser Thr Glu 305 310 315 Lys Ser Val Ala Trp Gln Asn Ser Asn Glu Glu Asn Ser Ser Ser 320 325 330 Ile Phe Pro Tyr Gly Glu Thr Phe Leu Phe Gln Arg Leu Glu Asn 335 340 345 Ser Lys Lys Arg Ser Ile Lys Asn Glu Phe Leu Thr Gln Gly Glu 350 355 360 Ala Leu Lys Gly Glu Ala Ala Thr Ala Thr Asn Ser Phe Ile Ile 365 370 375 Lys Ser Ser Ile Tyr Asp Asn Arg Lys Glu Lys Ile Ser Glu Asp 380 385 390 Lys Val Glu Asp Ile Trp Ile Pro Arg Glu Asp Lys Asn Asn Phe 395 400 405 Leu Ile Asp Thr Ala Ser Glu Ser Glu Tyr Ser Thr Val Glu Glu 410 415 420 Cys Phe Gln Ser Leu Arg Arg Lys Asn Ser Lys Ala Ser Lys Ser 425 430 435 Arg Thr Gln Lys Ala Leu Ile Leu Asp Ser Val Asn Arg His Ser 440 445 450 Tyr Pro Leu Ser Ser Thr Ser Gly Asn Ala Asp Ser Ser Ala Val 455 460 465 Ser Ser Gln Ala Ile Ser Pro Tyr Ala Cys Phe Tyr Gly Ala Ser 470 475 480 Ala Lys Lys Val Lys Ser Gly Trp Leu Asp Lys Leu Ser Pro Gln 485 490 495 Gly Lys Arg Met Phe Gln Lys Arg Trp Val Lys Phe Asp Gly Leu 500 505 510 Ser Ile Ser Tyr Tyr Asn Asn Glu Lys Glu Met Tyr Ser Lys Gly 515 520 525 Ile Ile Pro Leu Ser Ala Ile Ser Thr Val Arg Val Gln Gly Asp 530 535 540 Asn Lys Phe Glu Val Val Thr Thr Gln Arg Thr Phe Val Phe Arg 545 550 555 Val Glu Lys Glu Glu Glu Arg Asn Asp Trp Ile Ser Ile Leu Leu 560 565 570 Asn Ala Leu Lys Ser Gln Ser Leu Thr Ser Gln Ser Gln Ala Val 575 580 585 Val Thr Pro Glu Lys Cys Gly Tyr Leu Glu Leu Arg Gly Tyr Lys 590 595 600 Ala Lys Ile Phe Thr Val Leu Ser Gly Asn Ser Val Trp Leu Cys 605 610 615 Lys Asn Glu Gln Asp Phe Lys Ser Gly Leu Gly Ile Thr Ile Ile 620 625 630 Pro Met Asn Val Ala Asn Val Lys Gln Val Asp Arg Thr Val Lys 635 640 645 Gln Ser Phe Glu Ile Ile Thr Pro Tyr Arg Ser Phe Ser Phe Thr 650 655 660 Ala Glu Thr Glu Lys Glu Lys Gln Asp Trp Ile Glu Ala Val Gln 665 670 675 Gln Ser Ile Ala Glu Thr Leu Ser Asp Tyr Glu Val Ala Glu Lys 680 685 690 Ile Trp Phe Asn Glu Ser Asn Arg Ser Cys Ala Asp Cys Lys Ala 695 700 705 Pro Asp Pro Asp Trp Ala Ser Ile Asn Leu Cys Val Val Ile Cys 710 715 720 Lys Lys Cys Ala Gly Gln His Arg Ser Leu Gly Pro Lys Asp Ser 725 730 735 Lys Val Arg Ser Leu Lys Met Asp Ala Ser Ile Trp Ser Asn Glu 740 745 750 Leu Ile Glu Leu Phe Ile Val Ile Gly Asn Lys Arg Ala Asn Asp 755 760 765 Phe Trp Ala Gly Asn Leu Gln Lys Asp Glu Glu Leu His Met Asp 770 775 780 Ser Pro Val Glu Lys Arg Lys Asn Phe Ile Thr Gln Lys Tyr Lys 785 790 795 Glu Gly Lys Phe Arg Lys Thr Leu Leu Ala Ser Leu Thr Lys Glu 800 805 810 Glu Leu Asn Lys Ala Leu Cys Ala Ala Val Val Lys Pro Asp Val 815 820 825 Leu Glu Thr Met Ala Leu Leu Phe Ser Gly Ala Asp Val Met Cys 830 835 840 Ala Thr Gly Asp Pro Val His Ser Thr Pro Tyr Leu Leu Ala Lys 845 850 855 Lys Ala Gly Gln Ser Leu Gln Met Glu Phe Leu Tyr His Asn Lys 860 865 870 Phe Ser Asp Phe Pro Gln His Asp Ile His Ser Glu Gly Val Leu 875 880 885 Ser Gln Glu Ser Ser Gln Ser Thr Phe Leu Cys Asp Phe Leu Tyr 890 895 900 Gln Ala Pro Ser Ala Ala Ser Lys Leu Ser Ser Glu Lys Lys Leu 905 910 915 Leu Glu Glu Thr Asn Lys Lys Trp Cys Val Leu Glu Gly Gly Phe 920 925 930 Leu Ser Tyr Tyr Glu Asn Asp Lys Ser Thr Thr Pro Asn Gly Thr 935 940 945 Ile Asn Ile Asn Glu Val Ile Cys Leu Ala Ile His Lys Glu Asp 950 955 960 Phe Tyr Leu Asn Thr Gly Pro Ile Phe Ile Phe Glu Ile Tyr Leu 965 970 975 Pro Ser Glu Arg Val Phe Leu Phe Gly Ala Glu Thr Ser Gln Ala 980 985 990 Gln Arg Lys Trp Thr Glu Ala Ile Ala Lys His Phe Val Pro Leu 995 1000 1005 Phe Ala Glu Asn Leu Thr Glu Ala Asp Tyr Asp Leu Ile Gly Gln 1010 1015 1020 Leu Phe Tyr Lys Asp Cys His Ala Leu Asp Gln Trp Arg Lys Gly 1025 1030 1035 Trp Phe Ala Met Asp Lys Ser Ser Leu His Phe Cys Leu Gln Met 1040 1045 1050 Gln Glu Val Gln Gly Asp Arg Met His Leu Arg Arg Leu Gln Glu 1055 1060 1065 Leu Thr Ile Ser Thr Met Val Gln Asn Gly Glu Lys Leu Asp Val 1070 1075 1080 Leu Leu Leu Val Glu Lys Gly Arg Thr Leu Tyr Ile His Gly His 1085 1090 1095 Thr Lys Leu Asp Phe Thr Val Trp His Thr Ala Ile Glu Lys Ala 1100 1105 1110 Ala Gly Thr Asp Gly Asn Ala Leu Gln Asp Gln Gln Leu Ser Lys 1115 1120 1125 Asn Asp Val Pro Ile Ile Val Asn Ser Cys Ile Ala Phe Val Thr 1130 1135 1140 Gln Tyr Gly Leu Gly Cys Lys Tyr Ile Tyr Gln Lys Asn Gly Asp 1145 1150 1155 Pro Leu His Ile Ser Glu Leu Leu Glu Ser Phe Lys Lys Asp Ala 1160 1165 1170 Arg Ser Phe Lys Leu Arg Ala Gly Lys His Gln Leu Glu Asp Val 1175 1180 1185 Thr Ala Val Leu Lys Ser Phe Leu Ser Asp Ile Asp Asp Ala Leu 1190 1195 1200 Leu Thr Lys Glu Leu Tyr Pro Tyr Trp Ile Ser Ala Leu Asp Thr 1205 1210 1215 Gln Asp Asp Lys Glu Arg Ile Lys Lys Tyr Gly Ala Phe Ile Arg 1220 1225 1230 Ser Leu Pro Gly Val Asn Arg Ala Thr Leu Ala Ala Ile Ile Glu 1235 1240 1245 His Leu Tyr Arg Val Gln Lys Cys Ser Glu Ile Asn His Met Asn 1250 1255 1260 Ala His Asn Leu Ala Leu Val Phe Ser Ser Cys Leu Phe Gln Thr 1265 1270 1275 Lys Gly Gln Thr Ser Glu Glu Val Asn Val Ile Glu Asp Leu Ile 1280 1285 1290 Asn Asn Tyr Val Glu Ile Phe Glu Val Lys Glu Asp Gln Val Lys 1295 1300 1305 Gln Met Asp Ile Glu Asn Ser Phe Ile Thr Lys Trp Lys Asp Thr 1310 1315 1320 Gln Val Ser Gln Ala Gly Asp Leu Leu Ile Glu Val Tyr Val Glu 1325 1330 1335 Arg Lys Glu Pro Asp Cys Ser Ile Ile Ile Arg Ile Ser Pro Val 1340 1345 1350 Met Glu Ala Glu Glu Leu Thr Asn Asp Ile Leu Ala Ile Lys Asn 1355 1360 1365 Ile Ile Pro Thr Lys Gly Asp Ile Trp Ala Thr Phe Glu Val Ile 1370 1375 1380 Glu Asn Glu Glu Leu Glu Arg Pro Leu His Tyr Lys Glu Asn Val 1385 1390 1395 Leu Glu Gln Val Leu Arg Trp Ser Ser Leu Ala Glu Pro Gly Ser 1400 1405 1410 Ala Tyr Leu Val Val Lys Arg Phe Leu Thr Ala Asp Thr Ile Lys 1415 1420 1425 His Cys Ser Asp Arg Ser Thr Leu Gly Ser Ile Lys Glu Gly Ile 1430 1435 1440 Leu Lys Ile Lys Glu Glu Pro Ser Lys Ile Leu Ser Gly Asn Lys 1445 1450 1455 Phe Gln Asp Arg Tyr Phe Val Leu Arg Asp Gly Phe Leu Phe Leu 1460 1465 1470 Tyr Lys Asp Val Lys Ser Ser Lys His Asp Lys Met Phe Ser Leu 1475 1480 1485 Ser Ser Met Lys Phe Tyr Arg Gly Val Lys Lys Lys Met Lys Pro 1490 1495 1500 Pro Thr Ser Trp Gly Leu Thr Ala Tyr Ser Glu Lys His His Trp 1505 1510 1515 His Leu Cys Cys Asp Ser Ser Gln Thr Gln Thr Glu Trp Met Thr 1520 1525 1530 Ser Ile Phe Ile Ala Gln His Glu Tyr Asp Ile Trp Pro Pro Ala 1535 1540 1545 Gly Lys Glu Arg Lys Arg Ser Ile Thr Lys Asn Pro Lys Ile Gly 1550 1555 1560 Gly Leu Pro Leu Ile Pro Ile Gln His Glu Gly Asn Ala Thr Leu 1565 1570 1575 Ala Arg Lys Asn Ile Glu Ser Ala Arg Ala Glu Leu Glu Arg Leu 1580 1585 1590 Arg Leu Ser Glu Lys Cys Asp Lys Glu Ser Val Asp Ser Ser Leu 1595 1600 1605 Lys Glu Arg Ala Ser Met Val Ala His Cys Leu Glu His Lys Asp 1610 1615 1620 Asp Lys Leu Arg Asn Arg Pro Arg Lys His Arg Ser Phe Asn Cys 1625 1630 1635 Leu Glu Asp Thr Glu Pro Glu Ala Pro Leu Gly Gln Pro Lys Gly 1640 1645 1650 His Lys Gly Leu Lys Thr Leu Arg Lys Thr Glu Asp Arg Asn Ser 1655 1660 1665 Lys Ala Thr Leu Asp Ser Asp His Lys Leu Pro Ser Arg Val Ile 1670 1675 1680 Glu Glu Leu Asn Val Val Leu Gln Arg Ser Arg Thr Leu Pro Lys 1685 1690 1695 Glu Leu Gln Asp Glu Gln Ile Leu Lys 1700 41 243 PRT Homo sapiens misc_feature Incyte ID No 55117040CD1 41 Met Val Ala Glu Val Asp Ser Met Pro Ala Ala Ser Ser Val Lys 1 5 10 15 Lys Pro Phe Gly Leu Arg Ser Lys Met Gly Lys Trp Cys Cys His 20 25 30 Cys Phe Pro Cys Cys Arg Gly Ser Gly Lys Ser Asn Val Gly Thr 35 40 45 Ser Gly Asp His Asn Asp Ser Ser Val Lys Thr Leu Gly Ser Lys 50 55 60 Arg Cys Lys Trp Cys Cys His Cys Phe Pro Cys Cys Arg Gly Ser 65 70 75 Gly Lys Ser Asn Val Val Ala Trp Gly Asp Tyr Asp Asp Ser Ala 80 85 90 Phe Met Asp Pro Arg Tyr His Val His Gly Glu Asp Leu Asp Lys 95 100 105 Leu His Arg Ala Ala Trp Trp Gly Lys Val Pro Arg Lys Asp Leu 110 115 120 Ile Val Met Leu Arg Asp Thr Asp Val Asn Lys Arg Asp Lys Gln 125 130 135 Lys Arg Thr Ala Leu His Leu Ala Ser Ala Asn Gly Asn Ser Glu 140 145 150 Val Val Lys Leu Val Leu Asp Arg Arg Cys Gln Leu Asn Val Leu 155 160 165 Asp Asn Lys Lys Arg Thr Ala Leu Thr Lys Ala Val Gln Cys Gln 170 175 180 Glu Asp Glu Cys Ala Leu Met Leu Leu Glu His Gly Thr Asp Pro 185 190 195 Asn Ile Pro Asp Glu Tyr Gly Asn Thr Thr Leu His Tyr Ala Val 200 205 210 Tyr Asn Glu Asp Lys Leu Met Ala Lys His Cys Ser Tyr Thr Val 215 220 225 Leu Ile Ser Asn Gln Lys Thr Ala Trp Pro His Thr Thr Ala Thr 230 235 240 Trp Tyr Thr 42 248 PRT Homo sapiens misc_feature Incyte ID No 7472392CD1 42 Met Asp Val Leu His Ala Ser Val Arg Arg Ser Thr Ile Val Cys 1 5 10 15 Met Glu Glu Thr Glu Phe Leu Val Val Asp Arg Glu Asp Phe Phe 20 25 30 Ala Asn Lys Leu Asp Gln Glu Val Gln Lys Asp Ala Gln Tyr Arg 35 40 45 Phe Glu Phe Phe Arg Lys Met Glu Leu Phe Ala Ser Trp Ser Asp 50 55 60 Glu Lys Leu Trp Gln Leu Val Ala Met Ala Lys Ile Glu Arg Phe 65 70 75 Ser Tyr Gly Gln Leu Ile Ser Lys Asp Phe Gly Glu Ser Pro Phe 80 85 90 Ile Met Phe Ile Ser Lys Gly Ser Cys Glu Val Leu Arg Leu Leu 95 100 105 Asp Leu Gly Ala Ser Pro Ser Tyr Arg Arg Trp Ile Trp Gln His 110 115 120 Leu Glu Leu Ile Asp Gly Arg Pro Leu Lys Thr His Leu Ser Glu 125 130 135 Tyr Ser Pro Met Glu Arg Phe Lys Glu Phe Gln Ile Lys Ser Tyr 140 145 150 Pro Leu Gln Asp Phe Ser Ser Leu Lys Leu Pro His Leu Lys Lys 155 160 165 Ala Trp Gly Leu Gln Gly Thr Ser Phe Ser Arg Lys Ile Arg Thr 170 175 180 Ser Gly Asp Thr Leu Pro Lys Met Leu Gly Pro Lys Ile Gln Ser 185 190 195 Arg Pro Ala Gln Ser Ile Lys Cys Ala Met Ile Asn Ile Lys Pro 200 205 210 Gly Glu Leu Pro Lys Glu Ala Ala Val Gly Ala Tyr Val Lys Val 215 220 225 His Thr Val Glu Gln Gly Glu Ile Leu Val Ser Val Pro Arg Ala 230 235 240 Leu Phe Thr Met Glu Tyr Val Thr 245 43 310 PRT Homo sapiens misc_feature Incyte ID No 4028960CD1 43 Met Gly Lys Arg Arg Cys Val Pro Pro Leu Glu Pro Lys Leu Ala 1 5 10 15 Ala Gly Cys Cys Gly Val Lys Lys Pro Lys Leu Ser Gly Ser Gly 20 25 30 Thr His Ser His Gly Asn Gln Ser Thr Thr Val Pro Gly Ser Ser 35 40 45 Ser Gly Pro Leu Gln Asn His Gln His Val Asp Ser Ser Ser Gly 50 55 60 Arg Glu Asn Val Ser Asp Leu Thr Leu Gly Pro Gly Asn Ser Pro 65 70 75 Ile Thr Arg Met Asn Pro Ala Ser Gly Ala Leu Ser Pro Leu Pro 80 85 90 Arg Pro Asn Gly Thr Ala Asn Thr Thr Lys Asn Leu Val Val Thr 95 100 105 Ala Glu Met Cys Cys Tyr Cys Phe Asp Val Leu Tyr Cys His Leu 110 115 120 Tyr Gly Phe Pro Gln Pro Arg Leu Pro Arg Phe Thr Asn Asp Pro 125 130 135 Tyr Pro Leu Phe Val Thr Trp Lys Thr Gly Arg Asp Lys Arg Leu 140 145 150 Arg Gly Cys Ile Gly Thr Phe Ser Ala Met Asn Leu His Ser Gly 155 160 165 Leu Arg Glu Tyr Thr Leu Thr Ser Ala Leu Lys Asp Ser Arg Phe 170 175 180 Pro Pro Leu Thr Arg Glu Glu Leu Pro Lys Leu Phe Cys Ser Val 185 190 195 Ser Leu Leu Thr Asn Phe Glu Asp Ala Ser Asp Tyr Leu Asp Trp 200 205 210 Glu Val Gly Val His Gly Ile Arg Ile Glu Phe Ile Asn Glu Lys 215 220 225 Gly Val Lys Arg Thr Ala Thr Tyr Leu Pro Glu Val Ala Lys Glu 230 235 240 Gln Asp Trp Asp Gln Ile Gln Thr Ile Asp Ser Leu Leu Arg Lys 245 250 255 Gly Gly Phe Lys Ala Pro Ile Thr Ser Glu Phe Arg Lys Thr Ile 260 265 270 Lys Leu Thr Arg Tyr Arg Ser Glu Lys Val Thr Ile Ser Tyr Ala 275 280 285 Glu Tyr Ile Ala Ser Arg Gln His Cys Phe Gln Asn Gly Thr Leu 290 295 300 His Ala Pro Pro Leu Tyr Asn His Tyr Ser 305 310 44 838 PRT Homo sapiens misc_feature Incyte ID No 8227004CD1 44 Met Phe Trp Lys Phe Asp Leu His Ser Ser Ser His Ile Asp Thr 1 5 10 15 Leu Leu Glu Arg Glu Asp Val Thr Leu Lys Glu Leu Met Asp Glu 20 25 30 Glu Asp Val Leu Gln Glu Cys Lys Ala Gln Asn Arg Lys Leu Ile 35 40 45 Glu Phe Leu Leu Lys Ala Glu Cys Leu Glu Asp Leu Val Ser Phe 50 55 60 Ile Ile Glu Glu Pro Pro Gln Asp Met Asp Glu Lys Ile Arg Tyr 65 70 75 Lys Tyr Pro Asn Ile Ser Cys Glu Leu Leu Thr Ser Asp Val Ser 80 85 90 Gln Met Asn Asp Arg Leu Gly Glu Asp Glu Ser Leu Leu Met Lys 95 100 105 Leu Tyr Ser Phe Leu Leu Asn Asp Ser Pro Leu Asn Pro Leu Leu 110 115 120 Ala Ser Phe Phe Ser Lys Val Leu Ser Ile Leu Ile Ser Arg Lys 125 130 135 Pro Glu Gln Ile Val Asp Phe Leu Lys Lys Lys His Asp Phe Val 140 145 150 Asp Leu Ile Ile Lys His Ile Gly Thr Ser Ala Ile Met Asp Leu 155 160 165 Leu Leu Arg Leu Leu Thr Cys Ile Glu Pro Pro Gln Pro Arg Gln 170 175 180 Asp Val Leu Asn Trp Leu Asn Glu Glu Lys Ile Ile Gln Arg Leu 185 190 195 Val Glu Ile Val His Pro Ser Gln Glu Glu Asp Arg His Ser Asn 200 205 210 Ala Ser Gln Ser Leu Cys Glu Ile Val Arg Leu Ser Arg Asp Gln 215 220 225 Met Leu Gln Ile Gln Asn Ser Thr Glu Pro Asp Pro Leu Leu Ala 230 235 240 Thr Leu Glu Lys Gln Glu Ile Ile Glu Gln Leu Leu Ser Asn Ile 245 250 255 Phe His Lys Glu Lys Asn Glu Ser Ala Ile Val Ser Ala Ile Gln 260 265 270 Ile Leu Leu Thr Leu Leu Glu Thr Arg Arg Pro Thr Phe Glu Gly 275 280 285 His Ile Glu Ile Cys Pro Pro Gly Met Ser His Ser Ala Cys Ser 290 295 300 Val Asn Lys Ser Val Leu Glu Ala Ile Arg Gly Arg Leu Gly Ser 305 310 315 Phe His Glu Leu Leu Leu Glu Pro Pro Lys Lys Ser Val Met Lys 320 325 330 Thr Thr Trp Gly Val Leu Asp Pro Pro Val Gly Asn Thr Arg Leu 335 340 345 Asn Val Ile Arg Leu Ile Ser Ser Leu Leu Gln Thr Asn Thr Ser 350 355 360 Ser Ile Asn Gly Asp Leu Met Glu Leu Asn Ser Ile Gly Val Ile 365 370 375 Leu Asn Met Phe Phe Lys Tyr Thr Trp Asn Asn Phe Leu His Thr 380 385 390 Gln Val Glu Ile Cys Ile Ala Leu Ile Leu Ala Ser Pro Phe Glu 395 400 405 Asn Thr Glu Asn Ala Thr Ile Thr Asp Gln Asp Ser Thr Gly Asp 410 415 420 Asn Leu Leu Leu Lys His Leu Phe Gln Lys Cys Gln Leu Ile Glu 425 430 435 Arg Ile Leu Glu Ala Trp Glu Met Asn Glu Lys Lys Gln Ala Glu 440 445 450 Gly Gly Arg Arg His Gly Tyr Met Gly His Leu Thr Arg Ile Ala 455 460 465 Asn Cys Ile Val His Ser Thr Asp Lys Gly Pro Asn Ser Ala Leu 470 475 480 Val Gln Gln Leu Ile Lys Asp Leu Pro Asp Glu Val Arg Glu Arg 485 490 495 Trp Glu Thr Phe Cys Thr Ser Ser Leu Gly Glu Thr Asn Lys Arg 500 505 510 Asn Thr Val Asp Leu Met Gln Gln Met Thr Ser Asn Phe Ile Asp 515 520 525 Gln Phe Gly Phe Asn Asp Glu Lys Phe Ala Asp Gln Asp Asp Ile 530 535 540 Gly Asn Val Ser Phe Asp Arg Val Ser Asp Ile Asn Phe Thr Leu 545 550 555 Asn Thr Asn Glu Ser Gly Asn Ile Ala Leu Phe Glu Ala Cys Cys 560 565 570 Lys Glu Arg Ile Gln Gln Phe Asp Asp Gly Gly Ser Asp Glu Glu 575 580 585 Asp Ile Trp Glu Glu Lys His Ile Ala Phe Thr Pro Glu Ser Gln 590 595 600 Arg Arg Ser Ser Ser Gly Ser Thr Asp Ser Glu Glu Ser Thr Asp 605 610 615 Ser Glu Glu Glu Asp Gly Ala Lys Gln Asp Leu Phe Glu Pro Ser 620 625 630 Ser Ala Asn Thr Glu Asp Lys Met Glu Val Asp Leu Ser Glu Pro 635 640 645 Pro Asn Trp Ser Ala Asn Phe Asp Val Pro Met Glu Thr Thr His 650 655 660 Gly Ala Pro Leu Asp Ser Val Gly Ser Asp Val Trp Ser Thr Glu 665 670 675 Glu Pro Met Pro Thr Lys Glu Thr Gly Trp Ala Ser Phe Ser Glu 680 685 690 Phe Thr Ser Ser Leu Ser Thr Lys Asp Ser Leu Arg Ser Asn Ser 695 700 705 Pro Val Glu Met Glu Thr Ser Thr Glu Pro Met Asp Pro Leu Thr 710 715 720 Pro Ser Ala Ala Ala Leu Ala Val Gln Pro Glu Ala Ala Gly Ser 725 730 735 Val Ala Met Glu Ala Ser Ser Asp Gly Glu Glu Asp Ala Glu Ser 740 745 750 Thr Asp Lys Val Thr Glu Thr Val Met Asn Gly Gly Met Lys Glu 755 760 765 Thr Leu Ser Leu Thr Val Asp Ala Lys Thr Glu Thr Ala Val Phe 770 775 780 Lys Ser Glu Glu Gly Lys Leu Ser Thr Ser Gln Asp Ala Ala Cys 785 790 795 Lys Asp Ala Glu Glu Cys Pro Glu Thr Ala Glu Ala Lys Cys Ala 800 805 810 Ala Pro Arg Pro Pro Ser Ser Ser Pro Glu Gln Arg Thr Gly Gln 815 820 825 Pro Ser Ala Pro Gly Asp Thr Ser Val Asn Gly Pro Val 830 835 45 408 PRT Homo sapiens misc_feature Incyte ID No 3044763CD1 45 Met Arg Thr Asp Ser Gly Ala Arg Leu Glu Glu Gly His Leu Arg 1 5 10 15 Pro Pro Arg Ala Leu Pro Pro Val Pro Ser Gln Asp Asp Ile Pro 20 25 30 Leu Ser Arg Pro Lys Lys Lys Lys Pro Arg Thr Lys Asn Thr Pro 35 40 45 Ala Ser Ala Ser Leu Glu Gly Leu Ala Gln Thr Ala Gly Arg Arg 50 55 60 Pro Ser Glu Gly Asn Glu Pro Ser Thr Lys Glu Leu Lys Glu His 65 70 75 Pro Glu Ala Pro Val Gln Arg Arg Gln Lys Lys Thr Arg Leu Pro 80 85 90 Leu Glu Leu Glu Thr Ser Ser Thr Gln Lys Lys Ser Ser Ser Ser 95 100 105 Ser Leu Leu Arg Asn Glu Asn Gly Ile Asp Ala Glu Pro Ala Glu 110 115 120 Glu Ala Val Ile Gln Lys Pro Arg Arg Lys Thr Lys Lys Thr Gln 125 130 135 Pro Ala Glu Leu Gln Tyr Ala Asn Glu Leu Gly Val Glu Asp Glu 140 145 150 Asp Ile Ile Thr Asp Glu Gln Thr Thr Val Glu Gln Gln Ser Val 155 160 165 Phe Thr Ala Pro Thr Gly Ile Ser Gln Pro Val Gly Lys Val Phe 170 175 180 Val Glu Lys Ser Arg Arg Phe Gln Ala Ala Asp Arg Ser Glu Leu 185 190 195 Ile Lys Thr Thr Glu Asn Ile Asp Val Ser Met Asp Val Lys Pro 200 205 210 Ser Trp Thr Thr Arg Asp Val Ala Leu Thr Val His Arg Ala Phe 215 220 225 Arg Met Ile Gly Leu Phe Ser His Gly Phe Leu Ala Gly Cys Ala 230 235 240 Val Trp Asn Ile Val Val Ile Tyr Val Leu Ala Gly Asp Gln Leu 245 250 255 Ser Asn Leu Ser Asn Leu Leu Gln Gln Tyr Lys Thr Leu Ala Tyr 260 265 270 Pro Phe Gln Ser Leu Leu Tyr Leu Leu Leu Ala Leu Ser Thr Ile 275 280 285 Ser Ala Phe Asp Arg Ile Asp Phe Ala Lys Ile Ser Val Ala Ile 290 295 300 Arg Asn Phe Leu Ala Leu Asp Pro Thr Ala Leu Ala Ser Phe Leu 305 310 315 Tyr Phe Thr Ala Leu Ile Leu Ser Leu Ser Gln Gln Met Thr Ser 320 325 330 Asp Arg Ile His Leu Tyr Thr Pro Ser Ser Val Asn Gly Ser Leu 335 340 345 Trp Glu Ala Gly Ile Glu Glu Gln Ile Leu Gln Pro Trp Ile Val 350 355 360 Val Asn Leu Val Val Ala Leu Leu Val Gly Leu Ser Trp Leu Phe 365 370 375 Leu Ser Tyr Arg Pro Gly Met Asp Leu Ser Glu Glu Leu Met Phe 380 385 390 Ser Ser Glu Val Glu Glu Tyr Pro Asp Lys Glu Lys Glu Ile Lys 395 400 405 Ala Ser Ser 46 101 PRT Homo sapiens misc_feature Incyte ID No 4044519CD1 46 Met Cys Phe Leu Phe Phe Leu Leu Phe Phe Thr Met Val Ala Ser 1 5 10 15 Thr Cys Pro Ser Asp Leu Arg Leu Lys Asp Ser Phe Leu Lys Asn 20 25 30 Met Val Pro Ala Leu Lys Gly Cys Phe Arg Thr Tyr Phe Ile Cys 35 40 45 Phe Leu Leu Ile Leu Ile Phe Gln Leu Asn Pro Ser Ser Ser Leu 50 55 60 Pro Ser Ser Leu Pro Val Tyr Leu Phe Ser Phe Leu Ser Phe Phe 65 70 75 Phe Phe Phe Phe Phe Leu Glu Ala Glu Ser Cys Pro Val Thr Gln 80 85 90 Ala Glu Val Gln Trp Tyr Asp His Ser Ser Leu 95 100 47 256 PRT Homo sapiens misc_feature Incyte ID No 71351918CD1 47 Met Glu Asn Ser Gly Phe Phe Pro Ser Gly Leu Val Val Leu Ser 1 5 10 15 Gly Gly Met Asp Ala Gln Leu Lys Ile Trp Ser Ala Glu Asp Ala 20 25 30 Ser Cys Val Val Thr Phe Lys Gly His Lys Gly Gly Ile Leu Asp 35 40 45 Thr Ala Ile Val Asp Arg Gly Arg Asn Val Val Ser Ala Ser Arg 50 55 60 Asp Gly Thr Ala Arg Leu Trp Asp Cys Gly Arg Ser Gly Cys Leu 65 70 75 Gly Val Leu Ala Asp Cys Gly Ser Ser Ile Asn Gly Val Ala Val 80 85 90 Gly Ala Ala Asp Asn Ser Ile Asn Leu Gly Ser Pro Glu Gln Met 95 100 105 Pro Ser Glu Arg Glu Val Gly Thr Glu Ala Lys Met Leu Leu Leu 110 115 120 Ala Arg Glu Asp Lys Lys Leu Gln Cys Leu Gly Leu Gln Ser Arg 125 130 135 Gln Leu Val Phe Leu Phe Ile Gly Ser Asp Ala Phe Asn Cys Cys 140 145 150 Thr Phe Leu Ser Gly Phe Leu Leu Leu Ala Gly Thr Gln Asp Gly 155 160 165 Asn Ile Tyr Gln Leu Asp Val Arg Ser Pro Arg Ala Pro Val Gln 170 175 180 Val Ile His Arg Ser Gly Ala Pro Val Leu Ser Leu Leu Ser Val 185 190 195 Arg Asp Gly Phe Ile Ala Ser Gln Gly Asp Gly Ser Cys Phe Ile 200 205 210 Val Gln Gln Asp Leu Asp Tyr Val Thr Glu Leu Thr Gly Ala Asp 215 220 225 Cys Asp Pro Val Tyr Lys Val Ala Thr Trp Glu Lys Gln Ile Tyr 230 235 240 Thr Cys Cys Arg Asp Gly Leu Val Arg Arg Tyr Gln Leu Ser Asp 245 250 255 Leu 48 104 PRT Homo sapiens misc_feature Incyte ID No 8109363CD1 48 Met Pro Arg Ser Ser Gln His Ser Glu Ser Ser Pro Leu Asp Thr 1 5 10 15 Thr Thr Gln Arg Lys Gly Ala Ser Ser Leu Ala His Gln Val Arg 20 25 30 Val His Thr Leu Glu Thr Leu Leu Asp Trp Pro Glu Leu Pro Gln 35 40 45 Pro Leu Leu Thr Pro Pro Pro Val Ile Asp Thr Ala Ala Gly Ser 50 55 60 Arg Lys Arg Phe Leu Asn Lys Ala Gln Leu Ala Gln Cys Leu Ala 65 70 75 Gln Gln Thr Ile Asn Thr Cys Lys Leu Asn Cys Met Ile Leu Ala 80 85 90 Gln Val Leu Leu Met Trp Leu Thr Ala Thr His Leu His Gly 95 100 49 855 PRT Homo sapiens misc_feature Incyte ID No 1272746CD1 49 Met Ser Phe Val Arg Val Asn Arg Cys Gly Pro Arg Val Gly Val 1 5 10 15 Arg Lys Thr Pro Lys Val Lys Lys Lys Lys Thr Ser Val Lys Gln 20 25 30 Glu Trp Asp Asn Thr Val Thr Asp Leu Thr Val His Arg Ala Thr 35 40 45 Pro Glu Asp Leu Val Arg Arg His Glu Ile His Lys Ser Lys Asn 50 55 60 Arg Ala Leu Val His Trp Glu Leu Gln Glu Lys Ala Leu Lys Arg 65 70 75 Lys Trp Arg Lys Gln Lys Pro Glu Thr Leu Asn Leu Glu Lys Arg 80 85 90 Arg Leu Ser Ile Met Lys Glu Ile Leu Ser Asp Gln Tyr Gln Met 95 100 105 Gln Asp Val Leu Glu Lys Ser Asp His Leu Ile Ala Ala Ala Lys 110 115 120 Glu Leu Phe Pro Arg Arg Arg Thr Gly Phe Pro Asn Val Thr Val 125 130 135 Ala Pro Asp Ser Ser Gln Gly Pro Ile Val Val Asn Gln Asp Pro 140 145 150 Ile Thr Gln Ser Ile Phe Asn Glu Ser Val Ile Glu Pro Gln Ala 155 160 165 Leu Asn Asp Val Asp Gly Glu Glu Glu Gly Thr Val Asn Ser Gln 170 175 180 Ser Gly Glu Ser Glu Asn Glu Asn Glu Leu Asp Asn Ser Leu Asn 185 190 195 Ser Gln Ser Asn Thr Asn Thr Asp Arg Phe Leu Gln Gln Leu Thr 200 205 210 Glu Glu Asn Phe Glu Leu Ile Ser Lys Leu Trp Thr Asp Ile Gln 215 220 225 Gln Lys Ile Ala Thr Gln Ser Gln Ile Thr Pro Pro Gly Thr Pro 230 235 240 Ser Ser Ala Leu Ser Ser Gly Glu Gln Arg Ala Ala Leu Asn Ala 245 250 255 Thr Asn Ala Val Lys Arg Leu Gln Thr Arg Leu Gln Pro Glu Glu 260 265 270 Ser Thr Glu Thr Leu Asp Ser Ser Tyr Val Val Gly His Val Leu 275 280 285 Asn Ser Arg Lys Gln Lys Gln Leu Leu Asn Lys Val Lys Arg Lys 290 295 300 Pro Asn Leu His Ala Leu Ser Lys Pro Lys Lys Asn Ile Ser Ser 305 310 315 Gly Ser Thr Thr Ser Ala Asp Leu Pro Asn Arg Thr Asn Ser Asn 320 325 330 Leu Asp Val Leu Lys His Met Ile His Glu Val Glu His Glu Met 335 340 345 Glu Glu Tyr Glu Arg Trp Thr Gly Arg Glu Val Lys Gly Leu Gln 350 355 360 Ser Ser Gln Gly Leu Thr Gly Phe Thr Leu Ser Leu Val Ser Ser 365 370 375 Leu Cys Arg Leu Val Arg Tyr Leu Lys Glu Ser Glu Ile Gln Leu 380 385 390 Arg Lys Glu Val Glu Thr Arg Gln Gln Leu Glu Gln Val Leu Gly 395 400 405 Asp His Arg Glu Leu Ile Asp Ala Leu Thr Ala Glu Ile Leu Arg 410 415 420 Leu Arg Glu Glu Asn Ala Ala Thr Gln Ala Arg Leu Gln Gln Tyr 425 430 435 Met Val Thr Thr Asp Glu Gln Leu Ile Ser Leu Thr His Ala Ile 440 445 450 Lys Asn Cys Pro Val Ile Asn Asn Arg Gln Glu Ile Gln Ala Ser 455 460 465 Glu Ser Gly Ala Thr Gly Arg Arg Val Met Asp Ser Pro Glu Arg 470 475 480 Pro Val Val Asn Ala Asn Val Ser Val Pro Leu Met Phe Arg Glu 485 490 495 Glu Val Ala Glu Phe Pro Gln Glu Glu Leu Pro Val Lys Leu Ser 500 505 510 Gln Val Pro Asp Pro Pro Asp Asn Met Asn Leu Ala Lys Asn Phe 515 520 525 Pro Ala His Ile Phe Glu Pro Ala Val Leu Leu Thr Pro Pro Arg 530 535 540 Gln Lys Ser Asn Leu Lys Phe Ser Pro Leu Gln Asp Val Leu Arg 545 550 555 Arg Thr Val Gln Thr Arg Pro Ala Pro Arg Leu Pro Pro Thr Val 560 565 570 Glu Ile Ile Glu Lys Glu Gln Asn Trp Glu Glu Lys Thr Leu Pro 575 580 585 Ile Asp Thr Asp Ile Gln Asn Ser Ser Glu Glu Asn Arg Leu Phe 590 595 600 Thr Gln Arg Trp Arg Val Ser His Met Gly Glu Asp Leu Glu Asn 605 610 615 Lys Thr Gln Ala Pro Phe Val Asn Leu Ser Gln Pro Leu Cys Asn 620 625 630 Ser His Ser Asn Thr Gln Gln Ser Arg Ser Pro Thr Phe Ser Glu 635 640 645 Glu Leu Pro Val Leu Gly Asp Gly Gln Gln Leu Arg Thr Asn Glu 650 655 660 Ser Leu Ile Gln Arg Lys Asp Ile Met Thr Arg Ile Ala Asp Leu 665 670 675 Thr Leu Gln Asn Ser Ala Ile Lys Ala His Met Asn Asn Ile Ile 680 685 690 Glu Pro Arg Gly Glu Gln Gly Asp Gly Leu Arg Glu Leu Asn Lys 695 700 705 Gln Glu Ser Ala Ser Asp Met Thr Ser Thr Phe Pro Val Ala Gln 710 715 720 Ser Leu Thr Pro Gly Ser Met Glu Glu Arg Ile Ala Glu Leu Asn 725 730 735 Arg Gln Ser Met Glu Ala Arg Gly Lys Leu Leu Gln Leu Ile Glu 740 745 750 Gln Gln Lys Leu Val Gly Leu Asn Leu Ser Pro Pro Met Ser Pro 755 760 765 Val Gln Leu Pro Leu Arg Ala Trp Thr Glu Gly Ala Lys Arg Thr 770 775 780 Ile Glu Val Ser Ile Pro Gly Ala Glu Ala Pro Glu Ser Ser Lys 785 790 795 Cys Ser Thr Val Ser Pro Val Ser Gly Ile Asn Thr Arg Arg Ser 800 805 810 Ser Gly Ala Thr Gly Asn Ser Cys Ser Pro Leu Asn Ala Thr Ser 815 820 825 Gly Ser Gly Arg Phe Thr Pro Leu Asn Pro Arg Ala Lys Ile Glu 830 835 840 Lys Gln Asn Glu Glu Gly Trp Phe Ala Leu Ser Thr His Val Ser 845 850 855 50 427 PRT Homo sapiens misc_feature Incyte ID No 1839974CD1 50 Met Tyr Val Thr Met Met Met Thr Asp Gln Ile Pro Leu Glu Leu 1 5 10 15 Pro Pro Leu Leu Asn Gly Glu Val Ala Met Met Pro His Leu Val 20 25 30 Asn Gly Asp Ala Ala Gln Gln Val Ile Leu Val Gln Val Asn Pro 35 40 45 Gly Glu Thr Phe Thr Ile Arg Ala Glu Asp Gly Thr Leu Gln Cys 50 55 60 Ile Gln Gly Pro Ala Glu Val Pro Met Met Ser Pro Asn Gly Ser 65 70 75 Ile Pro Pro Ile His Val Pro Pro Gly Tyr Ile Ser Gln Val Ile 80 85 90 Glu Asp Ser Thr Gly Val Arg Arg Val Val Val Thr Pro Gln Ser 95 100 105 Pro Glu Cys Tyr Pro Pro Ser Tyr Pro Ser Ala Met Ser Pro Thr 110 115 120 His His Leu Pro Pro Tyr Leu Thr His His Pro His Phe Ile His 125 130 135 Asn Ser His Thr Ala Tyr Tyr Pro Pro Val Thr Gly Pro Gly Asp 140 145 150 Met Pro Pro Gln Phe Phe Pro Gln His His Leu Pro His Thr Ile 155 160 165 Tyr Gly Glu Gln Glu Ile Ile Pro Phe Tyr Gly Met Ser Thr Tyr 170 175 180 Ile Thr Arg Glu Asp Gln Tyr Ser Lys Pro Pro His Lys Lys Leu 185 190 195 Lys Asp Arg Gln Ile Asp Arg Gln Asn Arg Leu Asn Ser Pro Pro 200 205 210 Ser Ser Ile Tyr Lys Ser Ser Cys Thr Thr Val Tyr Asn Gly Tyr 215 220 225 Gly Lys Gly His Ser Gly Gly Ser Gly Gly Gly Gly Ser Gly Ser 230 235 240 Gly Pro Gly Ile Lys Lys Thr Glu Arg Arg Ala Arg Ser Ser Pro 245 250 255 Lys Ser Asn Asp Ser Asp Leu Gln Glu Tyr Glu Leu Glu Val Lys 260 265 270 Arg Val Gln Asp Ile Leu Ser Gly Ile Glu Lys Pro Gln Val Ser 275 280 285 Asn Ile Gln Ala Arg Ala Val Val Leu Ser Trp Ala Pro Pro Val 290 295 300 Gly Leu Ser Cys Gly Pro His Ser Gly Leu Ser Phe Pro Tyr Ser 305 310 315 Tyr Glu Val Ala Leu Ser Asp Lys Gly Arg Asp Gly Lys Tyr Lys 320 325 330 Ile Ile Tyr Ser Gly Glu Glu Leu Glu Cys Asn Leu Lys Asp Leu 335 340 345 Arg Pro Ala Thr Asp Tyr His Val Arg Val Tyr Ala Met Tyr Asn 350 355 360 Ser Val Lys Gly Ser Cys Ser Glu Pro Val Ser Phe Thr Thr His 365 370 375 Ser Cys Ala Pro Glu Cys Pro Phe Pro Pro Lys Leu Ala His Arg 380 385 390 Ser Lys Ser Ser Leu Thr Leu Gln Trp Lys Ala Pro Ile Asp Asn 395 400 405 Gly Ser Lys Ile Thr Asn Tyr Leu Leu Glu Trp Asp Glu Val Ser 410 415 420 Leu Phe Ser Tyr Ser Pro Ile 425 51 800 PRT Homo sapiens misc_feature Incyte ID No 1877336CD1 51 Met Ala Ala Asn Val Gly Asp Gln Arg Ser Thr Asp Trp Ser Ser 1 5 10 15 Gln Tyr Ser Met Val Ala Gly Ala Gly Arg Glu Asn Gly Met Glu 20 25 30 Thr Pro Met His Glu Asn Pro Glu Trp Glu Lys Ala Arg Gln Ala 35 40 45 Leu Ala Ser Ile Ser Lys Ser Gly Ala Ala Gly Gly Ser Ala Lys 50 55 60 Ser Ser Ser Asn Gly Pro Val Ala Ser Ala Gln Tyr Val Ser Gln 65 70 75 Ala Glu Ala Ser Ala Leu Gln Gln Gln Gln Tyr Tyr Gln Trp Tyr 80 85 90 Gln Gln Tyr Asn Tyr Ala Tyr Pro Tyr Ser Tyr Tyr Tyr Pro Met 95 100 105 Ser Met Tyr Gln Ser Tyr Gly Ser Pro Ser Gln Tyr Gly Met Ala 110 115 120 Gly Ser Tyr Gly Ser Ala Thr Pro Gln Gln Pro Ser Ala Pro Gln 125 130 135 His Gln Gly Thr Leu Asn Gln Pro Pro Val Pro Gly Met Asp Glu 140 145 150 Ser Met Ser Tyr Gln Ala Pro Pro Gln Gln Leu Pro Ser Ala Gln 155 160 165 Pro Pro Gln Pro Ser Asn Pro Pro His Gly Ala His Thr Leu Asn 170 175 180 Ser Gly Pro Gln Pro Gly Thr Ala Pro Ala Thr Gln His Ser Gln 185 190 195 Ala Gly Pro Ala Thr Gly Gln Ala Tyr Gly Pro His Thr Tyr Thr 200 205 210 Glu Pro Ala Lys Pro Lys Lys Gly Gln Gln Leu Trp Asn Arg Met 215 220 225 Lys Pro Ala Pro Gly Thr Gly Gly Leu Lys Phe Asn Ile Gln Lys 230 235 240 Arg Pro Phe Ala Val Thr Thr Gln Ser Phe Gly Ser Asn Ala Glu 245 250 255 Gly Gln His Ser Gly Phe Gly Pro Gln Pro Asn Pro Glu Lys Val 260 265 270 Gln Asn His Ser Gly Ser Ser Ala Arg Gly Asn Leu Ser Gly Lys 275 280 285 Pro Asp Asp Trp Pro Gln Asp Met Lys Glu Tyr Val Glu Arg Cys 290 295 300 Phe Thr Ala Cys Glu Ser Glu Glu Asp Lys Asp Arg Thr Glu Lys 305 310 315 Leu Leu Lys Glu Val Leu Gln Ala Arg Leu Gln Asp Gly Ser Ala 320 325 330 Tyr Thr Ile Asp Trp Ser Arg Glu Pro Leu Pro Gly Leu Thr Arg 335 340 345 Glu Pro Val Ala Glu Ser Pro Lys Lys Lys Arg Trp Glu Ala Ala 350 355 360 Ser Ser Leu His Pro Pro Arg Gly Ala Gly Ser Ala Thr Arg Gly 365 370 375 Gly Gly Ala Pro Ser Gln Arg Gly Thr Pro Gly Ala Gly Gly Ala 380 385 390 Gly Arg Ala Arg Gly Asn Ser Phe Thr Lys Phe Gly Asn Arg Asn 395 400 405 Val Phe Met Lys Asp Asn Ser Ser Ser Ser Ser Thr Asp Ser Arg 410 415 420 Ser Arg Ser Ser Ser Arg Ser Pro Thr Arg His Phe Arg Arg Ser 425 430 435 Asp Ser His Ser Asp Ser Asp Ser Ser Tyr Ser Gly Asn Glu Cys 440 445 450 His Pro Val Gly Arg Arg Asn Pro Pro Pro Lys Gly Arg Gly Gly 455 460 465 Arg Gly Ala His Met Asp Arg Gly Arg Gly Arg Ala Gln Arg Gly 470 475 480 Lys Arg His Asp Leu Ala Pro Thr Lys Arg Ser Arg Lys Lys Met 485 490 495 Ala Ala Leu Glu Cys Glu Asp Pro Glu Arg Glu Leu Lys Lys Gln 500 505 510 Lys Arg Ala Ala Arg Phe Gln His Gly His Ser Arg Arg Leu Arg 515 520 525 Leu Glu Pro Leu Val Leu Gln Met Ser Ser Leu Glu Ser Ser Gly 530 535 540 Ala Asp Pro Asp Trp Gln Glu Leu Gln Ile Val Gly Thr Cys Pro 545 550 555 Asp Ile Thr Lys His Tyr Leu Arg Leu Thr Cys Ala Pro Asp Pro 560 565 570 Ser Thr Val Arg Pro Val Ala Val Leu Lys Lys Ser Leu Cys Met 575 580 585 Val Lys Cys His Trp Lys Glu Lys Gln Asp Tyr Ala Phe Ala Cys 590 595 600 Glu Gln Met Lys Ser Ile Arg Gln Asp Leu Thr Val Gln Gly Ile 605 610 615 Arg Thr Glu Phe Thr Val Glu Val Tyr Glu Thr His Ala Arg Ile 620 625 630 Ala Leu Glu Lys Gly Asp His Glu Glu Phe Asn Gln Cys Gln Thr 635 640 645 Gln Leu Lys Ser Leu Tyr Ala Glu Asn Leu Pro Gly Asn Val Gly 650 655 660 Glu Phe Thr Ala Tyr Arg Ile Leu Tyr Tyr Ile Phe Thr Lys Asn 665 670 675 Ser Gly Asp Ile Thr Thr Glu Leu Ala Tyr Leu Thr Arg Glu Leu 680 685 690 Lys Ala Asp Pro Cys Val Ala His Ala Leu Ala Leu Arg Thr Ala 695 700 705 Trp Ala Leu Gly Asn Tyr His Arg Phe Phe Arg Leu Tyr Cys His 710 715 720 Ala Pro Cys Met Ser Gly Tyr Leu Val Asp Lys Phe Ala Asp Arg 725 730 735 Glu Arg Lys Val Ala Leu Lys Ala Met Ile Lys Thr Phe Arg Pro 740 745 750 Ala Leu Pro Val Ser Tyr Leu Gln Ala Glu Leu Ala Phe Glu Gly 755 760 765 Glu Ala Ala Cys Arg Ala Phe Leu Glu Pro Leu Gly Leu Ala Tyr 770 775 780 Thr Gly Pro Asp Asn Ser Ser Ile Asp Cys Arg Leu Ser Leu Ala 785 790 795 Gln Leu Ser Ala Phe 800 52 107 PRT Homo sapiens misc_feature Incyte ID No 2321054CD1 52 Met Ala Gly Gly Tyr Gly Val Met Gly Asp Asp Gly Ser Ile Asp 1 5 10 15 Tyr Thr Val His Glu Ala Trp Asn Glu Ala Thr Asn Val Tyr Leu 20 25 30 Ile Val Ile Leu Val Ser Phe Gly Leu Phe Met Tyr Ala Lys Arg 35 40 45 Asn Lys Arg Arg Ile Met Arg Ile Phe Ser Val Pro Pro Thr Glu 50 55 60 Glu Thr Leu Ser Glu Pro Asn Phe Tyr Asp Thr Ile Ser Lys Ile 65 70 75 Arg Leu Arg Gln Gln Leu Glu Met Tyr Ser Ile Ser Arg Lys Tyr 80 85 90 Asp Tyr Gln Gln Pro Gln Asn Gln Ala Asp Ser Val Gln Leu Ser 95 100 105 Leu Glu 53 522 PRT Homo sapiens misc_feature Incyte ID No 2796034CD1 53 Met Thr Pro Gly Lys His Ser Gly Ala Ser Ala Arg Ala Ala Asn 1 5 10 15 Ala Gly Ala Trp Gly Tyr Arg Asp Phe Arg Gly Gly Gln Lys Lys 20 25 30 Gly Trp Cys Thr Thr Pro Gln Leu Val Ala Thr Met Pro Val Ser 35 40 45 Pro Ala Gly Ser His Lys Gln Gln Asn Phe Gly Leu Asn Asn Ala 50 55 60 Thr Gln Pro Lys Lys Ser Ile Ser Phe Phe Ala Thr Met Lys Ala 65 70 75 Thr Ser Val Lys Gly Tyr Thr Gly Ala Asn Gln Ser Arg Met Ala 80 85 90 Val Ser Lys Thr Val Leu Ile Pro Pro Glu Leu Lys Thr Val Glu 95 100 105 Lys Pro Asn Pro Asn Ile Lys Thr Thr Gln Val Phe Asp Ile Asn 110 115 120 Gly Thr Asp Val Thr Pro Arg Pro Leu Tyr His Pro Asp Pro Leu 125 130 135 Thr Gly Thr Ala Lys Pro Ser Lys Leu Leu Thr Ser Gln Glu Gly 140 145 150 Ser Leu Gly Ser Glu Phe Ile Ser Ser Tyr Ser Leu Tyr Gln Asn 155 160 165 Thr Ile Asn Pro Ser Thr Leu Gly Gln Phe Thr Arg Ser Val Leu 170 175 180 Gly Ser Ser Thr Val Ser Lys Ser Ser Val Ser Ala Ser Glu Ser 185 190 195 Ile Ala Glu Asp Leu Glu Glu Pro Ser Tyr Lys Arg Glu Arg Leu 200 205 210 Thr Ser Phe Thr Asp Leu Gln Val Ile Arg Ala Ala Pro Glu Lys 215 220 225 Ile Val Thr Lys Glu Asp Leu Glu Lys Asn Ile Glu Ile Ile Leu 230 235 240 Thr Glu Thr Glu Thr Leu Arg Phe Phe Asp Leu Pro Thr Val Met 245 250 255 Val Ser Val Glu Ser Glu Glu Ala Glu Lys Val Thr Gln Arg Asn 260 265 270 Lys Asn Tyr Glu Val Leu Cys Arg Asn Arg Leu Gly Asn Asp Leu 275 280 285 Tyr Val Glu Arg Met Met Gln Thr Phe Asn Gly Ala Pro Lys Asn 290 295 300 Lys Asp Val Gln Cys Asp Lys Ile Ile Met Glu Asp Lys Gly Ile 305 310 315 Met Ser Thr Ala Trp Asp Leu Tyr Asp Ser Tyr Asn Ala Met Glu 320 325 330 Leu Val Ser Leu Ser Val Lys Gln Ser Val Val Glu Ser Ser Ser 335 340 345 Lys Ala Asn Val Leu Pro Lys Asp Gln Asp Gln Arg Leu Pro Gly 350 355 360 Ser Thr Thr Glu Lys Asn Ser Glu Thr Ser Ser Leu Met Asp Ile 365 370 375 Glu Asn Val Ile Leu Ala Lys Ile His Glu Asp Glu Glu Asp His 380 385 390 Ser Asp Ala Ile Leu Lys Ser Asp Lys Phe His Gln Asp Leu Phe 395 400 405 Phe Met Glu Arg Val Leu Met Glu Asn Ile Phe Gln Pro Lys Leu 410 415 420 Ala Ala Tyr Arg Gln Leu Pro Val Leu Lys Glu Pro Glu Pro Glu 425 430 435 Glu Pro Glu Asp Val Leu Glu Ser Ala Lys His Glu Glu Val Glu 440 445 450 Glu Glu Ser Lys Lys Glu Glu Glu Glu Glu Ile His Ala Glu Glu 455 460 465 Ser Thr Ile Pro Ala Asn Leu Glu Arg Leu Trp Ser Phe Ser Cys 470 475 480 Asp Leu Thr Lys Gly Leu Asn Val Ser Ser Leu Ala Trp Asn Lys 485 490 495 Thr Asn Pro Asp Leu Leu Ala Val Gly Tyr Gly His Phe Gly Phe 500 505 510 Lys Glu Gln Lys Glu Asp Trp Leu Ala Ala Gly Gln 515 520 54 305 PRT Homo sapiens misc_feature Incyte ID No 4413112CD1 54 Met Gly Gly Thr Leu Ala Trp Thr Leu Leu Leu Pro Leu Leu Leu 1 5 10 15 Arg Glu Ser Asp Ser Leu Glu Pro Ser Cys Thr Val Ser Ser Ala 20 25 30 Asp Val Asp Trp Asn Ala Glu Phe Ser Ala Thr Cys Leu Asn Phe 35 40 45 Ser Gly Leu Ser Leu Ser Leu Pro His Asn Gln Ser Leu Arg Ala 50 55 60 Ser Asn Val Ile Leu Leu Asp Leu Ser Gly Asn Gly Leu Arg Glu 65 70 75 Leu Pro Val Thr Phe Phe Ala His Leu Gln Lys Leu Glu Val Leu 80 85 90 Asn Val Leu Arg Asn Pro Leu Ser Arg Val Asp Gly Ala Leu Ala 95 100 105 Ala Arg Cys Asp Leu Asp Leu Gln Ala Asp Cys Asn Cys Ala Leu 110 115 120 Glu Ser Trp His Asp Ile Arg Arg Asp Asn Cys Ser Gly Gln Lys 125 130 135 Pro Leu Leu Cys Trp Asp Thr Thr Ser Ser Gln His Asn Leu Ser 140 145 150 Ala Phe Leu Glu Val Ser Cys Ala Pro Gly Leu Ala Ser Ala Thr 155 160 165 Ile Gly Ala Val Val Val Ser Gly Cys Leu Leu Leu Gly Leu Ala 170 175 180 Ile Ala Gly Pro Val Leu Ala Trp Arg Leu Trp Arg Cys Arg Val 185 190 195 Ala Arg Ser Arg Glu Leu Asn Lys Pro Trp Ala Ala Gln Asp Gly 200 205 210 Pro Lys Pro Gly Leu Gly Leu Gln Pro Arg Tyr Gly Ser Arg Ser 215 220 225 Ala Pro Lys Pro Gln Val Ala Val Pro Ser Cys Pro Ser Thr Pro 230 235 240 Asp Tyr Glu Asn Met Phe Val Gly Gln Pro Ala Ala Glu His Gln 245 250 255 Trp Asp Glu Gln Gly Ala His Pro Ser Glu Asp Asn Asp Phe Tyr 260 265 270 Ile Asn Tyr Lys Asp Ile Asp Leu Ala Ser Gln Pro Val Tyr Cys 275 280 285 Asn Leu Gln Ser Leu Gly Gln Ala Ser Met Asp Glu Glu Glu Tyr 290 295 300 Val Ile Pro Gly His 305 55 329 PRT Homo sapiens misc_feature Incyte ID No 7654832CD1 55 Met Ser Val Leu Glu Glu Asn Arg Pro Phe Ala Gln Gln Leu Ser 1 5 10 15 Asn Val Tyr Phe Thr Ile Leu Ser Leu Phe Cys Phe Lys Leu Phe 20 25 30 Val Lys Ile Ser Leu Ala Ile Leu Ser His Phe Tyr Ile Val Lys 35 40 45 Gly Asn Arg Lys Glu Ala Ala Arg Ile Ala Ala Glu Phe Tyr Gly 50 55 60 Val Thr Gln Gly Gln Gly Ser Trp Ala Asp Arg Ser Pro Leu His 65 70 75 Glu Ala Ala Ser Gln Gly Arg Leu Leu Ala Leu Arg Thr Leu Leu 80 85 90 Ser Gln Gly Tyr Asn Val Asn Ala Val Thr Leu Asp His Val Thr 95 100 105 Pro Leu His Glu Ala Cys Leu Gly Asp His Val Ala Cys Ala Arg 110 115 120 Thr Leu Leu Glu Ala Gly Ala Asn Val Asn Ala Ile Thr Ile Asp 125 130 135 Gly Val Thr Pro Leu Phe Asn Ala Cys Ser Gln Gly Ser Pro Ser 140 145 150 Cys Ala Glu Leu Leu Leu Glu Tyr Gly Ala Lys Ala Gln Leu Glu 155 160 165 Ser Cys Leu Pro Ser Pro Thr His Glu Ala Ala Ser Lys Gly His 170 175 180 His Glu Cys Leu Asp Ile Leu Ile Ser Trp Gly Ile Asp Val Asp 185 190 195 Gln Glu Ile Pro His Leu Gly Thr Pro Leu Tyr Val Ala Cys Met 200 205 210 Ser Gln Gln Phe His Cys Ile Trp Lys Leu Leu Tyr Ala Gly Ala 215 220 225 Asp Val Gln Lys Gly Lys Tyr Trp Asp Thr Pro Leu His Ala Ala 230 235 240 Ala Gln Gln Ser Ser Thr Glu Ile Val Asn Leu Leu Leu Glu Phe 245 250 255 Gly Ala Asp Ile Asn Ala Lys Asn Thr Glu Leu Leu Arg Pro Ile 260 265 270 Asp Val Ala Thr Ser Ser Ser Met Val Glu Arg Ile Leu Leu Gln 275 280 285 His Glu Ala Thr Pro Ser Ser Leu Tyr Gln Leu Cys Arg Leu Cys 290 295 300 Ile Arg Ser Tyr Ile Gly Lys Pro Arg Leu His Leu Ile Pro Gln 305 310 315 Leu Gln Leu Pro Thr Leu Leu Lys Asn Phe Leu Gln Tyr Arg 320 325 56 236 PRT Homo sapiens misc_feature Incyte ID No 7503849CD1 56 Met Ala Arg Gly Pro Gly Pro Leu Gly Arg Pro Arg Pro Asp Thr 1 5 10 15 Val Ala Met Pro Lys Arg Gly Lys Arg Leu Lys Phe Arg Ala His 20 25 30 Asp Ala Cys Ser Gly Arg Val Thr Val Ala Asp Tyr Ala Asn Ser 35 40 45 Asp Pro Ala Val Val Arg Ser Gly Arg Val Lys Lys Ala Val Ala 50 55 60 Asn Ala Val Gln Gln Glu Val Lys Ser Leu Cys Gly Leu Glu Ala 65 70 75 Ser Gln Val Pro Ala Glu Glu Ala Leu Ser Gly Ala Gly Glu Pro 80 85 90 Cys Asp Ile Ile Asp Ser Ser Asp Glu Met Asp Ala Gln Glu Glu 95 100 105 Ser Ile His Glu Arg Thr Val Ser Arg Lys Lys Lys Ser Lys Arg 110 115 120 His Lys Glu Glu Leu Asp Gly Ala Gly Gly Glu Glu Tyr Pro Met 125 130 135 Asp Ile Trp Leu Leu Leu Ala Ser Tyr Ile Arg Pro Glu Asp Ile 140 145 150 Val Asn Phe Ser Leu Ile Cys Lys Asn Ala Trp Thr Val Thr Cys 155 160 165 Thr Ala Ala Phe Trp Thr Arg Leu Tyr Arg Arg His Tyr Thr Leu 170 175 180 Asp Ala Ser Leu Pro Leu Arg Leu Arg Pro Glu Ser Met Glu Lys 185 190 195 Leu Arg Cys Leu Arg Ala Cys Val Ile Arg Ser Leu Tyr His Met 200 205 210 Tyr Glu Pro Phe Ala Ala Arg Ile Ser Lys Asn Pro Ala Ile Pro 215 220 225 Glu Ser Thr Pro Ser Thr Leu Lys Asn Ser Lys 230 235 57 1485 DNA Homo sapiens misc_feature Incyte ID No 2867236CB1 57 ctcttcctga gaaacgagca aacctgaaag ctactctctc agcttcagag ggaaaaaatg 60 gttgtagatt tctggacttg ggagcagaca tttcaagaac taatccaaga ggcaaaaccc 120 cgggccacat ggacgctgaa gttggatggc aaccttcagc tagactgcct ggctcaaggg 180 tggaagcaat accaacagag agcatttggc tggttccggt gttcctcctg ccagcgaagt 240 tgggcttccg cccaagtgca gattctgtgc cacacgtact gggagcactg gacatcccag 300 ggtcaggtgc gtatgaggct ctttggccaa aggtgccaga agtgctcctg gtcccaatat 360 gagatgcctg agttctcctc ggatagcacc atgaggattc tgagcaacct ggtgcagcat 420 atactgaaga aatactatgg aaatggcacg aggaagtctc cagaaatgcc agtaatcctg 480 gaagtgtccc tggaaggatc ccatgacaca gccaattgtg aggcatgcac tttgggcatc 540 tgtggacagg gcttaaaaag ctacatgaca aagccgtcca aatccctact cccccaccta 600 aagactggga attcctcacc tggaattggt gctgtgtacc tcgcaaacca agccaagaac 660 cagtcagctg aggcaaaaga ggctaagggg agtgggtatg agaaattagg gcccagtcga 720 gacccagatc cactgaacat ctgtgtcttt attttgctgc ttgtatttat tgtagtcaaa 780 tgctttacat cagaatgatg aaaataggct tgccactttc tcttatttta attccatggt 840 agtcaatgaa ctggctgcca ctttaatata actgaaaatt cattttgaga ccaagcagga 900 tcaagtttgt agaataaaca ctggtttcct agccatcctc tgaaaacagt atgaaacatg 960 accaagtaca taatggattt agtaataaat attgtcgaat tgctaaaaag tcttcaatca 1020 ttcattcact aagtcactca gtgatatcaa tatacttagc tcagaaagtg tgggaggctg 1080 aataatggtg tctcccaaca tatgcatgac ttaatcccca gaacctgtaa acatgttact 1140 ttacatggta gaatggactt tgcggatgta attaaggacc ttgaaatggt tagattattt 1200 catattgtcc gggtggataa gaaccaggat tttgtaacag ggaggcaaca agctcaaaat 1260 cagaaaaaag agatttgtca atggaacaag aggttgaagt gctttgaagt tggaggaaga 1320 ggtcacaggc aaaaaagtac aggcagcctt tagaaaacca aaaggacaaa ggaacagatt 1380 ctcccctgga gtctgcagaa ggaaccagcc ctgcctgcac atggctttag cccagtgaca 1440 ctgattttgg acatctgacc ttcagaaata ctagctcata cctcg 1485 58 6176 DNA Homo sapiens misc_feature Incyte ID No 1294096CB1 58 caccgctcgg ctccgcgcgg ctctaggagg tggcggcggt ggcggtggcg gcggtggcgg 60 cggcggcggc ggcggggcgc agggctgagc gagcgtccgg gttccggggc tccggggaag 120 gcggttgcag ctcctgagtg cagcgcggct tcctgccact gtcccggccc ggccacctct 180 ctgtcatggc tctggcggac agcacacgtg gattacccaa cgggggcggc ggcgggggcg 240 gcagtggctc ctcgtcgtcc tccgcggagc caccgctctt ccccgacatc gtggagctga 300 acgtgggggg ccaggtgtac gtgacccggc gctgcacggt ggtgtcggtg cccgactcgc 360 tgctctggcg catgttcacg cagcagcagc cgcaggagct ggcccgggac agcaaaggcc 420 gcttctttct ggaccgggac ggcttcctct tccgctacat cctggattac ctgcgggact 480 tgcagctcgt gctgcccgac tacttccccg agcgcagccg gctgcagcgc gaggccgagt 540 acttcgagct gccagagctc gtgcgccgcc tcggggcgcc ccagcagccc ggcccggggc 600 cgccgccctc gcggcgcggg gtgcacaagg agggctcgct gggtgacgag ctgctgccgc 660 ttggctactc ggagcccgaa cagcaggagg gcgcctctgc cggggcgccg tcgcccacgc 720 tggagctggc tagccgcagt ccgtccgggg gcgcggcggg cccgctgctc acgccgtccc 780 agtcgctgga cggcagccgg cgctcgggct acatcaccat cggctaccgc ggctcctaca 840 ccatcgggcg ggacgcgcag gcggacgcca agttccggcg agtggcgcgc atcaccgttt 900 gcggaaagac gtcgctggcc aaggaggtgt ttggggacac cctgaacgaa agccgggacc 960 ccgaccgtcc cccggagcgc tacacctcgc gctattacct caagttcaac ttcctggagc 1020 aggccttcga caagctgtcc gagtcgggct tccacatggt ggcgtgcagc tccacgggca 1080 cctgcgcctt tgccagcagc accgaccaga gcgaggacaa gatctggacc agctacaccg 1140 agtacgtctt ctgcagggag tgagctcccc agaccccctc gccactccag cgcccagtcc 1200 ttctcctgcc cgagagatga ttacagagcc tcttgtccca cctttgtccc ctggctgctg 1260 ccctcccatt ctccccctcc agtagtagct gggtgagacc tgtccgccca ccttccctcc 1320 actacagaac ctgcagccgc aaatcctctg ggctgcttcg tcttctttgg acctcctgaa 1380 ccgagagaac ccagaggaac ccccacccca cccccaccta ccactccatg ctttctctac 1440 tccctgcctc aaaccacccc tcccccagat ggtacttcag tttggatcta ttgggggagt 1500 gtggccacag accgggggat gattgaattg ttcagaacct gattggaccg tgtccaatgt 1560 gcggaagatt tccttgaaat cttctcaagc tcttatgact cactgggggt ttaagagatc 1620 aggattggtt ccactgtctg gggttagtgt tttacaaggt cattacacag tctttttgac 1680 ctcttttgaa ggtagagttt tagaaggctg gatggaagat tctgagcctg gaattaggac 1740 cccatggagg cagttcagta actaaactaa taaagttttg aaaagttaca cgtaaagtag 1800 aagaatctag tgcgtgggac agtaaaggat cctttctcgt acagaataaa aggtctcagc 1860 ctgtagctta aacttataga aagtgatccg cctgcctgca gaggcgccct tttcagctgc 1920 tgctcgccag aagcccttga ttccactggt tgacatggca gcagttactg gcaagaggga 1980 gaaaggacgc tgccgcctaa gagtgcaagg ctgctcaggt ctccaagcgc cgtaggaggt 2040 cacctggcag tgactgtagg gagctgggtc atagtgcacg tcgtgggtat taggaaagcc 2100 tgtattcttt caatgaatgt cagtaggacc ttcctttagc tgtaagactt ggtgggcggg 2160 gtggggtggg gagggaggaa agggtaggaa gggtgggaag ggagaagcag acatagtcat 2220 ttatgatttg aaagttggaa gtttgtacca tctgtttgag tatatgcaca tttaaaaaat 2280 atcatatagt aaatgcaaac atgccaagta ttttataaag attaataaca gacctactct 2340 tacctggcag tttacttaac ttactgtttt gagtcctaaa cttagagttg ttaatgctta 2400 tatataatct aaccaaagag ttacccagta gggttttagt ttttgaactt ttattttctt 2460 gttgattata aatcctgatt ttggaatcta ttgcgcaaaa gaagtttcat tttggttact 2520 tagacctaag atcacttatt aaaaatcctt attttctcca agcccagcaa acgttgactt 2580 ctgggcaaac ctgaaaacct gaaaatgcca ctttcatgca gtttgtttga agttaagtgg 2640 aatcctttca aatgacgagc tgcagagaac tcagcaccaa gggctgccta tctgtagata 2700 gctgtaaaat ggaatatttt taaatgaagg caaataagta cttaaaagtg agctgagcaa 2760 taaaatggtc caataatagg taaatgcaac agaaacagaa ggagacctgg ttgccttatg 2820 cctttactct tacatggaat aaattcccaa tgcatatcct atgtaaacca taagtgaagg 2880 gaaataaacc tcgtcatgct ccatgctgtg aggtgtcctt tggatattct gtgatgacag 2940 agaagcctat tttgttttgt tttcagcatc tttctctgat gtacgttttt aaggattttg 3000 taagagctgt tttcagtgtt taaattagtg ctatttttcc ttgtttttaa aaatgaatct 3060 cgtactgtat cttactatgt ccatacagat gttacaaatc gacagtttta ttcttagact 3120 catgtgatcc aagctgtata taccatatat aaacatttta catgaatcat ttagtttttt 3180 aattcattta ctaatgctat aaaatttcct atattacccc agtaatttgc atcagctggt 3240 ttatatacta aagcaacatg ttttgatgag tttcttacat ccttatcgag gaattgggtt 3300 aggaaaaaat acataattgt aaaactgagt ttgctgtatt atactttttt tcttgagtat 3360 tagttgtatt actaatcata tgttgattaa ctgtctactt aaagtcaagg tacctgtatt 3420 tttaatccac taattttttt ttagttggga aatagatttc aggtctttta ttagactaac 3480 attttttgag aagtaaaatt gacttcatat acaaagcctg taattttagg cgaaatggaa 3540 gcagaaatct aggaagttgt gcttgcttgt atgttgagtt tggtctcaga ctaagtaatg 3600 catcagaatt catctgtttg aagcctgaaa taatttagga ctctgattca ctgaccaaaa 3660 gtcagtgttg cagagatttc tctaccccgt atggtatttt gttagattgt tcaacaggaa 3720 gcacatgatt gagaacatct tgggacagac caaaaccact gacagatggc aaggctcggc 3780 gattctgatt tcccttctca aatctgctca actccaagag tcttgagaaa ctgctaaaat 3840 tttgcctctg tcactcaagt cttacaaatg ttatcttgta aacctttgag gtgaactatt 3900 ccactgtctt gtacataggc atcttattca ctgcaccctg tcacacccag caccccccgc 3960 cccgcacatt atttgaaaga ctgggaattt aatggttagg gacagtaaat ctacttcttt 4020 ttccagggac gactgtcccc tctaaagtta aagtcaatac aagaaaactg tctattttta 4080 gcctaaagta aaggctgtga agaaaattca ttttacattg ggtagacagt aaaaaacaag 4140 taaaataact tgacatgagc acctttagat cccttcccct ccatgggctt tgggccacag 4200 aatgaacctt tgaggcctgt aaagtggatt gtaatttcct ataagctgta atagtggagg 4260 tattgtgggt tcatttgagt aagccctcca aagataccat tcaaataacc tgggagaatg 4320 tcataaatta ttcagataat taacactgca tgaatctgat tcagaggcat gcatttacat 4380 atgttgccct aattaccatt tgatgatcat aaatacaagt gaatgacatt ggacttttag 4440 taacaaactt aatttttaaa aaggtgtaga caatggtggt taaaaaaaaa aaaaaacagg 4500 taccaggttc tgtgtgtttg caccaagtaa ttgacatgtt ttttgtttaa tacatgtgga 4560 ccatgaacag tattcattct cctttttcaa atgatatgct gtagaaaata ttccttgaag 4620 atgtgagatt taaaaatttt tccctttcaa tgttgtttta attgtatttc ttacttggtt 4680 tttttgattg atagcacagt gataaatcat aatactagac aaaattgtct tctctttcaa 4740 accagagcca tatatatgtc tgtatatatg ggacctactg cttctctgag gaaatgcata 4800 atctgttaat atcagacaaa atgagcaatt ggcagtgctc ataatatatt ccaattttta 4860 ttggaatttt cgatggaatg ttatttcaat aaagccatgt aaggtgaaac tttgataact 4920 ttttactctt caagttaggg taaattctga tccaatattc aattcatttg tgtactccca 4980 catgcaaaat gctaaattac aatgcagaca ttaagaaaaa gtattgactg gaggggttga 5040 attccttgag aatttatttt atagtctaaa tcacaaatac tttactcaat ttagttttta 5100 aaatagtaaa ctgaatattt ttgttgtaag cctatcagag tcaatccttc gtttggaatt 5160 gttttcctgt ttttccttac tataaatcat ttaaaaactg aattcatttt cttagatggc 5220 ataagtctgt ctcttgagaa ataagtaaaa tactcctatt ttcagtatct gtagcacctg 5280 aaataggtct ttgtatagcc agaaacaagt tatgttgaag ttagcttttc tttgtcaaca 5340 gttttggaca ataaaaatct gaaagtatta acacttgatt ttctactggg gcccttcaaa 5400 cttggttgga agaaattcaa ccagaatatc tacattagag tataatcatg tgtggtagga 5460 agatggacta gttaatcaag atttgttgtc acttaaattt tttgtgattt ttttccaagc 5520 cagttttttt aaattctaaa tgtgttttga ggtatgggta cattaattgt aatgtaaact 5580 attatacaac tgtttttgcg actttatagg caggtaaatt ttgctattac tattgaatac 5640 aaatgacaat tcatttatga ccactcaaac agcgttagta accatttagt gacaaaggat 5700 taaaacatcc atctggatgt taattttgaa gatgtaaatt atatgttgtt taaatttttc 5760 caggcatctg aaaaccttat ctgctagaca atgtaagatt cacacagagt tatctgggat 5820 tctgattttt taaatagtac atatcattaa accattttct ctaaatgtaa gaagagcaga 5880 aaaaatctta taagattatc agatttttct aatgacacag aaatgtaaga aaaaaatccc 5940 tttatattga aaaaagatgc agtcaaagtc ttttcagaca tgcccaaact ttgagaattt 6000 cttcaaccat ctaatgctat aaagattttt gttcttcctg ttcacaacca gttgtataac 6060 agaaatacta gctactgttt tccttcctgt gtgtgaagta atgaatcatt gattatgtga 6120 cttgttatgt attcaattaa acactaaaga ataaaacatt cactccttta attatt 6176 59 1944 DNA Homo sapiens misc_feature Incyte ID No 7238537CB1 59 ggggggtgtg ggatggccgc ggagccgggc ggagctggct tgcggctccc ggggccggct 60 ctccggccgg agacatggcc cgggggcccg gcccgctagg caggcctcgc cccgatacgg 120 tcgccatgcc caagagagga aagcgactca agttccgggc ccacgacgcc tgctccggcc 180 gagtgaccgt ggcggattac gccaactcgg atccggcggt cgtgaggtct ggacgagtca 240 agaaagccgt agccaacgct gttcagcagg aagtaaaatc tctttgtggc ttggaagcct 300 ctcaggttcc tgcagaggaa gctctttctg gggctggtga gccctgtgac atcatcgaca 360 gcagtgatga gatggatgcc caggaggaaa gcatccatga gagaactgtc tccagaaaaa 420 agaaaagcaa gagacacaaa gaagaactgg acggggctgg aggagaagag tatcccatgg 480 atatttggct attgctggcc tcctatatcc gtcctgagga cattgtgaat ttttccctga 540 tttgtaagaa tgcctggact gtcacttgca ctgctgcctt ttggaccagg ttgtaccgaa 600 ggcactacac gctggatgct tccctgcctt tgcgtctgcg accagagtca atggagaagc 660 tgcgctgtct ccgggcttgt gtgatccgat ctctgtacca tatgtatgag ccatttgctg 720 ctcgaatctc caagaatcca gccattccag aaagcacccc cagcacatta aagaattcca 780 aatgcttact tttctggtgc agaaagattg ttgggaacag acaggaacca atgtgggaat 840 tcaacttcaa gttcaaaaaa cagtccccta ggttaaagag caagtgtaca ggaggattgc 900 agcctcccgt tcagtacgaa gatgttcata ccaatccaga ccaggactgc tgcctactgc 960 aggtcaccac cctcaatttc atctttattc cgattgtcat gggaatgata tttactctgt 1020 ttactatcaa tgtgagcacg gacatgcggc atcatcgagt gagactggtg ttccaagatt 1080 cccctgtcca tggtggtcgg aaactgcgca gtgaacaggg tgtgcaagtc atcctggacc 1140 cagtgcacag cgttcggctc tttgactggt ggcatcctca gtacccattc tccctgagag 1200 cgtagttact gcttcccatc ccttgggggc agcctcgagt gtagtccatt agtaatcaga 1260 ttccagtttg gacagggtgg ctggattgta tatctcgtta gtaatgtaca tgctcttcag 1320 gttctagggc tcctgttagg ggagggagaa atgttgaatc aagagggaaa acaactacta 1380 tgatttataa acatatttta atgtaaaaat ttgcatttaa aaggagtggc cctgttttct 1440 gtgttaaaac cccatttggt gctattgagt ttgttcttta ttcttttatc ccagtgaaaa 1500 ttgttgatct tgctgtaggg aaaaattaaa ctctttgaat ctccaaacaa ggaagtttca 1560 gcattccctt atggatcaga ggaaccttag aggcctgaaa ttgttgcttc cagtttagct 1620 gcccctcaaa ttcaagtgaa tattttccct tctcccttta cccttctcca gaaataaagc 1680 aggtgacagg gttttcagaa tcttaccata ttgacttgtg tatctttttt aaaaaataat 1740 ttgtgatatt tattgcatac attttctttt ggcagttttg gattttaggt atttttttgc 1800 atgaggctga taatggtgat gatgacttta tacccttggt actatactag gaactttaca 1860 tagtatctct acttctcaca gtcttgcaaa gtaggtgata tttattccca ttttatagtt 1920 tgagaaaacg gaattaggtg actg 1944 60 1992 DNA Homo sapiens misc_feature Incyte ID No 7494391CB1 60 gggcggacag cgatgctcag ctggctgcgg ccgagtcatc gcctagcgct ggcagggccg 60 ctgaccgacc gacggaggcg ccgatggccg attgtccact gcgcagaagg agcagctgct 120 ccgcgccccg ccgcgccgcg ctgaggccga ggtccgcagg gccgcgggga agccgagggc 180 tgccggagaa ccctgcaggt gtcactcggg acgcggaagt gcgcttgccg agaatacagc 240 tacctaccca ggcaatatga agattttatt tgtagaacct gccattttcc ttagtgcatt 300 tgctatgact ttgaccggtc cactgacaac gcaatatgtt tatcggagaa tatgggaaga 360 aactggcaac tacacttttt catctgatag caatatttct gagtgtgaaa aaaacaaaag 420 cagcccaatt tttgcattcc aggaggaagt tcagaaaaaa gtgtcacgtt ttaatctgca 480 gatggacata agtggattaa ttcctggtct agtgtctaca ttcatacttt tgtctattag 540 tgatcactac ggacgaaaat tccctatgat tttgtcttcc gttggtgctc ttgcaaccag 600 cgtttggctc tgtttgcttt gctattttgc ctttccattc cagcttttga ttgcatctac 660 cttcattggt gcattttgtg gcaattatac cacattttgg ggagcttgct ttgcctatat 720 agttgatcag tgtaaagaac acaaacaaaa aacaattcga atagctatca ttgactttct 780 acttggactt gttactggac taacaggact gtcatctggc tattttatta gagagctagg 840 ttttgagtgg tcgtttctaa ttattgctgt gtctcttgct gttaatttga tctatatttt 900 attttttctc ggagatccag tgaaagagtg ttcatctcag aatgttacta tgtcatgtag 960 tgaaggcttc aaaaacctat tttaccgaac ttacatgctt tttaagaatg cttctggtaa 1020 gagacgattt ttgctctgtt tgttactttt tacagtaatc acttattttt ttgtggtaat 1080 tggcattgcc ccaattttta tcctttatga attggattca ccactctgct ggaatgaagt 1140 ttttataggt tatggatcag ctttgggtag tgcctctttt ttgactagtt tcctaggaat 1200 atggcttttt tcttattgta tggaagatat tcatatggcc ttcattggga tttttaccac 1260 gatgacagga atggctatga ccgcgtttgc cagtacaaca ctgatgatgt ttttagccag 1320 ggtgccgttc cttttcacta ttgtgccatt ctctgttcta cggtccatgt tgtcaaaagt 1380 ggttcgttcg actgaacaag gtaccctgtt tgcttgtatt gctttcttag aaacacttgg 1440 aggagtcact gcagtttcta cttttaatgg aatttactca gccactgttg cttggtaccc 1500 tggcttcact ttcctgctgt ctgctggtct gttactactt ccagccatca gtctatgtgt 1560 tgtcaagtgt accagctgga atgagggaag ctatgaactt cttatacaag aagaatccag 1620 tgaagatgct tcagacaggt gactgtgatt taaacaaaca aaaaaaatct atgaatgcac 1680 atatcatata ccatgacttc tgaagactat aaatgaattc cacaatcagt gcttcactga 1740 gaaccaattt tacctatctt ttcttctaaa ctgaacagtc agagagacag ctcctggctt 1800 tagcttcttg tggtaccacg cactttgagc actttgtgcg tatcatgcaa tatacttgca 1860 atacacagaa caatttcaaa tacgcctcac ttttagactt agaagagaaa cattaaaact 1920 taagggtgta aggagggatc aagaacttga taaggtcaaa cnatatctct ccttacagcc 1980 aggcaaatca tc 1992 61 3906 DNA Homo sapiens misc_feature Incyte ID No 6451054CB1 61 aagcccttgc ctgccaggga actagtatgt cctgtggggg gggagatttt ccctggtgtc 60 tcagggccac agagattgaa caatgggccc gagtcacact gcaagtcagc agcaaaggca 120 gcagtctaaa tgagccccca aaaagaggag gtacccatgt tctagaaagg tgagccaagg 180 agccccgggg tggcggcagc ggagtaggag gcgaggcaag acctgcggct cggcccggcc 240 acagccgcgg tagtgctagg caagcccacg gagtcacgcc ggcctcagcc agtctgcgaa 300 cctctcgccc ccgcccaccc ctgcatccgc ccggcccctg cccgcccgag tggtccgggg 360 aggcctagtc tgcaccaccc gccgggctcc tggggccgcg cccgcgcggt cctgtcggcg 420 tccgcggtcg cgcccggccc ctggcccgct cgcccgccgg caccatgatg gaggagatcg 480 accggttcca ggtgcccacc gcgcactcgg agatgcagcc gctggaccca gccgccgcct 540 ccatctctga cggagactgt gacgcccggg aggagaagca gcgggagctg gcccggaagg 600 gctccctgaa gaatggcagc atgggtagcc ctgtcaacca gcaacccaag aagaacaatg 660 tcatggcccg aacaaggctg gtcgtcccca ataaaggcta ctcctcactt gaccagagcc 720 ctgatgagaa gccactggta gcccttgaca cggacagcga tgatgacttt gacatgtcta 780 gatactcctc ctccggctac tcctctgctg agcagatcaa ccaagatttg aacatccagc 840 tgctgaagga cggctaccgg ttagatgaga tccccgacga cgaggaccta gacctcatcc 900 cccccaagtc cgtgaacccc acgtgcatgt gctgccaggc cacgtcctcc accgcctgcc 960 acattcagta gcgggcgggg ccactgcggt cgccggggcg gggccgccaa gggccgggta 1020 ggacgggcag aggccgaccc cttcccagct cgtctgcctg cccccggccc cgcgccccta 1080 cagccgccaa cctcgtataa cagtcattgc ttcctcctat ggtaggacgt gtacctctgt 1140 gtgttcatgg agctggagaa accaaaactg ggtctctctc cacccgggag ctgaggaggg 1200 gtgggggccg tttgttcagt tacctggggg aacctcaccc agcaccctgc cccgcttccc 1260 agggctggcc aagagagaag actggacggc agggaggtca acattaacga gtggggggat 1320 cacaaagcca ggggcttggc cccaccccag cgaagccatg aactcccaag ccccggcctc 1380 agcctaacca ggaaaggggc tcggagggag aaaggcccag ggcagtgggg acgggtccca 1440 gcacctcgga gcccccttca cacgccccct accggcccat gtttctattt gcatttcccc 1500 ctcctcagat gggaagcctg gcaaagctgc ccaaccgggt agtgcccctc acccatcgga 1560 tcactgcctt cttcctcctc ttgccccatt cacccgcttc cttgcactct gggagtgggg 1620 cagggtaagg tgggccttac agacaggctg aggtttgggt ggtgtgatct gtcctaattg 1680 gcccctcacc aatgcatcta tctgtctgcc accagcccac cccaccctgc ccccaccctc 1740 acccacgctt ctgctcattg gtctcaatcc cagcctggaa gcagggagta aggctggact 1800 ccaatggccc attcccctca ccccagccca agacgtggga ggctgcttcc cagtaagaat 1860 ccaggagcaa gctttggtga atccagtggg ctgagtggct ctatggatgt ggttgtttgg 1920 atgtggtagg gagtgcttag cagaatgtgt gtgtatctct gaggctgtca gggggtgggt 1980 gggtgtgtgt ctctgttgga cctgtctctc ctcagtctat tcctgtcata gatgtgggtg 2040 tccctggtag ggaagtgcct gtgtggtctg tttacagtgc agaaggcggc tcagcagtgc 2100 aatgggctga cagccttgga ccgggagtca gaagcctggg ttctggttgt agctctggcc 2160 cctccctgtg atcttcaaca agccacttgc tttctctcgt cttcagtttc ctcaactaga 2220 aaatgaacag cagctgaaat tatgttgaag atccttttat acctgaaaga gtttcttcat 2280 agaaatttct gtggtgggga gggggcaatc tctgtgtgtc tcagtatacc taaaggttgg 2340 ggtggggcgg agttgtgtgt ctctgtagaa aggcgaaggg gcagttccta tcaggactgt 2400 gtatgtctga gcacatgtgg ctctgtttgg gattacgtgt ttgtctgtga atgtgtgtgt 2460 gtgttggagg gttgtctatt gtgtgtggct gtatagggtg tctgtagatc aagatgtgta 2520 tacagctgct tctgctattg ctggtttggg ggaggggact ggaaagctga gactgaaaat 2580 caagagggaa gaggtgagga aggcccaccc ctggggctgg gcagtgtaga cctgccaccg 2640 tgtgaagaaa aatgaaagca cagatagcct aagactgcac aggcctgtgc ccacatacct 2700 tatagcacag gcccaggtgg atcatctcat gctaacaccc cacatgtgct ggtggatcca 2760 ctcccatgga tccactcaca tgctgcaggc atgcagtaga ctcacccaca gcccactctc 2820 tggacaccaa tcctgggagg tgggagctgg aatggggagc aatgagagga gggagtgaga 2880 ctgttggctt aggaagggtg gtacctctcc ctgcatcata cccaggaact tccagctcca 2940 aaatattggg gtacagctca ccacccccca ctccgccaac ccattcctac ctcctctagt 3000 gcagggaccc aagttagatg atgagaaaat gccaaacaaa gggaggcaag gacagagaag 3060 gtacctgcag gacccacaag gcccatactg gcccccatct gaacccacct ctcccaccca 3120 gatcaacatc cccccaaccc ctgtgccccc atcatctgga ccccagagcc agccctccca 3180 ctaccaccac caccaccccg gggctccttg gctcaccttt ctagaacatg ggtacctcct 3240 ctttttgggg gctcatttag actgctgcct ttgctgctga cttgcagtgt gactcgggcc 3300 cattgttcaa tctctgtggc cctgagacac cagggaaaat ctcccccccc cacaggacat 3360 actagttccc tggcaggcaa gggcttccaa ctgaggcagt gcatgtgtgg cagagagagg 3420 caggaagctg gcagtggcag cttctgtgtc tagggagggg tgtggctccc tccttccctg 3480 tctgggaggt tggagggaag aatctaggcc ttagcttgcc ctcctgccac ccttcccctt 3540 gtagatactg ccttaacact ccctcctctc tcagctgtgg ctgccaccca gccaggtttc 3600 tccgtgctca ctaatttatt tccaggaagg tgtgtggaag acatgagccg tgtataatat 3660 tttttttaac attttcattg cagtattgac catcatcctt ggttgtgtat cgtgtaacac 3720 aaataatgat attaaaagca tcaaacaaaa aaaaaataaa tggtgctgac gcctctggct 3780 tgcgccagga cttggcgtgg gcaccgggcg cccccatccc agtgtctgtg tgcgtccagc 3840 tgtgttgcac aggcctgggc tccccactga gtgccaaggg tcccctgagc atgcttttct 3900 gaagaa 3906 62 3236 DNA Homo sapiens misc_feature Incyte ID No 7494592CB1 62 gccggacggc tgacagagcg gctgacggag ccgggctcac caggtcgctg ccgcgaggga 60 gttgctgtgc tggggcctgg gtggcggctg gaggcctgag ttgggctcgc ggcgggggtc 120 gcgcaggggg cctgggtggc ggaatgatgg aggaggagga actggagttc gtggaggagc 180 tggaagccgt gctgcagctc acgcccgagg tgcagctggc catcgagcag gtgtttccaa 240 gccaggaccc tctagatcga gcagatttca atgctgttga gtatatcaat accctgttcc 300 caaccgagca atctctggcg aacatagacg aagtcgtgaa caaaattagg ctgaaaataa 360 ggagactgga tgacaatatt cgaactgttg taagaggtca gacgaacgtg gggcaggatg 420 gacggcaagc gcttgaagag gctcagaaag ctatccaaca actctttggc aaaatcaaag 480 atatcaaaga caaagctgaa aaatcagagc aaatggtgaa agaaatcacc cgtgatatta 540 agcaattaga tcacgccaaa cgccacctga ccacctcaat caccacactg aaccacctgc 600 acatgctggc aggaggtgtc gactccctcg aagccatgac caggcgaaga caatacggag 660 aagttgctaa tctccttcag ggtgtgatga atgtcctgga gcacttccac aagtatatgg 720 ggattccgca gatccggcag ctttccgaaa gagtgaaggc tgcacagact gagttaggac 780 agcaaatcct ggcagatttt gaagaagcgt ttccttccca gggcaccaag agaccaggag 840 gacccagcaa tgttctacga gatgcatgtc tggttgctaa tattctagat cccaggatca 900 aacaggaaat catcaaaaag tttattaaac agcatctgtc agagtatctg gtactttttc 960 aagaaaacca agatgttgcc tggctggaca aaatcgacag acgctatgcc tggataaaac 1020 gccagcttgt ggactatgag gagaaatacg gccgcatgtt tccacgtgag tggtgcatgg 1080 ctgagaggat tgcggtggaa ttttgccatg tgacaagggc agaacttgcc aagattatgc 1140 gtaccagagc gaaggaaatt gaagtgaaat tgcttctttt tgctattcaa agaacaacta 1200 actttgaggg gtttcttgca aaacgcttct ccggctgcac cctgaccgat gggaccctga 1260 aaaagcttga gtctccaccc ccatctacca atcccttcct ggaagatgag ccaacaccag 1320 agatggagga actggcaacg gagaaaggag atttagatca accaaagaag cctaaagccc 1380 cagacaatcc atttcatggc attgtttcca agtgttttga gcctcatctc tacgtgtata 1440 tcgaatccca agacaagaac ctcggagagc tgatagatcg gtttgtggct gatttcaaag 1500 cccaggggcc acctaagccc aacactgatg aagggggtgc cgtgctcccc agctgcgccg 1560 acctctttgt ctactacaag aagtgcatgg tgcaatgctc tcagctcagt actggggagc 1620 ccatgatcgc cctgaccacc attttccaga agtacctccg agaatacgcc tggaaaatcc 1680 tctctggcaa cctgcccaaa accacaacca gcagtggagg actgactatc agcagcctcc 1740 tcaaggaaaa ggagggctca gaagtagcca agttcactct ggaggagctc tgcctcatct 1800 gtaacatcct gagcacggca gagtactgtc tggccaccac ccagcagcta gaagaaaaac 1860 tcaaagaaaa agtggatgta agtctgattg aacgaatcaa tctgactgga gagatggaca 1920 cgttcagcac cgtcatctcc agcagtattc agctgctggt tcaggatctg gatgctgcct 1980 gtgatcctgc cctgactgcc atgagcaaga tgcagtggca gaacgtggag cacgttggtg 2040 accagagccc ctacgtcacc tctgtcattc tgcacatcaa gcagaacgtc cccatcatcc 2100 gtgacaacct ggcttccaca cgcaagtact tcactcagtt ctgcgttaaa tttgcaaact 2160 ccttcattcc caaattcatc acccacctct tcaagtgcaa gccaattagc atggtgggag 2220 cagaacagct gctgctggac acccactcgc tgaagatggt cctgctcgat ctcccctcca 2280 tcagctcgca ggtggtgagg aaggcacccg ccagctacac caagatcgtt gtcaaaggca 2340 tgacccgggc tgagatgatc ctcaaggtag tgatggcccc tcatgaaccg ttggtggtgt 2400 ttgttgacaa ctacatcaaa cttctcacag actgcaacac agaaaccttt cagaagatac 2460 tggacatgaa ggggctgaag aggagtgagc agagcagcat gctggaactc ctgcgccagc 2520 ggctccccgc accgccctcg ggggcagaaa gctccggctc actgtccctg acggcgccaa 2580 caccagagca agagtcgtca cgcatccgca agctcgagaa actcattaaa aagagactgt 2640 agcagcagca aggggccctt tgctcctggc tggagaccct cagcgcccgt tccccagaag 2700 cccccaacct ctcctgtgct ccccggcact ctcacatcgt cggtcttcaa acttcctggg 2760 acatgtgggt tgttactgag tctctcccat gccctgtctt acttcctgcc ctaatcggag 2820 acgctgagta agggctgggc tctaagaggg cgatttaggt gatctctggt tcgtgaagca 2880 gaggcagcag tggaggagtt tgagaccagt ctgggcaacc tggcaaaacc aaaaatacaa 2940 aaaattggct gggtgtggtg gctcatgcct gtaatcacag cactttggga ggctgaggca 3000 ggtggatcac ctgaggtcag gaattcgaga ccagcttgcc caacatggcg aaaccctgtc 3060 tcaactaaaa ataaaaaaat ttacccgggg tcaatgcgaa tgcctgtatt cccagtactg 3120 ggaagctaag gaagggattc acttgaaccc gggagttgaa ggttaattaa ccaagtttca 3180 ccaatgaatt caacctggtg aaaagcaaac ctctntcaaa agtttacggt taggga 3236 63 1906 DNA Homo sapiens misc_feature Incyte ID No 5202657CB1 63 cggaagccgg ggccggggct gcggggcgag ttgtcggccc tgggccggga gctggagtcc 60 cagactcata ggtcccggcc cagcccccga agagccgcct cagccggggg gagttgctcg 120 gactcaaacg tccagtcctc gtgcgaccgc gctgggtcgg aagtgagcag gctgaggcca 180 ccatggagca gtgtgcgtgc gtggagagag agctggacaa ggtcctgcag aagttcctga 240 cctacgggca gcactgtgag cggagcctgg aggagctgct gcactacgtg ggccagctgc 300 gggctgagct ggccagcgca gccctccagg ggacccctct ctcagccacc ctctctctgg 360 tgatgtcaca gtgctgccgg aagatcaaag atacggtgca gaaactggct tcggaccata 420 aggacattca cagcagtgta tcccgagtgg gcaaagccat tgacaggaac ttcgactctg 480 agatctgtgg tgttgtgtca gatgcggtgt gggacgcgcg ggaacagcag cagcagatcc 540 tgcagatggc catcgtggaa cacctgtatc agcagggcat gctcagcgtg gccgaggagc 600 tgtgccagga atcaacgctg aatgtggact tggatttcaa gcagcctttc ctagagttga 660 atcgaatcct ggaagccctg cacgaacaag acctgggtcc tgcgttggaa tgggccgtct 720 cccacaggca gcgcctgctg gaactcaaca gctccctgga gttcaagctg caccgactgc 780 acttcatccg cctcttggca ggaggccccg cgaagcagct ggaggccctc agctatgctc 840 ggcacttcca gccctttgct cggctgcacc agcgggagat ccaggtgatg atgggcagcc 900 tggtgtacct gcggctgggc ttggagaagt caccctactg ccacctgctg gacagcagcc 960 actgggcaga gatctgtgag acctttaccc gggacgcctg ttccctgctg gggctttctg 1020 tggagtcccc ccttagcgtc agctttgcct ctggctgtgt ggcgctgcct gtgttgatga 1080 acatcaaggc tgtgattgag cagcggcagt gcactggggt ctggaatcac aaggacgagt 1140 taccgattga gattgaacta ggcatgaagt gctggtacca ctccgtgttc gcttgcccca 1200 tcctccgcca gcagacgtca gattccaacc ctcccatcaa gctcatctgt ggccatgtta 1260 tctcccgaga tgcactcaat aagctcatta atggaggaaa gctgaagtgt ccctactgtc 1320 ccatggagca gaacccggca gatgggaaac gcatcatatt ctgattccta cctggaagga 1380 attttgttga aaggggtttt cacctgtgag ccttggtctg tctcggtagg gtggtcaact 1440 tcagtggact gtggttggtt tcagagcgcc tggctgagga gttccactga ggggagcact 1500 ggagcagccc tttggcagag gctgaggagg gagatggacc agcccacgcc tggcacctgg 1560 ctccatggca taaggaaagg gagatgctgg cctctgtgct cctgctgtct tttcctgttt 1620 ctgtttgcgt ttgacttagt agcaaccgac agagtggcaa gggatttggt cttcagcagt 1680 agacatcctt ccacccctgc cctcagccaa gtctcttgct gccatgccaa tgctatgtcc 1740 acccttgccc ctcggcccaa gagtgtccag cggtggccca cctcttcctc ccactacagc 1800 ctcaacagta tgtaccatct cccactgtaa atagtcccag ttagaacgga atgccgttgt 1860 tttataactt tgaacaaatg tatttactgc ccttctcaaa aaaaaa 1906 64 1347 DNA Homo sapiens misc_feature Incyte ID No 2013529CB1 64 gcccgggcgc aggcggcgga tggagcggaa cggctagggg tcttgagaag caatggccac 60 agaagcccct gtgaatatag caccacctga gtgtagcact gttgtcagca cagcagttga 120 cagcctcatt tggcagccaa actcactaaa tatgcacatg ataaggccca agtccgccaa 180 gggacggaca agaccgagtc tgcagaaatc ccagggcgtg gaggtgtgcg ctcatcatat 240 accatctccg cctccagcca ttccctatga gttgccaagc agccaaaaac caggagcctg 300 tgcacccaaa tctccaaacc agggagcttc tgatgagatc cctgagctgc agcagcaagt 360 acccactggg gcttcctctt ctctcaataa gtatccagtc cttccttcca tcaacagaaa 420 gaacctggag gaggaggctg tggaaaccgt tgccaaaaag gccagctcac tgcaactgag 480 cagtatccgg gctctttacc aagacgagac gggcaccatg aagacaagtg aagaagattc 540 cagagctcga gcttgtgccg tggagaggaa attcatcgtc cgaaccaaga aacagggctc 600 ttccagggct ggaaatctgg aggaaccatc ggaccaagaa ccaaggttgc tgcttgctgt 660 tagatcacca acaggccaaa ggtttgtacg ccatttccgg ccaacagatg atttgcaaac 720 cattgttgct gtggccgaac agaaaaacaa aacctcctac cgacactgca gcattgaaac 780 aatggaggtg cccaggaggc gattttctga cctcaccaaa tctctgcaag agtgcagaat 840 cccccacaag tctgtgctgg gcatctcact ggaagatggg gaagggtggc cctgagtcca 900 cagccaccca gctgaggtcc tgggtctctg agcaaaggag catgcttggg cgttgtggcc 960 tcttaggcag cctgtttcaa gtgccatgtg gacctggtgc agctgggaag cttgggactc 1020 tcgtctgcac tgcgtgtcct ctgaagcagt gaagtctgtg cctatgccga gcgcgctaag 1080 aagtctccct tccagctgtt ccattctctc caccaccagc gtaactggca agttaccaag 1140 gttgttcctg aaacagcagt gatcatgact tctcctttcc agagttttgg gtccttctga 1200 attaatggtc cttttcgaac accggcttgc ctttacagtg aactgtgatt ctctcgaagc 1260 caatgctttc ctgtctgtat ttgatgcagg attaaacact tcccagagag gattctagtc 1320 tggtaaataa ccaccaaaaa aaaaaaa 1347 65 1854 DNA Homo sapiens misc_feature Incyte ID No 3841351CB1 65 gcagagcgag tcgggaaacg attttaaact gaagaggcgg cggagggccg aattcccttt 60 tctcaacggc ttgatttcag agctgggctg gtctctgaca ggctcagctg gagagggacg 120 ggttgggacg cactgtcctt ttgcccttcc ccctccgcga gcagaagctg actccgcagg 180 agcgagggtc gcagagctgg gggatttcag tctccacata gttttggagc cggacttttg 240 aagaatgatt cgtgaatccg gaatgggtga cagcgtcatc acggcatttt attgacagac 300 catggattct tacagtgcac cagagtcaac tcctagtgca tcctcaagac ctgaagatta 360 ctttataggt gccactcctc tgcagaaacg attagaatcg gtcaggaagc agagttcatt 420 tatcctgact ccacctcgaa ggaaaattcc ccagtgttcg cagttgcagg aagatgttga 480 ccctcaaaag gttgcattcc ttctgcataa acagtggact ttatatagtt taactccctt 540 atataaattc tcctatagta atctcaaaga gtattctaga cttctcaatg cttttattgt 600 tgctgaaaag caaaaaggac ttgctgtgga agtgggagaa gacttcaaca tcaaagtgat 660 tttttctact ctcctaggaa tgaaaggaac acaaagggac ccggaagcat ttcttgtcca 720 gattgtgtca aaatctcaat tgccatctga gaatagagaa ggtaaagtgc tgtggactgg 780 ctggttctgc tgtgtatttg gagacagtct tctggagact gtttcagaag atttcacctg 840 tctgccctta ttccttgcaa atggagcaga gtctaacaca gcaataattg gaacttggtt 900 tcagaaaacc tttgactgtt atttcagtcc tttagcaatc aatgcattta atctttcctg 960 gatggctgcc atgtggactg catgcaaaat ggaccattat gtggctacta ctgaatttct 1020 ttggtctgta ccctgtagcc ctcaaagtct ggacatttct ttcgcaatac atccagagga 1080 tgcaaaagct ctatgggaca gtgtccacaa aacacctggg gaggttaccc aggaagaagt 1140 tgacctattc atggattgcc tttattcaca tttccataga catttcaaaa ttcatttatc 1200 agccacaaga ttagttcgtg tttcaacatc tgtagcttca gcacatactg atggaaaaat 1260 aaagattctg tgtcataaat accttattgg agtgttagca tatttgacag aactggcaat 1320 ttttcaaatt gagtgaagcc ttatgtggac tataagttat agattatata ctcttattga 1380 taacttgcct aattgctatg ctgaaagaga ctgcaggaga aataggcatc tatctctgca 1440 tctgttttcc ccaccatgcc tttggagttg ccaagatgga agccaagaag gatctagaag 1500 aacaaagaat atggtagtag atgagccaca gccaggtgcc catgtactaa tcatgataac 1560 ctgacatgcc attctcaaaa tgctgagttg ttaatttctt gtcatcttta aatatatata 1620 tataggctgg gcttggtggc tcacacctgt aattccagca ctttgggagg ctgaggtggg 1680 tggatcattt gaggccagga attcaagacc agcctggcca acatggtgaa accccttctc 1740 tactgaaaat acaataatta gctgggcgtg gtggcacatg cctatgatcc cagctactgg 1800 ggaggctgag gcaggagaat cgttttaacc cagaagacag gctgcagtga gcca 1854 66 1327 DNA Homo sapiens misc_feature Incyte ID No 152116CB1 66 tgcctcctct ggctgctgcc tccgcagctc cctcctccta ccccacctcc tccatctggg 60 gagcgtctgc gggggcctga ggggcggcgg cggcggcggc ggctgcgata tggagccagg 120 ggccggcggc cgaaatactg ctcgtgcgca gagggccggg tccccgaaca ctccgccgcc 180 ccgggagcag gagcggaaac tggagcagga gaagctctcc ggtgtggtga agagcgtcca 240 ccggcggctc cgcaagaagt accgagaagt gggagatttt gataagatct ggcgagaaca 300 ctgtgaggat gaagaaactc tttgtgaata tgccgttgca atgaaaaatt tggcagataa 360 tcattgggca aaaacttgtg agggcgaagg tcgtattgaa tggtgttgta gtgtatgcag 420 agaatatttc caaaatggtg ggaagagaaa agcacttgag aaagatgaaa aaagagctgt 480 acttgccact aagaccactc cagccttaaa tatgcatgag tcttctcaac ttgaaggtca 540 tttaaccaac ctcagcttta caaaccctga atttataact gagttgctac aagcctcagg 600 aaaaatcaga ttacttgatg ttggcagctg ctttaaccca tttctgaagt ttgaagaatt 660 tctaactgtt ggcatagata ttgtacctgc tgtagagagt gtctataaat gtgatttcct 720 gaacttacag cttcagcaac cactccagct tgcacaggat gctatagatg cttttttgaa 780 gcagctgaaa aaccctattg attctcttcc tggagagctt ttccatgtgg ttgttttctc 840 tctccttctt tcttattttc catctcctta ccagcgatgg atttgctgca agaaagccca 900 tgaactgtta gtgttaaatg gtttattact aatcatcaca cctgattcct cccatcagaa 960 ccgtcatgct atgatgatga aaagctggaa gattgctata gagtccctgg gctttaaacg 1020 cttcaagtac tcaaaatttt cacatatgca tctgatggca tttaggaaaa tctctctaaa 1080 aaccacaagt gacttggtta gtaggaacta cccaggaatg ttatatattc ctcaagattt 1140 caacagtata gaagatgagg aatattctaa cccttcctgc tatgttcgat cagatataga 1200 agatgaacaa ctagcatatg gtttcacaga actccctgat gcgccatatg actcagattc 1260 tggagaaagt caagccagct ctattccttt ctatgagcta gaagacccca tattactttt 1320 aagttaa 1327 67 627 DNA Homo sapiens misc_feature Incyte ID No 2381031CB1 67 atccgggcct gagagtgcag gcttgaggga agcatggagg tccatggcaa gcccaaggct 60 agcccgagtt gttcgtcgcc cacccgggat tcctcaggag tcccagtgtc caaggagctg 120 ctgacggcgg gaagcgacgg ccgcggaggt atatgggaca ggttgctcat caactcccaa 180 cctaagtcca gaaagacctc cactcttcaa acagttcgga tagagaggag tcccttattg 240 gaccaggtac agacatttct cccacagatg gcacgggcaa atgaaaagct aagaaaagaa 300 atggcagctg caccacctgg tcgtttcaat attgaaaaca ttgatgggcc tcatagtaaa 360 gttatacaaa tggatgtggc tttgtttgag atgaatcagt cggattcaaa agaagtggac 420 agttcagaag agagttcaca agacagttca gagaacagtt cagaatcaga agacgaagat 480 gacagcatcc catctgaagt caccatagat aacattaagc ttcccaattc tgaaggtgga 540 aaaggcaaga ttgaagtttt ggacagtcca gcaagtaaaa aaaagaaata gtcaaataaa 600 ttatctgaaa agaaaaaaaa aaaaaaa 627 68 2564 DNA Homo sapiens misc_feature Incyte ID No 2511371CB1 68 gcacgctgac tttgctctca ctgcccggcc agacgcactt cccgccttcg cctaggtctg 60 caccgccacc gccgccctct cccgcgcgtc cctcacccgg tccgccactg ccgcgcctca 120 gaatccgaag gctcggttcc agcgcagcca tccacgccgc cgccacgacc gactccggag 180 ccacgcgctg caaccgccac caacgccttg ccgccgccgc tcgcccgccg accaccatgg 240 cccagcagca aacaggtagc aggaaacgga aagcgcccgc ggtcgaggcg gacgccgaga 300 gctcgccgtc gcagggcttg gcggcagcgg acggtgaggg gccgctgcta ctcaagaggc 360 agaggcggcc ggcgacgtat cgctcgatgg cgcactatct gaaggttcgg gaggtaggcg 420 ggtggggccc cgccaggctc cagggcttcg atggcgagct gcggggctac gcggtacaga 480 ggctgcccga gctgctgacg gagcgccaac tggagctggg cacggtcaac aaggtgttcg 540 cgtcacagtg gctgaactcc aggcaggtgg tgtgcggcac caagtgtaac acgcttttcg 600 tggtggacgt ggagtcaggc cacatcgcgc gcattcccct cttgcgggac agtgaggcca 660 ggctggccca ggaccaacag ggctgcggca tccatgccat cgagctgaat ccctccaaga 720 cgcttctggc caccggcggc gaaaacccca acagcctggc catctaccag ctgccctccc 780 tggatcccct gtgcctgggc gaccgccatg gccacaagga ctggatcttc gccgtcgcct 840 ggctgagtga caccgtagcc gtgagcggct cccgcgacgg cactgtggcg ctgtggcgga 900 tggacccgga caagttcgat gacactgttg cctggcatag cgaggtgggt ctccccgtat 960 atgcccacat ccgtccgagg gatgtggagg ccatccccag ggccatcatc aaccccagta 1020 accgcaaggt gcgggccctg gcctgcggcg gcaagaacca ggaactggga gcggtgtcct 1080 tggacggcta cttccacctg tggaaagccg ggagcgcact atccaggctg ctgtccatca 1140 ggctgcccta cttccgggat aatgtgtgcc tgacctactg tgatgatatg tctgtgtacg 1200 ccgtgggctc ccattcccac gtctctttcc tggatctgcg ccaggaccag cagaacatcc 1260 ggcccctgtg ttctcgagag ggtggcacag gcgtgcggtc gctgagcttc taccgccaca 1320 tcatcactgt gggcaccggt cagggctccc tgctcttcta tgacgtccgg gcccagaaat 1380 tcctggagga aagagcctcc gccaccctgg agtcctcttc gggacctgca aggaggaagc 1440 tcaggcttgc ctgtggcaga ggctggctca accacaatga tttctgggtg aattactttg 1500 gtggcatgga agtgtttccc aatgcgctct acacccactg ctacaactgg cctgagatga 1560 agctctttgt ggctgggggg cctctccctg caggcctcca tgggaactat gcaggcctct 1620 ggagctaagg atgaccgcct tgtactccag gtggaaccag cccagcttaa tttgtactcc 1680 tccaagcaga gagagtgagt ggtcctttgg tcaatgaaaa cttggcttta agactttttg 1740 actcctttcc aacaccatct tttggaattt tcatacaaag aaatttggtt aatcgttaat 1800 ctttagttgc attctctctt tgagtgattc atacattctg tttctttaag aagatgcagt 1860 catggtcttt cagttatgta tatttgtttt ccttgttttt cctcgttacc aatattacaa 1920 cagcattgtt ttcagttatt tttcattgca gatacgaaga gaaaattttc tagtaagcaa 1980 ggtgttccta catcttttct ggagagctta ccatagtttt atagcattgt tcaattggaa 2040 aagtacattc caagttctag attacctacg tttggaaaca cttaatttac aaattgtgat 2100 cttagtgtat atagttttta cgttgttggt gctaaagtgc ttttttgaag tttattctct 2160 ttcaaaataa gttatcatag aatcttgtgc ttgtatcaaa ctcctaattg gtcggaacac 2220 tttaggagtg caggggttct gcttcattgc attttcagaa ttaacctgaa agttgaaaca 2280 accatttttt tttatttcaa aacttattta agttgttatc acctgtcctt aaatagataa 2340 aagaatgtgt attttttcac ttgttgcctt agtactatca agacttgtga atatatttga 2400 atgtatgttg tttgaaaaac ttgcacaggg cattggagcc atcatgaaaa gcaggaaatg 2460 taaacgtgga atgtatggca ggctgggcag aatgtatact gatccagggt atagactaga 2520 tatttttgct gttgctgttt ttattataaa atgttatatt tgag 2564 69 4134 DNA Homo sapiens misc_feature Incyte ID No 8068623CB1 69 tgctggtgct gtgccgtcgg ccctgccggc ggcgcagctc gggctgcgtt ccttctctgc 60 gtgcgcttgg cactgcgtcg tcgtctttct ggtttgtcct ctgtggttct ctccccgctc 120 ccttgtctgt gtcttcggct gtgctggtcg ggttcgttgt cgttgtgtgt tcctctgtcg 180 tgtcttgctc tgcgtttgct gcttgcgttg tctgtgctcg tcgtgtgctc gctgtgttgt 240 ggtgtgtttg tgctctggtt ggcgtttgct tgtcgtcctt gggcgtcggt gcttggttgt 300 gtcggttttc tcgtatgact gtcacgttgt ttatgttggt ctttgtgtgt tgtctttgtt 360 gtgtttcttt tcttgtctct tttctgtttg tgtgatttat ctatttagtg tcgttgttgt 420 gctcctctgc cttcgtgctg cttctttcct cctgcgtcgt ctcgtctgtc ggtctacggt 480 gttgcgatat atccgcgatg ctgctgtcca atggcggacc taacgcgttg tgttaaccgc 540 ctagcgggtt ctcttcctct agttcaccgt atcggcttgg tataagagcg tgactggccc 600 tacggtgaac ctcgaaattg ttaaggggag cactctatac gtagagtcta ttgaacgttc 660 gcattgtaac tgctgtaacg ttatagctct ggataattcg cgcttcgatg atttgggaaa 720 gaaatgggaa tatcatcttg ttatgacgga agaaagggaa atcgagatcc tgaatatacg 780 ccatgatgcc gctgcttcta cgattgacgt ggcccaccta tttcggcaca actctaaagg 840 gggggcaccg ggttcaaacc gtgaaacggt gctatcgtaa aaatgggcgc ttccccaagg 900 gccttcgtgc aagtgcaata actctggcgg atcccgttat tgaccatgga aacctggcct 960 agaatcctcc taagtatcct caatgttact gtatgaacag gtagtcttcg tgttggtggg 1020 tatttatcgt agatcaagga cagtgagatg aatgcgacaa actgataagg ctgatcagac 1080 ctaggctcgt ttgatgcgac gaactacgtc tgcatacgag cgccgacaca tcttataccc 1140 gctatgagat ttaacaaggc ggcaggacga agccaaactc ctcagagcgc tcaccgcgct 1200 ctttccgcag cctcccccgc cgccggccgg gcgtagcgca gggtcacgtg ccggcgacgg 1260 ggcggggcca gcggggcgcc tgcgcgcctg cgcgccgctg gccgacggag gggagcctgc 1320 cgatgccgag cgggtgctac gtcccgcggt cggagccgcg tcttctcccg gctccgccac 1380 cagccggggc tcgggtgggg gcccggggcc ccggggcatg gccctccgga gtgcgcaggg 1440 cgacggcccc acctccggcc actgggacgg cggcgcggag aaggcagact ttaacgccaa 1500 aaggaaaaag aaagtggcag agatacacca ggctctgaac agtgatccca ctgatgtggc 1560 tgcccttaga cgcatggcta tcagtgaagg agggctcctg actgatgaga tcagacgaaa 1620 agtgtggccc aagctcctca atgtcaatgc caatgaccca cctcctatat cagggaagaa 1680 cctacggcag atgagcaagg actaccaaca agtgttgctg gacgtccggc ggtcattgcg 1740 gcggttccct cctggcatgc cagaggaaca gagagaaggg ctccaggaag aactgattga 1800 catcatcctc ctcatcttgg agcgcaaccc tcagctgcac tactaccagg gctaccatga 1860 cattgtggtc acatttctgc tggtggtagg cgagaggctg gcaacatccc tggtagaaaa 1920 attatctacc caccacctca gggattttat ggatccaaca atggacaaca ccaagcatat 1980 attaaactat ctgatgccca tcattgacca ggtgaatcca gagctccatg acttcatgca 2040 gagtgctgag gtagggacca tctttgccct cagctggctc atcacctggt ttgggcatgt 2100 cctgtctgac ttcaggcacg tcgtgcggtt atatgacttc ttcctggcct gccacccact 2160 gatgccgatt tactttgcag ccgtgattgt gttgtatcgc gagcaggaag tcctggactg 2220 tgactgtgac atggcctcgg tccaccacct gttgtcccag atccctcagg acttgcccta 2280 tgagacactg atcagcagag caggagacct ttttgttcag tttcccccat ccgaacttgc 2340 tcgggaggcc gctgcccaac agcaagctga gaggacggca gcctctactt tcaaagactt 2400 tgagctggca tcagcccagc agaggcctga tatggtgctg cggcagcggt ttcggggact 2460 tctgcggcct gaagatcgaa caaaagatgt cctgaccaag ccaaggacca accgctttgt 2520 gaaattggca gtgatggggc tgacagtggc acttggagcg gctgcactgg ctgtggtgaa 2580 aagtgccctg gaatgggccc ctaagtttca gctgcagctg tttccctgaa agccagagaa 2640 gaccttcctc ttacatcaca ttaaggtctc acccttccat ggaaggattg ggaggggtgg 2700 aatttccttt attaaaaggg tttctgtcca gagtttttta ttcctgccac cctgccctgc 2760 ccgtttgtgt ttgcctttac ttcagaggcc aatagcagag cctacctgac acagagggga 2820 cctgggggcc tggcacagaa tcttatgcct ctcccagtgg gcttttggat gggctctctg 2880 ccacctccct ggtgttggag gaagtgggtt tctgaagctt gcagctgctt ttgcaacctg 2940 ctgggcctgg gctgccctag ttaccgggaa cctcctagtc accccataga aggtgaactg 3000 gaacatggga tgccctctta ctgctcctgc ttgcctgcat cagatggaca cagaaggagg 3060 gggctgctgc tgaaggagtc aggcttggga tggagagcaa gaggccaaag gactcgtctg 3120 ggagcatgat cggcccctct tactagcagc tccatcagct gatcagaaat cagagacaga 3180 agggaactag gttactcgtt aaatcctacc tattttcagc ctagaaatca catgggcgtt 3240 tccagtcaag tgggaaggaa gctcattttt agggcctaga cctagactag ttttgcctgc 3300 ctttttttcc tccctgcttt cttctacaag ccacacaaca ttgcttataa aaggtacttt 3360 tattactatt tttagaatat atacacccca tatgtaaatt accctcactt ttaaagtaat 3420 aatagttcct tcacggaaaa aaaaatagtt ctcatcagaa ggatgagctt ctaagatcct 3480 gaattttact ttctacttga ttaacatttt cgctttagcc agagttgcta tttgcaaaca 3540 gctttccact tccaaagtgc cactttctga ccggtttttc ttcctgtttt cctcaaatca 3600 tcctactccc aaataggcac ccactcacta ccttggcgtc gttttttggg tctgacttgt 3660 ctcgtcaact gctggtctct cccacctggt tggaaatgtc gttggaaact tgcaaagact 3720 ctccagacct tagggaacaa gaggcatcac tcagtccttc tgggacagct tccctgtaag 3780 caaagccagg tttgttttag attcactctg gcctgaaaaa aaaagtgcct tttgctgctt 3840 taaagaattg gggtatatgg tatgaagcag ccatgtactt gtattttcct ggtctttcct 3900 gggcactctt ctctcttggc agatgttttc ttaaagtgaa cacaccagaa gcactctacc 3960 ccaccatatc cagtcctctt tgcatgcctg ttgtgtgcag ggtggagggt gtcccacgtg 4020 ccagagcagc tgggagccct gtccgctgag ttacactaag cactttattt ttatttattt 4080 tattattatt ttcttttttc tgagatggag catgggcaaa aagagcgaaa gcta 4134 70 2329 DNA Homo sapiens misc_feature Incyte ID No 677977CB1 70 atgaaacatt gccttccgaa aagcctacta catccaagga caagttgcag gccatcgagc 60 cgcgtcaatg ggcggcgagc gcaaggccca gacgtgtgcc gcgacattca gcgtgccggc 120 gcgggcatgc gcggctggct caaggacgat gcccacatgc gctggttcct ggagcagctg 180 ggcggtgagg tgggcactca gcgcaagaag atgcggctgg ccaacgagga ggagatcgac 240 cgcgccgtgt acgcctggtt cctggcgctg cgccacgacg gggtgccgct gtctggcccg 300 ctcatccagg cgcagccgag gccttcgcgc gccagatcta cgggcccgag tgcaccttca 360 aggccagcca cggctggttc tggcgctggc agaagcgcca cggcatctcc agccagcgct 420 tctacggcga ggcgggcccc cagccccgag ccccgcgccc ggcccgcccg tcaaggagga 480 gcccgcgctg ccctccggcg ccggccccct gcccgaccgc gccccggccc cgccgccccc 540 ggccgagggc ggctacgggg acgagcagat ttacagcgcc agcgtcaccg gcctctactg 600 gaagctgctt ccggagcagg ctgcgccccc gggcgcaggg gaccccgggg cggggggctg 660 tggccggcgc tggcggggcg accgcgtaac ggtgctgctg gccgcaaacc tgaccggcag 720 ccacaagctg aagccgctgg tcatcgggcg gctgccggac ccgcccagcc tgcgccacca 780 caaccaggac aagttcccgg cctcctaccg ctacagcccc gacgcctggc tcagccgccc 840 gctgctgcgg ggctggttct ttgaggaatt tgtcccaggc gtcaaacgct acctgcgccg 900 aagctgcctg cagcagaagg ccgtgctgct ggtggcccac ccgccctgcc caagcccagc 960 tgccagtatg cccgccctgg acagcgagga tgcccccgtg cggtgcaggc cggagcccct 1020 cggtcccccg gaggagctgc agacaccgga tggcgctgtg cgggtgctgt tcctgtccaa 1080 aggcagcagc cgggcacata tccccgaacc ggtggagcag ggcgtggtgg ccgccttcaa 1140 acagctgtac aagcgcgagc tgctgcgact ggctgtgtcc tgcgccagcg gctccccgct 1200 ggacttcatg cgcagcttca tgctcaagga catgctctac ctggctggcc tctcctggga 1260 cctggtgcag gcgggcagca ttgagcgctg ctggctgctg ggcctgcggg ctgccttcga 1320 gccccggccc ggcgaggaca gtgctgggca gccggcccag gccgaggaag ccgccgagca 1380 cagcagggtg ctcagcgacc tcacccacct ggcggctctg gcctacaagt gcctggctcc 1440 ggaggaggtt gcggagtggc tgcacctgga cgatgatggg gccagtctgc cctctgccat 1500 ggggggcgga gaggacgagg aggaggccac cgactatgga gggacctcca gtctgccctc 1560 tgccattggg ggcggagagg acgaggagga ggccaccgac tatggaggga cctcagtgcc 1620 gactgccggg gaggccgtgc gggggctaga aacagctctg cggtggctgg agaaccagga 1680 ccccagagag gtggggccac tgaggctggt gcagttgcgc tcactcatca gcatggcccg 1740 gaggctgggg ggcatcgggc ataccccagc aggcccctat gacggtgtgt gaccaggcca 1800 gcccagtgac ctttctcctg ctgcacttgg agggagggga catacacaca gtctcccatc 1860 tctcctcccc tccccctggg gtggcccacc gcatgggtac agggggttcc aggaatccaa 1920 atccagcatg gcttggagga gctctgttgg tgagaggtcg ccctgcctca ctggcaccct 1980 gggggcacag ctggaagaga ggcctggccc atgctcctct cagggcaggc acatgtacgg 2040 ggcatacaag gcacagcgcc tgttggaaca ggtggctgtg ttcctgctct ggcccccgtg 2100 cggctgggcc tccgcccctt gcaccagtca catgcactgg acgagggccg aaactcctgt 2160 ctgctatcga gcctggtgct atgtggcccc ggagccacag caaatcatct cgagtggcga 2220 ggcacccact tgatctcttt ttcttaaccc tttatctggt tcaggttaca caaaaagggg 2280 gcgcccgatt gggccgcccg gaaaatccgc gcccggggac gtccttggg 2329 71 2960 DNA Homo sapiens misc_feature Incyte ID No 1661472CB1 71 tcaagttctg attctgagct gctccgccac tggcctgtgg gaagaggcag gaggcttggg 60 gtcccccagc ctgtgcccag cctcctgtgc cttgtagatc ttcacatatg agcgcaagtg 120 gtactcgcgc aaggacctgg cccggcatcg catgcagggt gaccccgatg acacgtcgca 180 ccgtgggcac ccgctctgca agttctgtga cgagcgctac ctggacaatg atgagctgct 240 taagcacctg cgccgcgacc actacttctg ccacttctgc gactcggacg gggcccagga 300 ctactacagc gactatgcct acctgcgtga gcacttccgg gagaagcact ttctgtgtga 360 ggaaggccgc tgcagcacgg agcagttcac ccacgccttc cgcaccgaga tcgacctcaa 420 ggcccacagg acggcctgcc acagtcgcag ccgcgccgag gcacgccaga accgccacat 480 cgacctgcag ttcagctacg cgccacggca ctcgcgccgg aacgaggggg tcgttggtgg 540 cgaagactac gaggaggtgg acaggtacag ccgccagggc cgagtggccc gggctggcac 600 tcgcggagcc cagcagagcc gccgaggaag ctggaggtac aaaagggaag aagaggaccg 660 agaagtagca gctgctgtcc gggcctccgt ggccgcacag cagcaggagg aggctcgcag 720 gagtgaggat caggaggaag gcggtaggcc caagaaggag gaggcagcgg cgcggggacc 780 tgaggatccc cgtggccccc ggcgctcacc ccggactcag ggcgaaggcc caggccccaa 840 ggaaacctcg acaaatggtc ctgtaagcca agaagccttc tcggtgacag gcccagccgc 900 cccagggtgt gtgggggtgc caggcgccct cccaccaccc agcccgaagc tcaaggacga 960 agacttcccc agcctctctg cctccacttc ctcctcctgc tccactgcag caaccccggg 1020 ccctgtgggg ttggcgctgc cgtacgccat ccctgccaga ggcaggagtg ccttccagga 1080 ggaggacttc cccgccctgg tgtcctcggt gcccaagcct ggcaccgccc ccaccagcct 1140 tgtctctgcc tggaacagca gcagtagcag caagaaggta gcacagcccc cactctcggc 1200 gcaggctacc ggcagcggcc agcccaccag gaaggctggg aaggggagca ggggcggcag 1260 gaagggcggc ccgcccttca cacaggagga ggaggaggac ggcggcccgg ccctgcagga 1320 gcttctgagc acacgcccca cgggctccgt ctcctccaca ctggggctgg cctccatcca 1380 accctctaaa gttgggaaga agaagaaagt gggctcggag aagccaggca ccacattgcc 1440 acagcccccg cccgctacct gtcccccagg ggctttgcag gccccggaag ctcctgccag 1500 cagagccgag gggccagttg ccgtcgtcgt taatggacac acggagggcc cggcccctgc 1560 tcggagtgcc cccaaggaac cccctgggct cccaaggccc ctggggtcct tcccctgccc 1620 cacgccacag gaggacttcc cagcgctcgg cggcccctgc ccaccccgga tgccgccgcc 1680 cccaggcttc agcgctgtgg tgctcctgaa gggcacgcct cccccacccc cgccgggcct 1740 ggtgccccca atcagcaagc cgccccctgg cttctctggc cttctgccta gcccccaccc 1800 ggccagtgtc cccagccccg ccaccaccac caccacaaaa gcacccaggc tgctgcctgc 1860 cccacgggcc tacctagtcc ccgagaactt ccgggagagg aaccttcagc tcatccagtc 1920 catcagggac ttcctgcaga gcgacgaggc ccgcttcagc gagttcaaga gccactcagg 1980 ggagttcaga cagggcctga tctccgcagc ccagtattac aagagttgcc gggacctgct 2040 gggggagaat ttccagaagg tctttaatga gctgctggtc ctgctgcccg acacggccaa 2100 gcagcaggag ctcctgtctg cacacacgga cttctgcaac cgcgagaagc ctctgagcac 2160 caagtccaag aagaacaaga agagcgcgtg gcaggccacc acccagcagg cgggcctgga 2220 ctgccgtgtg tgccccacct gccagcaggt gctcgcgcat ggcgatgcca gcagccacca 2280 ggcgctgcat gctgcccggg acgacgactt cccctccctg caagccatcg ccaggatcat 2340 cacgtagctc ccgccagcgt ggccagagct gtcgcaccgt gagcgtcctt cctccttcct 2400 ctccgggctg ccaggcagcc aggtaaggcc tggtgaggcc acttggcctc ttggttggcc 2460 aggcccacca ggaagtcacc aggacagtcc acccgccctg ttggcacact caagcgggag 2520 tccacccctg cctcagtggt gggccagtct cggtttgcat tcttgtgctt ttgggaggtg 2580 ccaggggagg gaagggctgg gatgctggga cctgttgttg ctggcaaagc cagaggtcac 2640 agtggcctga tctgggccct cccaaagctg agggctgcag cccgtggggc ctcagagctg 2700 aaagctgcgg cgccactggt gccagagtca gatgtcacag atgtgttgtg taaacagttg 2760 gctgtttcgt gcttcaagaa tgttcaggat taaaagcaga caagaaattg tgctacttga 2820 agttgaatct ttttatgaga caagctgaat ctgggatctc aaattgcctc tgacctttta 2880 taagacagtt tatcttcaaa taaatttatt ttgcaatacc acgcaaaaaa aaaaaaaaaa 2940 aaaaaaaaaa aaaaaaatat 2960 72 2623 DNA Homo sapiens misc_feature Incyte ID No 1748508CB1 72 tcagttgatg tgttaggaaa attgattata tgtatatact aaataaaatt tgttaaacat 60 acctataacc cttcaaaatt aaatttttaa aaacttttta ctgtttcatg taggtataac 120 ttacttcctt gtctcttgat agatttcagg cttaaactga agaagtaatt ggttcaaaaa 180 tcttattact agaaagtaat gacaaattta tagttttcat ttctagtgta cattaaccat 240 aggtcattgt aacatccctt ctccacaata aaaatggaaa cttattttgt ggaaatcatt 300 ttatgtaaat atgtatttaa tacttatttc atctttctta cctttcagaa ttaccatgaa 360 attatgactc gtcatcctga gaattatcaa tgggaaaact ggagtctaga aaatgttgct 420 accattttag cccaccggtt ccccaatagt tatatttggg tgataaaatg ttcccgaatg 480 catttgcaca aattcagctg ctatgacaat tttgtgaaaa gtaacatgtt tggtgcccca 540 gaacacaata ctgactttgg agcttttaag cacctttata tgttattagt taatgctttt 600 aatttaagtc agaatagttt atcaaagaaa agtttgaatg tttggaataa ggactccata 660 gcatctaact gtagatccag tccttctcat actacgaatg gttgccaggg agaaaaagtg 720 aggacctgtg aaaaatctga tgagtctgcc atgagttttt atccaccatc actaaatgac 780 gcatctttta ctttgattgg attcagtaaa ggttgtgttg ttttgaatca gttgcttttt 840 gaattgaaag aagccaagaa agacaagaac atagatgctt ttatcaaaag cataagaaca 900 atgtattggc tggatggtgg tcattctgga ggaagcaata cttgggttac ttatccagaa 960 gtcttgaaag aatttgcaca aacaggaatt atcgttcaca ctcatgtaac accttaccaa 1020 gtacgtgatc caatgagatc ttggattgga aaggagcaca agaaatttgt tcagatactt 1080 ggggatcttg gtatgcaggt gactagccaa attcatttta caaaggaagc tccttccata 1140 gagaatcact tcagggttca tgaagtattt tgagattaca ggtatattaa tgaacttgtt 1200 cagtggaaga acataagcac ttttgagtgt tataaattca gataatggga tgtaattcat 1260 agctgcattg tcagttttgg ggtatggggg gaagcacaca ttcctaaaat gtgagtgtaa 1320 tgtgcaatag tattttttgc ttgtgaatgt gagcagttat taatttggat tgagttagaa 1380 ttagttaatt tgaaatctaa caaggtggtt tgtaataatg ctgaggagat ataagaccct 1440 taaaatgaaa gttacaacat tgttcttata aaaggtaact aaaattgtta ctgttggaaa 1500 taactgattt tctgagtaat gttttaaact aatttggtga cattttaaca gtaattagct 1560 attttgagtg gaaatatttt catttctctt caaacaaaag caaaggtacg atgctgtttt 1620 ctatcatttt ggaataactg caccctgcct tttgtgtttt tgtaaactcc ttgactcatt 1680 ctttcatgtg tcaccaagta cttttctcat gagagtcaac atatatttgt ttccaaatgt 1740 ccacaagtgt acaatagtgt aaaggtggtt tttaaaaaca tagccaggtg tggtggcacg 1800 tgcctttagt tccagctact caggaggcta aggcaggagg attgcttgag cccaggctgt 1860 gtggttcacc ataattgtgt ttgtgactag ctactgcact ccaacctggg caacatagtg 1920 ggacttcatc tctaaaacaa aacaaaacaa aattacactt aagcactatt gtttaatttt 1980 taattgtcag tttatcatta ttttgggtaa gacattctgg ggtttcttga atcttgtcca 2040 aaaaccagtt gttttggaaa attgctttaa attgagcata tttatgtata ttggataaaa 2100 atgtactaca gagcaaattt caaatttttc attatatcag tctttttgaa aggatcaact 2160 tggataaaat aaatatataa tgctctattt gttagagctc tattaaaaag gaaacagatt 2220 ccatagatct aagtcaatgt ttctccagaa gcatgatttt gtctgccaaa agaaaatagc 2280 tctctttggc caaaatgcaa aattacattg ctataagaaa agttacaagg gaaagtttga 2340 agacacaaat gatttaattt tggctcaaaa actgaatttg cttaacactg ctacataatt 2400 tgggtgaagt ttccttctgc ccgtttttct tgacctagat aaatacactt tgagaaatcc 2460 agatctaata aatgtcaacc aacattgaca ttgtaattgg gtgattacaa taaaaggtga 2520 gcagtttgtt gtttattaat aattagcttt tgcaggtaat gaaatagcag ggaagtaaca 2580 tgctgcttta ggactaaaaa aaaaaaaaaa aaaaaactcg gtc 2623 73 4518 DNA Homo sapiens misc_feature Incyte ID No 2159545CB1 73 gtggctgcac cttagcgaca tcaggaagaa cagggtcgag gatcgagtca cagcaaactg 60 tacaatggca gttgagtggg ttttgaaaaa cgtctgaatt gtagtgtcta catctacctt 120 ctgccttctc tctacccttt gaaaaaaaat aaatggcatg tttgagaaga gagctctatt 180 aaaagaggaa tattgcaaat ggcttcagat tctatgagta gtaaacaagc taggaatcac 240 attacaaagg ggaaaaggca acaacagcac cagcaaataa agaacagatc ctcaattagt 300 gatggtgatg gagaagattc ctttattttt gaagcaaatg aagcttggaa agattttcat 360 ggttctcttc ttcgatttta tgaaaatgga gaactctgtg atgtcacact caaggttggc 420 tcaaagctaa tctcttgtca caagctggta ttggcttgtg ttattcccta ctttagagcc 480 atgtttcttt ctgaaatggc tgaagccaag caaacgctga ttgagattag agattttgat 540 ggtgatgcaa tagaagactt ggtaaagttt gtctattctt cacggctcac tttgactgtt 600 gacaatgtcc agcctctctt atatgcagcc tgtattctgc aggttgaact ggtggctaga 660 gcttgttgtg aatacatgaa gttacatttt catccctcca attgcctggc agtaagagcc 720 tttgcagaaa gtcacaatcg aatagactta atggacatgg cggatcagta tgcctgtgac 780 cattttactg aagtagtgga gtgtgaagac tttgtaagtg tatcaccgca gcacctccat 840 aagcttttgt cctccagtga tctaaatatt gaaaatgaaa agcaggtcta taatgctgcc 900 atcaagtggc ttcttgccaa tcctcagcat cattccaaat ggttggatga aacacttgca 960 caggttcgcc tgccattgtt gccggttgat tttcttatgg gtgttgtggc aaaagaacag 1020 attgtcaagc aaaatctaaa atgtagagat ttactggatg aagcaagaaa ttaccacctt 1080 cacttgagta gcagagcagt acctgacttt gaatactcca ttcggactac cccaaggaag 1140 catactgctg gtgtgctgtt ttgtgtaggt ggtcgaggtg gatctggtga cccctttcgc 1200 agtattgaat gctattctat caacaaaaac agttggttct ttggaccaga aatgaatagt 1260 cgaaggcgac atgtgggtgt aatctctgtg gaaggtaaag tgtatgcagt aggtggacat 1320 gatggaaatg aacatttagg gagtatggag atgtttgatc ctctcactaa taaatggatg 1380 atgaaggcat caatgaacac aaagaggcga ggaattgcct tggcttcctt aggaggccca 1440 atttatgcaa ttggagggtt agatgacaat acttgcttca atgatgtgga gagatatgac 1500 atagaatctg atcagtggag tacagtggca ccaatgaata ctccccgtgg aggagttggc 1560 tctgttgctc tagtaaacca tgtttatgca gtaggtggca atgatggaat ggcttcttta 1620 tctagcgtgg agagatatga tccacatctg gataagtgga tagaagttaa agaaatgggt 1680 cagcgaagag caggcaatgg agttagcaag cttcatggtt gcttatacgt agttggtggt 1740 tttgatgata attctcctct gagttcagtt gagcggtatg acccccgaag caacaagtgg 1800 gattatgtgg cagcacttac tactcccaga ggtggagtgg gaatcgcaac agtgatgggc 1860 aaaatctttg cagttggtgg tcataatggc aatgcatact taaatacagt agaagcgttt 1920 gatccagtgc tgaataggtg ggagcttgtt ggatctgtgt ctcactgcag agctggagca 1980 ggagtagctg tgtgttcctg tttaactagc caaattcgag atgtaggtca tggatccaat 2040 aatgtggttg actgtatgtg atttgagttc tggccaccaa caatttagtc atatctgata 2100 ggtacaaaag aaaaccaaga ttttgatatg accacctttc aacacttttt actgcaacta 2160 gagtcttatt taaatgttaa ctgttgtatt gtgactaagt acaacttttg gaatgatacc 2220 tgaagaatta ttagtaatag agttaaattt gatacttcct gcttttgcaa ataatggagt 2280 agggaagaag atagtcgaac ttaaaatcat acctaccctg aaaaatgctt aaagtagtgc 2340 caaaaatctt gaaatctctc tctctctctc tatttggatg aatcaaaatg taatttgttg 2400 agttttgcct tttcttttgc ctaaagatgt taacgtcagg cagtgggttt ttcctagagg 2460 agagattagt acctattcat taacacaagg atacataaga gacttgcccc ttttgaagat 2520 catttctact tggtgctgat gaatttatgc ctagcttttt ttttctaggt ggtgattttt 2580 caatttcttt tatatttacg gaagtagaaa aaatgttctg tctttttgaa tgccacttag 2640 ctgcattttc agaagcttat aggctataag aagcctttaa tttcagtttg atttgctagg 2700 acaccaaaag acctagctgg gctaactcca tccaaatgat tttacagttt tattttttca 2760 tcttttgcaa aaagtatttg ttacataatc aaaaggtgaa ccagaggaaa tattgaacaa 2820 ggttttagat ctgatgttat tctggtgccc aattgagaga ccttgagaaa gaatgatgca 2880 gattacatga ctctaatgtg ggcagtctga aaatatcttt aactgtcttc tttgatcatt 2940 tgattttgga tccaagattt atcatctctc tattttgcta tttgccacca tcctggtttt 3000 tctgactgta cagaatcaat ctgcatttat ttattatcag aaatgaatgc atttttacaa 3060 aaaccttttt gtagactgta gtttattgat tagttcaagc ccatcacgaa ctaattaaac 3120 atattgttgg taaaaacaga gattgaaatt actgttttta tcatatttaa atccctctgg 3180 tgtatttatt gaaatttaat taaaaatatt tctacatatt gatttgaagc caggatattg 3240 atggacctac agatttaaca gctcttcaaa gttttaacta gcattataaa atggcctatt 3300 cattatatgt atattttttt ataaatattt atcaagaaca tgaaaatatt ttattttgta 3360 tttgcagtgc agtttggcac ctctcttcca ggccttccta agtttttgtt agttgtgtct 3420 tcgaatttat tgtagttcac cgctggtcag taatctggtt cataaggaag ctggggcagt 3480 gaaaaacact tcgttgatcc atccagccct aaagttcatt gactaatagc tcatgcatct 3540 tattaaatgg gattttggac ttctacaata gtgtggaaag ccacatcaca aaaaaagcca 3600 catcacaaaa aaaagccagt gcctgttgag tatatcaaac caaaaaagaa aaaaaaaagt 3660 tttaagaggg gtcaggctgg cagataaaag tctcttatga agcagatata aatccagtaa 3720 gctatttttt tctacctatg ggcaagttca taagtcattg ctggatctga accagtgttc 3780 ttttgtgtaa gtacaaccat atttcagtca gtccagaggc agttaaccct gtagcactta 3840 ctagactggt gacaactggc tggatgtgga gaataagtgt caaaacctgg cttcaatgtc 3900 tatttcttat gtctaatgga gttcttatat tacagtgttt gtttagctat ggttactaat 3960 atgtttgtta tatttatttt cggggagagg atcttgttat tgtttcctga gattatttaa 4020 aatgtttttt ctttgatgta tttctgtctt tcttatatgt aaggagttat aagggttatt 4080 atattttcat ttctggtttt tactatacaa tggttatcta acatactaag ttggtaccct 4140 acctacccgt aaaatatgaa atactcagaa gtaaagtgtg tgggcaatca gaagcatagc 4200 cttgaaggac ctgacagcag tatgaaaaga taaataggcc aggcatggtg gctcacgcct 4260 gtgatcccag cactttgggg ggccgaggtg ggtggaccac ctgagatcag gtgttcaaga 4320 ccagcctgac caacatggtg aaaccctgtc tctactaaaa gtacaaaaat tagccaggcg 4380 tggtggcgca tacctgtaat tccagctact caggaggctg aggcaggaga attgcttgaa 4440 cccaggaggt ggaggttgca atgagccgag gttgagccat cgcactccag cggtgaaaca 4500 agagtgaaac tccatctc 4518 74 1238 DNA Homo sapiens misc_feature Incyte ID No 8560269CB1 74 ccgcccccgc gtcgcgggct ctttaaggcc ggcggttttc ggcagccagc ccggggcggg 60 gaaagcggag cgcgcgctcc acgcgggacc gcctcccggg ccgtctgagc agagggcggg 120 gtgcaggcgg aatggccctc gtgccctatg aggagaccac ggaatttggg ttgcagaaat 180 tccacaagcc tcttgcaact ttttcctttg caaaccacac gatccagatc cggcaggact 240 ggagacacct gggagtcgca gcggtggttt gggatgcggc catcgttctt tccacatacc 300 tggagatggg agctgtggag ctcaggggcc gctctgccgt ggagctgggt gctggcacgg 360 ggctggtggg catagtggct gccctgctgg gtgctcatgt gactatcacg gatcgaaaag 420 tagcattaga atttcttaaa tcaaacgttc aagccaactt acctcctcat atccaaacta 480 aaactgttgt taaggagctg acttggggac aaaatttggg gagtttttct cctggagaat 540 ttgacctgat acttggtgct gatatcatat atttagaaga aacattcaca gatcttcttc 600 aaacactgga acatctctgt agcaatcact ctgtgattct tttagcatgc cgaattcgct 660 atgaacggga taacaacttc ttagcaatgc tggagaggca atttattgtg agaaaggttc 720 actacgatcc tgaaaaagat gtacatattt acgaagcaca gaagagaaac cagaaggagg 780 acttataatt ggctataatt tataagaatg ttgtcattga gtgtgtcact taaggtctta 840 gactgcaaat ctaaccatat ttaatgaaat gtcttactgt acaaaaagtc taagccaaag 900 gttctcaggg gagaaagcac atgtgcagtt ttaaaacaaa gcagtgcttt gtcccattgc 960 tgtgattttt agtcagactt tactcagtct gaaatgcaat taacattaaa ggattaagtg 1020 tgagatttcg atttatgcta tttgtgtatc ccatactcct cccttttaat aaacagtttc 1080 cactgatgat atgaagggcc ggtataaaga agtctttaaa tgagtaagct ttcttggtaa 1140 gattaaatct tacaaattat ttttaaaacc ttgtgatata tacaatgtta gctgagtttt 1200 ctaattttct ggatgtaaaa caaaaggttt aacctata 1238 75 1771 DNA Homo sapiens misc_feature Incyte ID No 8710302CB1 75 gcgatacgcc gagcgctcaa catccgagga ctttggccca gagtaacccc gctctcgtga 60 cctttcccct ccattccgca cctccgagtg ctggccgggc gagaggctgg cggctgggct 120 ctcgcgcccc tccctgcagg gctcaggctc tccccctcct gtcttctccg cgctgttcct 180 cgtcatggcg gccctcagca agtccatccc tcataactgc tatgagatcg gccacacttg 240 gcacccttcc tgccgggtct ccttcctgca gatcaccggg ggcgccctgg aggagtccct 300 gaagatctat gctcctctgt acttgattgc agcaattctc cggaaacgga aattagacta 360 ttatttacac aaactactcc ctgagatcct acaatccgct tcatttctaa ctgctaatgg 420 ggccttgtat atggctttct tttgcatttt aaggagaggg ctgctcacaa tttatatggc 480 caacttggcc acagaaacac tattcagaat gggtgtagca agaggaacca tcacaacatt 540 aagaaatgga gaagtccttt tgttttgcat cacagctgcc atgtacatgt tctttttcag 600 gtgcaaggat ggcttgaaag gatttacatt ttctgcactt aggttcattg tagggaagga 660 agaaattccc acacattctt tttcaccaga ggcagcatat gcaaaagtgg aacaaaagag 720 agagcaacat gaggaaaaac ccagaagaat gaatatgatt ggtctagtca ggaaatttgt 780 ggattcaata tgcaaacatg gaccaaggca tagatgttgc aaacattatg aagataattg 840 catctcttat tgcattaaag gtttcatcag aatgtttagc gtggggtact tgatccagtg 900 ctgcctccga atcccttctg catttaggca tctgtttaca cagccatctc ggctactttc 960 tctcttctac aataaagaaa acttccagct tggagctttt cttggctctt ttgttagtat 1020 atacaagggt actagttgct tcctgcgctg gatcagaaac ttagatgatg aactacatgc 1080 tattatagct ggatttttgg caggtatatc aatgatgttt tataaaagca caacaatttc 1140 catgtattta gcgtccaaat tggtagagac aatgtatttc aaaggcattg aagcagggaa 1200 ggttccctat tttcctcatg cagatactat catctattcc atctctacag caatttgctt 1260 ccaggcagct gtcatggaag ttcagacttt gagaccatct tactggaagt tccttttaag 1320 actcaccaag ggcaaatttg ctgtcatgaa ccgaaaagtc cttgatgttt ttggtactgg 1380 tgcatctaaa cactttcagg atttcatccc caggttggat ccaagataca caactgtaac 1440 accagagttg cccacagagt tttcctgaag atgactgtaa cttattaatg tgactaaatg 1500 tttcatcttg aagagttaat tatgttgaac acaaaggagg gggcccaagc tcgaacttca 1560 gtgttatttc agttagagat actcttttca tttgttttgt ttttcttatg aatcagaaat 1620 tcagaagctt tttaggaaga tgttgcttaa taattaagct tcctccatag ccagaataag 1680 attctggatc actgtagtga ctgacattat atattattga tcaaattatg tccacaagca 1740 atattatata atctacgtag aagtgtaata a 1771 76 2909 DNA Homo sapiens misc_feature Incyte ID No 6778214CB1 76 tttccgtggc ccttcctgcc ctttgtttct ctcttgatgt cacccgcggg acaactctac 60 gtgcaagtcg ctgaaatcga ttttctgctt cttatagtaa gcggcgggct cgccagcctc 120 gagcgaaagt gtgactgcga acgggcaggc gcgcgcgggg ctcggcggag gcgcgcttgg 180 gctcccggcg gcgacgacta cgaccactag gagagcggac ggaggcggcg cctgaagcgg 240 cggcggagcc catgccccgg gacggcgggc ggacccggag agacaaatcc ggggcccggg 300 gcatgtcccc ggggcccccg tgaggaggcg gcggcggcta tggagatcgc gccgcaggag 360 gcgccgcccg tgccgggcgc ggacggcgac attgaagagg ccccagctga ggccgggtct 420 cccagccccg cgtcgccccc cgccgatggg cgcctcaagg ctgcagccaa gcgcgtcaca 480 ttcccgtccg acgaggatat cgtgtctgga gcagtggagc ccaaagaccc ctggagacat 540 gcccagaatg tgaccgtgga cgaggtcatc ggcgcctaca agcaggcctg ccagaagctg 600 aactgcaggc agatccccaa gctcctcagg cagctgcagg aattcacaga cctcgggcac 660 cgcctcgact gtctggacct gaaaggtgag aagcttgact acaagacctg tgaggccctg 720 gaagaggtct tcaagaggct gcagttcaag gtcgtggacc tggagcagac aaacctggat 780 gaagatggtg cctcggccct cttcgacatg atcgagtact acgagtcggc cacccacctc 840 aacatctcct tcaacaagca catcggcacc cggggctggc aggcggccgc ccacatgatg 900 cgcaagacga gctgcctgca gtatctggac gcccgcaaca cgcccctgct ggaccactcg 960 gcgcccttcg tggcccgtgc cctgcgcatc cgcagcagcc tggcagtgct gcacttggag 1020 aacgccagcc tgtcggggcg gcccctcatg ctgctcgcca cggccctgaa gatgaacatg 1080 aacctgcggg agctgtacct ggcggacaac aagctcaacg gcctgcagga ctcggcccag 1140 ctgggtaacc tgctcaagtt caactgctcc ctgcagatcc tggacctccg gaacaaccac 1200 gtgctagact cgggtctggc ctacatctgc gagggcctca aggagcagag gaaggggctg 1260 gtgaccctgg tgctgtggaa caaccagctc acgcacacag gcatggcctt cctgggcatg 1320 acactgccgc acactcagag cctggagacg ctgaacctgg gccacaaccc catcgggaac 1380 gagggtgtgc ggcacctcaa gaacgggctc atcagcaacc gcagcgtgct gcgcctcggg 1440 ctggcctcca ccaagctcac gtgcgagggc gcggtggcgg tggcggagtt catcgctgag 1500 agcccccgcc tcctgagact ggaccttcgg gagaacgaga tcaagacagg cgggctcatg 1560 gcactgtcgt tggccctcaa ggtgaaccac tcactgctgc gcctggacct cgaccgtgaa 1620 cccaagaaag aggcggtgaa gagcttcatc gagacgcaga aggcgctgct ggccgagatc 1680 cagaacggct gcaagcgcaa cttggtgctg gcgcgggaga gggaggagaa ggagcagccg 1740 ccacagctgt cggcctccat gcctgagacc accgccaccg agccccagcc cgacgacgag 1800 cccgccgctg gggtgcagaa cggggccccc agccccgcac ccagcccgga ctcagactca 1860 gactcggact cggatgggga ggaagaggag gaagaggaag gggagaggga cgagaccccc 1920 tccggggcca ttgacacccg ggacacaggg tcctctgagc ctcagccacc accggagccg 1980 cctcggtcag ggccaccact gcccaacggc ctgaagcccg agttcgccct ggcactgccc 2040 cctgagccgc ccccggggcc tgaggtcaag gggggcagct gcggcctgga gcacgaactg 2100 agctgctcca agaacgagaa ggagctcgag gagctgcttc tggaagccag tcaggaatcc 2160 gggcaggaga cactgtgaca ctttagttcc ctttttccgg tcggtctgcg atgagctgag 2220 gccagagcca tgagaatctg ctcaccttcc ccccagcctt cctgaggccc aggatgccag 2280 gggtgggggc cattctgggg cccccctccc cccacagcaa cactacaagg ggtgcaggag 2340 ctacagggag tggccctccg cgcgtgactc aagcacttct atttatgagc ccagcactgg 2400 aagactctgg gggtgaatgg gaggaggggg agcaggagga ggaggaggtc tccaagtaca 2460 tcaggcgcct gttctggagg ggccaggctt gccctgcgga gggcaggcgt cctgggtggt 2520 ggtgggatgg tcccctgtgg ccccgggcac agggccgggc aggcagcctg gtgccggaga 2580 ggcggtgcgt gctggtggtg gttgagatgc gcagaacagc cccagacagc gcaggccggg 2640 cagggtgggg ggatgggagc agaggatcag agctttcttt ttctcaagtg caataaatct 2700 atcagggagc tggggcggga gcagccggca ttccgggacc ctgttgtcca ggccactgga 2760 ggctgcgccc tgagaggcac tacagccctt tgggggcgag tggcatgggt gtgggtgagg 2820 gtgggcagag ggctggggcg actcctgtcg gtgcaactct gttcacacct tttagaataa 2880 actggcatgg tcggtaaaag acaaatagc 2909 77 2216 DNA Homo sapiens misc_feature Incyte ID No 258383CB1 77 gcgatacgcc gagcgctcaa catccgagga ctttggccca gagtaacccc gctctcgtga 60 cctttcccct ccattccgca cctccgagtg ctggccgggc gagaggctgg cggctgggct 120 ctcccgcccc tccctgcagg gctcaggctc tccccctcct gtcttctccg cgctgttcct 180 cgtcatggcg gccctcagca agtccatccc tcataactgc tatgagatcg gccacacttg 240 gcacccttcc tgccgggtct ccttcctgca gatcaccggg ggcgccctgg aggagtccct 300 gaagatctat gctcctctgt acttgattgc agcaattctc cggaaacgga aattagacta 360 ttatttacac aaactactcc ctgagatcct acaatccgct tcatttctaa ctgctaatgg 420 ggccttgtat atggctttct tttgcatttt aaggaagata cttggaaaat tctactcatg 480 gactcctggc tttggtgccg ctctgccagc atcttatgtg gccattctca ttgaaagaaa 540 aagcaggaga gggctgctca caatttatat ggccaacttg gccacagaaa cactattcag 600 aatgggtgta gcaagaggaa ccatcacaac attaagaaat ggagaagtcc ttttgttttg 660 catcacagct gccatgtaca tgttcttttt caggtgcaag gatggcttga aaggatttac 720 attttctgca cttaggttca ttgtagggaa ggaagaaatt cccacacatt ctttttcacc 780 agaggcagca tatgcaaaag tggaacaaaa gagagagcaa catgaggaaa aacccagaag 840 aatgaatatg attggtctag tcaggaaatt tgtggattca atatgcaaac atggaccaag 900 gcatagatgt tgcaaacatt atgaagataa ttgcatctct tattgcatta aaggtttcat 960 cagaatgttt agcgtggggt acttgatcca gtgctgcctc cgaatccctt ctgcatttag 1020 gcatctgttt acacagccat ctcggctact ttctctcttc tacaataaag aaaacttcca 1080 gcttggagct tttcttggct cttttgttag tatatacaag ggtactagtt gcttcctgcg 1140 ctggatcaga aacttagatg atgaactaca tgctattata gctggatttt tggcaggtat 1200 atcaatgatg ttttataaaa gcacaacaat ttccatgtat ttagcgtcca aattggtaga 1260 gacaatgtat ttcaaaggca ttgaagcagg gaaggttccc tattttcctc atgcagatac 1320 tatcatctat tccatctcta cagcaatttg cttccaggca gctgtcatgg aagttcagac 1380 tttgagacca tcttactgga agttcctttt aagactcacc aagggcaaat ttgctgtcat 1440 gaaccgaaaa gtccttgatg tttttggtac tggtgcatct aaacactttc aggatttcat 1500 ccccaggttg gatccaagat acacaactgt aacaccagag ttgcccacag agttttcctg 1560 aagatgactg taacttatta atgtgactaa atgtttcatc ttgaagagtt aattatgttg 1620 aacacaaagg agggggccca agctcgaact tcagtgttat ttcagttaga gatactcttt 1680 tcatttgttt tgtttttctt atgaatcaga aattcagaag ctttttagga agatgttgct 1740 taataattaa gcttcctcca tagccagaat aagattctgg atcactgtag tgactgacat 1800 tatatattat tgatcaaatt atgtccacaa gcaatattat ataatctacg tagaagtgta 1860 ataacaaaca agagtacact taaaattact ttaaaagatg tctttagttc attccaatat 1920 aattcttgat taaaattagg attatttcta cattttagga tttacaaagg atcacgggta 1980 catggatttg gtctatatat ttttttaaag ttttgaattg gtatctgtag tagtggaatg 2040 ttatagattt gaagtaactc tccacggaca gtgctgcttt cgtgtagagc aatttaattg 2100 gagaagtggc cattcttact tcagggatgc aaagatgggt ctcataccat ttggataaat 2160 gtcgtggtat ccatgctttt tttcaactaa taacatcatc tctcttcatg accagt 2216 78 5320 DNA Homo sapiens misc_feature Incyte ID No 2804937CB1 78 tcgccgtgaa cgcagcacat ttaggcgcca ggcagtacgg cgccggcaca atgcagggag 60 taaccctacc cctcctacat tgctcatcgg atcaccccta agccttcaag atggtcagca 120 aggccagcag tccacagccc aggtcaaagt ccagtcccgc cccccttccc aggctgcagt 180 gctcagtgct agtgcctcct tgctggtgag aaatgggagt gtccacttag aagcatcaca 240 tgacaatgca tctgctgtag gcggtagcag tttgcacgat gaacttggta agttctcttc 300 tacgctgtat gagactggtg gctgtgatat gtcacttgtg aattttgaac cagcagcaag 360 aagagcatcc aatatctgtg acacagattc tcatgtatcc agttctacct cagttcgatt 420 ttatccacat gatgtgctct ctctcccaca gattcgattg aatagactat tgaccattga 480 tacagatttg ttggagcaac aggacattga tctaagccct gacttggcag ctacttacgg 540 cccaacagaa gaagctgccc aaaaggttaa acactattat cgcttttgga tcctacccca 600 gctgtggatt ggcattaact ttgacagact cacacttttg gccctgtttg atagaaatcg 660 tgagatcctg gaaaatgtgt tagctgtcat cctggctatt ctcgtggcct ttttgggatc 720 tattcttctc atacaaggat tcttcagaga tatctgggtc ttccagttct gcctcgtcat 780 agccagctgt caatactcac tgcttaagag tgttcaacca gattcttctt ctcccagaca 840 tggtcataat cgtatcattg cctacagtag accagtttat ttctgcatat gttgcggtct 900 tatttggctc ttggattatg gtagcagaaa cctgactgca accaagttca aattatatgg 960 aataactttc accaatccac tggtgtttat atcagccagg gatttagtta tagtgtttac 1020 actctgtttc ccaatagtgt ttttcattgg tctcctgcct caggtgaata catttgtaat 1080 gtacctttgt gaacaattgg atattcatat ttttggtggt aatgccacta caagcctgct 1140 tgcagcactt tacagtttta tctgtagcat tgttgcagta gccttattgt atggattatg 1200 ttatggggct ttaaaggatt cttgggatgg ccagcatatt ccagtacttt tctccatttt 1260 ttgtggttta ttagtggcag tgtcttacca tctcagccga caaagcagtg atccatctgt 1320 acttttctct ttagtgcaat ccaagatttt tccaaaaacg gaagagaaaa atccagaaga 1380 ccctctatct gaagtaaaag atccactgcc tgaaaaactt agaaattctg ttagtgagcg 1440 attacagtct gacctggtag tatgcattgt aattggtgtg ctgtattttg ctattcatgt 1500 aagcacagtc ttcacagtat tgcagcctgc cctcaagtat gtgttgtata cattggttgg 1560 ctttgtgggt tttgtaaccc attatgtgct gcctcaagtt agaaaacagc taccatggca 1620 ctgtttctct catcctctgc taaagacact agagtataat cagtatgaag ttcgaaatgc 1680 agccactatg atgtggtttg agaaacttca tgtgtggctt ctttttgtgg agaagaatat 1740 aatctatcca ttgattgttc tcaatgaact gagcagcagt gcagagacaa ttgctagtcc 1800 aaagaaactg aatacagaat taggtgcttt aatgatcact gttgctggtt tgaagttgct 1860 acgatcctct tttagcagcc ctacatatca gtatgttaca gtcatcttta ctgtgctgtt 1920 tttcaaattt gactatgaag ctttttcaga gaccatgctg ttggatctct tctttatgtc 1980 catactcttc aacaagcttt gggaactact ttataaattg cagtttgtgt atacctatat 2040 tgccccatgg cagatcacat ggggttctgc tttccatgct tttgctcagc cttttgcagt 2100 gcctcattca gccatgctgt ttattcaggc tgctgtctcg gccttcttct ctactccact 2160 gaaccccttt ctgggaagtg caatattcat cacttcatat gtccgacctg tgaaattctg 2220 ggagagagac tataacacaa aacgagtgga tcattcaaat accagattgg cttcccagct 2280 tgatagaaat ccaggatcag atgacaacaa tctgaattcc atcttttatg agcatttaac 2340 tagatcccta cagcacagcc tctgtggtga tttgctacta ggacggtggg gaaactacag 2400 tacaggggac tgtttcatcc ttgcctctga ctatctcaat gcattagtac accttataga 2460 gataggcaat ggtctggtca cttttcagct gcggggactt gaattcagag gtacctactg 2520 tcaacaacgg gaagtggagg ccattactga aggtgtagag gaagatgaag gattttgctg 2580 ttgtgaacct ggccatattc ctcacatgct ttcatttaat gctgcattta gccagcgatg 2640 gctagcttgg gaagtgatag tcacaaagta cattctggag ggttatagca tcactgataa 2700 cagtgctgct tctatgcttc aagtctttga tcttcggaaa gtactcacca cttactatgt 2760 caagggtatc atttattatg ttacgacctc gtctaagcta gaggagtggc tagctaatga 2820 gacaatgcag gaaggacttc gtctgtgtgc tgatcgcaat tatgtcgatg tggacccgac 2880 ctttaatcca aacattgatg aagactatga ccaccgactg gcaggcatat ctagggagag 2940 tttctgtgtg atttacctca actggataga gtactgctct tcccgaagag caaagcctgt 3000 ggatgtggac aaagattcat ccctagtgac tctctgttat ggactctgtg ttctgggacg 3060 gagagctttg gggactgcat cccatcatat gtccagtaat ttagagtcat tcctctatgg 3120 attgcatgcc ctatttaaag gagatttccg tatttcttca attcgagatg aatggatctt 3180 tgctgacatg gaattgctaa gaaaagtagt agtccctggg atccgtatgt ccattaaact 3240 tcatcaggat cattttactt ctccagatga atatgatgac cctactgtgc tctatgaagc 3300 catagtatct catgagaaga acctcgtaat agcccatgaa ggggaccctg catggcggag 3360 tgcagtactt gccaactctc cctccttgct tgctctgcgg catgtcatgg atgatggcac 3420 caatgaatat aaaatcatca tgctcaacag acgctacctg agcttcaggg tcattaaagt 3480 gaataaggaa tgtgtccgag gtctttgggc agggcaacag caggagcttg tttttctacg 3540 taaccgtaac ccagagagag gtagcatcca aaatgcaaag caagccctga gaaacatgat 3600 aaactcatct tgtgatcaac ctattggcta cccaatcttt gtctcacccc tgacaacttc 3660 ttactctgac agccacgaac agcttaaaga cattcttggg ggtcctatca gcttgggaaa 3720 tatcaggaac ttcatagtgt caacctggca caggcttagg aaaggttgcg gagctggatg 3780 taacagtggt ggcaatattg aagattctga tactggaggt gggacttcct gcactggtaa 3840 caatgcaaca actgccaaca atccccacag caacgtgacc cagggaagca ttggaaatcc 3900 tgggcaggga tcaggaactg gactccaccc acctgtcaca tcttatcctc caacactagg 3960 cactagccac agctctcact ctgtgcagtc gggcctggtc agacagtctc ctgcccgggc 4020 ctcagtagcc agccagtctt cctactgcta tagcagccgg cattcatccc tccggatgtc 4080 caccactggg tttgtgcctt gtcggcgctc ttctactagt cagatatcgc ttcgaaactt 4140 gccatcatcc atccaatccc gactgtcgat ggtgaaccaa atggaaccct caggtcagag 4200 cggcctggcc tgtgtgcagc acggcctgcc ttcctccagc agctccagcc aaagcatccc 4260 agcctgcaaa catcacactc tcgtgggctt tcttgcgaca gagggaggtc agagcagtgc 4320 cactgatgca cagccaggca acaccttaag tcctgccaac aattcacact ccagaaaggc 4380 agaagtgatt tacagagtcc aaattgtgga tcccagtcaa attctggaag ggatcaacct 4440 gtctaaaagg aaagagctac agtggcctga tgaaggaatc cggttaaaag ctgggagaaa 4500 tagctggaaa gactggagtc cgcaggaggg catggaaggc catgtgattc accgatgggt 4560 gccttgcagc agagatccag gtaccagatc ccacatcgac aaggcagtgc ttctggtcca 4620 gattgatgat aaatatgtga ctgtaattga aactggggta ctagaacttg gggctgaagt 4680 gtgagccagt gtttattata aagacatttc tttttccctc tcaattccaa ggcattggaa 4740 aaagagagga acaagcagaa gatgcctgca ggtatcactt tgatcctatg tgggagcgac 4800 tgaaaataga atgagcttgg ttaagcacct ctcctttgcc cttcaccctg actcctgtca 4860 ctgtctccat ccccaaataa agctgaaata tttttttaag ttagctgccg agaaaacatt 4920 ttgcatgaag gataaagttc tgttaaaata catccttaaa aaaagttttt cctatgcatt 4980 gcctatgctt taaatcaaca aactcttcat ttctaaacta tgatctcata tttttctaat 5040 ttctttgcca aaaataattg ccatgttttg tcatagaaca tgaaattcat ttaccttgat 5100 ttttaagaac agaccagtgt agaaatgttc cttttgactt atagcagtat aaaagtttaa 5160 tgtacagtga aagagactat gaacagacat agatttatct tattccttga gcgctaaaaa 5220 ctttaataaa aaaaactgca ctaatttttt acagcaatgc actaaagtct gagatttctc 5280 agaacattta tttatatata aaaataaaat accattattt 5320 79 653 DNA Homo sapiens misc_feature Incyte ID No 7494915CB1 79 tgcctttcat gtgaagaacc aggggctact ccaggctaga tttccccatg atgccaggag 60 agaaaaaaca gtcaggctcc cagcaacaga acaatgggca ggcaagcaaa aaccgcacac 120 agaaagaaat agtaacccag aaaagaccaa taacaagcaa tgagattgaa ttagtagtta 180 aaaaaaaatt gccaagagaa aaaggtccag gaccagatgg attcatagct gaattcttcc 240 ggacagtcaa agaagaattg gaaccaaccc tactgaaact attccaaaag attgagagag 300 aaagaatcct ccctaacaca ttttatggag tcagtatcac ccttatgcca aagccagaaa 360 aggacacaac agcaacaaca acaacaacaa caacaaacta cagaccaaca tccctgatga 420 atgtagattc aaaaatcctc aacaaaatac tagctaacca aatccaacct cacatcaaaa 480 agataataca ccataatcaa aagctcttta gtttaattag atcccatttg tcaattttgg 540 cttttgttgc cattgctttt ggtgttttag acgtgaagcc tttgcccata cctatgcact 600 gaatggtaat gcctaggttt tcttctaggg tttttatggt tttaggtctt aca 653 80 1794 DNA Homo sapiens misc_feature Incyte ID No 2073751CB1 80 aattcggctc gagaggagtg gtccggggca ccggtttcaa agtcgcaggg cgggccgagt 60 ggacttccgc tgctggcctg gggcttccca gccgtcttgg cgttgtcctc tccaaccccc 120 gccgctccgc gtagaacgcc gctctcaggc tgccgtcaag ctcccgcggc actctcctag 180 gtggcccgac gagacccaga gtgacccgcg ggacgcctgt atcgaccgcg tcctcttccc 240 accagcgtgg gattcggttg aacgtggagt ccccagcaat cttcagtctc tcaccagggc 300 cagggactcg tctggggcgc gggggaaaga agcgtggcgg ggctgtagat gccgcgtgag 360 taggatgcag attgcaccgc tggagcgctt gacaaccaac cgagcgttgg cttagttttg 420 ttttcccgca cagcaagctc tctgtctttc agaggaaggt aaaggtggtg aaagctctaa 480 actaaaattg tatcgaaatg gctgcagaaa tcgactttct gagagagcaa aatcgaagac 540 taaatgaaga ttttaggcgg tatcaaatgg aaagtttttc caaatattca tctgtacaga 600 aagctgtctg ccaaggagaa ggagacgaca catttgaaaa cctagtattt gaccaaagct 660 ttttagctcc tcttgttact gagtatgata aacacctagg agaactaaat gggcagctga 720 aatattacca gaaacaggtg ggtgagatga aattacaatt tgaaaatgtc atcaaggaaa 780 atgaaaggtt gcacagtgaa ttaaaagatg ctgttgaaaa aaaattggag gcctttcccc 840 tgggcacaga ggtaggaact gacatatatg cagatgatga aacagtcaga aaccttcaag 900 aacaattgca gctagccaat caagaaaaaa ctcaggctgt ggaactctgg cagactgttt 960 ctcaggagtt ggacagacta cacaagcttt accaggaaca tatgactgag gcccagattc 1020 atgtatttga aagtcaaaaa caaaaggatc agctatttga ttttcaacaa ctgaccaaac 1080 aacttcatgt tactaatgag aacatggaag tgactaacca acagtttctg aaaacagtaa 1140 ctgaacaaag tgtgataatc gaacaactcc gaaaaaaact taggcaagcc aaattagagc 1200 tgagagttgc tgtagcaaaa gtggaagagt taactaatgt gactgaagat ctgcagggac 1260 agatgaaaaa gaaggagaag gatgtggtgt ctgcccatgg aagagaggaa gcatcagata 1320 ggcgtttaca gcagttacag tctagtataa aacaattaga aataagatta tgtgtgacaa 1380 tccaagaagc caaccaatta agaaccgaaa atacacatct ggaaaaacag accagagagc 1440 tacaagcaaa gtgcaatgaa ttagaaaatg agagatatga ggctattgta agagccagaa 1500 atagcatgca actcttagaa gaagctaacc ttcaaaaaag tcaggctcta cttgaggaga 1560 agcaaaaaga agaagacata gagaaaatga aagagacagt ttctcggttt gtacaagatg 1620 ctaccataag aaccaagaaa gaagttgcaa acaccaaaaa acaatgtaat atacaaattt 1680 ctcgattaac agaagaactt tcagcccttc aaatggagtg agctgagtcg acagaaactt 1740 catacccaag agctgctttc tcagctggaa atggcaaatg aaaaggtagc tgag 1794 81 2691 DNA Homo sapiens misc_feature Incyte ID No 3178841CB1 81 gcgaccagcg gaaggaggga gggggccgcg ctcggcgccc cggccgggcc actgggccac 60 aggccacgcg gccacgcagt ccgagcggga gccgagccgg gcggggcgag ggcagctccg 120 ggaaggaacg tcccagggat ggaagtgctt ggatgcggtg ctgctggctg cggatgtgcg 180 caaggagatg ggatggagag cctgagttgg cattcgtata aatgacctgc ctggctccca 240 ccatgagtgc tgagcttaac gtgcctatcg acccctctgc tcctgcctgc cctgagcccg 300 gccataaggg catggattac cgggactggg tccgccgcag ctacctggaa ctggtcacct 360 ctaaccacca ctcggtacag gccctgtcgt ggcggaagct ctacctgagc agggccaagc 420 tgaaggcctc cagcaggacc tccgccctcc tctccggctt tgccatggtg gccatggtgg 480 aggtgcagct ggagacgcag taccagtacc cgcggccgct gctgattgcc ttcagcgcct 540 gcaccacggt gctggtggcc gtgcacctgt tcgccctcct catcagcacc tgcatcctgc 600 ccaatgtgga ggccgtgagc aacatccaca acctgaactc catcagcgag tccccgcatg 660 agcgcatgca cccctacatc gagctggcct ggggcttctc caccgtgctt ggcatcctac 720 tcttcctggc cgaggtggtg ctgctctgct ggatcaagtt cctccccgtg gatgcccggc 780 gccagcctgg ccccccacct ggccctggga gtcacacggg ctggcaggcc gccctggtgt 840 ccaccatcat catggtgccc gtgggcctca tcttcgtggt cttcaccatc cacttctacc 900 gctccctggt gcgccacaaa acggagcgcc acaaccgcga gatcgaggag ctccacaagc 960 tcaaggtcca gctggacggg catgagcgca gcctgcaggt cttgtgaggg gccgagggcc 1020 ggggctggga gcggccctgt gcccgggagt ccgcagaggc ggggatttgt cagatgcaga 1080 cattttgcaa ggctgccggg tagttcaaga ccaaagtttt cctcttgtct taataccata 1140 aggactggat gacttctcct gagatagaac cgtttggttc aatgagggac tgtgttgcta 1200 agagcgttgg gggcaaagcc aggctggttc cttggcctcg gggtttcctg ggtcggggac 1260 acggtgaaga ggctccagcg ggacctgccc atcagtcctg ggccaggagg ggctccaagc 1320 agcacccagc ggtccggggg agtctcagac ccggcatgcg tggctggcag acctgggaga 1380 gccagggcag ggttttgcgt tcagagaagg attgccccag agacccgtgg tggacttcat 1440 gggtgctgag tggcccgtgt gacagtgatg acacgaaggc ttcggcgttt gagtgggtgc 1500 aggtgcacgc cagggcttgg tgcttccctg cctggccctg gagggagctg ggtggcctgg 1560 cttcagggga agacaggagc caggacacac gtcagcccag caggtgtggg gggtgctgca 1620 gccctcggca gtggggtcag gccctggggg atgtttccaa tggtgggcag cctggccagg 1680 ccggagaaga catgttcacg ggcatctatc agatgccccc ttgaggaggc tgagttattt 1740 gagggctgct gcaaagtacg ctaggctcaa attctctttt cccagccaga gccctggcca 1800 cacggactca gaggggccac cggggtgggg aaaggacccc tccccgaccc cccgcagcca 1860 ctggcctcca gctctcggcc acagaatggc ctctaaggct gactcagccg ctcccttggg 1920 ctgtggcagc aggaggcggg ggctctggct caggccccgg agcctgtgca gcttgcccat 1980 ggccctaggc agcgagggga cagcctgggg gacttcctgc ctaggcaagg tcattggccg 2040 ggcctggcct gtggatagtg gggccagggg ccggcccagg ccaaatgagt gccctccttg 2100 ttatgacacc aagtgactac aagggaggca agacccctcc aggcctctca gccgacactg 2160 ggtcccacca cacacagtga ctgtgccgtg cagtgcaggt tctggccttt tccttgaagg 2220 catctggtag acccgaagcc acgctctcgg gccgcacatg cacgccgcag caccagctgc 2280 cctgagctgc ttgtacaacc aaacaccttt cccctcttct ccagctgtaa cctggagagt 2340 cagccatgcc ttgtcttttg ttctcataaa tagtcactgg ggccgggcgc agtgactcac 2400 gcctgtaatc ccagcacttt gggaggccta ggtgggcgga tcacttgagg tcaggagttc 2460 gagaccagcc tggccaacat ggtgaaaccc tgtctctact aaaaaaatac agaaaattag 2520 ctgggcgtgg tggcgggcgc ctgtagcccc agctacttgg gaggctgagg cgggagaatg 2580 gcaatggcgt gaacccggga ggcagagctt gcagtgagct gagatggcgc cactgcactc 2640 cagcctgggc gacagagcca gactcaatct caaaaaaaaa aaaaaaaaaa a 2691 82 2056 DNA Homo sapiens misc_feature Incyte ID No 3674807CB1 82 gcagctgata gaaccatggc gaccattgct gctgctgcgt ttgaggccct catggatgga 60 gtgacatgct gggatgtccc cagaggcccc atccccagtg aactccttct tattggagaa 120 gccgccttcc ccgtgatggt gaatgacaag ggccaggtgc tcattgctgc ctcctcctac 180 ggccgaggcc gcctcgtggt tgtgtcccat gagggctacc tgtcgcatgc tggcttggct 240 ccatttctcc tcaatgcagt gagctggctc tgtccctgtc ctggggctcc cgtgggagtg 300 catccatccc tggcacctct agtaaacatc ctacaggatg ctgggcttga ggcacaggtc 360 aagccagaac caggagagcc cctaggggtt tactgtatca atgcctacaa tgacaccttg 420 actgcaacgc tgatccagtt tgtgaaacat ggagggggct tgttaatcgg gggccaggcc 480 tggtactggg ccagccagca cggccctgac aaggtgctct ccaggttccc tgggaacaag 540 gtgacaagtg tagccggagt gtacttcact gacacctatg gggacagaga ccggttcaag 600 gtctctaaga aggtgcccaa gatcccactc catgtcagga ggtagagccc ggtactcacc 660 cagcaatcat tgttgcctga caaaagtcac agagaaggct cagttcttcc ttcctatgtg 720 agtatatctc cacttggggc ctcccagccc ctcccagtgg tacagcttct cccctgtgta 780 tctcaagtca tccatacttc ttagactcat cccctctaaa ccttaagcag tgtcccaatc 840 cccatcttct tgaaagtacc tgatttttgt atttttagta gagacggggt ttcgccgtgc 900 tggccgggat ggtctggatc tcttgacctt gtgatccgcc agcctcagcc tcccaaagtg 960 ctgggactac aggtgtaagc caccatgccc ggcctggtct ttcttagtga tacataaaat 1020 aatggcattt ctcacaatca atttgtcata gatttgagga aacgctatag aggtagtgcc 1080 cttacttgca tatcttaaaa tccacatttt ctaaatgaac acctccagga attcctccca 1140 tttagtcaac tatgtgttga atattttggc ttcagtttct tgacttttaa aataattaaa 1200 catataaaca agttagaaaa actagtttat tatgcccaga gaaagtagta ctgcttatga 1260 atttctcgat ctaactttct gcaaaggaag gctgtaaaaa caccaaatct ggactctccg 1320 tagggtagtt ctgacctagg aacacatcac aattaaattg tttaacacta cgcttgaaga 1380 tttatacaaa cacacactgt ttttaaaact tcacttagat ctggttagag tattcacttc 1440 ttcttaagga atggtcaaaa tgtaatgaat caagaaaagg ctttgtattt caagaatttt 1500 tttaaaacaa tttgtatata ctgtaaatgt caagcaatag gaggttggtt aaataaatta 1560 tggttaacaa tagattgcaa accatatagt gattaaaata attattaggt aacttgaaaa 1620 atgcttaatg gaaaaagttt taaaattaga ttccaggata ccatgctctg aataagccaa 1680 attttggggt aaaaaaaata aaaaaccatg aaaccagaca tagaagcaga acctaaagca 1740 tatttatcaa aatatctttg tttaaaaaaa atgtcttcag tggtcgtctt ggctggtggg 1800 attttaggtc attttaatta tctttataaa actttattct ctcgaatttt aaaattaaca 1860 tctatttctc ttataattaa aaattaaatg ttatattttt taaaaagtat agtttattta 1920 ttccagtagt aaaacattgt tgaaaaatgt aactcttgtg cagattctct ttaatttctt 1980 ttcagcatga aaatgaggag atggcatgtc ttagttttgt catcccattt tcagactcac 2040 atggcaaatg tcatag 2056 83 2275 DNA Homo sapiens misc_feature Incyte ID No 1794922CB1 83 ctttcatatc cttagactgt atctgaaatt ttcatagctt tgcccacctt ttagggttca 60 gagttactac ccattcagtg tcggtggcct ttagctgttg gcaagcttcc aagtaaatag 120 ctcttttgca gagatctcta cccattctat tcttccactc ctgggtagtg gagaaccaaa 180 gttcacctga gtaatgcccg tgcccagcac ccagtttcct gcaggggtta gcacggatat 240 tggaggctcc cccgatccca cagatactca ggatgggtat tggagggggc ttggttttta 300 agaggacatg tgaaagtaat taacccgatt tacatttgta taatgagtcc aaacaccacc 360 ttgcaaaaga actgagagtt tagcctgctt aatggagttt ctgcttttca cggtccttgg 420 ccttaccgac ggtttacagt ccagccagat ttagttcaca aaaaaccaaa accaggtcga 480 cctcactgca gtatatgatg gcagcgagcg ttttaaagcg caggaccttt agtctcctca 540 atagttttgt gtaaagttgt ccaaaagtgt ttttttttaa agtgagatga tccagtcggt 600 aaacgctttg aaaaagaata gctgtcccct gagcgggcat tagtcgcgtg tgaggtcagg 660 gcccatcatt gcgcgtgttg ggagcgccgc gctggtctat gagcgagcgc ctcggcttgt 720 ggctgggccg ggccggggcg gggctgtctt cccgcggagc gtgctggggg cgggtcgcgc 780 cgggccgggc cgctagtgcg catgggcggg cgtcctcggc tctaactgcc gccactttcc 840 acacgctggg agggccgtta cctcagagat acccgtggcc ggcatgttgg ttgaaaaagc 900 ttcccggaag ggagacgaag agaaaggaga ggagcagctc gtgatcatcc ccggtagcga 960 gtacgcggcg aagtaggcgg cggcggaggg agcgctgatg aagatggatg tgtcagtgag 1020 ggccgcgggc tgctccgacg acctcagctc tggggaggcc gacgtagacc caaagctcct 1080 ggagctcacc gctgacgagg agaagtgccg cagcatccgc aggcagtacc ggcagctcat 1140 gtactgcgtg cggcagaacc gggaggacat cgtgagctcg gcgaacaact ccttaaccga 1200 ggctctggag gaagccaacg tcctctttga tggcgtgagc cgaaccagag aagcagccct 1260 cgacgcccgg tttcttgtta tggcttctga tttgggtaaa gaaaaggcaa agcagttaaa 1320 ctcagatatg aacttcttta atcagttagc attttgtgac tttctgtttc tgttcgtggg 1380 tctgaattgg atggaaggcg atcctgacaa gttgagtgat tgtgatgata gcatagctct 1440 ttccttctgg aaggcaatag aaaaggaagc aacatcctgg atggtaaaag ctgagacatt 1500 ccattttgtt tttggttcat tcaagctaga acgttctgca ccaaagcccc gacttgaaca 1560 ccagaaaaaa gttcgcaaga tggaagaaaa tggcaacatg cctacaaagt tgcagaagtt 1620 ggacctgagt agttatccag aagcgacaga aaaaaacgta gaaaggattt tgggattgtt 1680 gcaaacctac tttcgaaagt atcctgatac tcctgtgtcc tattttgagt ttgtgattga 1740 tccaaactct ttttctcgta ctgtggagaa tatattttat gtttctttta ttgtaagaga 1800 tggttttgca agaataaggc ttgatgaaga caggctgcca atattagagc cgatgaatgt 1860 taaccaaatg ggtgagggaa atgattccag ttgccatggc aggaaacagg gagttatatc 1920 tttgacttta caggagtgga aaaacattgt ggcagctttt gaaatttctg aggctatgat 1980 tacatactcc tcatactaaa gatttcttag tatagcatcc tttttgtgtt ttttttctga 2040 agttagatgg agagtaaaat gtaaactgaa gcacatattg tatctcttgt aaagtgaaaa 2100 agtattttca agaacatcag acattgtttt actgtgcagc atatttttct tagtaattta 2160 taaggtcatg atcttctgtt attaaaacaa attcactggc atatttatgg gaacgtttta 2220 ttgaatgccc tttaagacta ttaataaaaa caagttttgg ataccaaaaa aaaaa 2275 84 1219 DNA Homo sapiens misc_feature Incyte ID No 1795509CB1 84 gcttgttgca gctctagccc aggtcctgcc ctcttcccgc cccgccccta gggtccagct 60 cccttcacct aggagctgcc aaacatctgg atcaacctgg gcactacgag gggttgaatt 120 tctaccatta tcgcgccttt tgatattttt ttccagacct cctgctcaca tccgtaaagc 180 ccactgattc ttttactaca ctttttatga gaacaagaca ttttctagga agatggtggc 240 agaaaaagag accctgagct taaacaaatg cccagacaag atgccgaaga ggaccaagct 300 gctggcacaa cagccgctcc cggtgcacca gcctcactct ctggtttctg agggtttcac 360 agtcaaagcc atgatgaaaa actcagtcgt gagaggccct ccagctgcag gggcatttaa 420 agaaagacca accaagccca cagcatttcg aaaattctat gagcgaggtg acttcccaat 480 tgcccttgag catgattcga aaggaaacaa aatcgcctgg aaggtagaaa ttgagaagct 540 ggattaccat cattatctgc ctctgttttt tgatgggctt tgtgaaatga catttcccta 600 tgagtttttt gctcggcaag gaatccacga catgctggaa cacggtggga acaagatcct 660 acctgtcctt ccacagctca ttatcccgat aaaaaatgcc ttgaacctcc gaaaccgaca 720 ggtcatctgt gtcactctca aggtcctcca gcatctggtt gtgtcagctg agatggtggg 780 caaggccttg gtgccttatt accgtcaaat cctccctgtc ctgaacatct ttaagaatat 840 gaatgtgaac tccggagacg gcattgacta cagccagcag aagagggaga acattgggga 900 cttgatccag gagacactgg aggccttcga gcgctacgga ggagaaaatg cctttatcaa 960 cattaagtac gtggtcccaa cctacgagtc ttgcttgcta aactaacagt ggcagcagct 1020 gggacttgaa acctcccgtt ggtgttggga tcatctgtct ctgttgcttt tagcatctca 1080 ttccttgtga cttccacagc tttcttttct acagctgcta aaatagtggc ttatgggcca 1140 ttggactgtt agccctattg agagcaaggc tttccaatac ataaatagtg cctgtttctt 1200 agattaaaaa aaaaaaaaa 1219 85 1015 DNA Homo sapiens misc_feature Incyte ID No 2017180CB1 85 ggaagcgggg gtgcagcgcg gcagaatgag ggttgattcc tcggctgacc ccacaatgtc 60 gcaggagcaa gggccggggt cctccacgcc tcccagttct ccgacacttc ttgacgctct 120 gctccagaac ctttacgact ttggaggtac agaaggtgaa acagaacaga agaagatcat 180 aaagaaaagg gaaaacaaga agagagatgt gatggcttca gcggccttgg cagcagagcc 240 atctccccta cctggttctc tcataagagg ccagaggaag agcgcttcga gcttcttcaa 300 ggaacttaga gaagagcggc attgtgctcc ttctgggacc cccacaggac cagagatcct 360 tgctgctgca gttcctccct cttccctaaa gaacaatagg gaacaagtag aagtggtaga 420 atttcacagc aataaaaaaa gaaaattgac gccagatcat aacaagaaca caaagcaggc 480 taatcctagt gttttggaga gagatgtgga tacacaagaa tttaacctag aaaaagctcg 540 tttagaagtg caccggtttg gtatcacggg ttatggaaaa ggaaaggaga gaatcctgga 600 acaggaacgt gccattatgc tgggcgctaa gcctcctaaa aagagttatg tgaattacaa 660 ggttttacag gagcaaatta aagaaaaaaa ggcagcaaag gaagaagaaa agagactggc 720 ccaagaaaca gatattttca agaaaaagaa gaggaaagga caggaggaca ggaaatccaa 780 aaagaagtcc gctcccagta ttttgtcaaa tggacggatt ggacaggttg gaaaattcaa 840 aaatggaaca ctgattctga gcccagttga tatcaagaaa ataaattctt ccagagtggc 900 caaatgaagt actttgtcaa ataaaacgag gatgggaaca actgagtcaa ctgcagcggc 960 cctggaccct gtgcgactct agatagatcg ttcttaacac gcatttcaca gactg 1015 86 2392 DNA Homo sapiens misc_feature Incyte ID No 219442CB1 86 ggcggagtga ccacatagag taaaaagaat gtaaccctct ttggttttat gtgttttggc 60 tcaggttgga catacttata taaatgtgat tgacattgaa gctaatgatc ttctacagga 120 attacctgtg agagaagagc cttcaaatga taatgttatc aaacagcaaa gcgatcatct 180 agcagttcca tcgtctgcag agttacatta tatggcagct tcagttacta atgctgttcc 240 cccacataat tttaagagtc aagaagtaac tccagcttgt ctggatggaa aaagcttgag 300 agcaggcatt acagaagtga aggagcctag tgtcacctca cctacaccat cagacataca 360 gcagaacaaa ggtctgccaa aaccagagtt ccgattcaaa ggacagagca caaagtcaga 420 ctctgcagaa gattatctat tgtggaaacg gctgcaaggt gtctctgcag cttgccctgc 480 accaagctct gcagctcacc aactagagca tctcagtgct aagcttcaga aaattgacga 540 gcagttgcta gcaatacaga acattgctga aaacatagaa caggatttcc ccaagcctga 600 aatgctagat ctacattgtg ataagattgg accagtggat cacattgaat tctcttctgg 660 ccctgaattc aaaaaaacat tagcttcaaa aaccattagc atttctgaag aagtgcgttt 720 tttgacccat atggatgaag aagatcaaag tgacaaaaag gagacttcag aacctgaatt 780 ttcaataaca gaaaattatt ctggtcagaa aacctgtgtg tttcctactg ccgattcagc 840 tgtcagcctt tccagttcca gtgatcagaa tactacttct cctggtatga atagcagtga 900 tgaattgtgt gagagtgttt cagtacatcc gctccagatg actggattga ctgatattgc 960 agacattatt gatgacctta taattaaaga cggagtttcc agtgaagaac ttggcttaac 1020 agaacaagct atgggcacct ccagaattca gcattattct ggcagacatt cacaaagaac 1080 tgacaaggaa agaagagaga ttcaagcctg gatgaaaaga aaacgaaaag aaagaatggc 1140 aaagtactta aatgagctgg cagaaaagag agggcaagaa catgatcctt tctgtcccag 1200 aagcaatcca ctttacatga cttcaaggga aataaggctg agacaaaaga tgaagcatga 1260 aaaagacaga ttgctgctct ctgaacacta tagtcgtcga atctcacaag cgtacggtct 1320 gatgaatgaa ctgttatctg agtcagtaca gctaccaact ctaccacaga aaccattgcc 1380 taacaaaccc agccctactc agtcttccag ttgtcaacac tgcccttctc caagaggaga 1440 gaatcaacat ggtcacagtt ttctaataaa tcgacctgga aaagtcaaat atatgtccaa 1500 accgagttat atccataaga ggaagtcttt tgggcaacct caaggctcac cttggccaca 1560 tggaactgcc actttcacca tacagaaaaa agctggtgga gccaaagcag cagtaagaaa 1620 ggctacgcag tctccagtta ccttccaaaa aggctctaat gctccgtgtc atagtctgca 1680 gcatacaaaa aaacatggaa gtgctgggct tgcacctcaa accaagcagg tgtgtgtaga 1740 gtatgaaaga gaggagactg tggtgagtcc ctggacgata ccttcagaaa tccataagat 1800 tcttcatgag agtcacaatt cccttctaca agacttgtct ccaactgaag aggaagagcc 1860 agagcatcct tttggggtgg gcggtgtgga cagcgtgtct gagagcactg gcagcatcct 1920 cagcaagctg gactggaatg ccatcgaaga catggtggcc agcgtggagg accagggcct 1980 gtctgtccac tgggccctgg acctgtaaga cctggatatc attgggtttc catgcacagg 2040 ccagcacctc agtaatgtgg ttctgaaaga ttaacaggtt taagggacag aagcaatgaa 2100 agaagcaatg tgaattttcc atttgctttc atattattac ctggattagc cattaccaga 2160 ggaaaaataa acatttctca gtaactttgc ctttatgggg aaagggttga ctattgatgt 2220 attatatgtt tttgtatttg atgcatcatt aggcataatt tttaaaatga taagtacctt 2280 tcaagccaag tttgcataac ctactttcaa taaaaaccct ctatcttgcc tcctccttta 2340 ttaccctctg agttttgaga aacaaccata tacagatgaa tctaatagga aa 2392 87 1799 DNA Homo sapiens misc_feature Incyte ID No 2597459CB1 87 gcagagcgaa gctactgcgg gttctgttaa cctcagcatc gtggggcgaa gcagagccat 60 tgtgcatcaa ggagaggccg gtgcctgcgc tgccgtctct ggcacctaac ccagcagacc 120 gctcacccca tcggctggaa tgcttgctga ttcctctgca cacttctaag gctgagaacc 180 tgaggaaccc agctggaaaa tgccgtctga acgctgcctc agtattcaag aaatgctgac 240 aggccagagg ctctgccact ccgaatctca caatgacagt gtcctggcag cgctgaatca 300 gcagaggagt gatggcatcc tctgcgacat caccctgatt gctgaggaac agaaattcca 360 tgctcacaag gcagtcctag cagcatgcag tgactatttc cgggcaatgt tcagtctttg 420 tatggtggaa agtggagctg atgaggttaa tttgcacggt gtgaccagcc ttggcttaaa 480 gcaggctctg gagtttgcat acacaggaca gattttgctg gagccaggtg tgatccagga 540 tgtgctagca gcgggcagtc acctacagct gttggagctt ctcaatttat gctcccacta 600 tctcatccag gaattaaata gctttaatta cttggatctg tacagacttg ctgacctctt 660 taacctcact ttgttggaga aggcagtgat cgatttctta gtgaaacatc tctctgaact 720 cctgaagagc cgcccagaag aagttctaac gcttccctat tgcctgcttc aggaggtgct 780 gaagagcgac cgcctgacct ccctgagtga agagcagatc tggcagctag ctgtgaggtg 840 gttggaacac aactgccact accagtacat ggacgagctc ctgcaataca tccgctttgg 900 cctaatggat gtggatactc tccatacagt tgccctgtcc cacccccttg tccaagcaag 960 tgagactgca acagcccttg tcaacgaggc cctggaatac caccagagca tctatgcaca 1020 gcctgtctgg cagactcgca ggaccaaacc acgattccag tcagacactc tgtatatcat 1080 tggtgggaaa aagcgcgagg tctgcaaggt caaggaactt cggtacttca atcctgttga 1140 tcaggagaat gctctcatag ctgccattgc caactggagt gagctggctc ccatgcctgt 1200 gggaaggagc caccattgtg tggcagtcat gggggacttc ctgtttgtgg caggagggga 1260 agttgagcat gccagtggcc ggacgtgtgc tgtgaggact gcctgtcgct atgacccccg 1320 cagtaattcc tgggcagaga tagcacccat gaaaaactgc cgggagcatt ttgtgctggg 1380 tgccatggag gaatacctct atgcagttgg gggcagaaat gaactgcgcc aggttctgcc 1440 tacagttgag cgatattgcc ccaagaagaa caaatggact tttgttcagt cctttgacag 1500 atccctttca tgccatgctg gatatgtggc tgatggtctt ctttggatat caggtagaac 1560 atacctcatg ttggatttat caaaacacac tttcattgtg gtatatattt aaaagtcaag 1620 ctttaatact gtggccatgt gtaattgaaa gattgaacca agcatgccat tttagctaat 1680 taacattcat ttattgagca cctactctag agagcaatgt aattggaaat aatatgcctt 1740 tctgtgactt tctgagtgac taatggaata aaaattcaag gtggaaaaaa aaaaaaaaa 1799 88 3718 DNA Homo sapiens misc_feature Incyte ID No 2783863CB1 88 ggcgctggcg gcagtggccg gtgtgagcgc agagccgggc cctgggcagc agcggcagcg 60 cggtaggacc tcgcgcagcg tccgcgggct ccggggcggg ggcgccagcg gcgaagcccc 120 ctccccgggg aggcgggacc tgggggagct cccgagccgg ggagcggcgg cggccgggaa 180 cgatgcatca gaagctgctg aagagcgcgc attacatcga gctgggcagc taccagtact 240 ggccggtcct ggtgccccgt ggcatccgcc tgtacaccta cgagcagatc cccgggtccc 300 tcaaggacaa cccgtacatc accgacggct accgggccta cctgccgtcc aggctgtgta 360 tcaaaagttt gtttatttta tctaatgaga cagtaaacat ctggagtcat ttgctgggtt 420 tctttctctt cttcaccctg ggaatatatg acatgacatc tgtgttacct tcagcaagtg 480 cgtccagaga agattttgta atttgttcta tttgtctttt ctgcttccag gtctgtatgc 540 tttgctctgt gggctatcat cttttttcct gccatcggtc agaaaaaaca tgtcgaagat 600 ggatggcatt agattatgca ggaatttcta ttggaatact gggctgctat gtctcaggag 660 tattttacgc attttattgt aataactact ggcgtcaggt gtacttgatc acagtgcttg 720 ctatgatcct ggcagtgttc tttgcgcaga ttcatcccaa ttacctcacg cagcaatggc 780 aaaggctccg ttctatcatc ttttgttctg tttcgggata tggagtgatt cctactcttc 840 actgggtttg gctcaatgga ggaattggtg ctcctattgt acaggacttt gcaccccgtg 900 taattgtgat gtatatgatt gctcttcttg ctttcctatt ctacatttcc aaagtcccag 960 agcggtactt tccaggacaa ctaaactacc tcggatcaag ccaccaaata tggcatatcc 1020 ttgcagtagt gatgttatat tggtggcatc agtcaacagt gtatgtcatg cagtacagac 1080 atagcaagcc ttgtcctgac tatgtttcac atttgtgaat taggtatggc cacctggtga 1140 attcagttgt taagcaatat ataatgggga attgtatacc ccactatttc taagattccc 1200 attagttttc cctttttcct ttttaatatg agtaatgctt tataaaaatg ggaaaaaaag 1260 tatacttaag gatctgtagt aataactgct ttacaaaatc cttaaaacta ctaatttgct 1320 gcttgtacag aaagtgaaaa ttagttggca atcataagaa acatctgaat aacaacgatg 1380 aatgggaaac tagtgttgaa ataggattca ttttacttag caccagctta atttccttag 1440 gaagggctca tctccattag aaaatggagt catcttatgt gcttaattat tttcagttaa 1500 ttgtcaagtt taagtgccta atcaaggcaa gtgttgtttc agcctatgct taatgcaagc 1560 taggatagtg attttaaata atcactaaaa tcactagatt taaataatca ctaaaatgat 1620 ttgtgagaaa ctggcacttc agatattata tcctttagct ataggttctt ctctccctaa 1680 gaacattaga tattttagtt ttccagaaca aaagctttaa acttctgcag taagttgaga 1740 gaagggttga gaagaggaaa agaacttctc attttctatc agataagaat cacattagaa 1800 actaagtaca agattagaca acaaattatg tggtcaaata atatagtcat tagccaccta 1860 aacattttaa ttccagatat tatttaattc catataataa ctgaattctt gtgagtggat 1920 tacaggtttt tgatcccaaa attccagagc tttcaactct ctgaatttgt agtcctgaat 1980 atcccagtgg tgggggttcc cagcattgtg ggtgctactt gcaaggccat agaatctaga 2040 tggccctgtc ttgaccctga aatgaacctt aagccttaga acaaagtcat gcagatgccc 2100 catttgataa taatcttatt cacctgtgct ctggtcctcg gtttctgcat gtgttagcat 2160 tgcattgata actcagaatc ttgataaaca cttaatattt gggcctgaag cattaaactt 2220 tctttttatt gtatatactt aaaaaataga actcactgcc ctatcataca ttgtagccct 2280 cttattcttt ggtctttcat atgcattagt taaatccctt aaagtagaca ttcataaaaa 2340 cttacattgt ttattggagt ataaaatatt acccaagttt cttcatgagt tgacatgagc 2400 tgttttaaat actggtgtat tttcagaaca gtaaaattac tgaatatcag aaaaaatgtt 2460 aattgatgat gaagcttatt cccaaaatgc cttttgtgca tatgatactt ggaaagtcac 2520 taatgtgcct cagttaatac atcagtaaaa tgttgtgttt cttttccagt gtagtgtttt 2580 tggaatataa attccccatg ctagtatagt atctcagcaa agagaatttc cccccaggag 2640 gctcagtaaa ggaataccgt gtcttaccca tcgttatgat ggaaggctgc tttgaaaatg 2700 gctgttttac cttataaggt taaaattttg atccatatgt taagtgatag aagattttgg 2760 tgcaacagta gtaggatata tttctcctag aacatccctt attggcttac atgattttat 2820 tgccttttaa tagatatttt gtcattttgg ccaaacaaaa gacactgagt agttacactt 2880 aagttaaaaa tgaggggaaa atcattattt taggtgtgga gccattttta ttataaaact 2940 ttctcaaaat aaaaaaacat tgaatcattt caatttttgc agtccctgta ttagtatatg 3000 aatacatact tgccatttga attaataaca tgaaaagagt atactgtgtt tttaaatccg 3060 tgtttctttg aatttaaagg gtgtacaggt ctttctgtag ggaaaattat tccatgtaaa 3120 catttcaact ctgtatgaaa atgttaaata ttgtaagaaa gttatcctct cattttttca 3180 ctgctatgat atatttatta taaaataggg aatgaatgaa tgaatatgga ttgctgttaa 3240 ctagaaacac ttctgtatgt cagtcagcat ttaatgacca cctactgtgt gcacagcact 3300 actggtaaaa ttttgaagac attgttaaca ttaaaaaata ttttaaagtt gtctacaaat 3360 ctgagccttg taatgatgta tatttaagtt atttttgttt ttatagatta aagtaagatt 3420 atactatcca gttttattac taaaaaagac tggttttaat tttaccaatg tgtgaactat 3480 aaaagctttt tgcctacaga ttttacattt taaaattatc tatggctgtt ttaaattgtc 3540 tagcaattta tatggttgtg gttaactcat ttaagaaaca attatctttc tatattaagc 3600 cattttcaaa tagcaagaca gtgcttgtct ttttttgtta ttacactaac tgcaattcag 3660 taagctgcat gacaaaatat gtattatgta aataaactgg gtttactaaa tactttct 3718 89 3250 DNA Homo sapiens misc_feature Incyte ID No 2902971CB1 89 atggcaacaa gtatggcggc tgctagtggt agatttgaaa gtgcgaagag tatcgaagag 60 cggaaagaac agacccggaa tgccagggcc gaggtgttgc gccaggctaa agccaatttt 120 gaaaaagaag aaaggcgtaa agaacttaag cgacttcggg gtgaggatac atggatgcta 180 cctgatgtga atgagagaat tgaacagttc tcacaggaac actctgtgaa gaaaaagaag 240 aaaaaagaca agcattcaaa aaaagcaaag aaagaaaaga aaaaaaagag caagaaacag 300 aaatatgaaa aaaacaatga gtcatctgat agctcatcaa gctctgaaga tgagtgggtt 360 gaggctgttc catcccagac tcctgacaag gaaaaagcct ggaaagtgaa agatgaaaag 420 tcaggaaaag atgacaccca aattatcaag agggatgagt ggatgactgt tgattttatg 480 tctgttaaaa ctgtgtcatc atcatcactc aaagctgaaa aggaaactat gaggaaaata 540 gagcaagaga aaaaccaagc gcttgaacag tccaaactga tggaaagaga attgaatccg 600 tactggaagg atggtgggac aggtcttcca cctgaagact gtagtgtgtc atcgattact 660 aaagtttcag tggtagaaga tggtggatta agctggctaa ggaaatctta tctaagaatg 720 aaggaacaag ctgagaaaca aagtagaaac tttgaggaca ttgtagccga aagatatggg 780 tcaatggaaa tatttcagtc aaaattagaa gatgctgaaa aagctgcatc cacgaaagaa 840 gattatagac gggaacggtg gaggaaaccc acatattcag ataaagcaca aaattgtcaa 900 gaaagtagag aatcagactt agtaaaatat ggtaacagtt caagggatag atatgctaca 960 acagatactg caaaaaatag caataatgaa aaatttattg gtgatgaaaa agataagaga 1020 cctgggtctt tagaaacgtg tagaagagaa tctaacccaa ggcaaaatca agagttttct 1080 tttggcaatt tgagagctaa attcttgaga ccctctgatg atgaagaact gtcatttcac 1140 agcaagggca gaaaatttga accacttagt tcatcttcag cattggtagc tcagggctct 1200 ttgtgtagtg gttttagaaa acccaccaag aacagtgaag aaagattaac atcatggagt 1260 cgctctgatg ggagaggaga caagaaacat tcaaatcaaa agccatcgga aaccagtact 1320 gatgaatacc aacatgttcc agaagaccca agagaaaaat cacaagatga agtcttgaga 1380 gatgaccctc caaaaaaaga acatctacgg gatacaaagt ctacatttgc tggcagtcca 1440 gagcgtgagt ccattcacat cctgagtgtt gatgagaaga acaagttggg agccaagatt 1500 atcaaagcag agatgatggg gaatatggaa ttagctgaac aacttaaagt tcaacttgaa 1560 aaggcaaata aattcaaaga aactataaca cagataccaa aaaaatctgg ggtagagaat 1620 gaagaccagc aagaagtaat ccttgtcaga acagatcagt ctggaagagt atggcctgtg 1680 aacacacccg gaaaatctct ggaatcacaa ggaggaagaa gaaagagaca gatggtttca 1740 acccatgagg aaagagaaag ggtcagatac tttcatgatg atgataatct aagcctaaat 1800 gatttagtca aaaatgaaaa gatgggaaca gcagaaaatc aaaacaagct ctttatgaga 1860 atggcatcta agtttatggg aaaaacagat ggagactatt acaccctgga tgacatgttt 1920 gtctccaaag cagctgagag agaacgtctt ggtgaagagg aagagaacca aaggaaaaaa 1980 gctattgctg agcatcggag tcttgctgca caaatggaaa aatgtctgta ttgttttgac 2040 agctctcaat ttcccaagca tcttattgtt gcaataggtg ttaaggttta tttatgttta 2100 cccaacgtac ggtctcttac tgaggggcac tgcctgatag tccctttgca gcaccataga 2160 gcagctactt tgttggatga agacatctgg gaggagatcc agatgttcag aaaatcattg 2220 gtaaagatgt ttgaagataa aggattagac tgcatttttt tggaaactaa tatgagcatg 2280 aagaaacagt atcacatggt ttatgaatgt attcctcttc ccaaggaagt gggtgacatg 2340 gctcccatct attttaagaa ggccataatg gaatctgatg aagagtggtc catgaacaag 2400 aagttgatgg atctctcttc aaaagatatc agaaagtctg tacccagagg gttaccttac 2460 ttctctgtgg attttggcct tcacggaggg tttgcccatg tcattgaaga tcagcacaaa 2520 ttccctcatt actttggaaa ggaaatcata ggtgggatgc tggatataga accaagactt 2580 tggaggaaag gcatccgaga aagctttgag gatcagagga aaaaagcact gcagtttgct 2640 cagtggtgga aaccatatga cttcaccaaa agtaaaaact attgaggtgt accttccatt 2700 ttaaaatttt tcttcagatc ccgttcagtt ttatttccat tgcatctaat gaagcaactg 2760 accctcaggt cacaggcaga gagagtcaca gcagcagact gctctgggtc agtgacaact 2820 gtacatcagg agattgtgtt gttttcttct tcacctgctc ctatctatgg acttcatttt 2880 agtcaccatg gagtaaaaac atatattcga tgatctgctc acattcctgc tctctaccta 2940 cttcttggta ttccgaattg ttcagttaat ttagagaagg ccttttctga agggatatct 3000 agaaagcata ggaaatcctt ggttcagagg gaagtgggtc tgcttcatgg ttgttaagtc 3060 tactgtctgg cttcttttgc atttttaaaa ataagacgat ttaattttaa tttcatagga 3120 ttttatagaa aagctcttaa ttttctacta gcagtatata gtatcacttc tattcttttt 3180 gttaaaggaa aaggaaatgt ccccaaagta ttaaagaatt aaatgatact gaaaattaaa 3240 aaaaaaaaaa 3250 90 2295 DNA Homo sapiens misc_feature Incyte ID No 368660CB1 90 gtaccacccg gctcaagtag cggacacgga acagggaact atcagcccgt cggcctccgg 60 gccctgcatt ctctagccat ggaccgggac cttttgcggc agtcgctaaa ttgccacggg 120 tcgtctttgc tctctctact tcggagcgaa cagcaggaca atccacactt ccgtagcctc 180 ctggggtcgg ccgccgagcc agcccggggc ccgccgcccc agcacccgtt gcagggcaga 240 aaagagaaga gagttgacaa catcgagata cagaaattca tctccaaaaa agcggatctg 300 ctttttgcac tttcctggaa atcagatgca cctgcaactt ctgaaattaa tgaagacagt 360 gaagatcatt atgcaatcat gccaccttta gagcaattca tggagatacc tagtatggat 420 cggagagagc tgtttttccg agatattgag cgtggtgata tagtgattgg aagaattagt 480 tctattcggg aattcggttt tttcatggtg ttgatctgtt taggaagtgg tatcatgaga 540 gatatagccc acttagaaat cacagctctt tgtcccttaa gagatgtgcc ttctcacagt 600 aaccatgggg atcctttatc atattaccaa actggtgaca tcattcgagc tggaatcaag 660 gatattgaca gataccatga aaagctagca gtatctctgt atagctcttc tcttccacca 720 cacctatctg gtattaaatt aggtgtaatt agctctgaag agcttccttt atactacagg 780 agaagtgttg agctaaatag caattctttg gagtcctatg aaaatgtcat gcagagttcc 840 ttgggatttg ttaatccagg agtagttgaa ttccttctag aaaaactagg aatagatgaa 900 tctaatccac catctttaat gagaggccta caaagcaaaa atttctctga agatgatttt 960 gcttctgcat tgagaaaaaa acaatccgca tcttgggctt taaaatgtgt gaagatcgga 1020 gttgactatt ttaaagttgg acgccatgtg gatgctatga atgaatacaa taaagctttg 1080 gaaatagaca aacaaaacgt ggaagctttg gtagctcgtg gagcattata tgcgacaaaa 1140 ggaagtttga acaaagcaat agaagatttt gagcttgcat tagaaaactg tccaactcac 1200 agaaatgcaa gaaaatacct ctgccagaca cttgtagaga gaggaggaca gttagaagaa 1260 gaagaaaagt ttttaaatgc tgaaagttac tataagaaag ctttggcttt ggatgagact 1320 tttaaagatg cagaggatgc tttgcagaaa cttcataaat atatgcagaa atctttggaa 1380 ttaagagaaa aacaagctga aaaggaagaa aagcagaaaa caaagaaaat agaaacaagt 1440 gcagaaaagt tgcgtaacgt cttaaaagaa gagaagaggc taaagaagaa aagaagaaaa 1500 tcaacttctt cttcaagtgt ttcttctgct gatgaatcag tgtcttcatc atcatcctct 1560 tcctcttctg gtcacaaaag gcataagaaa cataagagga accgttcaga gtcttctcgc 1620 agttccagaa ggcattcatc tagggcatcc tcaaatcaga tagatcagaa taggaaagat 1680 gagtgctacc cagttccagc taatacttca gcatcttttc ttaaccataa acaagaagtg 1740 gagaaactac tggggaagca ggataggtta cagtatgaaa agacacagat aaaagagaaa 1800 gatagatgcc ctctctcttc atcttcactt gaaataccgg atgattttgg agtgtactcc 1860 tatttattta aaaagttaac tataaaacag cctcaggcag gtccttcagg agatattcca 1920 gaagagggca ttgttatcat agatgacagc tccattcatg ttactgaccc tgaagacctt 1980 caagtgggac aagatatgga ggtggaagac agtggtattg atgatcctga ccacgggtag 2040 gcttaggttt atgtgtgtgt atgtgtctta gtttttaaca aaaaaattaa aaagtaaaaa 2100 aactaaaaat agaaaaatgc ttagagaata aggatataaa gaatattttt gtgcagttga 2160 acaatgagtg cttaagctaa atgtcatcac aaaagagtaa aaaaatttta caaaattaaa 2220 aatgtttaaa gttaaaaagc tctaggaagc taaggtcaat ttattattgg agaaataaaa 2280 ttatttttat gaatt 2295 91 1777 DNA Homo sapiens misc_feature Incyte ID No 2804990CB1 91 actaaatgtg ccagtacctg agattccagg aaaaactaaa aatttgtttt tgcaattagc 60 caaacatgta gcccagtctc tacaagtcgc ctatgtcatg tttgtggagg aaccgtaaca 120 ggagatcaat ggccatggga agcccgagaa ttggttccta tagacccggt tcctgatgaa 180 ttcccagccc aaaagaacca ccctgacaaa ttttgggttc tgaaagtctt attattggac 240 agtattgcat agctagagaa ggaaaaggat ttactcatcc tgtagggcag cttagttgtc 300 ttgggcaaaa gatgtataat ggtaccacaa aaacagttac atggtggagt tccaattaca 360 cagaaaaaaa tccattcagt aaatttccaa agttgcagac tgtttgggcc cacccagaat 420 tgcactggga ctggacggcc cccactgggt tatactggat atgtggacac agagcttatg 480 ctaagctgcc tgatcagtgg acaggtagct gtgtaattgg caccattaag ccatctttct 540 tcttagtgcc cataaaaaca ggtaaacttc tgggcttccc agtctgtgct tcctgtgaaa 600 aatgaagcat agccataggt gattggaaag acgatgaatg gccccctgaa aaaatcttac 660 aatactatgg acctgccact tgggcacaag atggctcatg gggatatcga acccccatct 720 acatgctcaa ccgaatcata tggttacaag ctgttttaga aattattact aataaaacca 780 ctcaagcctt gactgttctt gcctggcaag agactctgat gagaaatgct atctatcaaa 840 atagactagc tcttgattac ttgctagcag ctgaaggagg agtttgtgaa aaatttgacc 900 ttactaatta ttgtctacac atagatgatc aggggcaagt agttgaggat atagttaaag 960 atataacaaa actggcacat gcacctgtgc aagtgtggca cggactcaat ctgggagcca 1020 tgtttggaaa ttggttccca gcaataggtg gatttaaaac tcttataata agagtaataa 1080 tagtaatagg aacctgctta ctgctccctt gtctgatacc tgtatttctc caaatgataa 1140 aaaacttcgt cgcttaacct tagttcacca aaatgcttca gcacaagcat actatataaa 1200 tcactatcaa tctattgcac gaaaatacat aagtagcaaa aataagagtg agaactccca 1260 ctgataaaaa gtgagagtct caaagagggg aaatgaggga agagagagac cctctcatat 1320 tgttttatat tgttttatac tcagtacctc ttttaagaaa aaaacaacaa ggaagtagaa 1380 ccaaagacaa gcagcccagc gccaggccca aaaccaggcc tgggcctgcc tggcctaaac 1440 ccagtagtta aaaatcaact cataacttag aaactgatgt tattcataga ttccagacat 1500 tgtatagaag aacattgtga aactccctgc cctgttctgt ttctctctga ccaccggtgc 1560 atgcagcccc tgtcacatac cgcctgcttg ctcaaatcaa tcatgaccct ttcatgtgaa 1620 atctttagta ttgtgagccc ttaaaaggga cggaaattgt gcattcgggg agctcggatt 1680 ttaaggcagt agcctgctga tgctcccagc tgaataaagc ccttccttct acaaaaaaaa 1740 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaag 1777 92 3181 DNA Homo sapiens misc_feature Incyte ID No 168571CB1 92 gactccacca gccacccctg agctccaacc ttggggggat gcagagatcg gggaggccca 60 aggccacctc ctcaggccca aagggaggcc actgcaggca agatgaggtg gcccagagga 120 gccacatggg gcctggaggc catctgggcc gaggcagagc caccgtcaca cgtggatctc 180 agagacccac aggaagagga tggtggctgg gagggctgag gcagtccccc agagaactgt 240 cctgccaggc cacaaggtca gtgagaggga gcccggctcc caccccaggg accaggtgtc 300 ctttttcagg tccaggtggc agtgtccatc actccagggg cccccactgg ggaacttctg 360 agaagccagg gcatggagca agagggtgat acccacaaac tctttcctca tccttccctg 420 atttgaaatg gagggtggga tgcagaggag agaggtggaa agacaggtgc acagccccag 480 gcctctcccc cacccctgcc tcgcccacca tgtggctgga acggtgacca cccagcaaga 540 acccatctcc caccctcacc agtgatcccg gaaaaccagt cactggggtc ccgcggggca 600 tccgaaggcc caagggcaag tcacctttca gaatgtcccc tctgtgcagc ctttgccagg 660 aaggaagctg gaccgggcca gctgcatgga tgccaggacc tctaggccct gagcatcagg 720 gggtccagcc caggacaccc caagcctggg cccctctccc tgctgaaggg ctctggggag 780 cgcggggaga agccagcagg catggaggct gcccatcccc cagccatggc ctggggcccc 840 acgcagctct ctgcctcccc caggagaacc cccgcctcac agaagacttc gtgtcccacc 900 tggagaccga gctggagcag tcgaggctgc gggagacgga gacactgggg gcccttcggg 960 agatgcagga caaggttctc gacatggaaa agaggaacag ctcgctgccc gacgagaaca 1020 atgtggcgca gctgcaggag gagctgaagg cgctcaaggt gcgggaaggc caggcggtgg 1080 cctcgacgcg agagcttaaa ctgcagctgc aggagctctc ggacacctgg caggcccatc 1140 tggcccgcgg cggccgctgg aaggagtccc cacggaagct ggtcgtgggc gagctgcagg 1200 acgagctgat gagcgtgcgt ctgcgcgagg cccaggccct ggccgagggc cgcgagctgc 1260 ggcagcgcgt ggtggaactt gagacgcagg accacatcca ccgcaacctt ctgaaccgcg 1320 tggaggcgga gcgcgcggcg ctgcaggaga agctgcagta cctggctgca cagaacaagg 1380 ggctgcagac gcagctcagc gaaagccgcc gcaagcaggc cgaggccgag tgcaagagca 1440 aggaggaggt gatggctgtg cgactgcggg aggcggacag catggctgcg gtggccgaga 1500 tgcggcagcg cattgccgag ctggagatcc agagggagga aggccgcatc cagggccagc 1560 tgaaccactc ggactcatcg cagtacatcc gcgagctcaa ggaccagatc gaggagctga 1620 aggccgaggt gcggctgctg aagggcccgc cgcccttcga ggacccgctg gctttcgatg 1680 ggctgagcct ggcgcggcac ttggacgagg actcgctgcc gtcgtcggac gaggagctac 1740 ttggcgtagg cgtgggcgct gccctgcagg acgcattgta ccctctgtcc ccgcgcgatg 1800 cgcgcttctt ccgccgtctg gagcggccgg ccaaggacag cgagggcagc tcagacagcg 1860 acgccgatga gctggccgcg ccctacagcc agggtctgga caactgaggc catgcccagc 1920 gcgcccggag tcaggaggcc gcagccgcgg ggggcgcccg ggcagtccgc gttctgctcc 1980 ccacctgccg cacttgacaa actacgcgcc ctctgtggct cggccacccc taaagcgagg 2040 cccggcgagg cagcgcagag ggtagggtcc gacctgggct cctcagggcc ccggggcagg 2100 ctctctctcc ccagcagtgt ttacccatct tggtctgtac ccctccgggc cctctggcgt 2160 tccaggggtg cctggagggg ctgactgctc tcttaacagg agggcagagg gcaggggaca 2220 gacgacccag aggtcccagc actgaatgag caggcagctc ccacctcctg gcaggcttcc 2280 ttctgggaca ggggcgacat tgctgggaag tgctcaggag gtagccgagg cctgaggaag 2340 gagagcgcca gctctgggct ggacatcagc accccacaac actcctcggg atgaagtgac 2400 ccttgactag cccctggcca tctctagggg agtcaggccg ctggggacag atggccaggc 2460 cggcctctcc tgcctggcgc aggcaccgtg gcccctgcag cggaaaccaa agtcccccta 2520 ctatgtgcgg ggcgcctggg gactgagtgg ctaacgggaa gcctccctgc ttctctgggg 2580 ccagagcagc ttccaggaag tgaagagacc cctctcccca gtgccccaca tctttctctg 2640 ggagacactc gcgcccccta tcctggccag tgatggaggg gtatctctac aggggtcctc 2700 ggtctccatc tacttccctt tcttcatgtg tttccagccc caccctcagc cagagccagg 2760 cccccaggca ggagcttccc agcgagcggc ctcccctcac ttcctcctgg tggtcccgtt 2820 gtctctgctg aatcagagct gagaacggtg ccaaaatcca acgatgcccc ccaggcccct 2880 tcctcccttc ccccggcccc ccgggcctca tgaccctggg ggctgccccc ctcggtgctc 2940 ccggagcctc cagtagagta gcgtcacaag caatctccct ggcgcttcct gggtggggac 3000 ccctgctccg tccccgcttc ctagctgccc acttttcagt gttacgaagc ctggggaccg 3060 gggcaggcac ccacggggct ctccacacgc cccctacact gcccgccacc attttgcaca 3120 ctgcctgttc acatgtcgcc caggcgggaa aaatggaaaa taaagtgtat ttacacagtc 3180 a 3181 93 5987 DNA Homo sapiens misc_feature Incyte ID No 1286391CB1 93 ccagtgctgc caacagggca agggaagccc gtggctcaag gggggctgac agatcagtca 60 gtacctggag ctcaaacagt gcctgaaact ctcaaagtgc ccatggctgc agcagtgccc 120 aaagctgaaa atccctccag aactcaagtg ccatctgcag ctcccaaact gcctacatct 180 cgaatgatgc tggcagtgca cacagagcct gcagctcccg aagtgccttt ggctccaaca 240 aagccaacag ctcaactgat ggccacagct caaaaaacag ttgtgaatca accagtgttg 300 gtagctcaag tggaacccac aactccaaaa actccccagg ctcagaagat gcctgtagca 360 aaaacatcac ctgcaggtcc caaaacaccc aaagctcaag ccgggcctgc agctacagtt 420 tccaaagcac ctgcagcttc caaagcacct gcagctccca aagtacctgt gacccccaga 480 gtctccagag ctcccaaaac acctgcagct cagaaggtgc ccacggatgc agggccaacc 540 ttggatgtag ccagacttct gagtgaggtc cagcctacat caagggctag tgtctcctta 600 ctgaagggcc aggggcaggc tggaaggcag ggtccccagt ccagtggcac cttggccctc 660 agcagtaagc accagtttca gatggagggg ctcctggggg cttgggaggg ggccccaagg 720 cagccacctc gccacctgca agcgaacagc acagtgacca gcttccagag gtaccacgag 780 gccctgaata cacccttcga gctgaacctg tcaggggaac ctggaaacca ggggttgcgg 840 cgagtggtca tcgatggcag cagtgtggcc atggtgcatg gcctgcagca cttcttctcc 900 tgccgaggaa ttgccatggc agtgcagttt ttctggaacc ggggacaccg agaggtcact 960 gtgtttgtac ccacctggca gctgaagaag aaccggaggg tgagagagag ccactttctg 1020 acgaagctac actcgctcaa gatgctttca atcacaccct cccagcttga gaatggcaag 1080 aagatcacca cctacgatta taggttcatg gtaaagctgg cagaggagac agatggcatc 1140 attgtcacca atgagcagat tcacatcctg atgaatagtt ccaagaaact gatggtcaaa 1200 gatcgcttgc tgcctttcac ctttgcgggg aatctcttca tggtgcctga tgaccccctg 1260 ggccgtgatg gccccacctt ggatgagttt ctgaagaagc caaacaggtt ggacactgac 1320 attggcaact tcctgaaggt gtggaagacc cttcctccca gctcagccag tgtcactgag 1380 ctgagtgatg acgctgactc tgggcccctg gagagtctgc cgaatatgga agaagtcagg 1440 gaagagaagg aggagaggca ggatgaggag cagagacagg ggcagggcac acagaaggcg 1500 gctgaggagg acgaccttga ctcttcgctg gcgtcagtgt tcagggtgga gtgcccgtcc 1560 ctttcggagg agatcctgcg gtgcctcagc ctccatgatc cccctgatgg ggccctggac 1620 atcgacctcc tgccaggggc agcttctccc tacctgggca tcccctggga tggaaaggct 1680 ccctgccagc aggttcttgc ccacctggcc cagctcacca tccccagcaa cttcaccgca 1740 ctctccttct tcatgggctt catggactcc cacagggatg ccatccctga ctatgaagcc 1800 ctagtgggcc ccctgcacag cctcctcaag cagaagcctg actggcagtg ggaccaggag 1860 catgaggagg ccttcctggc cctgaagcga gccctggtgt ctgccctctg cctgatggcc 1920 cccaactccc agctgccctt ccgcctggag gtgaccgtga gccacgtggc cctgacggcc 1980 atcctccatc aggagcactc agggaggaag caccccatag cctatacctc aaaacccctc 2040 ctccctgatg aggagagcca gggcccccag tcagggggtg acagccccta tgctgtggcc 2100 tgggccctca agcatttttc ccgctgcatt ggagacaccc cggtggtcct ggacctttcc 2160 tatgcctccc ggaccactgc ggaccctgag gtgcgggagg gccgcagggt ttccaaagct 2220 tggttgatcc gatggtccct cttggttcag gacaaaggca agagggccct ggaattggcc 2280 ctcctccagg gcctgctggg ggagaaccgc ctgctcaccc ccgcggcctc catgcctcgc 2340 ttcttccagg ttctgccgcc tttctctgac ctgtccacgt tcgtctgcat ccacatgtcg 2400 ggctactgct tctaccgtga ggatgagtgg tgtgctggct ttggtctcta tgttctatcg 2460 cccaccagcc cccctgtctc cctttccttc tcctgctccc cttacacgcc aacctatgcc 2520 cacctggcag ccgtggcctg cggcctggag cgctttggcc agtccccact cccagtggtt 2580 ttcctcactc actgcaactg gatcttcagc ctcctgtggg agctcctgcc cctctggagg 2640 gctcggggct tcctctcctc tgatggggct ccactccctc acccaagcct gctctcctac 2700 attatatccc tcacctctgg cctctcatcc cttccgttta tctaccgaac ctcctaccgg 2760 ggctctctgt ttgctgtgac agtggacacc ctggccaagc agggtgccca ggggggtggg 2820 cagtggtgga gtttgccaaa ggatgtgcca gcccctacag tgagtcccca tgccatgggc 2880 aagaggccca atttgctggc attacagctg agtgacagca ccctggccga catcattgcc 2940 aggctgcagg ctgggcagaa actgtctggc tcctcaccgt ttagttctgc ctttaactca 3000 ctcagcctcg acaaggagag tggcctgctt atgttcaagg gagataagaa gcccagggtc 3060 tgggtagtcc cgacgcaact ccggagggat ctgattttct ctgtgcatga cattcccttg 3120 ggggcccacc agaggcccga agagacctac aagaagttgc gtttgctggg gtggtggcct 3180 gggatgcagg agcatgtgaa agattactgc aggagctgct tgttctgcat cccccgaaat 3240 ctcataggca gcgagttgaa ggttattgag tccccatggc ccctcaggtc gaccgccccc 3300 tggtcgaacc tgcagatcga ggtggtgggc ccggtcacca taagtgagga gggccataag 3360 catgtactta ttgtggctga cccaaacacc aggtgggtgg aggcattccc cctgaagccc 3420 tacacacaca cggctgtggc ccaggtgctg cttcagcatg tgtttgcaag gtggggtgtt 3480 cctgtgaggc tggaggcagc ccaggggccc cagtttgccc ggcacgtcct tgtgagctgt 3540 gggctggccc tgggagccca ggtggcctcc ctgagtcggg acctccagtt cccctgcctg 3600 acgagctcag gggcctactg ggaattcaag agggccctca aggagttcat cttcctgcat 3660 gggaagaagt gggcggcctc cctgcctttg ctgcacctgg ccttcagggc ctcctccact 3720 gatgccacac cgttcaaggt cctgaccggg ggtgagtcaa ggctcacgga gcccctgtgg 3780 tgggagatga gcagcgcaaa cattgaaggg ctcaagatgg acgtcttcct gctacagctg 3840 gtgggggagc tgctggagct ccactggagg gtggctgaca aggcgagtga aaaggccgag 3900 aacaggcgtt tcaagcggga gagccaggag aaggagtgga atgtgggtga ccaggtcctt 3960 ttgctgtccc tccccaggaa tggcagcagt gccaaatggg tgggtccctt ctatatcggg 4020 gaccggctga gcctgtcact ctataggata tggggcttcc caaccccaga gaagctgggg 4080 tgcatctatc ccagcagtct gatgaaggcc tttgccaaga gtggcacccc gctgtccttc 4140 aaggtcttgg agcagtgagc gggagcagcg ggggtgcccc ctgccccagg gccgtgggtt 4200 tctgctgcta ggcctccccc tgtcccagca gtgctctcag tccactgggg gccctcagtt 4260 gtgccttttg tagagaactt gcttcataaa gctttgctga attgccttga actagggacc 4320 agcatcccca tggaaacatc cccagtttgg ggtacttgga gaatttgcca aaggctgtca 4380 gatatgggtc cctggcagtt ttacactggg aaatagagtg ctcctctagg ctataccagg 4440 ctcagtgtct tctccccaag tatcctcttt ccccttcaca tgtaggtgtg tggtggtgtg 4500 cacacacact cacgaaagaa tctatcttgg ccatgaaact gtggctgttg accttggaat 4560 tggaaccaca gtcctttccc atacagaaac cccaaatgtg ggctcctccc tccaacctgt 4620 tcttttgggg gaccctttgc ccttagagct gtcacagatg acataagcct gggcaggctg 4680 tggggaggcc gctgcctcct agcctcacgg tcagctttct caagccaggt gtggcctgca 4740 cagctgtcag ggcagggctg gccatcctcc caggcctcaa gggcagtgtc ttggagtggg 4800 aggatggcca gccacaagcc accagcttgt cagcatggga agggcaaggg ggaaatgggt 4860 tggcctacct catttgactc cagccaatgg agacaattcc tgacccctgc tttgatggtg 4920 ttgaccccac aggaatcaag gatcttgatg ccaagtgtgg catctctacc tgaagagctg 4980 cttctgttag acccaggggc cccggcctct gttttaaggg ggcagggcgt ctgcaacagg 5040 agtggcacac ggtgaagtgc tggcatggct ctacctccca acccctccca accccatccc 5100 aaagcctaca gtcctctgct ccttctacct ccactgtatc ctgcatccca gaccctacag 5160 attgtgtgat tgcttcatct gtatcacccc ccgagtcctg tggacctgcc ttctgtgtag 5220 agcaaaaccc aggctccctc acagccattc tttgcagaga tcacccttgc agtgagtgtg 5280 agttccttcc aggtgtgtgc gcgtacactc accctctgaa ttgctgccgc tgccaaggaa 5340 gtgggctcca ggtgaaggcc agtgccacgt cactctggct ggccttctta gtagtttcat 5400 ttctccggaa gctgagccag tctcctggtc tagcccaggt tgccagaacg cttggcattg 5460 cagagtgcta gagccagtgg agaacttgcc aacttgattg ttttacagca gaggaaagag 5520 gatcacagag ggaaagtgat tcacccaaag tcacacagca agttcatggc tgagctgaga 5580 ccaggattaa gcttcctgac tcccagttcg ccatgaaaag ggttctggca acaggttcaa 5640 gctggagaat ccttcaaaat gctacaccca cattctctcc aactcttcat ctccctgatc 5700 ttccagacaa actacctgga tgttgccctt aaaccatttc tagctgttaa ccctgtccag 5760 aaaaatgatt gagtgatagc tgagaagtgg aaagtgtggg atttttggca ggtgctctct 5820 ttcctccgcc ccccgcgcca ttctttctct tcctcctctc tgtaatggta tgtccagcct 5880 cactctccct ccctggtgct gtatgcgttc cccctgttag ctacatttgt gatcacatac 5940 ccttctttta agtgaatttt tttcatttga tttgtcaata aacgaat 5987 94 765 DNA Homo sapiens misc_feature Incyte ID No 2007684CB1 94 gtcggggctc tgaggctccg gcctgacctc tcctcggggt cgacgggaag gtctccggat 60 gccaggactc gcaaagggcc gaccagaatg aggaaatccc aggcggagtc cgggggaggc 120 agcacggcat cccagcctca gggctgcccg gacggtgttg gttggggtaa gattggggaa 180 gatgccaggt gatagaatcc accctgcctc tgacagcatc caatctggag caaaggcttc 240 tttcaacctt cccccaagct cccaatacaa gcccaaattc tggaacaagt cctttccaac 300 acctccttca gagaagctcc ctggctccag gcagtgcttg ctcccctcac tgcagcagga 360 agcctaactt gcgaactgca ggtgtgctcc aggtggtcac tggatgcaag aaatggtgcg 420 agaactttgg atgtggaacg tggaggagga ggaacacgaa gtggggatct gcacttgggg 480 tggtcagcac tgcggatgcc cagcaaagtc actgcctggt ccacatcccg gaggggtctc 540 tgcgcctcag tcggcatcgc agctgatggt gaaacttttg gtgtggcaga agagtgtcca 600 caaacttcgg aagttgctag agaaaactga aaactactag ttttgaaagc ctcacttctg 660 ccaatggaag cacattccag catgtcgcca acgcaatcca ctttccacca ctttcacaaa 720 aaacgttact gcacaattat actatcctac ccttaaaaaa aaaaa 765 95 2674 DNA Homo sapiens misc_feature Incyte ID No 2227040CB1 95 gcgacctcct aaatcaaagt tgggcggcga ggactgggcg gaggggccgc cgggtgccgg 60 gctggggccg gcgggggagg ggaggggatg gggggcgggc gcagcggacg gcggagccgg 120 ctggacacgg acagctcctt ggctccctcc ctcggctcat ccccgcggcc ccacttccct 180 cctccccgcg ctgcgagcag catcctctgc agaccctcgg tcctcgcgcc cggggtcgtc 240 ccgctcctgc ggctcagcgt ggtggcctcc cctcgcccgc caccccggca actttctctg 300 cccgctcccg cgggttgggg gctgccgtgc cgggggctaa ctgggggcag cctctggaga 360 acggcttcag agtcccggag acgcccgcca cccgcagcct gcccgcggtg ggcctgccgt 420 cggatctcgg caccctctcc tcccctctcc ccgaaccatg accgagatga gcgagaagga 480 gaacgaaccg gatgacgcgg ccacccacag ccccccaggg accgtctccg ccctccagga 540 aaccaagctc cagcgattca agcgctccct ctccctcaag accatcctcc gaagtaagag 600 cttggagaac ttcttccttc gctcgggctc tgagctcaag tgccccaccg aggtgctgct 660 gacgccccca accccactgc cccctccctc cccaccaccc acagcctcgg acaggggcct 720 ggctacccca tccccctccc catgcccagt cccacgcccc ctggcagcgc tcaaaccagt 780 gacgctgcac agcttccagg aacatgtctt caagcgagct agcccttgtg agctgtgcca 840 ccagctcatc gtaggaaact ccaaacaggg cttgcgatgt aagatgtgca aagtcagcgt 900 ccacctctgg tgctctgagg agatctccca ccagcaatgc ccaggcaaga cgtccacctc 960 cttccgccgc aacttcagtt cccctctcct ggtgcatgag ccgccaccag tctgtgccac 1020 aagcaaagag tccccaccca ctggggacag tgggaaggtg gaccctgtct acgagaccct 1080 gcgctatggc acctccctgg cactgatgaa ccgctccagt ttcagcagca cctctgagtc 1140 cccgacaagg agcctgagtg agcgggatga gctgaccgag gatggggaag gcagcatccg 1200 cagctctgag gaggggcctg gtgacagtgc atctccagta ttcacagccc cagcagagag 1260 tgaagggcca ggaccagagg agaagagtcc tggacagcag ctccccaaag ccaccctgcg 1320 gaaggatgtg gggcccatgt actcctacgt tgcactctac aagtttctgc cccaggagaa 1380 caatgatctg gctctgcagc ctggagatcg gatcatgctg gtggatgact ctaacgagga 1440 ctggtggaag ggcaagatcg gcgaccgggt tggcttcttc ccagctaatt ttgtgcaacg 1500 ggtgaggcca ggcgagaatg tttggcgctg ctgccaaccc ttctccggga acaaggaaca 1560 gggttacatg agcctcaagg agaaccagat ctgcgtgggc gtgggcagaa gcaaggatgc 1620 tgacggcttc atccgcgtca gcagtggcaa gaagcggggc ctggtgccag tcgacgccct 1680 gactgagatc tgagaggagc caagggaacc cagatgacac ccttgcccat gcctggacct 1740 tgcttctggc cagggagggg atcaggcccc cttgtccact ccataccctt cctccctctg 1800 tccctctcct aggtgccact taccgtggct taggagcctt ttgtactggg gaagatttta 1860 tttcttgggt ggggtgccct gagtgggttg atcctctggg acttggcggg gatggggtgg 1920 ggtgggaggg aatgaggaag ctacaggtag gtccacccaa cgcccaggca ccccagtcta 1980 cttgctgggc tgagtccagc cctggggaag attcctgggg aatttatttg ctgcttctcc 2040 cagccttccc ctgcccacac cacctgcgca tgcctggcac aaccctctcc ccacagagcc 2100 tctgcttggg tctatgtgtg tgtgaccgtg catctgctcc tttgcaagtg gggtcttggg 2160 agcaggcctt tttgtgtcct cggccctcca cccttggtgg ggaggggacc caggaccata 2220 ggaaggtcct gagtccacct cctggtctcc acctctgtca ttccgtcaat tctcaggaaa 2280 gttttgcagg aatctctccc gttacttgaa acctgggcgg acagatgagg ggaaggctga 2340 ggtccctgga aggtgtaaca aatcagagac tatctgttca agtagaaaac ccaagagctg 2400 gccaggtgtg gtggctcatg cctgtaatcc cagcactttg ggaggctgag gtgggcagat 2460 cacctgaggt caggagttca agaccagcct ggccaacatg gtgaaacccc ctctctacta 2520 aaagtacgaa acttagccag gcatgatggg ggtctgcctg taatgccagc tactccagag 2580 gctgaggcaa gagaatcact tgaacccggg aggcggaggt ttcagtgagc cgagattgca 2640 ccattgcacc ccagcctggg caacagagcc gaga 2674 96 5920 DNA Homo sapiens misc_feature Incyte ID No 4346130CB1 96 cgccaggcag cagaggcgac tgcggacagc cggcggggac cgggaaagag gaggcctggc 60 gcctccggca gaggggcgag gaccgagcgc ccaaggctgg gagagacgcc ggcgctgagc 120 ttcccagcgc cgcctcacct cgcttttcga actccgcgac ccgagcgcaa ggcttaagca 180 ggtaaagcag tcactgtgaa gaaaataaca ttttaagaaa cttttctgtc acaattgata 240 gaggaaaagc cagtagagaa gtacatcttc ttgtgtgtgt gtctcatcgt gccacttttt 300 gtaactcagc ttagtaatga agccaccatt atgtcctcag tcagtgaagt aaatgtggat 360 ataaaagatt tcctaatgag cattaatttg gagcagtatc tcttacattt ccatgagtct 420 ggttttacta ctgtgaagga ctgtgcagca ataaatgaca gcctgctgca gaaaattgga 480 atatcaccta caggtcaccg taggaggata cttaaacagt tacagataat cttgtcaaaa 540 atgcaagata ttccaatata tgcaaatgtt cataaaacta agaagaatga tgacccttca 600 aaggattacc atgttccatc ttctgatcag aatatctgca tagaactttc caattctggt 660 agtgttcaga catctagccc accgcagttg gagactgtta gaaaaaatct tgaagacagt 720 gatgcaagtg tggaaagaag ccagtatcct caatcagatg ataagctgtc tcctcctaaa 780 cgcgacttcc ccactgcaga ggaaccacac ctgaatttgg gttctttgaa tgattcttta 840 tttggtagtg acaatattaa aatagaatca ttgattacaa agaagactgt ggatcacaca 900 gttgaagaac aacaaacaga aaaagttaaa ttgatcacag aaaatctcag taagctccct 960 aatgcagact ctgaatgcct ttcttttgtt ggctgttcaa catcaggaac aaattctgga 1020 aatggaacaa atggtttatt agaaggatca ccaccatccc cattctttaa gtttcaagga 1080 gaaatgattg taaatgactt gtatgttcca tcatcaccaa tcctagcacc tgtgagaagt 1140 cgtagcaagt tggtttcaag accatctcga tcttttctgc taagacatcg acctgtacca 1200 gagattccag ggtcaacaaa aggagtttct gggagctatt tccgtgaaag aagaaatgtt 1260 gctacctcaa ctgaaaaatc tgtggcatgg caaaattcaa atgaggagaa ttcatcttcc 1320 atctttcctt atggagagac ctttctcttc cagagactag aaaattccaa gaagcgatct 1380 ataaagaatg aatttttgac ccagggagaa gcactcaaag gggaagcagc tactgcaaca 1440 aactctttta tcatcaaatc aagcatatac gataacagaa aggagaaaat aagcgaggac 1500 aaggtggaag atatttggat acctcgagag gacaaaaaca attttttgat agacactgct 1560 tctgaatcag aatactcaac agtagaagaa tgctttcaga gtttaagaag aaaaaattca 1620 aaggcatcta aatctaggac tcaaaaagcc ttgattttgg actccgttaa taggcacagt 1680 tatccgttaa gctcaacaag tggaaatgct gattcatcag ccgtttcttc acaggcaata 1740 tctccctatg cctgctttta tggagcatct gcaaagaagg ttaaatcagg atggctggat 1800 aaactctctc ctcaaggaaa acgcatgttt caaaagagat gggtgaaatt tgatggcctt 1860 agcatttctt actacaataa tgagaaggag atgtattcga aaggaataat tcccctttct 1920 gctatatcaa cagtacgagt tcaaggagac aacaaatttg aagttgttac aacacaaaga 1980 acttttgttt ttagagtaga aaaagaagag gagagaaatg actggatcag catactatta 2040 aatgcactga aatcacaatc ccttacctcg cagtctcaag ctgttgttac acctgagaaa 2100 tgtggatatc ttgaattgag aggctataag gcaaaaattt ttactgtgtt aagtggaaac 2160 agtgtgtggc tttgcaaaaa cgaacaggat tttaagagtg gacttggtat taccataatt 2220 cctatgaatg tagcaaatgt aaagcaagtg gaccgaactg tgaaacaatc ttttgaaata 2280 atcactccct acaggagttt cagctttaca gccgagactg aaaaggagaa acaagactgg 2340 attgaagctg tgcagcaatc aatagcagaa actctctctg attatgaagt agctgagaag 2400 atttggttca atgaatccaa caggagctgt gcagattgta aagccccaga tcctgactgg 2460 gcatccatca atctctgtgt tgtcatctgt aagaagtgtg caggacagca tagatcttta 2520 ggaccaaaag attccaaggt tagaagtcta aaaatggatg ctagcatttg gagcaatgaa 2580 ctcatcgagc tttttattgt cattggaaac aaaagagcaa atgacttttg ggctggtaat 2640 cttcaaaagg atgaagaatt acatatggac tcaccagtag aaaagagaaa aaactttatt 2700 actcagaaat ataaagaagg aaaattcaga aaaactcttt tggcatctct caccaaagaa 2760 gaattaaata aggctctatg tgctgctgta gtgaaaccgg atgttctaga aacaatggct 2820 ttgctgttca gtggagcaga tgtcatgtgt gccaccggag accccgtgca tagcaccccc 2880 tatctgctag ccaagaaagc tgggcaaagt ctgcaaatgg aatttctcta ccataacaaa 2940 ttctcagatt tccctcaaca tgatattcat tccgagggtg tattaagtca agagtcttcc 3000 cagtccacat tcctctgtga ctttttatat caagctcctt ctgctgcttc taaactctct 3060 tcagagaaaa aactgcttga agagacaaat aaaaaatggt gtgttttgga aggaggcttc 3120 ttgagttact atgaaaatga taagtctacc acacctaatg gcaccattaa tatcaatgaa 3180 gttatctgcc tggctataca caaagaggac ttctatttaa atactgggcc catctttatc 3240 tttgagatct acttaccctc cgaacgtgtg tttttatttg gagctgaaac atctcaagct 3300 caaagaaaat ggacagaggc aatagccaag cattttgttc ccttatttgc tgaaaactta 3360 acagaagctg actatgattt gattggtcaa ctcttctaca aagactgcca tgccctggat 3420 cagtggagaa aaggctggtt tgctatggac aaatccagct tgcatttttg ccttcaaatg 3480 caagaagttc agggagatag aatgcactta agaagactgc aagagctaac aatcagcaca 3540 atggttcaaa atggggaaaa actggatgtt ttactcttgg tagaaaaagg gagaacatta 3600 tacatccatg ggcataccaa gttggatttc acagtctggc atactgcaat tgaaaaagca 3660 gcaggtacag atggtaatgc tttacaagat cagcagctca gcaaaaatga cgttcccatt 3720 atagtgaaca gctgtatagc atttgttaca cagtatggtt taggatgcaa atatatctat 3780 caaaagaatg gtgatccttt gcatataagt gaactcctgg agagtttcaa aaaggatgca 3840 agaagcttta aattgagggc tggaaaacat cagcttgaag atgtgacggc tgtgttgaaa 3900 agttttctct ctgacattga tgatgcactg cttactaagg agctctaccc atattggatc 3960 tctgctttag atacgcaaga tgacaaggaa agaattaaaa aatatggagc atttatacgt 4020 tctcttccag gggtcaaccg agcaacacta gcagctatca ttgaacacct gtatagggtt 4080 cagaaatgct cagaaatcaa tcacatgaat gcccataatt tggccttggt cttttcatcc 4140 tgtttgtttc aaacgaaggg acaaactagt gaagaagtga atgtaattga ggacctaatt 4200 aataattatg tagaaatatt tgaggttaaa gaagatcaag tcaaacaaat ggacatagaa 4260 aatagcttta ttaccaagtg gaaagacacc caagtttccc aggctggaga tttgttaatt 4320 gaagtatatg tagaaaggaa ggaacccgac tgtagtatta taattcggat atctcctgtg 4380 atggaagcag aagaattaac taatgatata ttagcgataa aaaatattat tcctacaaaa 4440 ggtgatattt gggccacatt tgaagtcatt gaaaatgaag agctagagcg tcctcttcac 4500 tacaaggaaa atgtactgga gcaggtgctt cggtggagtt cattagctga acctggctct 4560 gcttacctgg tggtgaagag attcttaacc gctgacacaa ttaaacactg cagtgaccgg 4620 agtacactgg gaagcatcaa agaaggaatc ttgaaaatca aagaagaacc atccaaaata 4680 ctatctggaa ataagtttca agaccggtat tttgttttac gagatgggtt tctctttctt 4740 tacaaggatg tgaagagtag taaacatgac aagatgtttt ctctcagttc catgaagttt 4800 tatcgtggag tgaaaaagaa aatgaagcct ccaacaagct ggggattgac cgcatattct 4860 gagaaacatc actggcacct gtgttgtgat agttcacaaa ctcagacgga gtggatgacc 4920 agtatcttta ttgcccagca tgaatatgat atatggccac cagctggaaa ggaacgaaaa 4980 cgttcaataa ccaaaaatcc caaaattgga ggtttgcctc tgattcctat acagcatgag 5040 gggaatgcaa ccttggcccg gaaaaatatt gagagtgcaa gagcagaact tgaaaggctg 5100 cggctcagtg aaaagtgtga taaagagtcc gtggactcta gcttaaagga gagagcttcc 5160 atggtggccc actgcctgga gcacaaggac gataaacttc gaaatcgacc ccgaaaacat 5220 cggagtttca actgcctgga ggacacagag cctgaagccc cacttgggca accaaaaggc 5280 cataaaggcc taaagacatt gaggaagact gaggacagga atagcaaagc tactttggac 5340 tctgatcata agttaccatc aagggtaatt gaagaactta atgtggttct acaacggtca 5400 agaacccttc caaaagaatt acaggatgag cagattttga agtaggaaat aaaatgaatt 5460 gctccccaga ttattttttt aatattgtat gcaatcttta tgtgtaactc caaaactgaa 5520 ctataagata attcataaga atttgcctat tgataggcaa atttgtctat gcttaggcat 5580 ttaaggagca tttaaaaata tgtatatatg tgactgaatg taagattaac tttattttgg 5640 tctgaacaaa ccttgtaaag ttccattgta ttaacgtgtg taagaagaca ttgggttact 5700 taggtggtca gtccttttaa agtagttgtc tgttaagtgg tataatttat gagcagaaat 5760 ctcaaactgt actgtattgt ataaaatgct gtgtttaaat gaagcctaag aaactatctg 5820 taacatattt tgcactttga gaaaccttgt atattaaatt accatatgtt tttaggttta 5880 cagaagttct accttaggga aaagaaaggg aagtaaattg 5920 97 1689 DNA Homo sapiens misc_feature Incyte ID No 55117040CB1 97 ctggtttctc ctggctgtta aaagcagatg gtggctgagg ttgattcaat gccggctgcc 60 tcttctgtga agaagccatt tggtctcagg agcaagatgg gcaagtggtg ctgccactgc 120 tttccctgct gcagggggag cggcaagagc aacgtgggca cttctggaga ccacaacgac 180 tcctctgtga agacgcttgg gagcaagagg tgcaagtggt gctgccactg cttcccctgc 240 tgcaggggga gcggcaagag caacgtggtc gcttggggag actacgatga cagcgccttc 300 atggatccca ggtaccacgt ccatggagaa gatctggaca agctccacag agctgcctgg 360 tggggtaaag tccccagaaa ggatctcatc gtcatgctca gggacacgga tgtgaacaag 420 agggacaagc aaaagaggac tgctctacat ctggcctctg ccaatgggaa ttcagaagta 480 gtaaaactcg tgctggacag acgatgtcaa cttaatgtcc ttgacaacaa aaagaggaca 540 gctctgacaa aggccgtaca atgccaggaa gatgaatgtg cgttaatgtt gctggaacat 600 ggcactgatc caaatattcc agatgagtat ggaaatacca ctctacacta tgctgtctac 660 aatgaagata aattaatggc caagcactgc tcttatacgg tgctgatatc gaatcaaaaa 720 acagcatggc ctcacaccac tgctacttgg tatacatgag caaaacagca agtggtgaaa 780 ttttaatcaa gaaaaaagcg aatttaaatg cgctggatag atatggaaga actgctctca 840 tacttgctgt atgttgtgga tcagcaagta tagtcagccc tctacttgag caaaatgttg 900 atgtatcttc tcaagatctg gaaagacggc cagagagtat gctgtttcta gtcatcatca 960 tgtaatttgc cagttacttt ctgactacaa agaaaaacag atgttaaaaa tctcttctga 1020 aaacagcaat ccagaacaag acttaaagct gacatcagag gaagagtcac aaaggcttaa 1080 aggaagtgaa aacagccagc cagaggcatg gaaactttta aatttaaact tttggtttaa 1140 tgtttttttt tttggcctta ataatattag atagtccaaa tgaaattacc tatgagacta 1200 ggcttggaga atcaatagat tcttttttta agaatctttg ggctaggagc ggtgtctcac 1260 gcctgtaatt ccagcacctt gagaggctga ggtgggcaga tcacgagatc aggagatcga 1320 gaccatcctg gctaacacgg tgaaacccca tctctactaa aaatacaaaa acttagctgg 1380 gtgtggtggc gggtgcctgt agtcccagct actcaggagg ctgaggcagg agaatggcat 1440 gaacccggga ggtggaggtt tgcagtgagc cgagatccgc aatacactcc agccctgggt 1500 gacagagcaa gactcttgtc tcacaaaaaa cataaaacac aagggggggc cgtcaacatg 1560 cttttaaagg gcccaatttc gccttatagg gagtcggttt tacacaaatt caggggcccg 1620 gcgttttaac aacgtccgga attgggaaac cccttgggtt taccccaatt taaatcgcct 1680 tggaagatc 1689 98 1314 DNA Homo sapiens misc_feature Incyte ID No 7472392CB1 98 gcgagctgcg cgtggcctgg gctccttccg aatggtggcg cctctgagcg ccagttcgag 60 gaggagtcgg aggaggagcc tgaatgtttg gagatagact tcaagtcccg gaccttatcc 120 gtgcgccgct tcggtttgca gggactgtac cagctcgcca tggatatcat cataatgatc 180 cgagtgtgta aaatgttccg ccaaggcctc aggggattcc gggaatatca aatcattgag 240 actgctcact ggaagcaccc tatcttctcc ttctgggata aaaagatgca aagccgagtc 300 acatttgata ccatggactt cattgcagag gagggtcact ttcctccaaa ggccattcag 360 atcatgcaga agaagccttc ctggagaaca gaggatgaga tccaggccgt ctgtaacatc 420 ttgcaggttc tggatagcta tcggaactac gcagagcccc tgcagctgct cctggccaaa 480 gtcatgcgct ttgaacggaa atggacgttc tgcatgcttc agtgaggagg tccaccatcg 540 tctgtatgga agaaacggag ttcctggttg ttgaccggga ggacttcttt gctaataagc 600 tggaccagga agttcagaag gatgctcagt atcggtttga attttttagg aagatggagc 660 tgtttgcatc atggtctgat gagaagctct ggcagctggt agccatggcg aagatagaga 720 ggttctcgta tgggcagctg atctcaaaag attttggaga gtcacccttc atcatgttta 780 tcagcaaggg cagctgtgaa gtcctgcggc tgttggacct tggggcctcc ccttcctacc 840 gtagatggat ctggcagcac ctggagctga tagatggcag acctctgaag acccacctga 900 gtgaatactc tcctatggaa agatttaagg aattccagat caaatcatat cctctgcaag 960 actttagctc cttgaaactt ccacatctca aaaaagcctg ggggctacag gggacaagct 1020 tcagcaggaa gatcagaacc tcaggagaca ctctccccaa gatgctgggc ccgaagatcc 1080 aatccaggcc tgctcagtcg atcaaatgtg ccatgatcaa tatcaagcct ggtgagctcc 1140 ccaaggaggc tgcagtgggg gcctacgtga aggtgcacac tgtggagcag ggagaaattt 1200 tggtgagtgt gccaagagct ctgttcacca tggagtacgt aacatgaatg ggctggaatg 1260 ttaagtaaat gacagtaaag gttttacaaa caaaaaaaaa aaaaaggggc ggcg 1314 99 3322 DNA Homo sapiens misc_feature Incyte ID No 4028960CB1 99 ggagccccca cccaggcgca tggctccatg aagcaagagg aggaggcaga gcgcgagagg 60 tcccgtccgc cccagccgcg tctgggccag gagaaaaggt acaggaagaa ggaatggaat 120 cggaaggaag aaaattcatt ccagagacaa aatagctccc ctcctctgtt gtagctgttc 180 ctctggcaat acaaactttc tgctttcagg ttctgcagca ttccagacct tgagcactga 240 atcaggatgg gaaaaagacg ttgtgttcct ccactcgagc ccaagttggc agcaggctgt 300 tgtggggtca agaagcccaa attatctgga agtggaacgc acagtcacgg gaatcagtcc 360 acaactgtcc ccggctctag ttcaggacct cttcaaaacc accagcatgt ggacagcagc 420 agtggacggg agaatgtgtc agacttaact ctgggacctg gaaactctcc catcacacga 480 atgaatcccg catcgggagc gctgagccct cttccccggc ctaatggaac tgccaacacc 540 actaagaatc tggtggtgac tgcagagatg tgctgctact gcttcgacgt actctactgt 600 cacctctatg gcttcccaca gccacgactt cctagattca ccaatgaccc ctatccgctc 660 tttgtgacgt ggaagacagg gcgggacaag cggcttcgtg gctgcattgg gaccttctca 720 gccatgaatc ttcattcagg actcagggaa tacacgttaa ccagtgcact taaggacagc 780 cgatttcccc ccctgacccg agaggagctg cctaaacttt tctgctctgt ctccctcctt 840 actaactttg aggatgccag tgattacctg gactgggagg taggggtcca tgggattcga 900 attgaattca ttaatgaaaa aggtgtcaaa cgcacagcca catatttacc tgaggttgct 960 aaggaacaag actgggatca gatccagaca atagactcct tgctcaggaa aggtggcttt 1020 aaagctccaa ttaccagtga attcagaaaa acgatcaaac tcaccaggta ccgaagtgag 1080 aaggtgacaa tcagttacgc agagtatatt gcttcccgac agcactgttt ccagaacggc 1140 actcttcatg ccccgcccct ctacaatcat tactcctgac acacggctgc atgaccagtc 1200 ccaccccccc gtggccacca atggctatga catcattgga gcagatgcct cctcttcctg 1260 gtccagttac ttctattact gcaccatttt atgatgctag cttccgttgc caagtctgcc 1320 tcccgctgac tgagggaggg tagggttacc ttgaacgaaa cagaacttga ggggcccaag 1380 ccttatctca gcctttcctc aatatggggt tccgttggat tggggctcct ccatgactag 1440 tgggaattac tgtgggttca gaagaccctt gtctggtatt tgccacatgg ggtattggcc 1500 acacgctgga agctgaaatt gatgatccct gaaggttgaa cccacacaca cccctgcagc 1560 ctccccagat gaagtaggtg tattcccctg gcagtctggg caacggagac caagaaacat 1620 ttttaggttg ttttaaattc ctttttttaa acttccagtt tattgcgtac caagagttga 1680 ttacaacctc catgcttcat aagcggacgc cacgttaggg ttggacgtgg gcaccacgag 1740 tcctttgagg ctcctggaca gagacccaca tcaagatcgg aagccctttg ggtggcgttg 1800 cagatctcat tgctcagtag gccgtgaaga ttttcatcct catcccactc tcagttggat 1860 tttctggcac tcttcctgca ttgagtctcc tgattactga acagagctcc gtcatgtagc 1920 ctgctgagga atggaatgga atggagatgc ccacaggagg tcctgatgtc atcactgcac 1980 gcaggtgtga gaggagagac ctcttctgca ccgcctggct acctcactcc tctgctggta 2040 gcagtgccta tagctggacc taagttctca gaagcgtaga tgtgcaaaca agcgattgag 2100 ttgggcttta ggaggacaca tcataggaga gaatccaggg tctgtaagct ggttttcttt 2160 tcaggtgaca tcctgagggg cctgtaagca ggggagctcc tttttctagt ttgcctgtag 2220 aggtgggaag actgttggtg tttctgtcct ttacaggaca ttaggaaaca gttgtgtaat 2280 tacacaaggt ggacctttat cttgcctgac atgctgggaa tcttcacccc accagggcaa 2340 atttccaaat agctcatttt attctaggtc tttcaaactt tcatgtgaca tatttccctt 2400 tcccattgtt gctgatttcc aaatcgctgt cagcaatttt ttcctctctc cttgcctatt 2460 cttcactcat ttggtggcaa agttcataga actaggggac ttggaagatg ctttgaaaat 2520 attgttacaa aggcactgct aaaatgattc acagggagag tggccagttg gaagaaggat 2580 cctaaggatg tgacactggt tttcaacaac atgcttagag aactcatgaa gtggattggg 2640 tgtcaaccca gtgaacatgt ttttatttaa tttatttttt gaagtttatg tggtgatggt 2700 gtggctttcc gaaatgggca aatattcaga agatcttttg cattttcttc tgccaggaat 2760 ggggaagggg agtgggggca caatctgaga aaggacacct gtgctgttct aggcatcgct 2820 ggcaagtttg tgggaaggga tgggcaaggg tgagtgggtt tgctccacac cgtcctgtgc 2880 tgctcgagag gacctgggac gtgcgaggga aacgtgggtg acggtgccta ggctgcggcc 2940 cttcactgct gtgctgggtt cctgcagcct gctacgtttc ccttggcaat gtaaatgaag 3000 atggaggggt cgtttcgtga tttcctgctg ctgagaataa atgtcttgtt aaaaacgtgg 3060 caacggttac tcttaggtgt catggatcga tgtcagggtg gtcagctctg gactaagcca 3120 cccacctcca atttgtacaa cagtattgat acatagggct acactcatta ctgttcaagt 3180 gttctatgtt aagagttgtg tttaatttct aaagattaaa aaaagcaaaa aaattggtgc 3240 taaaccttca cccctgagca cgctcagtga gactggtcat gcaagcattt acagtgccat 3300 gctcctcaag accattggca gg 3322 100 3621 DNA Homo sapiens misc_feature Incyte ID No 8227004CB1 100 cggtgagcgc gtttcccgcc tgagcgcaac tagcggcggg tcgtgggcac ctccagacca 60 gcatgttttg gaaatttgat cttcactcat catcccacat agacacactt ctagaaagag 120 aagatgtaac actgaaggag ttaatggatg aggaagatgt tttacaggaa tgtaaagctc 180 agaaccgcaa acttatagag tttctgttaa aagcagaatg tctcgaagat ttagtctcat 240 tcattataga agaaccacct caagacatgg atgaaaagat cagatacaag tatccaaata 300 tatcttgtga gttgctcact tctgatgtct cccagatgaa tgatagactg ggagaagatg 360 aatccttgct aatgaaatta tatagcttcc tcctaaacga ttcccctttg aatccactac 420 ttgccagttt cttcagcaag gtgctaagta ttcttatcag cagaaaacca gaacagattg 480 tggatttctt aaagaagaag catgattttg tagaccttat tataaagcac ataggaactt 540 ctgctatcat ggatttgttg ctcaggctcc tgacgtgtat cgaacctcca cagcccaggc 600 aagatgtgct gaattggtta aatgaggaga aaattatcca gaggcttgtg gaaatagttc 660 atccatcgca agaagaagat cgacattcaa atgcatcaca atcactttgt gaaattgttc 720 gcctgagcag agaccagatg ttacaaattc agaacagtac agagcccgac cccctgcttg 780 ccactctaga aaagcaagaa attatagagc agcttctatc aaatattttc cacaaggaga 840 aaaatgagtc agccatagtc agtgcaatcc agatattgct gactttactt gagacacgac 900 gaccaacatt tgaaggccat atagagatct gcccaccagg catgagccat tcagcttgtt 960 cagtaaacaa gagtgttcta gaagccatca gaggaagact tggatctttt catgaactcc 1020 tgctggagcc acccaagaaa agtgtgatga agaccacatg gggtgtgctg gatcctcctg 1080 tggggaatac ccggttgaat gtcattaggt tgatatccag cctgcttcaa accaatacca 1140 gcagtataaa tggggacctt atggagctga atagcattgg agtcatattg aacatgttct 1200 tcaagtatac atggaataac tttttgcata cacaagtgga aatttgtatt gcactgattc 1260 ttgcaagtcc ttttgaaaac acagaaaatg ccacaattac cgatcaagac tccactggtg 1320 ataatttgtt attaaaacat cttttccaaa aatgtcaatt aatagaacga atacttgaag 1380 cctgggaaat gaatgagaag aaacaggctg agggaggaag acggcatggt tacatgggac 1440 acctaacgag gatagctaac tgtatcgtgc acagcactga caagggcccc aacagtgcat 1500 tagtgcagca gcttatcaaa gatcttcccg acgaagtcag ggaacgatgg gagacgttct 1560 gcacaagctc cttaggagaa actaacaaga ggaacacggt agatctaatg caacaaatga 1620 cgtccaattt tattgaccag tttggcttca acgatgagaa gtttgcagat caagatgaca 1680 ttggcaatgt ttcttttgat cgagtatcag acatcaactt tactctcaat acaaatgaaa 1740 gtggaaatat tgccttgttt gaagcatgtt gtaaggaaag aatacaacag tttgatgatg 1800 gtggctctga tgaggaagat atatgggagg aaaagcacat cgcattcaca ccagaatccc 1860 aaagacgatc cagctcgggg agtacagaca gtgaggaaag tacagactct gaagaagaag 1920 atggagcaaa gcaagacttg tttgaaccca gcagtgccaa cacggaggat aaaatggagg 1980 tggacctgag tgaaccaccc aactggtcag ctaactttga tgtcccaatg gaaacaaccc 2040 acggtgctcc attggattct gtgggatctg atgtctggag cacagaggag ccgatgccaa 2100 ctaaagagac gggctgggct tctttttcag agttcacgtc ttccctgagc acaaaagatt 2160 ctttaaggag taattctcca gtggaaatgg aaaccagcac tgaacccatg gaccctctga 2220 ctcccagtgc ggctgccctg gcagtgcagc cagaagcggc aggcagtgtg gccatggaag 2280 ccagctctga cggagaggag gatgcagaaa gtacagacaa ggtaactgag acagtgatga 2340 atggcggcat gaaggaaacg ctcagcctca ctgtagatgc caagacagag actgcggtct 2400 tcaaaagtga ggaagggaaa ctgtctacct ctcaagatgc tgcttgtaaa gacgcagagg 2460 agtgtcccga gactgcagag gcgaagtgcg cggcgcccag gcctcccagc agcagtcccg 2520 agcagaggac tggccaacca agcgcaccag gtgacacttc agtgaatggc cctgtatgac 2580 gggtgacgtc tgctgctgct gactgaggac tgcagaccgc caccactcag gggctctgga 2640 ggggtcagct ggagcccacc aagctgtcac tgctgcactc actctgcaag ggatcaggac 2700 cagcaacctt tatattctag attctaagac attgtacaga gaaattcaga agtgtaaaaa 2760 tattgcacat tgacaaatac caagaatttt tgcgtatgtt tatattgtat tgttctaaat 2820 aatgggtagc ctgtgaaata agatcttgcc acccatgtaa taatagtagt aatactatag 2880 ttaaaatggc tgtaagaata gttttataaa agtgaataca cagatctatt gtatttgaaa 2940 cataactttg acaattatta gtgtgaccaa agtattaggc ggttttcata catttttcac 3000 cttgtacaaa attatgaatt catttttcct ccaggccgac aaggagttgt agaatgaaaa 3060 tgccctctaa gtgttatttt ggttgttcta acttacaaaa gtgattttga ataagaaata 3120 tttggtgttc tttttataac cagtttttga ttggtaattg ttttctgtat tgtttaaaac 3180 ggatcaaaaa tgtaagtcta ttggtagaga ttaagtattt attgctacat catagttgat 3240 aaattgatgt tatcgtaaag ccatatgttc tgttcaagtc ttgtttgctt gaaatgatta 3300 ttcctacaag tgaaacacta gactatttgg agtgtatatg gcttgtgttt tgggattttt 3360 tttttttttt ttggcttttg tttttgtttg tatttttggt tcgtttggta gttcatctgc 3420 cttttaaccc attcaccaaa atttaccttg ttaacaagca tcaccaatga acatttcaga 3480 gcaatctgca tatttaacag acctaaaata aatcctatta agcaagtcag ttgaaaatgc 3540 tcgtgctgct aatgggaata aagtgcgttc catttacagg gcaagtattt ttaaaatagg 3600 aatcaaaatc tgggcaccga a 3621 101 2704 DNA Homo sapiens misc_feature Incyte ID No 3044763CB1 101 ctggctcagg gggcggctgc ctcgccaggc gccacgaaga cccggcgtcc cacaggtccc 60 ggaggccgct gcgtcgcggg gagctgggct cgggccgccg gcggttgcgc cggggcagcc 120 ccgcagggag agcaccatga ggactgactc gggggctcgg ctggaggagg gccacctgcg 180 tcctccacga gctcttccac ctgtgccaag tcaagatgat attccactta gtcgtcctaa 240 gaaaaagaag cccagaacaa aaaacacacc agcaagtgct tctttggaag gccttgctca 300 gactgctggt cgaaggccct ctgagggcaa tgagccatca actaaagaac tcaaagagca 360 cccagaggct cctgttcaaa gaagacagaa aaagacaagg ctacctcttg aattggagac 420 ttcctccacc caaaagaagt catctagttc atctttatta cgaaatgaaa atggtattga 480 tgcggagcca gctgaggagg cagttattca aaaacctcgg aggaagacaa agaaaaccca 540 gccagcagaa ttacagtatg ccaatgagct aggagtagaa gatgaagaca taatcactga 600 tgagcaaact actgtggaac agcagtctgt attcactgca cccactggca ttagccagcc 660 tgtaggcaaa gtatttgtgg aaaaaagccg gagattccag gctgctgatc gttcagagtt 720 gataaagacc acagaaaaca tagatgtgtc aatggacgtg aagccttcct ggaccaccag 780 agatgtggca cttacagtgc accgggcttt caggatgatt ggtctctttt ctcatggatt 840 cttggctggc tgtgctgtgt ggaatattgt tgtgatatat gttctagcag gagatcagct 900 atccaacctc tcaaaccttc tgcaacaata caagacccta gcgtatccat tccagagtct 960 tctgtacttg cttttggctc tgagtacaat ttcagctttt gacaggattg actttgctaa 1020 aatatcagta gcaatccgaa attttttggc cctggatcct acagctttag catctttctt 1080 gtactttact gctcttatac tatctctgag tcagcaaatg acaagtgaca gaatccacct 1140 ttacacacct tcttctgtta atggtagcct ctgggaagca ggaattgagg aacagattct 1200 ccagccatgg attgtggtga atctcgtggt ggctcttctg gttggattat cttggctatt 1260 tttgtcttat aggccaggca tggatcttag tgaagagtta atgttctcct cagaggtgga 1320 agaatatcct gataaagaga aagaaatcaa agcctcttca taataccagc tcacctttgg 1380 aggaataatg acccagtatt tgtcccattt ttgtttttaa atgtattttt ataagatgta 1440 tacatgtgta tttgtaatag attttttgat tatataatac tgaaacatct ctcaatatta 1500 tgaaaaatgt taaaattgtg tttgctgttt atgtctaaac attaatttgt ctagcattat 1560 catcttaatg acaaagggaa taatgaacta gaaaccagca agtgaaagtg tttatttcct 1620 attttctcaa aacagttgta tttataacta ttaccttaaa aagcactggt ttagaaaaag 1680 ccataactta aatagtgtta taaaatatat atcaggttta aacataaatt tagcgaatat 1740 ggtagaaggg aaaaaagcct tcatttttga cctcccctta ctgaataaat tgaaatatga 1800 agtttgtctt ttctgaaact ggcttagtga ttgagtatca tgtaataatt ataatataat 1860 ttagcttgaa agatgctcta cattatgacc aataaaaagg gaatgtatgt tttgtttgaa 1920 aaattatata acctaaattt cttacctaga agtaactaaa aagttgcttc tcattataat 1980 ctgtactagt ggttctcata tctggttgta catcaggatc atagagggag attttaaaaa 2040 tctatgtagc aaaagaggct gagcagggca aggctcaggg gaataaagga gagacctgtg 2100 agcttgtggg ctcccagttg acatctgcag taccctttcc tctgtccctt ttttctgagt 2160 gacaagaaat aggagtagaa attcaccatc tctgttctcc agctctttgt cagagaggtt 2220 tctggttttc caggaaatcc ccctcttgag atgggtcctg cactgggaaa gatctcttca 2280 gaactatatc caatggtacc tcagctgttg tatatgagac cctaaagctc aagttgagga 2340 gaagactagc tatgggaaaa aatgtttcaa aggctgttga gcacatcaat aaaactattg 2400 agcctgccct gattagcaag cacctgaatg ttatagaaca gaagaggatt gacaaattga 2460 tgatagagac agttgaccct gacaataggt ctaaatttgg agtgaacatt atactgggaa 2520 tctcttttgc tgtttgtaag gctggagctg ccgaaaaggg attctccctg ctgtcacaga 2580 attgtgaatt tgctggcaat tctgaaggca tcctgctagt tccagctttc actgtgacca 2640 gcaatggttc tcaatctggc aataagctgg cagtatagga gttcataatc ttccccgtca 2700 gcaa 2704 102 1345 DNA Homo sapiens misc_feature Incyte ID No 4044519CB1 102 cagaattcaa attcaatctt gtcacatccc tgtttaaaac tttttggtta ctacttactg 60 cttttaggag aaagaacaaa atcctcaggt ggctgacaga tctgccatga tctggttccc 120 acctacccct tggctgggtt ccacaccatt tcttgtctct ctcagtgaca ggacagttct 180 gctaattttc tttgagttaa ctaaatgcct aattccaccc actcccagta gcccttcatt 240 tcaaaggatt cacatgggct gctccttctg cttgaatgtg cttccttttt tttcttttgt 300 tcttcactat ggtagcttct acctgccctt cagatctcag gctcaaagat tccttcctca 360 agaacatggt ccctgcattg aaaggctgtt tcaggactta ttttatatgc ttccttctca 420 ttctaatttt ccaattgaac ccaagttcca gtttaccatc cagtttacca gtatatcttt 480 tttcttttct ttcttttttt tttttctttt tttttcttga ggcagagtcc tgccctgtca 540 cccaggccga agtgcagtgg tatgatcata gctcactgta gtctcaaact cctgggctta 600 agtgatcctt cagcctcagc ctcccaagaa tctggaacta caggtgtgca ccaccatacc 660 tggctagctt atctaatttt tttgtatagc cagagcctca gtatgttgcc catgttggtc 720 tcaaacttct ggactcaagt gatagtccct ccttggcctc tcaaagtgct aggattacag 780 acctgagcta ctgcacctga ctactgtttt ccctttttaa atctatttat taatgcctat 840 ctctcctatg agactatcag cgcacacata catcttttct atattcttca taactttgtt 900 cttataactt cctaccacat gacctgtcac acaatagcca ttcaaaaaac ttgttcaatg 960 aatgcacaca tagattattt gcttctccga atatgccaca aatgcatgtt gatataatct 1020 tctgcaaatt gagttccgtg ttcgtatata aagtgtatgt actttctaca tatgttgaat 1080 atatttagat tatcttcctc attcacaaat gaagaaacta agatctaagg gaggtaagtg 1140 acttttccag ggtcactcag ggaatttgtg aacagatcgt aaccaaaatt caggccagta 1200 aactgacagt ccagacagtt tagtaaaatt gaaactgcaa atggcgattg tcttcaactg 1260 acttgaatcc aaatcctgaa gttatttctt gttaagtcta ttactttggg aaatgttccc 1320 tactgaagaa aaaaaaaaaa aaagg 1345 103 1607 DNA Homo sapiens misc_feature Incyte ID No 71351918CB1 103 ttgggcggaa gaggtgggct ggtggaggcg gggtcgagat ggcggcgcct ttgaggattc 60 agagcgactg ggcgcaagcc ctcaggaagg atgaagggga ggcctggctg agctgtcatc 120 ccccagggaa accatctttg tatggcagcc tgacttgtca aggaattggc ctagatggca 180 tcccagaggt tacagcttca gaaggattta ctgtgaatga aataaacaag aaaagcattc 240 atatttcatg tccaaaggaa aatgcatctt ctaagttttt ggcaccatat actacttttt 300 ccagaattca tacaaagagt ataacatgcc tggacatttc cagcagagga ggtcttggtg 360 tgtcttctag tactgacggg accatgaaaa tctggcaggc ttccaatgga gaactcaggg 420 tttttcccat caggccttgt ggtcctgagt gggggaatgg atgcccagct gaagatatgg 480 tcagctgaag atgctagctg cgtggtgacc ttcaaaggtc acaaaggagg tatcctggat 540 acagccatcg ttgatcgggg gaggaatgtg gtgtctgctt ctcgagatgg gacagcacga 600 ctttgggatt gtgggcgctc aggctgcttg ggagtccttg cagattgtgg ttcttctatc 660 aatggagtgg cggtgggtgc tgctgacaac tccataaacc ttggctcccc tgagcagatg 720 cccagtgaac gggaggttgg aacagaggcc aaaatgctgc tcttggcccg ggaagataag 780 aaacttcagt gcttgggact acagagcagg cagctggtgt tcctctttat tggctcagac 840 gctttcaact gctgtacttt tctctctggc ttcttgctat tggctgggac tcaagatgga 900 aacatttatc agctggatgt gaggagtcca agggctccgg tacaagtcat ccacagatca 960 ggagcaccag ttctatccct gctaagtgtc agagatggat tcattgctag ccaaggtgat 1020 ggaagctgtt ttattgtcca gcaagactta gactatgtca ctgagctcac tggggctgac 1080 tgtgaccctg tgtacaaggt agccacatgg gagaagcaga tctacacatg ctgtcgagac 1140 ggtcttgtac gacgctacca gctttctgac ctctgacttc ttggaaagag cagtcccggt 1200 tagtgaaaag gtttgaccct gatcaacaat gagcagaaac atcatcagtc cttcccaagg 1260 accatggcgt ttaatgtctt gggcacccct tggaaatcac agaaagtcag ctgtactggc 1320 cgtgtggaac tctcatccca agacctactt tgaactgagt aagaaggtca ttgtgcccac 1380 tgcatttgtt ccaacttctc cttgtataaa ctcaccccag caacacaggg caaggatata 1440 gatgctttta gtttgttctt aaaccagttt tgttaaatgt ttacaaggac ctcagtacta 1500 aagcctgttc tctggaggaa ataaagaaaa tatgtttgga ggtgcctgaa tatgaagaac 1560 tttgttaaat actcttactc cagcaaaaag ttggtcagga cgatgga 1607 104 2622 DNA Homo sapiens misc_feature Incyte ID No 8109363CB1 104 atcaattccc tggtcccagg agaagtttta ttgtgagttt gttaatttaa gaactcactc 60 agcagaagga catgtaatgt ctgagtaatc ttgatggaag aaaggaaata gatctgtgat 120 taaaacacac acacacacac acacacacac accctacttc ggagagagaa tgtagaatgg 180 aggaggtgag gaatttaact aatagagatg ctttttctaa caggcagaaa ttagagaaat 240 ggatcaaaag atttaaacat tgattacata taaacgagtt tccttttttt ctacatagca 300 cacaggtgct caacatttaa tgaataatat aacagatact gtcttaaaag tttaaaaaca 360 ggatttgtac ttaatcctaa attcctctta tcacacacca gaaaataatt tggattttat 420 ttacaaacta catccaaata ctcttaagga aagagtgtca tttagcttgg agtagggact 480 gactggggtc taagtgttgg aaattaaatt ctgccattca gtccaacctc aaaggtcttc 540 caggcaagga gttttgcaag gactagaaac cctttcacac ttgaagtgca ggtgttggct 600 gaaagaatag agggacattt cacaaacaca gaacacggct cccctacagg aaagggatgg 660 agacagctac ctttgctctt gctctcacat tctctgtcct catggacttt cttctctgtt 720 tccctctgcc tatctatctg cctggttctc ttgcttctcc tggccaacca gctttctcat 780 tagtgcatat gtagctgaaa aatccacccc tcaagaaccc actccacaca acctttcctt 840 ttcagtaccc accacgctct gactagcatc tctgtgatgc ctaaggcaaa tttttgagga 900 tctgattggt ttagttcatc tgcctatggg tgagccaccc tggggtcagg tgcctgtcca 960 atcacctgtt accaaggagg cagggccgtg tcatttaagc atggccccat ggactgaccc 1020 tttcagcagg gacttttatt gggggctggt acccagaaga aggagcatga gtgggcaaga 1080 ccttcaaaaa gaacctacta cacactggaa ctgactagta ctcctgggat gccatgccac 1140 gcagcagcca gcactcggag agcagtcccc tggatactac cacacagaga aaaggggcat 1200 cttcacttgc acatcaggtg agggtgcaca cacttgaaac tctgctagac tggccagagc 1260 tgccccagcc acttctcacc ccaccaccag ttattgatac agccgctggg tctaggaagc 1320 gatttctgaa caaggcccag ttagcacaat gtcttgctca gcagacaata aatacttgta 1380 aattgaattg catgatctta gctcaggtgc tactaatgtg gctcacggcc acacacttgc 1440 atggataaga aaaccaatga gcccctcaac agagtctttt gaaacaaaat tggtttcaag 1500 tgaaacttac attatttttt ggctgtgacc ttctgaatat aataacttag tgtcctgaga 1560 attgaaaggc ctcttgattt cttaggtgaa ctgttacaga atcctagcct gtggtaaatg 1620 ctaaaatgta aggcgtttct gagaaggaat atttaggaaa tataattgtg ccacacacac 1680 attactttag aagatatgca gttgctctga ttctgcaggt ttaaaaaaaa tgggaagttt 1740 gtgatatggc agaatctgtc tccattggtc aaaccatact tcagtgagag ccattataag 1800 tgaaatctaa aaattgatcg ttttcattct ctgactttgg tcagactttt gcaaattatg 1860 gagagaggcc atcaacatat tttacataaa ttactgtggc cccatcttat ttctcctcat 1920 ttcttcctta tgtttaaaca cgcccccatc tcacacacaa actgagaaaa gatttgtatc 1980 aaacagaatc agaggcatat gaatggactg gaaattgtga aaaaggtata aatatcctag 2040 accttgatca actcacttta aactggtctc tgattcctca tctgtcaaat gagtataaga 2100 ccctctgtac ttcccatggt gattttgagg agcacatgca taatgtatct gaaaatggct 2160 tgacaagcac ttgaagccat tcttactaaa ttattagttt tgtaattcgg ttttatccag 2220 gaaaatattt tagctcctcc tatctgctga attaatttat acagtcacat gttccatgac 2280 accatgtttt gccaaggaaa aataaagaaa ttcctaaatt tgaaattgcc cacaagatct 2340 agcctcatct ggagttgctg ttattgtcct tgttgtctat gatttggagg atatgtaagt 2400 acttgtacat gtgctttaac tctgggtgaa aaaccccaac cggtgagtct ttaaaaccat 2460 attagacaca ttgggcaaag tactgagcag aagctttgaa tgtagctgtt gttattttaa 2520 tgttcgcttt ctaatgaact ttgtacgtcc ttagcctctg ccgggaacag agtgttcata 2580 tgctgttaga attttttatt gtaaaataaa atgacaaagg ct 2622 105 3489 DNA Homo sapiens misc_feature Incyte ID No 1272746CB1 105 cggcagtcgg gaccgactgc aaggcaggtt gagatgatgg atctgaggct tgcagctcgc 60 agtcccaacg agccttaggg accagggcta ccaaaagggt ggggagaacg gtggtggcat 120 ctgtctgttg cctgggatcc aggcgcccgg ttggggaatc cttacttcag gaagcgcagc 180 cgcggctctg tgttttgaga gtgcaaatgt catttgtcag agtgaaccgc tgtggtcccc 240 gagttggtgt aagaaagaca ccgaaagtaa agaagaagaa aacttcagtg aaacaagaat 300 gggataatac cgtgactgat ctaaccgttc atcgggcaac tcccgaagat ctggtacgcc 360 gtcatgaaat acacaaatcg aagaatagag cattagtaca ctgggaactc caagaaaaag 420 ctttgaagag aaaatggagg aagcagaaac cagaaacttt aaatcttgag aaaagaagat 480 tgtctatcat gaaggagatt ctttctgatc aataccagat gcaagatgtg ttggagaaat 540 ctgatcatct aatagctgca gcaaaagagc tgtttcctcg taggcgcaca gggtttccaa 600 atgtaacagt ggctcctgat tcctctcagg gtcccattgt ggtaaatcaa gaccctatca 660 cccaatctat ctttaatgag tctgtcatag aacctcaggc tcttaatgat gtagatggtg 720 aagaagaagg aactgttaat agccagtcag gagaaagtga gaatgagaat gagttggata 780 actctctaaa ctctcagtct aacacgaata cagacaggtt tctccaacaa ctaacagaag 840 agaattttga gttaattagt aagttgtgga ctgacattca gcagaaaata gcaacccagt 900 cacaaataac tcctccagga acgccatcat ctgctctttc atcaggggag caaagagctg 960 ctctgaatgc taccaatgct gtcaagagac tccaaaccag gcttcagcct gaagaatcta 1020 ctgagactct agactcaagc tacgttgtgg gacacgtgct gaactcaagg aagcaaaaac 1080 agctgttaaa taaagtgaaa aggaaaccga atttgcatgc tctttccaag ccgaagaaaa 1140 acatatcatc aggtagcaca acctctgcag acttaccaaa taggactaat tccaacctgg 1200 atgtcctcaa acacatgata catgaagtgg aacatgaaat ggaagaatat gagcggtgga 1260 caggtcgcga ggtcaagggt ctgcagagca gtcagggtct tacaggcttc actttgtcgc 1320 tggtgagctc cctctgtcgc ctggttcggt accttaaaga gagtgagatc cagctacgta 1380 aagaagtaga gacaaggcaa caactggaac aagtattagg tgatcatcga gagctcattg 1440 atgctctgac agctgaaatt cttcgtctta gagaagaaaa cgctgctaca caggcaagac 1500 ttcagcagta catggtcaca acagatgagc aactgatatc actcacacat gctattaaga 1560 actgtcctgt gataaataac agacaagaaa ttcaggcatc agaaagcgga gccacaggta 1620 gaagagttat ggacagtcca gagcgtccag ttgtaaatgc caatgtctca gtgccattga 1680 tgttcagaga ggaagtggct gaattcccac aggaagagtt gcccgttaaa ctgtctcagg 1740 tgccagaccc tccagataac atgaatctgg ccaagaattt tccagcacat atttttgagc 1800 cagctgtgtt gttaacacca cccaggcaga agagcaactt aaaattctct cctcttcagg 1860 acgtattgag aaggactgtt caaactcgtc ctgctccacg acttcctcca actgtggaaa 1920 taattgagaa ggaacaaaat tgggaagaga agaccttacc tattgataca gacattcaga 1980 attcaagtga agagaatcgt ctcttcactc agagatggag agtctctcac atgggagaag 2040 atttggagaa caaaactcag gctccttttg ttaacctctc acagcccctc tgcaattccc 2100 attccaacac tcaacagtca agaagcccca cattctcaga agagctccca gtactgggag 2160 atgggcagca gctgagaaca aatgagtcat taatacaaag aaaggacata atgacacgaa 2220 ttgctgattt gacattgcag aattcagcta tcaaggcaca tatgaataat attattgagc 2280 ccagaggaga gcaaggggat ggactccggg agttgaacaa acaagaaagt gcaagtgaca 2340 tgacttctac ttttccagta gcacagtctc taacaccagg tagtatggag gaacggattg 2400 cagaattgaa tcgacaaagt atggaggctc gtggaaaact actgcagttg atagagcagc 2460 agaaacttgt tggtttgaat ctttctccac caatgtcacc tgttcagtta cctctcagag 2520 catggactga aggagcaaag aggacaattg aggtatctat tccaggagca gaagccccag 2580 aaagctcaaa atgtagtact gtctctcccg tcagcgggat aaatacaaga agatcttccg 2640 gggctactgg taattcttgt tctccactaa atgccacctc aggaagtggg agattcacac 2700 ctcttaatcc aagagcaaag attgagaaac agaatgaaga aggctggttt gctctttcta 2760 cccatgtatc ataagtgaag tcaagtctca ctgagtttgt tcttaataat ttattacttc 2820 cctttccctg ctctgacttt taagttttta tatccttctt tcagataaaa cctacaaaga 2880 tcctgtgaat tagtactaat gaaacagaga aataaagcaa ttattttttg actttctcaa 2940 ataagttttc aacaaccaac tgacctacag ctccctgtga atgaaacttt gactgtagag 3000 aagttaaagt tttgtatttt aatactttct taagtatttt aagggttttt ttttattaat 3060 acatttttac ctttatcttt attcagggtt ttttgaggtt tagtatatct tagttgatcc 3120 atttatttat ttattttcct gaagaactaa tttgctttgc atgtaactta caataaaatt 3180 cctctgtgtg attagagtct ggctttcagg aatatgtaac acccactttt ctttcttttt 3240 tcttgggaag tcattgctgt tcatcacttt ttccatcaag tgaaatatac agccttaaaa 3300 acaataggcc tgggagtgtt tgtttatatt tgcttaagca ggtaagagtg gttgcattta 3360 ttataaaatc ttatgtagtt tttaaatgtg aaaatgtcat caataatggt aatgcaaatc 3420 aaataaatat gattctagag ctcaaaaaaa aaaaaagggg ggggcgccga ataagtgggt 3480 tcgtgaacg 3489 106 2269 DNA Homo sapiens misc_feature Incyte ID No 1839974CB1 106 ggctggagga ggagagcggc ggcggcggga gcagcgaagg gggcggcagg atcctccagg 60 ctgccggctg ggaaggcgtg ggcgacccgg tgtgtggcgc gcccagagcc ccgcgtttca 120 gccctaggga aggaagccag ttgagggaag ttctccatga atgtacgtca caatgatgat 180 gaccgaccaa atccctctgg aactgccacc attgctgaac ggagaggtag ccatgatgcc 240 ccacttggtg aatggagatg cagctcagca ggttattctc gttcaagtta atccaggtga 300 gactttcaca ataagagcag aggatggaac acttcagtgc attcaaggac ctgctgaagt 360 tcccatgatg tcacccaatg gatccattcc tcccattcat gtgcctccag gttatatctc 420 acaggtgatt gaagatagta ctggagtccg ccgggtggtg gtcacacccc agtctcctga 480 gtgttatccc ccaagctacc cctcagccat gtctccaacc catcatctcc ctccctatct 540 gactcaccat ccacatttta ttcataactc acacacggct tactacccac ctgttaccgg 600 acctggagat atgccgcctc agttttttcc ccagcatcat cttccccaca caatatatgg 660 tgagcaagaa attataccat tttatggaat gtcaacctac atcacccgag aagaccagta 720 cagcaagcct ccgcacaaaa aactgaaaga ccgccagatc gatcgccaga accgcctcaa 780 cagccctcct tcttctatct acaaaagcag ctgcacaaca gtatacaatg gctatgggaa 840 gggccatagt ggtggaagtg gcggaggcgg cagcggtagt ggtcccggaa ttaagaaaac 900 agagcgacga gcaagaagca gcccaaagtc gaatgattca gacttgcaag aatatgagtt 960 ggaagtaaag agggtgcaag acattctttc gggaatagag aaaccacagg tttctaatat 1020 tcaggcaaga gcagttgtgt tgtcctgggc tccccctgtt ggactttcct gtggacccca 1080 cagtggtctt tccttcccct acagttacga ggtggcctta tcagacaaag gacgagatgg 1140 aaaatacaag ataatttaca gtggagaaga attagaatgt aacctgaaag atcttagacc 1200 agcaacagat tatcatgtga gggtgtatgc catgtacaat tccgtaaagg gatcctgctc 1260 cgagcctgtt agcttcacca cccacagctg tgcacccgag tgtcctttcc cccctaagct 1320 ggcacatagg agcaaaagtt cactaaccct gcagtggaag gcaccaattg acaacggttc 1380 aaaaatcacc aactaccttt tagagtggga tgaggtaagc ttattttcat attcacccat 1440 ctaaaacacc atttcaaaaa caaaattaac tgaacaaatg ccatcttatt cttttataag 1500 acatgctaaa cacagaaaaa aggaatgcta gtagagaaat ttaaatcaat agttattgac 1560 tatggaaaat gaagttagat tgaagtagta ttatgagttg tgtattgaaa tatatgtacc 1620 tggcttattt gcaagcacta ctgctgaaag aaaaaaagtg gggtcttatc tattttggat 1680 ctccagtgtc tagccagcca ataatttgta ttaaaaattg actgctttgt catcttgact 1740 gctcagatga ttttgataag gtaaaacaca ctgccgcttg gaaagcataa tttgcttttc 1800 ctttttgaat gccatgtatg tactttggtg ttacactgtt gagtggcctc tgtgagagca 1860 gagcagtaca tagaagtcac attctaccca tgtgcgagtg ccctgtgggt tagaatgtcc 1920 tgtatcggat gccccccttg ctgttcatgt caccagaggc ccttggaagg tatctacggt 1980 ggagtgtcct tattctcaaa gccactgtgt gccaactggt ggacccagtg catttctggc 2040 ctagctaact ctacacacag aatctcaggc aggaaacact tgacctagaa gcctttcatt 2100 tctaaaaagc aactgtaggt cgggcgcgat gactcacgcc tgtaatccca gcactttggg 2160 aggccaaggc aggtggaaca cgaggtcagg agatcaagac catcctggct aacacgatga 2220 aacaccgtct ctactaaaaa tacaaaaaaa aaaaaaaaaa aagatcttt 2269 107 3075 DNA Homo sapiens misc_feature Incyte ID No 1877336CB1 107 aagaagacca gagccagccg ggtggcacag cggtgtcgtg gccgtgttgc tgatcgcctg 60 ggtggttgtt ggcgtgtccc tgcagcgaag gatcctggtt gacagtgaaa aagcagtctg 120 gctcccgagg tccacccctt ataccccaag gtccagatgg cggccaacgt gggtgatcaa 180 cgtagcacag attggtcttc tcagtacagc atggtggctg gggcaggccg agagaatggc 240 atggagacgc cgatgcacga gaacccggag tgggagaagg cccgtcaggc cctggccagc 300 atcagcaagt caggagctgc cggcggctct gccaagtcca gcagcaatgg gcctgtggcc 360 agtgcacagt acgtgtccca ggcagaagcc tcagctttgc agcagcagca gtactaccag 420 tggtaccagc agtacaacta tgcctacccc tacagctact actatcccat gagcatgtac 480 cagagctatg gctccccttc ccagtatggg atggccggct cctatggctc agccacaccc 540 cagcagccat ccgcacccca acaccaaggg actctgaacc agcccccagt ccccggcatg 600 gatgagagca tgtcctacca ggctccccct cagcagctgc cgtcggctca gccccctcag 660 ccctcaaatc ccccacatgg ggctcacacg ctgaacagtg gccctcagcc tgggacagct 720 ccagccacac agcacagcca ggcggggccc gccacgggcc aggcctatgg gccacacacc 780 tacaccgaac ctgccaagcc caagaagggc caacagctgt ggaaccgcat gaaacccgcc 840 cctgggactg gaggtctcaa gttcaacatc cagaagcgac cctttgctgt taccacccag 900 agctttggct ccaacgcaga gggccagcac agtggttttg gcccccagcc caaccctgag 960 aaagttcaga accacagcgg gtcctctgcc cgggggaacc tgtctgggaa gccggatgac 1020 tggccccagg acatgaaaga gtatgtggag cgctgcttca ccgcctgtga gtcggaggag 1080 gacaaggacc gcacggaaaa gctgctcaag gaggtgctgc aggcgcggct gcaggacggc 1140 tcggcctata ccattgactg gagccgggag cccttgccgg ggctgacccg ggagcctgtg 1200 gctgagagcc ctaagaagaa gcggtgggag gccgctagca gccttcaccc tcctagaggg 1260 gcaggctcgg cgacaagggg cgggggtgcc ccgtcccagc gagggacgcc cggggctggg 1320 ggtgccggtc gagcccgggg caacagcttc accaagtttg gcaaccgcaa cgtcttcatg 1380 aaggacaaca gctcttcttc cagcacagac tcccgctccc gctcctcctc caggtccccg 1440 acgcgccact tccgcagaag tgactcccac tcagactccg acagctccta ctcagggaat 1500 gagtgtcacc ctgtgggccg caggaacccg ccccctaagg gccggggcgg tcgaggggcc 1560 catatggatc ggggccgagg cagggcgcag cgtgggaaga ggcacgatct ggcgcccacc 1620 aagcgcagtc gaaagaagat ggcggcgctg gagtgtgagg acccggagcg agagctgaag 1680 aagcagaagc gggcagcccg cttccagcac ggacactccc gccgcctgcg cctcgagccc 1740 ctggtgctgc agatgagcag cctggagagc agtggggctg accctgactg gcaggagctg 1800 cagatcgtgg gcacctgccc tgacatcacc aagcactacc tgcgcctcac ctgtgccccc 1860 gacccgtcca ccgtgcgccc tgtggcagtt ttgaaaaagt cgctgtgcat ggtcaagtgc 1920 cactggaaag agaagcagga ctacgcgttt gcctgcgagc agatgaagtc gatccggcag 1980 gatctgacgg tgcagggcat ccgcaccgag ttcacggtgg aggtgtacga gacccatgcc 2040 cggatcgcct tggagaaggg tgaccatgaa gagtttaacc agtgccagac gcagctcaag 2100 tcgctgtacg ccgagaactt gcctggcaat gtgggcgagt ttactgccta ccgaatcctc 2160 tactacatct tcaccaagaa ctcgggagac atcaccacgg agctggcata cctcacacga 2220 gaactgaagg cagatccttg cgtggcccac gccttggcat taaggacagc ctgggccctg 2280 ggcaactacc accgcttttt ccggctctac tgccatgcac cctgcatgtc tggctacctc 2340 gtggacaagt ttgcagatcg ggagcgcaag gtcgccctca aggccatgat caaaaccttc 2400 cgccctgcgc tgccagtctc ctacctgcag gccgagctgg ccttcgaggg cgaggccgcc 2460 tgccgggcct tcctagagcc cctgggcctg gcctacacgg gcccggacaa ctccagcatc 2520 gactgccgcc tcagcctggc gcagctgtca gccttctgag cacccagcga ggaggggcgg 2580 gggcaggggc tgcagccccc agcgctgcct ttgcggattc tgtttttgag ccgtggactt 2640 gggttgtaaa tttatttgtg gggagtgcgc tccaggaaga gccaccatcc ctgcccccgt 2700 tttcccttgg ttcagcacag gtaaaacggg ttcccctccc tccctgcctt catggatcac 2760 cagctcacgt catgttgcct tctcttttct ttgtgtgtgt gtttatttaa gttatttttc 2820 ttcctcctct cccttttctt tttggccctc cctccctccc tcttctgcca tgtaactgga 2880 ggatgtgcta tgagtttgca aacagctgga ctgtcaggct gctttttttc cagatgttcc 2940 tcctctgcct ccccttcccc tcctctcccc tccttttcct tccttccttc ctttccttgg 3000 agcactgagc accatttgga agcttgagag aaaccaaaat taaagagaga aagagagagc 3060 gtgcaaaaaa aaaaa 3075 108 849 DNA Homo sapiens misc_feature Incyte ID No 2321054CB1 108 cgtccctaga gcctcgccgc cctgggaccc gggctgcttc ctgggagagg attacatttt 60 ctccctgctc cacttgactt tcttccggaa ggagcaggtc tcgcaggatc ggggccaaga 120 ctggaagagt tcagccccat ggctgggggt tatggagtga tgggtgacga tggttctatt 180 gattatactg ttcacgaagc ctggaatgaa gccaccaatg tttacttgat agttatcctt 240 gttagcttcg gtctcttcat gtatgccaaa aggaacaaaa ggagaattat gaggatattc 300 agtgtgccac ctacagagga aactttgtca gagcccaact tttatgacac gataagcaag 360 attcgtttaa gacaacaact ggaaatgtat tccatttcaa gaaagtacga ctatcagcag 420 ccacaaaacc aagctgacag tgtgcaactc tcattggaat gaaacctcag aaaaagagca 480 acagaagtaa ttgtttcaag ctcctgattc tttctactaa atcatgaaca gctttaaaaa 540 catttctgtc tgcataaaat tattttactt gtaacttttc cccaattgtt ctgtgcattg 600 ttttgccttt ttaaattaca tctccaagtg gctcaaaagg ccttgacaca gggaacctgc 660 acatatccag gatatgtgta accagcgatg gtgacttgac cttgccaaga cctgtgattc 720 cttcaggata caatcagtga gaaataaaaa cacatcttgg gaagtgggaa tcctggagtt 780 tatgccattt gcaatattaa aaaataaaaa tgcaagttat tatttcaata ataaaaaaaa 840 aaaaaaaaa 849 109 2659 DNA Homo sapiens misc_feature Incyte ID No 2796034CB1 109 atatactttt tcatttcttt gtatctacaa tggccaactg gaatttctgc ttgaaacatg 60 gagcccacca taatctcctt tttccagtct tctgatggaa tataatcttc atcttcttca 120 gattcttctt ctacttcact atttgtatca aaatatttac atcgacgtgg cggattattt 180 cctgggcatc ttgagaagca acagattgtg atggatcatc attggaagac tgagtttcat 240 cctcctgacc tgatgaatcc tttatattct cctctttatt ttccccacta cagccactgt 300 tgtcatcatt atcagcatct tcatcatctt caccttcttc ttcctcttct tcctcttcct 360 catcttcttc aggtagtcga acagtactac cataaccata aaggctgaga agttcatgaa 420 ttggcatgtc gccttccctt gcaagatctt ctatttcaga gctgaagttt gtttctcctt 480 ccatcatttc ttcctcttct aatgttcgtt catcatcaaa atcatgaacc agcatgtcag 540 ctgatggatc aaattcatgg tcatctgatg ttgctgaacc tcctggactt gaagattcaa 600 cagatggcag catcacatcc gtcttgtctg cattgaacct caaccagttg gttcttaacc 660 acgtccgaaa ctcagccagg cactgggaga atcgagcgac cacaccatag ccgctgccgc 720 tgctgccgcc gccaccttcg ctgctgccgc caccgcctga agaagcccca tccatccgcc 780 tgcagccggg agactcagag cctgggaggg gcctgaggcc cgggccgccc gcctccttct 840 tccagtcgtc gtccggagct tcctccagct ccaccaaccc tctgccctcc cctccgcctc 900 cgccctcctc ctcggcctcg tgccgccagc caaccgcgcg gccgcttgtt gagccaggct 960 ccaccgtcgc catgacgccc ggcaaacatt ccggagcctc ggcccgagcc gctaacgcag 1020 gagcttgggg gtacagggac ttcagaggcg gccaaaaaaa ggggtggtgc accactcccc 1080 agctggtcgc caccatgcca gtctctccgg caggcagtca caagcagcag aacttcgggt 1140 tgaacaatgc cacacaacca aagaagtcta ttagcttttt tgctacaatg aaagcaactt 1200 cagtgaaagg atatactggt gcaaatcaaa gcagaatggc tgtgtccaaa accgtgctta 1260 ttccacctga actgaaaact gtagaaaaac caaatcccaa tataaagaca acacaggtat 1320 ttgacataaa tggaactgat gttactcccc gacctcttta ccatccagat ccacttactg 1380 gtacagcaaa accaagtaaa ctcttgacat cacaagaagg atcacttgga tcagaattta 1440 tatcttccta tagcctttat cagaatacaa taaatcctag tacgttaggg cagtttacaa 1500 ggtcagtttt aggaagcagt acagtttcta agtcaagtgt atcagcaagt gaatcaatag 1560 cagaagacct ggaagaacca tcctataaac gggaaagatt gactagtttc acagatttgc 1620 aagttataag ggcagcacct gaaaaaattg taacaaaaga agacctggag aagaatatag 1680 agataatact cacagagaca gaaacactga gattttttga cttgcccaca gtcatggtct 1740 ctgtagaatc tgaagaagct gagaaagtaa ctcagagaaa caagaattat gaagtccttt 1800 gtagaaacag attaggcaat gacctatatg ttgaaaggat gatgcagact ttcaatggag 1860 caccaaagaa taaagatgtt caatgtgata aaatcataat ggaagataaa ggcataatgt 1920 ccactgcctg ggatttgtat gattcttaca atgctatgga acttgtatct ttatcagtaa 1980 aacaatctgt ggttgagtca agtagtaaag caaatgtact tcctaaagat caggaccaaa 2040 gattgccagg gagcactaca gaaaaaaata gtgaaactag ttctctaatg gacatagaaa 2100 atgtaattct ggcaaaaatc catgaagatg aggaagacca ctcagatgca atattaaaat 2160 ctgacaaatt tcatcaggac ttatttttta tggaacgggt tctgatggaa aatatatttc 2220 agcccaaact tgcagcttat cgtcagcttc ctgttttaaa agaacctgaa cctgaagagc 2280 ctgaagatgt tttagaaagt gcaaaacatg aagaggtaga ggaagaatct aagaaggagg 2340 aggaagaaga aatacatgca gaagaatcaa caatacccgc caacttggaa cgactttggt 2400 ctttttcctg tgacttaacc aaaggcctca atgtgagcag ccttgcctgg aataaaacaa 2460 atccagatct tttggctgtt ggctatgggc actttggatt taaagagcaa aaagaggact 2520 ggcttgctgc tggtcaataa agaatcccat ggtaacccaa acaagaataa gaagcatttt 2580 tatctggctg ttgacaaaat tctcataaaa tatataatta catgtaataa ttaaataaag 2640 tctagaaaat tttatcaaa 2659 110 2205 DNA Homo sapiens misc_feature Incyte ID No 4413112CB1 110 ggaacgccag cgaccccagc agcgctgcgg acggtgctgg ccgtggccgc tgcggccccc 60 gtgtccaggt gggccaggac gcagcctctg ggcgccgtcg cttttccagc atcgcagagg 120 caaaagcgtg gcagtgggac ccaaaaggta ggactgaggc tctagaactt gcacctgtgc 180 agggactgca aaccagacct gggaggaccc tttcagcagc ccccactcca ccctatccca 240 ggacttccca gcgacccgcc gttctgggag ataccgggag cgtgatcagg gggcggggcc 300 gtttccaagg caaccgctta tttgcatagg gtcccgtcct ggccaacgag ggcgccccaa 360 atgttcagga catagaagaa ggggttaact ggcccggatc tcctcctcgc cttccaagcc 420 cgctaagcac tggggttatc tacccattcc ccagaagggg agactgaggc agcccaccag 480 ccaaaggagg cgaccagact ggggctgcgt tttaccattt cagaagcggc ttgagctggt 540 ctgagctata ataataaaca ctggcggtgg aggcgagggc gaccacaggg ctgaggtcag 600 ggctaggatt ccggtgtctc tacgtaggtt gcttgaatgg ggggcaccct ggcatggacg 660 ctgctgttgc cgctgctgct gcgggagtca gacagcctag aaccgtcgtg caccgtgtcc 720 tccgcggatg tggactggaa cgcggagttc agtgccacgt gcctgaattt cagtggcctc 780 agcctgagcc tgcctcacaa ccagtctctg cgggccagca acgtgattct ccttgacctg 840 tctgggaacg gcctgcgaga gcttccagtg accttctttg cccacctgca gaagcttgag 900 gtcctgaacg tgctacgcaa ccccttgtct cgtgtggatg gggcgctggc cgcccgctgt 960 gaccttgacc tgcaggccga ctgcaactgt gccctggagt cctggcacga catccgccga 1020 gacaactgct ctggccagaa gcctctgctc tgctgggaca caaccagctc ccagcacaac 1080 ctctctgcct tcctggaggt cagctgcgcc cctggcctgg cctctgcaac tatcggggca 1140 gtggtggtca gcgggtgcct gcttcttgga cttgccatcg ctggccctgt gctggcctgg 1200 agactctggc gatgccgagt ggccagaagc cgggagctga acaaaccctg ggctgctcag 1260 gatgggccca agcccggttt aggcttgcag ccacggtacg gcagccggag cgcccccaag 1320 ccccaagtgg ccgtgccatc ctgcccctcc actcccgact atgagaacat gtttgtgggc 1380 cagccagcag ccgagcacca gtgggatgaa caaggggctc acccttcaga ggacaatgac 1440 ttttacatca actacaagga catcgacctg gcttcccagc ctgtctactg taacctgcag 1500 tcactgggcc aggcctcaat ggatgaagag gagtacgtga tccccgggca ctgagcctaa 1560 gatgtcctaa cctccaccca gaaccccttc agtccctgct gggtgactca gggcgtccta 1620 actcctccat ggcctcagtt tccccatctg aagaatgggg acaggaaagg attgtccttg 1680 aggccccagg aagctctgcc gccccctccc tgtccctcat gccgctcctc agctccctca 1740 gctcctagag ggggaagagg agagaccccc aacaagggga caggagggtc actgtgccaa 1800 tcctgtcatc accctcctgt ggatgtacag gcagtgctca ataaatgctt cgaggctgat 1860 gaggctgctg gctcagggtg cgtgggttcc tcaaggtggg gatttctgag ttctaagacc 1920 aagtctccat ctgagactcc caaattgctc cccacctccc atccctgttt ttttttgttg 1980 ttgttgtttg tttgtttgtt tttgaaactg agtctcactc tgtcacccag gctggagtgc 2040 aatgctgcga tctcagctca ctgcaacctc cgcctcctgg gttcaagtga ttctcctgcc 2100 tcagcctcct gagtagctgg gattacagca cccaccacca tgccgagcta atttttgtat 2160 ttataataga gatggggttt cgccatgttg gccaggctgg tctcg 2205 111 3042 DNA Homo sapiens misc_feature Incyte ID No 7654832CB1 111 accagctgat attttctttc ctcaggacca gctgttcagg agcatcccgg acgagagcca 60 ggcacatttg agacttggat ccaactaaag accgccgcag attcttctgc agcaatgtcg 120 gtgttagaag aaaatcggcc gtttgctcaa caattatcca atgtctactt tacaatactt 180 tcgctgttct gttttaagct ttttgtgaaa atcagccttg ccatcctcag tcatttctac 240 atagtgaaag gcaaccgcaa ggaagcggca aggatagcag ctgaatttta tggagtaacc 300 caaggacaag gttcctgggc agatcgatca ccactacatg aagcagcaag tcaaggtcgc 360 cttcttgctc tgagaacatt attatcacag ggttataatg taaatgcagt aaccttagac 420 catgtcaccc cattgcacga agcctgcctt ggagatcacg tggcatgtgc cagaactctg 480 ctggaagcag gagctaatgt aaatgcaatc acgatagatg gcgtgactcc gttattcaac 540 gcatgctccc aaggcagtcc aagctgtgca gagctgcttc tggagtatgg tgccaaagcc 600 cagctggagt catgtcttcc atccccaacg catgaggccg ccagtaaagg tcaccatgaa 660 tgtcttgaca tcctgatatc ctggggcata gatgttgacc aagaaattcc tcatttggga 720 actcctctct atgtagcttg tatgtcacag caattccatt gcatctggaa gcttctttat 780 gctggtgctg acgtacagaa aggcaaatat tgggatactc cattacatgc tgctgctcaa 840 caatccagca cagaaattgt aaacttactg ctagaatttg gagcagatat caatgccaaa 900 aatacagagc ttctgcgacc tatagatgta gctacgtcta gcagtatggt ggaaaggata 960 ttgcttcaac atgaagctac cccaagctct ctttaccaac tttgccgact ctgtatccga 1020 agctacatag gaaaaccaag attgcacctt atcccacaac tccagctgcc aacgttactg 1080 aagaatttct tacagtatcg ataaaacagt aaagtaattc taaatacctt gaaaatcaaa 1140 atttctattt cttttgctta aggaatagtt catataaaaa tatgctaaag ataggataaa 1200 agtgagtgtg agatcaccca gggaagcagt aaaatatcaa ttttcatttt aagtgtatta 1260 gtactattgt tttatcattt atgctgtctt tggattatag catatttata atatctattt 1320 tttgttattt caatataccc tcttgtttat tcaggaaaaa ataataaagt cactatctta 1380 tgttttcttt tggattggaa agaaataaag ctcctagtaa agttattcat attatattta 1440 aaaaggtcta tgttcttcaa ctaatgggtt aactttttaa ttttggctat tgtaattggc 1500 taacttgtta ctgatattga cataaaatat gaatatggct tagcaaagag caactaatat 1560 gttttctgaa accaggatga tgctcattca ggaaatccac tatgttgaat gtccactggt 1620 cattagaatg aacacttcat aaagataaat tgcccccctc ccccccactt acccctggca 1680 aaggactcac aagtcacttc tcttccccat agtacatgga cttgttacag aaaagtgata 1740 ggatgaaagg tcaatactgc cctctcaccc tgagatattt agaacattac acaccttcta 1800 aggctatgtt aagactgcct ccttctcagg agtagcccct gatgatctct tatcaaggcg 1860 gttatatgca tattactcca gccttcttcc atttcagaaa ttgtcaatag ctagtgatac 1920 ttggacttaa gaaaatgaac tatatatcta attaacaaac aggccctgga tcatattccg 1980 gggatcatca catcagtcca aggatataaa aaaatggaag attaaaaact caaattgtgg 2040 agtttttaaa gagtgggtgc cacttaacac attggagacc ttaaaaaatg tatatagaga 2100 acttaatcgc actgtttcta attcttttta cacaaaacaa gggcttagag tatactgtat 2160 ttgcaagtaa tagcaagaga gtattgtata aaagaagata ttactaagct agtcctctgc 2220 aagggtaaat actatgttta ttctcttcag ctttaactat acttgagtgc aataaaaaac 2280 ttaataaaat tttatgcctg ttttgtaatt cagggcctat tatgatttta gaaataagat 2340 aatcaacgta caactctttg taaaacaaaa gcaactttgg gtgagtttta tagatttatt 2400 aaattttgat aaagtaaata ttttgaccac tattttcaac aacccagggc ttattttctt 2460 ctgacttctt ggctaacttc cagactatgg gaaaataaat tatgattgta tgtgaccccc 2520 agatcactaa gcttgcattt tggcagaaag aaaaaaaatc agttgtgatt taaaacgttt 2580 gttgagattt tcaaacatag aaataaagct gtagcatatt cactaaacaa tgttttatat 2640 gaggataggg acctttaaat atgtgtttta tagaatatct cacacatttg taatggataa 2700 cgtgcattaa aatggagttc ttattataga ataacctggt taaacagata ttaaagctgc 2760 ttttgggtaa aacaggtttc caccagtatt ttccctgagc tagaggagaa gtcttagatt 2820 ttaagagtaa tacaacccat ctatcttatt agtcttgtgc caataagaga agtaaatatc 2880 aaacattaaa atggtcactt tacaatttca gtatgtctgt accttgtatc ttagcttgag 2940 tatgattgtc ttatcaaagt agtgttctaa ctttaatgta ttgtatgttt gttattatat 3000 taaagtgtga ttattattca ttggaataaa aaaaaaaaaa aa 3042 112 2112 DNA Homo sapiens misc_feature Incyte ID No 7503849CB1 112 ggcctccggt gtgggatggc cgcggagccg ggcggagctg gcttgcggct cccggggccg 60 gctctccggc cggagacatg gcccgggggc ccggcccgct aggcaggcct cgccccgata 120 cggtcgccat gcccaagaga ggaaagcgac tcaagttccg ggcccacgac gcctgctccg 180 gccgagtgac cgtggcggat tacgccaact cggatccggc ggtcgtgagg tctggacgag 240 tcaagaaagc cgtagccaac gctgttcagc aggaagtaaa atctctttgt ggcttggaag 300 cctctcaggt tcctgcagag gaagctcttt ctggggctgg tgagccctgt gacatcatcg 360 acagcagtga tgagatggat gcccaggagg aaagcatcca tgagagaact gtctccagaa 420 aaaagaaaag caagagacac aaagaagaac tggacggggc tggaggagaa gagtatccca 480 tggatatttg gctattgctg gcctcctata tccgtcctga ggacattgtg aatttttccc 540 tgatttgtaa gaatgcctgg actgtcactt gcactgctgc cttttggacc aggttgtacc 600 gaaggcacta cacgctggat gcttccctgc ctttgcgtct gcgaccagag tcaatggaga 660 agctgcgctg tctccgggct tgtgtgatcc gatctctgta ccatatgtat gagccatttg 720 ctgctcgaat ctccaagaat ccagccattc cagaaagcac ccccagcaca ttaaagaatt 780 ccaaatagca tagcttgtgt gggacactgg agccgttgtg atggcagcag aagtgttttc 840 cccttaaagc caagcccatt aattttgatg gaacagcagg acgtacaggg catgtctgaa 900 gggcaggaca gctggcacgg cggacgaccc accccttatc ccctgggagt gcttactttt 960 ctggtgcaga aagattgttg ggaacagaca ggaaccaatg tgggaattca acttcaagtt 1020 caaaaaacag tcccctaggt taaagagcaa gtgtacagga ggattgcagc ctcccgttca 1080 gtacgaagat gttcatacca atccagacca ggactgctgc ctactgcagg tcaccaccct 1140 caatttcatc tttattccga ttgtcatggg aatgatattt actctgttta ctatcaatgt 1200 gagcacggac atgcggcatc atcgagtgag actggtgttc caagattccc ctgtccatgg 1260 tggtcggaaa ctgcgcagtg aacagggtgt gcaagtcatc ctggacccag tgcatcagcg 1320 ttcggctctt tgactggtgg catcctcagt acccattctc cctgagagcg tagttactgc 1380 ttcccatccc ttgggggcag cctcgagtgt agtccattag taatcagatt ccagtttgga 1440 cagggtggct ggattgtata tctcgttagt aatgtacatg ctcttcaggt tctagggctc 1500 ctgttagggg agggagaaat gttgaatcaa gagggaaaac aactactatg atttataaac 1560 atattttaat gtaaaaattt gcatttaaaa ggagtggccc tgttttctgt gttaaaaccc 1620 catttggtgc tattgagttt gttctttatt cttttatccc agtgaaaatt gttgatcttg 1680 ctgtagggaa aaattaaact ctttgaatct ccaaacaagg aagtttcagc attcccttat 1740 ggatcagagg aaccttagag gcctgaaatt gttgcttcca gtttagctgc ccctcaaatt 1800 caagtgaata ttttcccttc tccctttacc cttctccaga aataaagcag gtgacagggt 1860 tttcagaatc ttaccatatt gacttgtgta tcttttttaa aaaataattt gtgatattta 1920 ttgcatacat tttcttttgg cagttttgga ttttaggtat ttttttgcat gaggctgata 1980 atggtgatga tgactttata cccttggtac tatactagga actttacata gtatctctac 2040 ttctcacagt cttgcaaagt aggtgatatt tattcccatt ttatagtttg agaaaacgga 2100 attaggtgac tg 2112 

1. An isolated polypeptide selected from the group consisting of: a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-55, b) a polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:56, c) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:7-12, SEQ ID NO:14-20, SEQ ID NO:23-24, SEQ ID NO:26-36, SEQ ID NO:38-43, SEQ ID NO:45-46 and SEQ ID NO:48-54, d) a polypeptide comprising a naturally occurring amino acid sequence at least 93% identical to the amino acid sequence of SEQ ID NO:37, e) a polypeptide comprising a naturally occurring amino acid sequence at least 94% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:22 and SEQ ID NO:55, f) a polypeptide comprising a naturally occurring amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:13, g) a polypeptide comprising a naturally occurring amino acid sequence at least 97% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:44, h) a polypeptide comprising a naturally occurring amino acid sequence at least 98% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:21 and SEQ ID NO:25, i) a polypeptide comprising a naturally occurring amino acid sequence at least 99% identical to the amino acid sequence of SEQ ID NO:1, j) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56, and k) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-56.
 2. An isolated polypeptide of claim 1 selected from the group consisting of: a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-55 and b) a polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:56.
 3. An isolated polynucleotide encoding a polypeptide of claim
 1. 4. An isolated polynucleotide encoding a polypeptide of claim
 2. 5. An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112.
 6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim
 3. 7. A cell transformed with a recombinant polynucleotide of claim
 6. 8. (CANCELED)
 9. A method of producing a polypeptide of claim 1, the method comprising: a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and b) recovering the polypeptide so expressed.
 10. (CANCELED)
 11. An isolated antibody which specifically binds to a polypeptide of claim
 1. 12. An isolated polynucleotide selected from the group consisting of: a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:57-112, c) a polynucleotide complementary to a polynucleotide of a), d) a polynucleotide complementary to a polynucleotide of b), and e) an RNA equivalent of a)-d).
 13. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim
 12. 14. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.
 15. A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.
 16. A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising: a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.
 17. A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient. 18-19. (CANCELED)
 20. A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting agonist activity in the sample. 21-22. (CANCELED)
 23. A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising: a) exposing a sample comprising a polypeptide of claim 1 to a compound, and b) detecting antagonist activity in the sample. 24-26. (CANCELED)
 27. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising: a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1, b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim
 1. 28. (CANCELED)
 29. A method of assessing toxicity of a test compound, the method comprising: a) treating a biological sample containing nucleic acids with the test compound, b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof, c) quantifying the amount of hybridization complex, and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound. 30-45. (CANCELED)
 46. A microarray wherein at least one element of the microarray is a polynucleotide of claim
 13. 47-167. (CANCELED) 